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Abstract 
 
 
Honey has various bioactivities with health-benefiting properties.  It has been 
registered for use in wound dressings but before it can be registered with 
regulatory authorities for sale with claims for therapeutic actions the 
components responsible for these bioactivities must be identified to allow 
standardisation.  This thesis focuses on the anti-inflammatory activity of honey.  
Emphasis was put on identifying the mode of action of the anti-inflammatory 
component, creating an in vitro assay to measure the anti-inflammatory activity 
of individual honeys and attempting to identify and characterise the 
component(s) responsible for the activity.   
A cell line (THP-1) was selected for this study based on its macrophage 
phenotype upon activation and its role as an inflammatory regulator.  Initially 
this cell line was characterised to better understand the treatments that activate 
its phagocytosis ability, mobility, phenotype and gene expression profile.  The 
cell line was then monitored for the change in expression of its pro-inflammatory 
and anti-inflammatory cytokines and growth factors in response to common cell-
activating treatments (LPS, PMA and Vit-D3) and Manuka honey.  It was found 
that Manuka honey increased the expression of pro-inflammatory cytokines  
TNF-α and anti-inflammatory cytokines IL-10, IL-1ra and the growth factors PDGF 
and TGF-β.  This indicated that Manuka honey may allow inflammation to 
proceed at a modulated level, allowing healing to occur.     
The cell line THP-1 was further investigated as a model of a phagocyte when 
activated.  A phagocytosis assay using latex particles was utilised to study the 
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effect of honey on the ability of cells to phagocytose.  It was found that honey 
reduced phagocytosis, and that Manuka honey had a superior ability to other 
honey types to do this.  The activity was isolated to the high molecular weight 
compounds in honey.  As phagocytosis produces large amounts of reactive 
oxygen species (ROS) and ROS are pro-inflammatory, the ROS produced by 
phagocytising THP-1 cells was investigated using a dichlorofluorescein assay.  It 
was found that ROS produced by phagocytising THP-1 cells decrease in the 
presence of Manuka honey but not artificial honey or Rewarewa honey which 
has high anti-oxidant activity.  This indicated that the effect of Manuka in 
decreasing ROS was not solely due to its osmotic effects or anti-oxidant 
capabilities.  As phagocytosis starts the inflammatory cascade, it was 
hypothesised that the phagocytosis-inhibiting component resulted in honey 
having anti-inflammatory activity. 
Next, attempts were made to identify the anti-inflammatory component.   
Manuka honey was separated using chromatography and the fractions obtained 
assayed for their inhibitory activity in the phagocytosis assay.  The active 
fractions were found to contain MRJP-1 and to a small extent MRJP-3, which 
were identified by MALDI-TOF mass spectrometry.  It was confirmed that these 
were glycoproteins with a high mannose content by using a ConA lectin column.   
Next a mode of action for the glycoproteins was investigated.  It was 
demonstrated by using mannan that honey was acting on a mannose-binding 
phagocytic receptor on the cell surface of macrophages, most likely the mannose 
receptor.  It was hypothesised that with the glycoproteins bound to the receptor, 
the cell was unable to have phagocytosis triggered thus ROS production and 
expression of inflammatory cytokines in response to ROS produced were 
prevented.   
A wide range of honey varieties was assayed and the anti-inflammatory activity 
was found in high levels only in Manuka honey and to a lesser extent in Kanuka 
and Rewarewa.  To identify why this activity was much greater in Manuka honey, 
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as all honey contains the glycoproteins MRJP-1 and MRJP-3, the effect of the 
recently discovered high levels of MGO in Manuka honey was investigated.  It 
was found that Manuka honey had a high fluorescence that was not seen in 
other honey types to the same extent and that this fluorescence was due to 
MGO modifying the proteins in honey.  It was found that this fluorescence could 
be used as an indicator of anti-inflammatory activity for Manuka honey and that 
this fluorescence, and anti-inflammatory activity increased over time upon 
incubation of honey with high MGO levels.   
The anti-inflammatory activity seen in the phagocytosis assay was compared 
with that seen in a commonly used in vivo assay of anti-inflammatory activity, 
the HET-CAM assay.  The HET-CAM assay depends on the experimental 
production of inflammation and the reduction of this inflammation with an anti-
inflammatory agent on the chorionic membrane of a fertilised hen’s egg.  It was 
concluded that highly fluorescent Manuka honey at a concentration of 5% had 
and anti-inflammatory effect equivalent to that of 5 mg/ml hydrocortisone, a 
commonly prescribed anti-inflammatory drug. 
The anti-inflammatory activity seen in the honeys assayed in the in vivo HET-CAM 
assay concurred with the results for the same honeys assayed in the 
phagocytosis assay which indicated that the phagocytosis assay was a reliable 
indicator for assaying the anti-inflammatory activity of honey in vitro. 
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Preamble 
 
 
This thesis has been divided into separate chapters each containing an 
introduction, methods, results and discussion section.  The references are found 
at the end of the thesis.  A brief introduction (Chapter 1) and final discussion 
(Chapter 10) are presented but the main topics are introduced and discussed in 
each chapter. 
Chapter 2 is focussed on characterising the THP-1 cell line used in the research 
requiring monocytes and macrophages.  
Chapter 3 looks at pro- and anti-inflammatory cytokines expressed by THP-1 
after stimulation by LPS, honey or a combination of these. 
Chapter 4 identifies Manuka honey as having an anti-inflammatory effect in an 
in vitro assay measuring phagocytosis of latex particles by THP-1 cells. 
Chapter 5 studies the effect of honey on ROS generated by THP-1 cells. 
Chapter 6 identifies an anti-inflammatory component of Manuka honey. 
Chapter 7 attempts to identify the receptor on THP-1 cells that the anti-
inflammatory component of Manuka honey works on. 
Chapter 8 looks at the fluorescence of Manuka honey and the effect of MGO on 
protein in honey. 
Chapter 9 compares the phagocytosis assay with an in vivo HET-CAM assay for 
inflammation. 
  
Chapter 1  
Introduction and Literature review 
 
 
 
 
1.1  Introduction  
Honey has been used for thousands of years as a medicinal agent and dietary 
supplement.  It has been prescribed for a wide range of ailments, most 
successfully in recent times, for wound healing (Zumla and Lulat 1989).  Being 
considered a “natural cure” means that honey is not always accepted as a 
therapeutic product.  What for some are seemingly outlandish claims have been 
made for honey, with talk of anti-cancer, anti-viral, anti-bacterial, anti-
inflammatory and anti-fungal properties to name a few.  Honey has been said to 
cure athlete's foot, jock itch, ringworm and nail fungus, bacterial 
contamination and skin infection in wounds and burns, including Methicillin-
resistant Staphylococcus aureus, acne, stomach aches, stomach ulcers, sore 
throats, strep throat, gastritis, acid reflux disease, irritable bowel syndrome, 
heartburn, indigestion, cold and flu symptoms, cold sores, arthritis, gout, 
smallpox and even baldness.  At least, these are the claims made by companies 
marketing honey products.  All bee products, it seems, have important medicinal 
properties.  Propolis, thought to be one of the earliest bee products used by 
man,  provides relief of various conditions, including inflammation, viral diseases, 
ulcers, superficial burns or scalds, tumorous growth to name but only a few.  
Royal Jelly is another product with health-benefiting properties.  While it is 
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accepted that it provides a good health supplement due to its free amino acids, 
sugars, minerals and vitamins, there is possibly no health complaint that Royal 
jelly has not been claimed to fix.  Bee venom is also said to have important 
health benefits for the treatment of rheumatism and joint diseases, due to its 
anti-coagulant and anti-inflammatory properties.   
 
Honey is registered for use in wound dressings, but for honey to be registered 
with regulatory authorities for sale in the pharmaceutical market as a 
therapeutic agent, components responsible for the various bioactivities must be 
identified to allow quality assurance and standardisation of products. This will 
also be needed to carry out the clinical trials necessary for therapeutic claims to 
be made when honey products are registered as medicines. Without 
standardised honey (i.e. honey with a known amount of the bioactive substance 
present) being used, a trial would only prove that the particular batch of honey 
being used had the observed effect. Ideally, the bioactive components of honey 
need to be chemically identified and assayed as known substances, but there 
needs to be at least a reliable bioassay available for each activity to be able to 
standardise honey for use in clinical trials. 
 
Progress is slow in proving many of these declarations so most claims for honey 
remain unsubstantiated by modern science, but one of the best established is 
honey’s anti-bacterial properties (Molan 2009). All honey appears to have, to 
some extent, anti-bacterial properties.  Claims that Manuka honey from New 
Zealand in particular is exceptional for its wound healing abilities are commonly 
known and these claims have some acceptance in the medical community based 
on in-vitro studies (Allen, Molan et al. 1991).   Derived from particular floral 
sources in Australia and New Zealand (Leptospermum spp) the actual anti-
bacterial component of Manuka honey was, until recently, unidentified.  The 
new discovery of methylglyoxal (MGO) in Manuka honey, however, has brought 
this “natural cure” back into the limelight (Adams, Boult et al. 2008; Mavric, 
Chapter 1                                                   Introduction 
3 
 
Wittmann et al. 2008).  MGO has been shown to originate from 
dihydroxyacetone, which is present in the nectar of Manuka flowers in varying 
amounts (Adams, Manley-Harris et al. 2009).  MGO is highly anti-bacterial.  It has 
been demonstrated that the bioactivity of MGO, at the levels at which it is 
present in the honey, correlates to the non-peroxide activity (Adams, Boult et al. 
2008; Mavric, Wittmann et al. 2008).   No longer unidentified, Manuka honey’s 
main anti-bacterial component can be measured and precisely listed on the jar, 
enabling better prescription for different ailments and perhaps putting to rest 
the disputed anti-bacterial property of Manuka honey.  Further anti-bacterial 
agents may contribute to the total anti-bacterial activity of honey but have yet to 
be identified. 
 
The purpose of the research in this thesis was to focus on another therapeutic 
aspect of honey, its anti-inflammatory properties.  These have been observed in 
wound healing associated with deep and superficial burns and full thickness 
wounds (Molan 2002) and in other ailments such as inflammatory bowel 
conditions (Prakash, Medhi et al. 2008).  Section 1.6.7 discusses the anti-
inflammatory activity in more detail. 
 
The investigations for this thesis are based upon the effect honey has on the 
inflammatory stage of tissue repair.  Therefore this chapter reviews the active 
components of the immune system involved in wound healing and the 
therapeutic effects of honey.   
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1.2  The Immune system 
The immune system plays an integral role in successful wound healing after 
injury (Park and Barbul, 2004).  Park and Barbul (2004) state that the immune 
system is designed to defend the body against foreign or dangerous substances 
that invade it or to recognise damaged tissue due to wounds or burns. This is 
achieved with controlled inflammation.  Inflammation (from the Latin, 
inflammare, to set on fire) is a complex biological response to harmful stimuli or 
irritants or to necrotic tissue.  Inflammation is a protective attempt by the 
organism to remove the injurious stimuli or debris and to initiate the healing 
process.  
The wound healing process can be subdivided into three consecutive and 
overlapping stages:  inflammation, new tissue formation and remodelling 
(Gurtner, Werner et al. 2008).  The transition through the stages is dependent on 
the maturation and differentiation of the main cell populations involved.  Of 
interest to the study in this thesis is the inflammation stage.  Substances which 
induce inflammation include micro-organisms (bacteria, viruses and fungi), 
parasites (such as worms), cancer cells and even transplanted organs and tissues.   
The first line of defence against invaders is mechanical or physical barriers - the 
skin, conjunctiva of the eye cornea and membranes lining the respiratory, 
digestive, urinary and reproductive tracts.  If a barrier is broken, for example 
open wounds or burns on skin, the risk of infection is increased.  The first event 
after injury is the formation of a blood clot.  To prevent blood loss, blood vessels 
constrict within seconds after wounding, platelets aggregate and clotting and 
complement cascades are activated (Midwood, Williams et al. 2004).  The clot 
serves as a temporary protection of the wound.  Platelets are one of the earliest 
sources of cytokines which mediate macrophage activation and chemotaxis to 
the wound site.  TGF-β and PDGF are two of the cytokines released by platelets 
in the clot to act as chemo-attractants.  Platelets also release thrombin which 
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stimulates the release of pro-inflammatory cytokines like IL-6 and IL-8 from 
endothelial cells which induce monocyte chemotaxis (Marin, Montero-Julian et 
al. 2001).   
 
The next line of defence is initiated with the newly recruited white blood cells 
that travel through the bloodstream and into tissues searching for and 
immobilising micro-organisms.  This defence has two parts: specific and non-
specific immunity.  These two parts interact, influencing each other directly or 
through substances that attract or activate other cells of the immune system, 
part of the mobilisation step of defence.  There is a predictable sequence of 
immune cell migration into the wound which is vital to the regulation of the 
wound-healing process through the secretion of signalling molecules (Park and 
Barbul 2004) called cytokines, chemokines, and lipid derived mediators such as 
prostaglandins, leukotrienes and platelet-activating-factor amongst others. Such 
molecules are released from the cell sending the signal, cross the gap between 
cells by diffusion, and interact with specific receptors in another cell, triggering a 
response in that cell by activating a series of enzyme-controlled reactions which 
lead to changes inside the cell, rather than from physico-chemical effects on the 
plasma membrane or other membranes of the cell. 
   
The term professional phagocytes can be used to describe both macrophages 
and neutrophils, as these are considered to have phagocytosis as their primary 
function.  Professional phagocytes are essentially the main responding cells to 
the signalling molecules. 
 
1.2.1  Neutrophils 
Neutrophil granulocytes, generally referred to as neutrophils, are the most 
abundant type of white blood cell (~70% of all white blood cells) and form an 
integral part of the immune system.  They are normally found in the blood 
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stream.  However, during the acute phase of inflammation, particularly as a 
result of infection, neutrophils leave the vasculature and migrate to the site of 
infection by chemotaxis, becoming highly motile, and act within an hour of the 
insult (Gelderman et al. 1998).  During an inflammatory response neutrophils are 
the first cells to infiltrate the wound. Their role is primarily phagocytosis and 
wound debridement.  Within 24 hours neutrophils become the dominant 
leukocyte in the wound.   
 
Unlike the longer-living macrophages, non-activated neutrophils in the 
circulation live for 4-10 hours and 1-2 days in the tissue upon activation from 
pathogenic stimuli (Rico, Ripamonti et al. 2002).  They only execute one 
phagocytic event, expending all their glucose content in an extremely vigorous 
“respiratory burst”.  The respiratory burst involves the activation of an NADPH 
oxidase enzyme, which produces large quantities of superoxide, a reactive 
oxygen species.  Superoxide is toxic to pathogens but can also lead to tissue 
damage, prolonging the inflammatory event, and can also be converted to 
hydrogen peroxide (H2O2) which gives rise to very reactive hydroxyl radicals 
(•OH) (Cathcart 2004).  Neutrophils communicate the inflammatory status to 
other immune cells using ROS, cytokines and chemokines, recruiting them to the 
site.  Although they contribute to decreasing the likelihood of infection in the 
wound, neutrophils are not paramount to the overall process of wound healing 
(Butterfield, Best et al. 2006). 
 
1.2.2  Monocytes and macrophages 
Macrophages develop from a type of white blood cell called monocytes, after 
monocytes are signalled to leave the bloodstream to enter tissues (Silva, de Assis 
et al. 2002).  These transformed monocytes, now termed macrophages, migrate 
into the wound 48 to 96 hours after injury and become the predominant cell 
population before fibroblast migration and replication (Park and Barbul 2004).  
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Over a period of approximately eight hours, monocytes greatly enlarge and 
develop into macrophages.  Macrophages stay in the tissues and ingest foreign 
and damaged cells, and are important in participating in and concluding the 
inflammatory and debridement process.  Impaired wound debridement and 
fibroplasia occur in guinea pigs treated with anti-macrophage serum and steroids 
to fully deplete circulating monocytes (Leibovich and Ross 1975).   
Macrophages are phagocytic and secretory cells, vital to the regulation of 
immune responses and the development of inflammation.  After digesting a 
pathogen, a macrophage will present the antigen of the pathogen to a 
corresponding helper T cell.  The presentation is done by integrating it into the 
cell membrane and displaying it to other T cells.  Eventually the antigen 
presentation to the T cells results in the production of antibodies by the B cells 
that attach to the antigens of other circulating identical pathogens, making it 
easier for macrophages to adhere to and phagocytose the pathogen.  This is a 
process termed opsonisation.  In some cases, pathogens are very resistant to 
adhesion by the macrophages. Some receptors on the macrophages are believed 
to function in innate immunity by recognizing unopsonised microorganisms 
bearing terminal mannose, fucose, N-acetylglucosamine, or glucose residues on 
surface oligosaccharides (Celli and Finlay 2002).  Most mammalian cells and 
serum glycoproteins do not express terminal mannose-bearing carbohydrate.  
Macrophages have evolved receptors that recognize and directly bind these 
terminal residues.  Engagement of these receptors is termed opsonin-
independent phagocytosis (Celli and Finlay 2002).  Relevant to the research in 
this thesis is the stimulation of Toll-like receptor 4 (TLR4) by lipopolysaccharide 
(LPS) found in the outer membrane of Gram-negative bacteria which induces the 
release of critical pro-inflammatory cytokines that are necessary to activate 
potent immune responses (Lu, Yeh et al. 2008).  TLR4 plays a pivotal role in the 
induction of inflammatory responses. TLR4 activation by LPS is achieved by the 
coordinate and sequential action of three other proteins, LPS binding protein, 
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CD14 and MD-2 receptors, that bind LPS and present it to TLR4 by forming the 
activated (TLR4-MD-2-LPS)(2) complex (Peri and Piazza 2011). 
A major contribution of macrophages to wound healing is the secretion of 
cytokines, complement proteins and growth factors.  These substances activate 
and recruit other cells and regulate fibroblast chemotaxis, proliferation and 
collagen synthesis (Wahl 1985).  Macrophages also express inducible nitric oxide 
synthase (iNOS) and are a source of nitric oxide production in the early phase of 
wound healing (Schaffer, Tantry et al. 1997; Reichner, Meszaros et al. 1999; Lee, 
Efron et al. 2001).  The importance of nitric oxide in this process surpasses its 
antimicrobial functions (Efron, Most et al. 2000).  In murine models, inhibition of 
iNOS significantly impairs re-epithelialisation (Stallmeyer, Kampfer et al. 1999), 
reduces the rate of closure of full thickness wounds (Yamasaki, Edington et al. 
1998), and decreases collagen deposition (Schaffer, Tantry et al. 1999).   
Occasionally, inflammation is not controlled and macrophages especially are 
responsible for chronic inflammation developing.  Macrophages produce large 
quantities of reactive oxygen species (ROS) upon activation, due to the increased 
energy requirements for membrane reorganization required for actin 
polymerisation during phagocytosis (Castellano, Chavrier et al. 2001; Novo and 
Parola 2008) and produce it for directly killing pathogens (Slauch 2011).  Many 
signalling pathways that have a ROS signal component can be overloaded, with 
excess ROS upsetting the balance and control of feedback loops, self-amplifying 
the inflammatory response by oxidative activation of nuclear transcription factor  
NF-κB, which then promotes the production of pro-inflammatory cytokines from 
leukocytes (Iles and Forman 2002). 
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1.2.3  Involvement of macrophages in symptoms of diseases 
Due to their role in phagocytosis, macrophages are involved in many diseases of 
the immune system.  Two cell populations of macrophages perform multiple 
functions at various times in the inflammatory process.  The pro-inflammatory 
classically activated macrophages (M1) are most prominent within necrotic 
tissue as early as 1 day after neutrophil invasion and are activated by the pro-
inflammatory cytokines, such as TNF-α and IL-1β.  This cell signalling serves to 
magnify the macrophage response in the tissue but may also recruit additional 
neutrophils, resulting in a positive pro-inflammatory feedback loop (Mantovani, 
Sica et al. 2004).   
Once pro-inflammatory macrophages are activated, they contribute to the 
exacerbation of inflammation by producing and releasing more than 100 
substances, including pro-inflammatory cytokines such as IL-1β and 
prostaglandins (Scott, Khan et al. 2004).   
The alternately activated M2 macrophages appear during the latter stages of 
inflammation and can be divided into three sub-populations:  M2a macrophages 
which promote a Th2 type of inflammation resulting in increased IgE as observed 
in allergy and parasite immunity; M2b macrophages, that promote Th2 
inflammation and bear some immune-regulation properties; and the deactivated 
macrophages, M2c which are able to control the inflammation and are 
implicated in tissue remodelling (Mantovani, Sica et al. 2004).    The primary role 
for M2 macrophages is tissue repair through cell signalling and cytokine 
production, releasing a series of growth factors such as fibroblast growth factor, 
insulin-like growth factor, and transforming growth factor-β1, essential for tissue 
repair and regeneration (Butterfield, Best et al. 2006).   
Pro-inflammatory macrophages participate in the formation of granulomas, 
inflammatory lesions that may be associated with and/or reflect chronic 
inflammation (Levine, Smith et al. 2005).  Macrophages are the predominant 
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cells involved in creating the progressive plaque lesions of atherosclerosis (Tabas 
2009). 
1.3  Immunity 
To be able to eradicate invaders of the body, the immune system must first 
recognise them.  Distinguishing self from non-self is important here.  The 
immune system can make this distinction as all cells have identification 
molecules on their surface (antigens).  Antigens may be contained within or on 
bacteria, viruses, other micro-organisms or cancer cells.  Antigens may also exist 
on their own, for example, as pollen or food molecules.  A normal immune 
response consists of recognising a foreign antigen or damaged tissue, mobilising 
forces to defend against it and attacking it.  The immune system can make a 
distinction between foreign invading antigens and the body’s own familiar 
antigens.  When a foreign antigen is found, the immune system attacks that cell.  
B and T lymphocytes need help from other cells in the immune system to 
recognise invaders.  Two immune categories are at work here, specific and non-
specific. 
1.3.1  Specific immunity 
Specific immunity is often sub-divided into two major types depending on how 
the immunity was introduced.  Naturally acquired immunity which occurs 
through contact with a disease causing agent, when the contact was not 
deliberate and artificially acquired immunity which develops only through 
deliberate actions such as vaccination (Pulendran and Ahmed 2006). Both 
naturally and artificially acquired immunity can be further subdivided depending 
on whether immunity is induced in the host or passively transferred from an 
immune host. Passive immunity is acquired through transfer of antibodies or 
activated T-cells from an immune host, and is short lived, usually lasting only a 
few months, for example the transfer of maternal antibodies across the placenta 
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to the fetus (Keller and Stiehm 2000).  Active immunity is induced in the host 
itself by antigen, and lasts much longer, sometimes life-long (Pulendran and 
Ahmed 2006).  The specific (or adaptive) immune system acts as a second line of 
defence to the innate immune system and affords protection against re-
exposure to the same pathogen.  Specific immunity takes time to develop after 
lymphocytes are exposed to a new antigen.  However, because a memory is 
formed, subsequent responses to a previously encountered antigen are more 
rapid than those generated by an un-encountered antigen.  Lymphocytes enable 
the body to remember antigens and to distinguish self from non-self.  This 
lymphocyte memory can continue for years or even decades (Schmidlin, Diehl et 
al. 2009) preventing certain diseases from recurring.  Lymphocytes include B 
lymphocytes, T lymphocytes and natural killer cells (involved in non-specific 
immunity). 
1.3.1.1  B-Lymphocytes 
The abbreviation "B", in B cell, comes from the ‘bursa of fabricius’ in birds, where 
they mature. In mammals, immature B cells are formed in the bone marrow, 
which is used as a backronym for the cells' name.  After reaching the IgM+ 
immature stage in the bone marrow, these immature B cells migrate to the 
spleen, where they are called transitional B cells, and some of these cells 
differentiate into mature B lymphocytes (Allman, Srivastava et al. 2004).  B-
lymphocytes have receptors for specific antigens recognition.  When an antigen 
attaches to a receptor on a B-lymphocyte, the B-lymphocyte is stimulated to turn 
into a plasma cell which, in turn, produces antibodies.  These antibodies are 
specific to the antigen that stimulated their production. Based solely on 
histological studies the role of these cells is unclear and, given the absence of 
activating factors, B-lymphocytes are unlikely to play a significant role in the 
regulation of wound healing (Park and Barbul 2004). 
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1.3.1.2  T-Lymphocytes 
T-Lymphocytes are white blood cells that are made in the bone marrow but 
matured in the thymus gland.  They circulate in the blood stream and can attack 
particular or abnormal cells.  They can be distinguished from other lymphocyte 
types by the presence of a special receptor on their cell surface called T cell 
receptors (TCR).  The T cell receptor exists as a complex of several proteins. The 
actual T cell receptor is composed of two separate peptide chains, which are 
produced from the independent genes for T cell receptor alpha and beta (TCRα 
and TCRβ). The other proteins in the complex are the four CD3 proteins; CD3γ, 
CD3δ and two CD3ε which associate with the TCR.  T-lymphocytes migrate into a 
wound after inflammatory cells and macrophages, on the fifth day following 
injury and peak at day seven (Fishel, Barbul et al. 1987).  Several different 
subsets of T cells have been discovered, each with a distinct function: 
 
1. Cytotoxic T cells (TC cells) which recognise and destroy foreign cells by 
injecting enzymes into the abnormal cell. They are also known as CD8+     
T cells since they express the CD8 glycoprotein at their surface (Walsh, 
Gleeson et al. 2011). 
 
2. T-helper cells (TH cells) which help B-lymphocytes recognise and produce 
antibodies against foreign cells.  TH cells assist other white blood cells in 
immunologic processes, including maturation of B cells into plasma cells 
and B memory cells, and activation of cytotoxic T cells and macrophages, 
among other functions. These cells can differentiate into one of several 
subtypes, including TH1, TH2, TH3, TH17 or TFH which secrete different 
cytokines to facilitate a different type of immune response (Walsh, 
Gleeson et al. 2011).  
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3. Regulatory T cells (Treg cells), are crucial for the maintenance of 
immunological tolerance. Their major role is to shut down T cell-mediated 
immunity toward the end of an immune reaction and to suppress auto-
reactive T cells that escaped the process of negative selection in the 
thymus (Walsh, Gleeson et al. 2011). 
 
4. Memory T cells are a subset of antigen-specific T cells that persist long-
term after an infection has been resolved. They quickly expand to large 
numbers of effector T cells upon re-exposure to their cognate antigen, 
thus providing the immune system with "memory" against past 
infections.  Memory T cells comprise two subtypes: central memory T 
cells (TCM cells) and effector memory T cells (TEM cells) (Walsh, Gleeson et 
al. 2011). 
 
T-lymphocytes that develop without the ability to distinguish self from non-self 
are responsible for auto-immune disorders in which the body’s own tissues are 
attacked. 
1.3.2  Non specific immunity 
Non-specific (innate) immunity is present at birth.  Non-specific immunity 
components treat all the foreign substances they encounter in much the same 
way.  The white blood cells involved in non-specific immunity are monocytes, 
neutrophils, eosinophils, basophils and natural killer cells.  Each type has a 
slightly different function.  The complement system and cytokines also 
participate in non-specific immunity. 
1.3.2.1  Eosinophils 
Eosinophils can ingest bacteria and other foreign cells.  However they are less 
active against bacteria than are neutrophils and macrophages.  Their main 
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function may be to attach to and immobilize invaders, allowing the macrophages 
and neutrophils to destroy them.  Eosinophils, like neutrophils, freshly isolated 
from blood, are capable of responding vigorously to chemokines (Ponath, Qin et 
al. 1996).  Following activation the effector functions of eosinphils include 
production of growth factors, ROS and cytokines.  Eosinophils also produce 
RNases, contained within their granules which combat virus infections and also 
play a role in fibrin removal during inflammation (Rothenberg and Hogan 2006). 
1.3.2.2  Basophil granulocytes 
Basophil granulocytes, sometimes referred to as basophils, are the least common 
of the granulocytes, representing about 0.01% to 0.3% of circulating white blood 
cells.  Basophils do not ingest foreign cells.  They contain granules that release 
the vasodilator histamine which promotes blood flow to tissues and produce 
substances that attract neutrophils and eosinophils to the wound site.  Basophils 
also contain the anticoagulant heparin, which prevents blood from clotting too 
quickly.  Basophils have been shown to constitute a significant source of 
cytokines (IL-4 and IL-13) which play a major role in the pathogenesis of allergic 
disease, and may modulate T-helper 2-type inflammation at the level of T 
cell/dendritic cell interactions (Schroeder and Frederick 2009). 
1.3.2.3  Natural killer cells 
Natural killer cells are lymphocytes that attach to receptors on foreign cells and 
release enzymes and other substances that damage the outer cell membrane of 
the foreign cell.  They are often the first type of cell to destroy invading cells as 
they are ready to kill as soon as they are formed.  Natural killer cells also produce 
cytokines that regulate some of the functions of T lymphocytes, B lymphocytes 
and macrophages (Park and Barbul 2004). 
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1.3.2.4  Mast cells 
Mast cells express critical effector functions in classic IgE-associated allergic 
disorders, but also play important roles in host defence against parasites and 
bacteria.  Mast cells can contribute to host defence in the context of either 
acquired or innate immune responses through the release of a myriad of pro-
inflammatory and immunoregulatory molecules and the expression of a wide 
spectrum of surface receptors for cytokines and chemokines. Mast cells also 
exert distinct non-immunological functions, playing a relevant role in tissue 
homeostasis, remodeling and fibrosis as well as in the processes of tissue 
angiogenesis (Park and Barbul 2004). 
1.3.2.5 The complement system 
The complement system is one of the major mechanisms by which pathogen 
recognition is converted into an effective host defence against initial infection. 
Complement is a system of more than 30 plasma proteins that can be activated 
directly by pathogens or indirectly by pathogen-bound antibody, leading to a 
cascade of reactions that occurs on the surface of pathogens and generates 
active components with various effector functions. Complement proteins can 
work as chemo-attractants, kill bacteria directly (cell lysis) or help destroy 
bacteria by attaching to them making them easier to detect for macrophages and 
neutrophils (opsonisation).  They can also cause bacteria to clump together, and 
neutralise viruses by altering the molecular structure of the virus (Mastellos, 
Morikis et al. 2003).   Three biochemical pathways activate the complement 
system: the classical complement pathway, the alternative complement 
pathway, and the mannose-binding lectin pathway. 
The classical pathway is triggered by antigen-bound antibody molecules, IgG or 
IgM. The initial enzyme, C1, is a complex formed through a calcium-dependent 
association between two reversibly interacting subunits, C1q and C1 (C1qr2s2) 
(Kishore and Reid 2000).  It is the binding of a specific part of the antibody 
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molecule to the C1 component that initiates this pathway (Mastellos, Morikis et 
al. 2003). 
The alternative pathway is triggered by spontaneous hydrolysis of the protein 
complement-component-3 (C3) to form protein fragments C3a and C3b. It does 
not rely on pathogen-binding antibodies like the other pathways.  Macrophages 
and neutrophils possess receptors for C3b, so cells coated with C3b are targeted 
for phagocytosis (opsonization) (Janeway, Travers et al. 2001). 
The lectin pathway is homologous to the classical pathway, but with the opsonin, 
mannose-binding lectin (MBL), and ficolins, instead of C1q. This pathway is 
activated by the binding of mannose-binding lectin to mannose residues on the 
pathogen surface, which activates the MBL-associated serine proteases, MASP-1, 
and MASP-2 (very similar to C1r and C1s, respectively), which can then split C4 
into C4a and C4b and C2 into C2a and C2b. C4b and C2b then bind together to 
form the C3-convertase, as in the classical pathway (Janeway, Travers et al. 
2001). 
1.3.3  Dendritic cells 
The main function of dendritic cells is antigen presentation to other cells of the 
immune system bridging innate and adaptive immunity.  Two main types of 
dendritic cells have been identified, myeloid or plasmacytoid.  The myeloid 
dendritic cell is similar to a monocyte and is made up of at least two subsets: (1) 
the more common myeloid dendritic cell-1, which is a major stimulator of T cells 
and (2) the extremely rare myeloid dendritic cell-2, which may have a function in 
fighting wound infection (Schuurhuis, Fu et al. 2006).  Once activated, they 
migrate to the lymph nodes where they interact with T cells and B cells to initiate 
the adaptive immune response. At certain development stages they grow 
branched projections, the dendrites, that give the cell its name (δένδρον or 
déndron being Greek for "tree".  Dendritic cells produce cytokine IL-12, amongst 
others, a signal that helps send naive CD4 T cells towards a Th1 phenotype 
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activating the immune system against the antigens which the dendritic cell 
presents on its surface (Schuurhuis, Fu et al. 2006). 
1.4  Cytokines 
Cytokines are messengers of the immune system.  White blood cells and certain 
other cells of the immune system produce cytokines when an antigen is 
detected.  There are many types which affect different parts of the immune 
system.  Cytokines may stimulate or inactivate activity of the immune system, 
attract cells to damaged tissues (chemokines), or help end the immune response.  
Chemokines (chemotactic cytokines) are classified according to shared structural 
characteristics such as small size (they are all approximately 8-10 kilodaltons in 
size), and the presence of four cysteine residues in conserved locations that are 
key to forming their 3-dimensional shape. Some chemokines are considered pro-
inflammatory and can be induced during an immune response to recruit cells of 
the immune system to a site of infection, while others are considered 
homeostatic and are involved in controlling the migration of cells during normal 
processes of tissue maintenance or development (Laing and Secombes 2004). 
1.4.1  Interleukins 
Interleukins are a group of cytokines that were first seen to be expressed by 
white blood cells (leukocytes, hence the leukin) as a means of communication 
(inter-).  It has since been found that a wide variety cells produce interleukins.  
The function of the immune system depends, in a large part, on interleukins, and 
rare deficiencies of a number of them have been described, all featuring auto-
immune diseases or immune deficiency.  Of interest to this study are the 
interleukins IL-1β and IL-6 secreted by macrophages, and IL-8 involved in 
neutrophil chemotaxis and IL-10 which inhibits cytokine production in Th1 cells.  
It is important to note that some cytokines have both pro- and anti-inflammatory 
effects.  The net effect of an inflammatory response is determined by the 
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balance between pro-inflammatory cytokines and anti-inflammatory cytokines. 
The cytokine TNF-α has both pro- and anti-inflammatory properties.  It has been 
shown that TNF-α induces the release of the type II IL-1, which represents a 
unique pathway of negative regulation of the IL-1 system resulting in a net anti-
inflammatory effect (Orlando, Matteucci et al. 1997). 
1.4.2  Anti-chemokine therapy 
CCL5 and CCL2 (small cytokines belonging to the CC chemokine family) are 
mediators of acute inflammatory responses (Castellani, De Lutiis et al. 2010).  
CCL5 is an 8kDa protein classified as a chemokine also known as RANTES 
(Regulated upon Activation, Normal T-cell Expressed, and Secreted). CCL5 is 
chemotactic for T cells, eosinophils, and basophils, and plays an active role in 
recruiting leukocytes into inflammatory sites in conjunction with particular 
cytokines (i.e., IL-2 and IFN-γ) that are released by T cells.  CCL5 also induces the 
proliferation and activation of certain natural-killer (NK) cells to form CHAK (CC-
Chemokine-activated killer) cells.  CCL5 is strongly induced by viral and bacterial 
infections and plays a role in allergic diseases, in exacerbation of asthma, in 
interstitial pneumonia, in allograft rejection and in cancers.  CCL2 is also known 
as monocyte chemotactic protein-1 (MCP-1) and small inducible cytokine A2. 
CCL2 recruits monocytes, memory T cells, and dendritic cells to sites of tissue 
injury, infection, and inflammation (Castellani, De Lutiis et al. 2010).   
These chemokines have become targets for diagnostic procedures and 
therapeutic intervention, for example, administration of anti-CCL2 antibodies in 
a model of glomerulonephritis have shown reduced macrophage and T cell 
infiltration, as well as reduced scarring and renal impairment (Castellani, 
Bhattacharya et al. 2007).   Treatment with the anti-CCL5 antibodies results in 
reduced circulating levels of chemokines and a reduction of neutrophil and 
macrophage infiltration in models of atherosclerosis (Montecucco, 
Braunersreuther et al. 2011). 
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1.5  Inflammation 
Without inflammation, wounds and infections would never heal. Similarly, 
progressive destruction of the tissue would compromise the survival of the 
organism. Inflammation can be classified as either acute or chronic. Acute 
inflammation is the initial response of the body to harmful stimuli and is 
achieved by the increased movement of plasma and leukocytes from the blood 
into the affected area. A cascade of biochemical events propagates the 
inflammatory response involving the local vascular system, the immune system, 
and various cells within the injured tissue.  Early on in this cascade, phagocytic 
cells such as macrophages and neutrophils, recognise and remove the 
inflammatory stimuli.  Once the stimulus is removed, the inflammation subsides. 
However, excessive and prolonged (chronic) inflammation in wounds, when the 
stimulus is not removed, leads to a progressive shift in the type of cells present 
at the site of inflammation and is characterized by simultaneous destruction and 
healing of the tissue from the inflammatory process.  ROS released by phagocytic 
cells, attempting to remove the initial inflammatory stimuli, play a major role in 
chronic inflammation by generating harmful feedback loops preventing the 
resolution of inflammation.  Chronic inflammation can cause pain, ulceration, 
scarring and fibrosis and result in non-healing wounds (Singer and Clark 1999; 
Menke, Ward et al. 2007). It is for that reason that inflammation is normally 
closely regulated by the body.  Anti-inflammatory agents therefore are of great 
importance to medicine. 
1.5.1 Anti-inflammatory agents 
Anti-inflammatory refers to the property of a substance or treatment that 
reduces inflammation, remedying pain, as opposed to opioids, which affect the 
central nervous system.  Several main types of anti-inflammatory agents used to 
control inflammation with are briefly discussed here.  As mentioned previously, 
Chapter 1                                                   Introduction 
20 
 
wounds must progress through three distinct phases of healing: acute, 
proliferative, and remodelling, yet these wound healing processes can be 
vulnerable to inhibition by drug therapy and therefore new anti-inflammatory 
agents that do not inhibit these processes are being sought. 
 
1.5.1.1  Corticosteriods 
Corticosteroids reduce inflammation or swelling by binding to glucocorticoid 
receptors. Corticosteroids can inhibit fibroplasia, vascular proliferation, and 
wound contraction in soft tissue healing (Karukonda, Flynn et al. 2000).  
1.5.1.2 Non-steroidal anti-inflammatory drugs 
Non-steroidal anti-inflammatory drugs (NSAIDS) are agents/analgesics such as 
aspirin and ibuprofen.  These medications relieve pain by blocking the 
production of pain-signaling molecules. One of the steps in this pathway involves 
certain types of cyclo-oxygenase (COX) enzymes. By blocking the COX-2 type, 
NSAIDs relieve pain felt in joints, muscles, and other soft tissues (McDaid, Maund 
et al. 2010).  NSAIDS and COX-2-selective inhibitors may impair the acute phase 
of healing and compromise the normal process of wound healing (Karukonda, 
Flynn et al. 2000). 
1.5.1.3  Herbs 
Certain herbs have been investigated extensively for their anti-inflammatory 
qualities based on age old remedies, including Harpagophytum, hyssop, ginger, 
turmeric (Aggarwal 2010), Arnica montana (Zhao, Lee et al.), and willow bark, 
which contains salicylic acid, the active ingredient in aspirin (Jones 2011). 
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1.5.1.4  Immune Selective Anti-Inflammatory Derivatives 
The immune selective anti-inflammatory derivatives (ImSAIDs) represent a new 
category of anti-inflammatory and are unrelated to steroid hormones or non-
steroidal anti-inflammatory agents.  ImSAIDs have diverse biological properties, 
including anti-inflammatory properties.  ImSAIDs work by altering the activation 
and migration of leukocytes responsible for amplifying the inflammatory 
response (Bao, John et al. 2006). 
1.6   Honey  
Honey is a commercial product of the bee hive, along with propolis, royal jelly 
and bee venom.  Made from a wide range of nectar gathered and processed by 
the honeybee (Apis mellifera) its content varies greatly but generally consists of 
sugars, vitamins, minerals and bee proteins along with phytochemicals that act 
as antioxidants (Gheldof, Wang et al. 2002).  Compelling research has been 
presented on the healing properties of honey with its antibacterial and anti-
inflammatory activities.   
 
1.6.1  Anti-bacterial activity of honey 
Infection of wounds by micro-organisms have been successfully cleared by 
honey, demonstrating its anti-bacterial activities (Molan 2009).  Even antibiotic 
resistant strains of bacteria have been successfully cleared from wounds (Vardi, 
Barzilay et al. 1998; Dunford, Cooper et al. 2000a).   Briefly the known 
antibacterial properties of honey are as follows: 
1.6.1.1  Osmotic effects 
The high sugar content of honey inhibits microbial growth.  The low water 
content (15-21%) deprives bacteria of the water needed for cells to function 
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(Willix,  Molan et al., 1992; Chirife,  Scarmato et al., 1982), and can draw water 
out of bacterial cells by osmosis (Manjo, 1975).  This has been demonstrated by 
using artificial honey solutions containing the same proportions of sugars as 
honey, and measuring bacterial inhibition (Postmes, van den Bogaard et al., 
1993). 
1.6.1.2  Hydrogen peroxide 
Hydrogen peroxide is a well-known antibacterial molecule and a key component 
in honey (Weston, 2002; Molan, 1992; Bang, Buntting et al., 2003).  Honey 
contains the enzyme glucose oxidase which is secreted into the nectar by bees 
when honey is made.  It is this enzyme that produces hydrogen peroxide from 
glucose and oxygen (White, 1975). 
1.6.1.3  Acidity 
During the ripening of nectar into honey, the action of glucose oxidase also 
produces gluconolactone/gluconic acid which gives honey its characteristically 
low pH of 3.2-4.5 (White, 1975).  This means honey has a lower pH than the 
tolerated values for survival by many wound-infecting bacteria (e.g. 
Pseudomonas aeruginosa, pH 4.4, Escherichia coli, 4.3, Salmonella sp. 4.0) 
(Molan 1992 a).  
1.6.1.4  Non-peroxide anti-bacterial components 
The non-peroxide antibacterial activity (NPA) found in Manuka honey has proven 
to be a very effective antibacterial component and the major part of this activity 
has been attributed to the methyglyoxal content (MGO) (Adams, Boult et al. 
2008; Mavric, Wittmann et al. 2008).  Manuka honey also has very high amounts 
of MGO, ranging from 38 to 828 mg/kg, which is up to 100-fold higher compared 
with non-Manuka honeys (Adams, Boult et al. 2008).  Other components have 
been isolated from honey with anti-bacterial properties (e.g. chrysin, 
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pinobanksin and pinocembrin (Marcucci, Ferreres et al. 2001)) but are thought to 
have ineffective low concentrations in honey. 
 
1.6.2  Variation between honey types 
There is a demonstrated variation in antibacterial activity between honeys 
obtained from different floral origins and geographical sources that confirm 
different honey types will have different antibacterial properties (Allen, Molan et 
al., 1991; Farouk, Hassan et al., 1988; Molan, 1992b).  For example, Manuka 
honey is high in NPA but low in hydrogen peroxide activity whereas Pasture 
honey has the opposite profile (Willix, 1992).   
 
Variation also exists in the antioxidant content of honey.  Antioxidants, which are 
abundant in natural honey, are free-radical scavengers that either reduce the 
formation of or neutralize free radicals and determined to be due to the phenolic 
compounds in honey (Kishore, Halim et al. 2011; Tonks, Cooper et al. 2001).   
 
Honeys immuno-stimulatory activity has also been determined to be variable, 
most notably by increasing inflammatory cytokine release in monocytes (Tonks, 
Cooper et al. 2003). 
 
1.6.3  Honey promotes tissue repair as a cell growth stimulant 
There is existing evidence for honey as a cell growth stimulant (Lusby et al., 
2002; Wood et al., 1997).  Though the mechanisms have been speculated, they 
have not been identified.  Recent relevant work showed that 1% Manuka honey 
concentrations stimulated epithelial cell division in a respiratory epithelial cell 
line model (Harcourt, 2005).  Increasing concentrations beyond this had no 
effect.  Adding to this, tumor necrosis factor α (TNF-α), IL-1β and IL-6 cytokine 
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release is increased following stimulation with honey and these cytokines have 
been determined to promote the healing process in wounds (Tonks, Cooper et al. 
2003). 
 
Honey has also been demonstrated to: promote the development of connective 
tissue around regenerating blood vessels (Subrahmanyam, 1998; Efem, 1993; 
Efem, 1988), stimulate formation of epithelial cover (Misirlioglu, Eroglu et al., 
2003; Topham, 2002), stimulate collagen synthesis and stimulate new 
development of blood vessels to increase oxygenation (Kumar, Sharma et al., 
1993).  Nutrient supply may also be increased along with the osmotic outflow of 
lymph (Lusby, Coombes et al., 2002).   Compared with sugar alone, it appears 
that honey has a superior ability to promote re-epithelialisation (Bose, 1982).   
1.6.4  Honey as an immune stimulant 
There is evidence that honey may reduce infection by stimulating the immune 
system.  Studies by Arbuharfeil et al. (1999) have shown that honey stimulates 
the proliferation of B and T lymphocytes and activates neutrophils. Al-Waili 
(2003) showed that oral ingestion of honey increased the number of circulating 
monocytes and lymphocytes in blood.   Honey has been found to stimulate 
monocytes in vitro to release TNF-α (Tonks, Cooper et al. 2001).  This was 
determined to be due to a 5.8kD component in honey which acts via the TLR-4 
receptor (Tonks, Dudley et al. 2007).  Honey has also been found to stimulate the 
release of IL-1, IL-6 (Tonks, Cooper et al. 2003) activating the immune response.   
1.6.5  Debriding action 
It has been documented that honey provides a rapid debriding action (removal of 
attached pus and dead cells) on wounds (Molan 2009).  It has been suggested 
that this is due to the flushing effect that occurs as lymph is drawn out by the 
osmotic action of sugars (Topham, 2002; Molan 2009), although it has also been 
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suggested that it may be due to the stimulation of proteolysis (Molan 2009).  This 
osmotic activity also lifts dead tissue from the wound bed, eliminating the need 
for surgical debridement.  Debridement of the wound is crucial as a 
contaminated wound cannot heal due to the growth of bacteria in the dead 
tissue (McInerney, 1990; Cavanagh, Beazley et al., 1970).   
1.6.6  Reduction of scar formation 
Honey also provides a moist environment essential for the healing of wounds as 
protein-digesting enzymes function more effectively (Molan, 2001; Bradley, 
Cullum et al., 1999; Archer, Barnett et al., 1990).  In these moist conditions 
fibroblast proliferation is also optimised as is keratinocyte migration across the 
wound bed to restore epithelial cover.  This reduces the likelihood of a scar 
forming (Misirlioglu, Eroglu et al., 2003; Niessen, Spauwen et al., 1999).  It has 
been observed (Topham, 2002) that honey is associated with scar-free healing. 
1.6.7  Anti-inflammatory evidence 
An anti-inflammatory effect of honey has been observed clinically in numerous 
reports where it has been applied to wounds.  Localised swelling, redness, pain 
and heat associated with inflammation were reduced (Molan, 1999).   In clinical 
studies there have been direct evidence of anti-inflammatory activity obtained in 
the form of decreased levels of malondialdehyde (Subrahmanyam, Sahapure et 
al. 2001) and histological observation of reduced numbers of inflammatory cells 
present in biopsy samples (Subrahmanyam 1998) in clinical trials where burns 
were dressed with honey compared with silver sulfadiazine.  Microscopic 
examination confirmed that the application of honey to tissues significantly 
reduced the leukocyte count (Postmes, Bosch et al., 1997).  In studies by 
Postmes and Bosch et al. (1997); Kumar and Sharma et al. (1993) and Oryan and 
Zaker et al. (1998) reduction of inflammation in wounds where honey was 
applied was taken as evidence that honey had a direct anti-inflammatory effect.  
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As infection was not present, the observed anti-inflammatory effect could not 
have been due to any removal of bacteria promoting inflammation.   
 
Though the process by which honey acts as an anti-inflammatory agent has yet 
to be demonstrated, processes have been speculated such as the possibility that 
honey inhibits the prostaglandin synthesis which is often responsible for the 
observed characteristic heat, itchiness and pain associated with inflammation 
(Kassim, Achoui et al. 2010).   
 
Hydrogen peroxide has been proven to stimulate inflammation in separate 
studies by Reth (2002) where it diffused through cell membranes to enter the 
cell nucleus.  Honey has been shown to reduce the ROS levels (Tonks, Cooper et 
al. 2001) promoting wound healing.  The antioxidant content of honey may be 
partially responsible for the observed anti-inflammatory effects. The antioxidants 
in honey were hypothesised to be responsible for inhibition of ROS production 
by activated human PMNs, (van den Berg, van den Worm et al. 2008). 
 
1.7  Research aims of this thesis 
The aim for this thesis was to create an in vitro assay to measure the anti-
inflammatory effect of honey and to characterise this activity.  Initially cytokine 
release was studied as it has been reported that at a 1% concentration, honey is 
immuno-stimulatory increasing the levels of TNF-α, IL-1β and IL-6 (Tonks, Cooper 
et al. 2001, 2003).  A wider range of cytokines and growth factors were 
investigated including the ones used in previous studies: IL-1β, IL-6, IL-10, IL-1ra, 
TGF-β, PDGF, and TNF-α.  Standard PCR and real time quantitative PCR was used 
with LPS stimulated THP-1 cells. 
 
The ROS production from activated monocytes was also studied.  Honey was 
found to reduce ROS levels (Harcourt 2005; Tonks, Dudley et al. 2007) and this 
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was determined to be due to the antioxidants in honey.  To discover if this was 
the only reason for ROS reduction, an assay was created to measure the effect of 
honey on phagocytosis of fluorescent latex beads using LPS stimulated 
immunocompetent THP-1 cells.  As phagocytosis produces ROS, this assay was 
used in conjunction with a method of measuring the ROS release from actively 
phagocytising macrophages.  Observations were made microscopically to 
determine bead uptake. 
 
To identify whether the active component in honey was widespread amongst all 
honey varieties, a honey survey was undertaken, assaying different honey 
varieties using the phagocytosis assay in conjunction with the NPA and other 
relevant qualities.  Correlation was sought between the variables for each honey 
variety to determine if there was an indicator for the anti-inflammatory activity 
in honey. 
 
Next, the component in honey responsible for the observed activity on 
phagocytic cells was isolated and identified using chromatography and matrix-
assisted laser desorption/ionization (MALDI) methods.  A mechanism of action of 
honey was also sought, focusing on the receptor that the active component in 
honey binds to.  
 
An in vivo assay was considered important to the anti-inflammatory research of 
honey.  Therefore the anti-inflammatory properties of honey were further 
investigated using the in vivo assay the hen egg chorioallantoic membrane test 
(HET-CAM) which is a commonly used assay for measuring the anti-inflammatory 
properties of an agent against irritants such as SDS. 
  
 
Chapter 2 
Characterising THP-1 
 
 
 
 
2.1  Summary 
This chapter covers preliminary investigations of the cell line and treatments 
used throughout the research contributing to the thesis.  Several methods were 
utilised to characterise the cell line.   
 
The monocyte cell line THP-1 and three activating cell treatments were 
investigated.  Phorbol-12-myristate-13-acetate (PMA), lipopolysaccharide (LPS) 
and 1,25-dihydroxyvitamin D-3 (Vit-D3) were all used to activate the monocyte 
cells to generate active macrophages.  These three activators were compared for 
their effect on phenotype according to adherence, loss of proliferation, cell 
shape, phagocytosis of latex particles and expression of two macrophage 
markers,  human cartilage group protein-39 (HCgp-39) and carboxypeptidase M 
(CPM),  so that the most effective and efficient treatment could be selected for 
further research. 
 
 LPS was selected for the main activator in further research due to its quick 
activation time, low mortality rate and the ability to produce a highly active and 
phagocytic macrophage.  
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In addition it has been proposed that a previously unknown state of activation 
can be achieved with THP-1. Parts of this research were presented at the 2008 
QMB conference in the form of a poster. 
2.2  Introduction 
The THP-1 human monocyte/macrophage cell line, commonly used by 
researchers to study the response to LPS at various stages in the 
monocyte/macrophage differentiation process, was chosen for the study.  THP-1 
cells have been used in numerous studies investigating cytokine expression and 
phagocytosis.  
 
The THP-1 cell line was cultured from the blood of a one-year-old-boy with acute 
monocytic leukemia (Tsuchiya, Yamabe et al. 1980).  The monocytic nature of the 
cell line was characterized by the presence of alpha-naphthyl butyrate esterase 
activities which could be inhibited by sodium fluoride, lysozyme production, the 
phagocytosis of latex particles and sensitized sheep erythrocytes and the ability 
to restore T-lymphocyte response to Concanavalin A (Con A). This indicated that 
THP-1 was a leukemia cell line with distinct monocytic features. During culture, 
THP-1 maintained these monocytic characteristics for over 14 months, meeting 
the requirements for banking a new cell line, and subsequently the cell line was 
submitted to cell banks (ATCC, TIB-202) for future research. 
THP-1 cells have previously been shown to be an appropriate model for studying 
LPS-induced changes in gene expression. Though THP-1 cells are transformed 
and immortalised, their LPS-induced gene expression signature remains very 
similar to primary monocytes (Sharif, Bolshakov et al. 2007).  Sharif et al. used a 
focussed microarray strategy and real-time PCR to characterise and compare the 
response to LPS in THP-1 cell lines and human PBMC derived macrophages.  They 
found a close correlation between THP-1 cells and PBMC-derived macrophages, 
suggesting they provide a good model system.    
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Research since then has shown THP-1 can differentiate along the monocytic 
lineage following exposure to a range of activators, most commonly LPS 
(Megyeri, Issekutz et al. 1990), PMA,  and Vit-D3 (Schwende, Fitzke et al. 1996) 
forming macrophage-like cells inducing inflammatory responses such as release 
of cytokines,  ROS and promoting cell chemotaxis towards them. 
As mentioned previously, macrophages are central to inflammation and wound 
healing.  They can encourage chronic inflammation by producing inflammatory 
cytokines and reactive oxygen intermediates that cause tissue damage and 
create feedback loops amplifying the inflammation.  Macrophages are 
responsible for the generation of bioactive substances, orchestrating the 
complex processes of cellular proliferation and functional tissue regeneration 
within wounds.  Specific proteins produced by macrophages have a variety of 
functions most importantly, 1) chemo-attractants that recruit and activate 
additional macrophages at the site of injury, 2) growth factors that promote 
cellular proliferation and protein synthesis, 3) proteases and extra-cellular matrix 
molecules, and 4) factors that may restrain tissue growth once repair is 
completed (DiPietro 1995).  
Release of cytokines by monocytes and macrophages stimulates the synthesis 
and secretion of a variety of other cytokines including IL-1 and TNF-α. This 
initiates further pro-inflammatory cytokine release, causes fever by stimulating 
the release of prostaglandins (Dinarello 2000) and activates NF-κB. Additionally 
activated monocytes and macrophages release chemokines which induce 
directed chemotaxis in nearby responsive cells escalating the inflammation (Arai, 
Nishida et al. 1990). 
The literature states that monocyte activation can be determined by observing  
1) loss of proliferation, 2) increased adherence, 3) development of a different 
gene expression profile, 4) the ability to phagocytose latex particles, 5) adoption 
of an irregular cell shape with obvious pseudopodia (Verreck, de Boer et al. 2006; 
Sharif, Bolshakov et al. 2007).    
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Expanding on the observation of morphology changes, Verreck et al. showed that 
type 1 macrophages (M1) typically appear as adherent cells with a classical “fried 
egg morphology” whereas type 2 macrophages (M2) appear as adherent and 
stretched, "spindle-like" cells.  Verreck et al., observed that LPS-activated THP-1 
cells have a very similar gene expression signature to that of primary 
macrophages, even though they are a transformed and immortalised cell, making 
them an ideal cell line for LPS-activated gene expression studies. Other studies 
have found two macrophage phenotypes M1 being classically activated and M2 
being alternatively activated (Van Ginderachter, Movahedi et al. 2006, Martinez, 
Sica et al. 2008).   
Tissue macrophages have many important roles but essentially they are involved 
in phagocytosis of pathogens, the elimination of dying cells and the secretion of 
immune system regulators which influence the physiological functions and 
differentiation of neighbouring cells (Auwerx 1991). 
During the monocyte activation process at the site of inflammation the 
monocyte rolls along the blood vessel wall, slows down and binds to the surface 
of endothelial cells, then moves into sites of inflammation by extravasation of 
capillary walls. This contact is possible due to adhesion molecules (selectins and 
integrins), expressed on the surface of phagocytising and endothelial cells of 
blood vessels upon endothelial activation (Alom-Ruiz 2008).  The phagocytes 
move up the chemo-tactic gradient to accumulate at the site of inflammation to 
initiate the clearance of pathogens.   
There are several types of receptors involved in the recognition of target 
pathogens. These are localized on the surface of the phagocytising cells.  
Examples of these receptors are lectins (proteins binding carbohydrate 
structures), mannose and galactose receptors, receptors for lipopolysaccharide, 
scavenger receptors, Fc receptors for antibodies (binding Fc fragment of 
immunoglobulin) and receptors for complement fragments C3b and iC3b 
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(Newman, Mikus et al. 1991; Allen and Aderem 1996). After adherence of the 
pathogen to the surface of the phagocytising cell the ingestion phase is initiated. 
The ingestion phase is enabled by activating an actin - myosin contractile system 
which extends pseudopodia around the particle. The plasma membrane is pulled 
around the pathogen until the pathogen is completely enclosed in a vacuole 
(phagosome).  Cytoplasmic granules fuse with the phagosome and the pathogen 
is then destroyed by microbicidal mechanisms.  This may consist of reactive 
oxygen species (ROS), nitric oxide or oxygen- independent mechanisms such as, 
lysozyme, lactoferrin, cathepsin G or other proteolytic enzymes (Aderem and 
Underhill 1999).  It is the product of these microbicidal mechanisms that left 
unregulated, cause the tissue damaging component of inflammation. 
Macrophages control the balance between pro- and anti-inflammatory 
responses, depending on the activating stimuli.  During an infection, 
inflammatory processes are critical to pathogen removal.  However, prolonged 
inflammation is associated with deleterious effects in the tissue and must be 
controlled and/or repressed to allow for healing and homeostasis of the tissue.  
Macrophages control the state of inflammation by responding to their 
environment accordingly.  To achieve this, monocytes can be activated in one of 
two subsets to generate a pro- or anti-inflammatory collection of cells.  M1 cells 
are pro-inflammatory effectors defined by their ability to produce pro-
inflammatory cytokines (IL-1α and β, IL-6, IL-8, TNF-α) and M2 exhibit anti-
inflammatory properties as they produce cytokines antagonistic to M1 cytokines 
(IL-4, IL-10, TGF-β).  M2 macrophages are mostly observed during the healing 
phase of acute inflammation and wound healing (Porcheray, Viaud et al. 2005; 
Verreck, de Boer et al. 2006).  These activation states have been characterised by 
their cytokine expression and the presence of macrophage-specific markers. 
However, Porcheray et al. (2005) found that macrophages stimulated towards a 
specific phenotype (M1 or M2) have the ability to return to a quiescent state 
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after signal arrest, or to switch their activation phenotype rapidly upon counter-
stimulation.   
The acquisition of a mature macrophage phenotype is clearly distinct from that 
of monocytes and requires expression of a new set of genes (Verreck, de Boer et 
al. 2006).  This characteristic can be used to determine the extent of activation 
by different treatments.  Most "macrophage-specific" marker genes that have 
been documented are already expressed in peripheral blood monocytes and do 
not show up-regulation which would confirm the macrophage phenotype.   
Several genes were selected to find one that would offer the best indication of 
monocytes/macrophage populations.  Krause et al., (1996) identified several 
genes that can be used for this purpose with one in particular, HC-gp39, that is 
expressed only in late-stage macrophage differentiation.   
HC-gp39, also known as YKL-40, is a mammalian member of glycosyl hydrolase 
family.  In vivo, HC-gp39 levels are increased in serum, synovial fluid, and 
cartilage of rheumatoid arthritis patients (Johansen, Jensen et al. 1993), in 
various inflammatory disorders (Vos, Steenbakkers et al. 2000), in the liver of 
patients with alcoholic cirrhosis (Johansen, Møller et al. 1997), in serum of 
patients with recurrent breast cancer (Johansen, Cintin et al. 1995), colorectal 
cancer (Cintin, Johansen et al. 1999) and in macrophages in the atherosclerotic 
plaque (Boot, van Achterberg et al. 1999).  The described expression pattern 
suggests a predictable role in inflammation, tissue remodelling, and tumour 
metastasis.  
The expression of HC-gp39 is restricted to a small number of cell types such as 
chondrocytes, synovial cells, neutrophils, and macrophages (Krause, Rehli et al. 
1996) and shows a strict correlation with late macrophage differentiation in vitro; 
expression is undetectable in monocytes and only marginally detectable in 
monocyte-derived dendritic cells (Krause, Rehli et al. 1996). 
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During differentiation of human blood monocytes the expression of cell surface 
antigens changes.  Two monoclonal antibodies Max.1 and Max.11 recognize cell 
surface antigens that are almost undetectable on monocytes but highly 
expressed on differentiated macrophages (Rehli, Krause et al. 1995).  Rehli et al. 
found that Caboxypeptidase is identical to the antigens recognised by Max.1 and 
Max.11 and is produced by activated THP-1 cells. Specific primers for 
Carboxypeptidase M mRNA can be used to determine the macrophage 
population and extent of activation after exposure to certain agents.   
To confirm that the activating treatments (LPS, PMA, Vit-D3) used on THP-1 cells 
were in fact generating macrophages, two markers HC-gp39 and 
Carboxypeptidase M, were screened for after treatment. 
 Macrophages are not proliferative cells.  Their main goal is to remove pathogens 
and foreign debris or apoptotic cells.  Monocyte precursors replenish the 
monocyte/macrophage population in response to growth factors (Sluiter, van 
Waarde et al. 1982; Nicola and Metcalf 1985).  A monocyte cell suspension will 
differentiate into one expressing functional properties and differentiation 
markers of macrophages in response to an activating treatment such as PMA 
(Traore, Trush et al. 2005), LPS (Suzuki, Hashimoto et al. 2000) or Vit-D3 
(Hmama, Nandan et al. 1999).  However this leads to a decrease in cell 
proliferation (Traore, Trush et al. 2005).  This drop in cell proliferation can be 
used as an indicator for successful cell activation, providing that cell viability does 
not decrease. 
During the change-over from the monocyte to macrophage, the ability to 
phagocytose increases.  This can be easily monitored in THP-1 cells due to their 
non-specific ability to phagocytose particles such as polystyrene latex particles 
upon activation using latex particles labelled with fluorescein isothiocyanate 
(FITC). Phagocytosis can be measured by visually counting the number of 
fluorescent particles inside live cells. 
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To assess the amount of expression of macrophage marker genes, a 
housekeeping gene was selected as a reference.  A housekeeping gene should be 
expressed in stable amounts between treatments as gene of interest (GOI) 
expression levels may be affected by culture, stimulation or disease severity 
(Bustin 2000).  Beta-2-microglobulin (β2M) was chosen for this study as β2M is 
expressed with low variability between cell treatments (Ishii, Wallace et al. 
2006).  This allows for the direct comparison of samples as long as the amounts 
of β2M remain stable between treatments.  It is assumed that the appearance of 
the macrophage markers after stimulation with activating treatments would be 
gradual until a peak level indicates that monocytes have changed over to 
macrophages. 
2.2.1  Outline of experiments 
Several assays were employed in this research to confirm these properties in  
LPS-, PMA-, and Vit-D3-stimulated THP-1 cells after suitable activation times.  
The morphology of the resulting cells was investigated using microscopy 
techniques (Section 2.3.9).  Macrophage markers were screened for in the 
activated THP-1 cells (Section 2.4.3).  A phagocytosis assay was used to 
determine the ability of macrophages to phagocytose latex particles after an 
activating treatment with LPS, PMA or Vit-D3 (Section 2.4.4).  The proliferation 
rate of the cells activated by each of the treatments was determined (Section 
2.4.5). 
2.3  Materials and Methods  
2.3.1  Cell culture 
THP-1 cells (ATCC TIB-202, acquisition date 2006) were maintained at 37°C, 5% 
CO2, and 95% relative humidity (RH) in growth medium and used between 
passage 40 and 50.  Cells were cultured in 25 ml Falcon culture flasks (Sigma-
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Aldrich) in a 5 ml suspension and split as required to maintain densities between 
5 x 105 and          1 x 10 6 cells/ml.  Cells were activated in a 24 well plates 
(Greiner, Sigma-Aldrich) in 1 ml samples. 
2.3.2  THP-1 growth medium 
The growth medium contained an endotoxin-free RPMI 1640 (Sigma) 
supplemented with 10% volume by volume (V/V) heat-inactivated foetal bovine 
serum (GIBCO) and 25 mmol/l HEPES with 50 U/ml penicillin, 50 μg/ml 
streptomycin, 40 μg/ml vancomycin and 50 μg/ml gentomycin. The medium was 
sterilised by filtering.  The medium was then stored at 4°C.  
2.3.3  Tetrazolium salt (MTT) assay 
MTT was purchased from Sigma-Aldrich (Cat. No.# M-0283).  This test is a 
quantitative colorimetric method to determine cell proliferation or viability for 
THP-1 cells (Auwerx 1991). It utilizes the yellow tetrazolium salt [3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide] which is metabolized by 
NAD(P)H oxidoreductases in the cytosol of proliferating/live cells to yield a 
purple formazan reaction product.  A solubilization solution, diluted hydrochloric 
acid, is added to dissolve the insoluble purple formazan product into a coloured 
solution. The resulting purple solution is spectrophotometrically measured. 
Briefly, cells were treated and grown in a 96-well plate for 1 – 7 days.  Prior to 
assay suspended cells were removed, and adherent cells and wells were washed 
twice in PBS and incubated in the presence of 50 µl of MTT solution (5 mg/ml) for 
2 h at 37°C.  For the non-adherent control cells or cells where the treatment did 
not promote adhesion, the cells were removed from the test well, transfered to 
an Eppendorf tube and briefly spun down to pellet cells.  The medium was 
removed and the cells were gently washed in 500 µl PBS.  The test well was also 
washed briefly in PBS.  The cells were spun again to pellet them and 50 µl MTT 
added to the Eppendorf tube to re-suspend the cells.  The cells were then 
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returned to the test well and incubated in the same way as the other test wells.   
After incubation 0·3 ml of extraction buffer (8% HCl in isopropanol) is added and 
optical density measured at 540–630 nm. The OD of blank wells (lacking cells, but 
manipulated in the same way) is subtracted from the values obtained for the test 
wells.  
2.3.4  Trypan Blue exclusion 
Trypan blue was purchased from Gibco in a ready-to-use 0.4% solution.  The dye 
exclusion test is used to determine the number of viable cells present in a cell 
suspension. It is based on the principle that live cells possess intact cell 
membranes that exclude certain dyes, such as trypan blue, whereas dead cells do 
not.  Dead cells are therefore blue and live cells are not.  The cell suspension was 
mixed 1:1 with 0.4% trypan and cells counted on a haemocytometer to give a 
percentage of viable THP-1 cells (Auwerx 1991). 
2.3.5  Lipopolysaccharide 
1 mg of E.coli LPS (E. coli serotype 0127:B8; Sigma-Aldrich; Cat. No.# L4516-1 mg) 
was purchased.  The LPS was diluted with 1 ml of RPMI 1640 medium and stored 
at -20°C. LPS was used at a final assay concentration of 100 ng/ml unless 
otherwise stated.   
2.3.6  Phorbol 12-myristate 13-acetate (PMA)  
PMA was purchased from Sigma-Aldrich (Cat. No.# P1585-1 mg) and diluted in 1 
ml DMSO, and further diluted to a working concentration of 10-6 mol/l in RPMI 
1640 medium and stored at -20°C.  PMA was used at a final concentration of 10 
nmol/l unless otherwise stated. 
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2.3.7  1α,25-dihydroxyvitamin D(3) (Vitamin-D3) 
Vit-D3 was purchased from Sigma-Aldrich (Cat. No.# D1530-10 µg) and diluted in  
1 ml ETOH and stored at -20°C.  Vit-D3 was used at assay concentrations of 100 
nmol/l in RPMI medium unless otherwise stated.   
2.3.8.  Latex particles 
Yellow/green fluorescent latex-coated polystyrene particles with carboxylate 
modifications were purchased from Sigma-Aldrich (1.0 μm, Cat. No.# L5405)  and 
used at densities of approximately 25 particles per cell.  The particles were 
sterilized by pasteurization for 24 hours at 70°C as recommended by the 
supplier.  Detection wavelengths used were excitation 470 nm and emission 505 
nm. 
2.3.9  Morphology Assessment 
The cell morphology, cell viability and phagocytosis activity was assessed using a 
Axostar plus Zeiss inverted microscope and 40x lens.   
The images of macrophages phagocytising latex particles were recorded with a 
Nikon PCM2000 laser scanning confocal microscope equipped with a 100 mW 
argon laser. The 488 nm laser line was selected with a band-pass interference 
filter. The sample was visualized with a 60x oil-immersion objective lens 
(numerical aperture, 1.4) with a 20 µm confocal pinhole. GFP fluorescence was 
selected with a 505 nm dichroic mirror and an interference band-pass filter 
transmitting light from about 500 to 527 nm.  Images were recorded by scanning 
the laser over a field of view that was typically 30.8 by 30.8 µm.  Images were 512 
by 512 pixels, with a scan speed of 3 µs per pixel. Images were averaged from 10 
successive scans. The xy resolution of the microscope was approximately 250 nm. 
The resolution was dependent on the confocal pinhole used. With the 20 µm 
confocal pinhole, it was about 0.75 µm (half-width at half-maximum).   
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The images are taken from a time lapse movie generated using a confocal 
microscope one frame per second in conjunction with Dr Barry O’Brien from the 
University of Waikato.    
2.3.10  Agarose gel electrophoresis 
2.3.10.1  Tris-acetate-EDTA (TAE) buffer 
To make 1 l of 50 x TAE buffer:  242 g Tris, 100 ml of 0.5  mol/l EDTA pH 8.0, 57.1 
ml glacial acetic acid.  Add enough MilliQ H2O to dissolve solids, then bring up to 
final volume of 1000 ml.   
2.3.10.2  Tris-EDTA (TE) buffer 
To make 100 ml of TE buffer;  Add 1 ml of 1 mol/l tris HCL (pH 8.0) and 0.2 ml 
EDTA (0.5 mol/l) and make up with MilliQ H2O to 100 ml. 
2.3.11   Preparation of a 2% agarose gel 
Agarose (2 g) was added to 100 ml 1 x TAE buffer and weighed.  The agarose was 
dissolved by microwaving on high for approximately 2 minutes and then re-
weighed and topped up to the original weight with purified water.  The agarose 
was cooled by swirling the flask in a cold water bath, and  2 µl of ethidium 
bromide was added before being poured (about 30 ml) into a gel caster 
(Horizon® 11.14, GibcoRBL) with 12 well combs.  The gel was left to set at room 
temperature.   
2.3.12   Oligodeoxynucleotide Primers 
Olgodeoxynucleotide primer pairs for the macrophage markers HC-gp39 and 
CPM, as well as the house keeping genes β-actin and β2M, were either selected 
based on previous publications or constructed using a primer designer 
programme (Genamics Primer Designer).  All primers were purchased from 
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Sigma-Aldrich.  Accession numbers for genes and primer sequences are listed in 
Appendix 2.  Original individual primer concentrations varied depending on 
olgodeoxynucleotide length, and so were subsequently diluted with TE (10 mM 
Tris, 1 mM EDTA pH 8) buffer to give a stock solution of 200 ng/ml. Working 
primer solutions were prepared for each cytokine by adding 80 µl of TE buffer to 
10 µl each of forward and reverse primer stock, and stored at 4°C. 
 
2.4  Experiments  
2.4.1  Activating treatment concentrations 
The use of varying concentrations of LPS, PMA and Vit-D3 have been described in 
the literature and it was important to find concentrations that were tolerable to 
the cells, yet effective in initiating macrophage differentiation for THP-1 cells.  A 
range of LPS, PMA and Vit-D3 concentrations were used and the mortality 
recorded to find the highest tolerable concentration for the cell line that would 
still produce a macrophage, determined by morphological changes.  Mortality 
was assessed using the trypan blue viability assay (Section 2.3.4).   The literature 
was used as a guideline for starting concentrations in the range and were as 
follows:  LPS;  100 ng/ml – 1 µg/ml for 24 hours (Suzuki, Hashimoto et al. 2000), 
PMA; 1 nmol/l – 1 µmol/l from 24 hours (Traore, Trush et al. 2005)., Vit-D3;  10 
nmol/l –1 µmol/l from 24 hours (Schwende, Fitzke et al. 1996; Hmama, Nandan 
et al. 1999 ).  
To grade treatments of THP-1 with LPS, PMA or Vit-D3, cells were assessed using 
an inverted microscope to observe morphology changes which indicate a 
successful transformation.  Control THP-1 cells (no activating treatment) 
maintained a round shape and did not clump or adhere to the culture plate 
surface whereas activated THP-1 cells became flat and amoeboid with obvious 
pseudopodia, and adhered to the culture plate surface with the exception of the 
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Vit-D3 treatment which resulted in a non-adherent suspension.  The time to 
achieve this morphology change differed between treatments, as did the actual 
morphology.    
The treatments were assessed over 7 days and optimum conditions for activation 
were found by assessing the time required to achieve morphology change, and 
the viability of the cells, to arrive at a concentration of activating agent and the 
time of treatment best to use for assays in subsequent research. 
2.4.2  Viability assay 
Cells stimulated with LPS, PMA and Vit-D3 were assayed for viability using the 
tetrazolium salt (MTT) assay and trypan blue exclusion assay.  A period of two 
days of activation was utilized as any cell death relating to the treatment 
concentrations would be expected in the typical life span of the cell (26 hours). 
MTT results were representative of the number of viable cells, confirmed by 
counting the number of cells in five microscope fields per well by trypan blue 
exclusion. The results obtained with trypan blue were similar to those obtained 
with the MTT assay (data not shown) but due to the Vit-D3-treated cells and the 
untreated-control cells being non-adherent, the trypan blue assay was used in 
subsequent experiments requiring testing for each treatment and incubation 
time in triplicate wells.   
2.4.3  Macrophage marker gene expression assay 
THP-1 cells were incubated (37°C, 95% air, 5% CO2) in growth medium, with LPS, 
PMA or Vit-D3 for up to 7 days to assess macrophage marker mRNA expression.  
Cells were grown in 3 ml aliquots in individual tissue culture flasks.  At time 
intervals of 1, 3 and 7 days, medium was removed and RNA extracted.   At these 
time intervals optimal transformation from monocyte to macrophage is expected 
for all three treatments.   After 3 days and 6 days, treated medium was removed 
and replaced to ensure optimum growing conditions.  As a control, the 
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housekeeping gene β2M was also amplified from monocytes and macrophages to 
normalising gene expression between samples.   
2.4.3.1  Lysis of cells and RNA extraction 
Flasks were placed upright for 20 minutes to allow suspended cells to settle.  The  
medium was pipetted off carefully to leave cells behind.   The Trizol reagent (1 ml 
of ProGenz) was added to the flask and the flask slowly agitated for 2 minutes on 
its side to remove adherent cells.  The flask was then vortexed for 10 seconds to 
lyse cells and then incubated at room temperature for a further 3 minutes.  This 
way adherent cells and suspended cells could be lysed together.   
The flask was then briefly centrifuged to pool lysed cells and these were then 
pipetted out into a 1.6 ml Ependorf tube.  After incubation 200 μl chloroform 
was added and the tube vortexed for 10 seconds.  The tubes were incubated on 
ice for 10 minutes then centrifuged for 15 minutes at 12 000 x g.  The upper 
aqueous layer was removed and placed in a 1.5 ml Eppendorf tube containing an 
equal amount (~ 500 µl) of isopropanol and the tube incubated at -20° for 30 
minutes.  The tubes were then centrifuged for 10 minutes at 12 000 x g and the 
supernatant discarded.  The RNA pellet was washed with 1 ml of 75% ethanol 
and centrifuged for 5 minutes at 12 000 x g.  The ethanol was removed by 
pipette and the pellet was allowed to air dry at room temperature for 5 minutes.  
The RNA samples were then dissolved in 20 µl of 10 mM Tris (pH 7.8) with 0.66 
mol/l MnCl2 by vortex.  Residual DNA was removed by treating with 1 µl (1 unit) 
Promega DNAse and incubated for 30 minutes at 37°C.  One unit (1 µl) of 
Promega DNAse Stop solution was added to each tube and then incubated at 
65°C for 10 minutes.  To check the quality of the RNA in the extract 2.5 µl was 
run on a 2% agarose gel in TAE buffer (for agarose gel methods see Section 
2.3.11).   
The samples were electrophoretically separated at 55 volts for 45 minutes.  RNA 
integrity was indicated by the sharp, clear 28S and 18S rRNA bands.  RNA bands 
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were visualised using a GIBCO BRL ultra-violet trans-illuminator (Life 
Technologies) at 312 nm, photographed using a COHU High Performance CCD 
camera and digitally stored.  All RNA-band base-pair lengths were checked by 
comparison with a 1 kb DNA ladder (Invitrogen) unless otherwise stated.  The 
RNA was then stored at -70°C until required for cDNA synthesis. 
2.4.3.2  First strand cDNA synthesis 
To obtain an estimate of concentration of RNA each RNA sample was measured 
on a nano-drop spectrophotometer.  Readings were done in duplicate to ensure 
accuracy.   Reagents used to produce cDNA were as described by the protocol 
outlined by SUPERSCRIPT III (GibcoBRL).  An appropriate amount of RNA in water 
was used to ensure cDNA samples were uniform.  Briefly, for each sample 
approximately 5 µl of RNA (50 ng measured by nanodrop spectrophotometer) 
and 1 µl of oligo dT (GibcoBRL) were used and the balance made up to 11 µl with 
MilliQ water in a 200 µl Axygen PCR tube.  The tubes were incubated for 10 
minutes at 65°C to separate secondary structures and then placed on ice for 10 
minutes to allow the oligo dT primers to anneal to single stranded RNA. 
In a separate tube, 4 µl MilliQ water, 5 µl buffer, 1 µl Dithiothreitol (MDTT), 1 µl 
of deoxynucleotide triphosphates (dNTPs) and 1 µl of SUPERSCRIPT III reverse 
transcriptase was added and this mixture was incubated on ice until being added 
(9 µl) to the tubes containing RNA. The tubes were then incubated for 1 hour at 
50°C and then the enzyme inactivated at 65°C for 10 minutes. 
2.4.3.3  Conventional RT-PCR analysis of cDNA 
Conventional RT-PCR analysis was used to confirm cDNA synthesis from RNA 
using the primer set for β-actin.   Briefly, the PCR process involves multiple cycles 
of template denaturisation, primer annealing, and primer elongation to amplify 
DNA sequences.  HotStar® Taq DNA Polymerase (Qiagen, Valencia, NV) was used 
for PCR amplifications using the manufacturer’s instructions.   
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A PTC-100 Thermocycler (MJ Research, Reno, NV) was used for thermo cycling.  
After pre-incubation for 2 minutes at 94°C, to activate Taq polymerase (Qiagen), 
the target DNA was amplified with 40 cycles, each cycle consisting of a 
denaturisation step at 94°C (20 seconds melting), annealing for 20 seconds at 
55°C (optimised for specific genes, as presented in Appendix 2) and extension at 
68°C for 35 seconds. 
2.4.3.4  Electrophoresis of cDNA 
A 2% gel was run to confirm that cDNA had been successfully amplified.  A DNA 
ladder (10 µl of 100 bp, Invitrogen) was run alongside 10 µl of sample.  Gels were 
prepared as described in Section 2.3.11.  The cDNA samples were premixed with 
a loading dye (40% sucrose, 0.25% bromophenol blue, 0.25% xylene cyanol).    
Electrophoresis was carried out in Horizon tanks (Invitrogen) containing TAE 
buffer, at 100 volts until separation of cDNA bands was achieved.  Bands were 
visualised using a GIBCO BRL ultra-violet trans-illuminator (Life Technologies) at 
312 nm, photographed using a COHU High Performance CCD camera and digitally 
stored.  All product band base-pair lengths were checked by comparison with a 
100 bp DNA ladder (Invitrogen) unless otherwise stated. A single cDNA band 
confirms no contamination or miss-priming is present.  The primers used for β-
actin (described in Appendix 2) amplify a product 100 bp in size (see Figure 2.5).  
Once the presence of β-actin was confirmed the samples were then quantified 
for expression of macrophage specific markers CPM and HC-gp39 and the 
housekeeping gene β2M, using RT-PCR primer sequences that are listed in 
Appendix 2.   
2.4.4 Phagocytosis assay 
In order to transform the monocytes to macrophages THP-1 cells were 
maintained as described in Section 2.3.2.  Cells were sub-cultured with fresh 
growth medium prior to the assay and assessed for viability as described in 
Sections 2.3.1 and 2.3.4. 
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LPS, PMA and Vit-D3 were each added to freshly sub-cultured cells to a final 
concentration of 100 ng/ml LPS, 10 nmol/l PMA and 100 nmol/l Vit-D3. THP-1 
cells had a viability of 95% or higher.  Cells were plated out at 1 ml per well 
(approximately 5 x 105 cells) in a 24 well plate (Cellstar, Greiner bio-one) and the 
plate partially sealed with tape to reduce evaporation but allow CO2 passage.  
Plates were incubated for 24 hours (LPS), 3 days (PMA) or 7 days (Vit-D3) at 37°C 
with 5% CO2, and 95% relative humidity to allow activation (according to 
previous findings, Section 2.4.1 indicating time to macrophage differentiation).   
Prior to the phagocytosis assay, each well was checked on an inverted 
microscope to observe morphological changes which indicate a successful 
transformation.  Control THP-1 cells (no treatment) maintained a round shape 
and did not clump or adhere to the culture plate surface whereas LPS- and PMA- 
treated THP-1 cells adopted macrophage characteristics as described in Section 
2.4.1.  Vit-D3 activated cells were notably less adherent than the LPS or PMA 
activated cells. 
Each well had sterile 1.0 μm latex-coated polystyrene particles (approx 25 
particles per cell) added to the wells, then the plates were resealed with tape 
and re-incubated.  For each treatment there where at least three replicates per 
experiment. 
After four hours of incubation, any suspended cells were removed by pipette and 
phagocytosis halted by washing the monolayer with 1 ml of ice-cold sterile 
phosphate-buffered saline (PBS) three times (adherent LPS and PMA treated 
cells) or plates chilled to 4°C (suspended control cells and Vit-D3 treated cells) 
and cells removed by pipette and gently spun down by centrifuge (500 x g) in 1.5 
ml Eppendorf tubes.  The medium was then pipetted off and replaced with 1 ml 
of ice-cold PBS.  This was repeated two more times to remove any dead cells or 
cell debris.  Adherent cells were loosened from the plate by gentle pipetting of 
100 µl PBS up and down on the well.  At least 200 cells from each sample were 
counted and examined on a haemocytometer using an Axostar Plus Zeiss 
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fluorescent microscope phase II 40x lens.  Cells that contained at least three 
particles were considered positive for phagocytosis.   Non-activated control   
THP-1 cells (monocytes) had a phagocytosis rate less than 5% as observed in 
preliminary assays.  Viability was checked to ensure treatments had not induced 
apoptosis.   
The ability of THP-1 cells to phagocytose latex particles was quantified as a 
percentage of cells undergoing phagocytosis.  The phagocytosis rate was 
obtained by dividing the number of phagocytic cells by the number of cells 
counted on a haemocytometer.   
For the phagocytosis assay with PMA transformed cells, counting on a 
haemocytometer was hampered by the adhesion of the transformed cells.  These 
cells could not be loosened from the plate without damaging them.  PMA treated 
cells were examined adhered to the plate under the microscope.  To give a 
percentage of phagocytosis, 200 cells from randomly selected fields of view were 
counted. 
2.4.5  Proliferation 
Due to the nature of macrophages described earlier, a drop in proliferation, yet 
not viability, indicates a transformation from a proliferative monocyte to a non-
proliferative macrophage.  The doubling time for THP-1 cells is approximately 26 
hours. Therefore, a cell count of viable cells (determined using trypan blue 
exclusion) was undertaken at 48 hours post-treatment.  
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2.5  Results 
2.5.1  Cell viability after activation treatment 
The viability of the cells assessed over a period of incubation with a range of 
concentrations of activating treatments is shown in Figures 2.1-2.3.  The 
optimum incubation time required for successful morphology change was found 
to be: LPS 24 hours, PMA 1-3 days, Vit-D3 7 days.  The concentrations of 
activating agents selected for subsequent research were as follows: LPS; 100 
ng/ml, PMA; 10 nmol/l and Vit-D3; 100 nmol/l.  At these concentrations there 
was no significant loss of viability (viability remained 95% or higher).  In the case 
of Vit-D3, which was diluted in ethanol, a control assay was carried out with 
ethanol only at identical concentrations and it was found that ethanol did not 
have an effect (results not shown).  resist 
 
 
Figure 2.1.  Viability of THP-1 cells after treatment with various concentrations of 
LPS for varying periods of time, as determined by trypan blue staining. Error bars 
show ± 1 SD of the mean from three experiments.   
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Figure 2.2.  Viability of THP-1 cells after treatment with various concentrations of 
PMA for various periods of time, as determined by trypan blue staining. Error 
bars show ± 1 SD of the mean from three experiments.   
 
 
Figure 2.3.  Viability of THP-1 cells after treatment with various concentrations of 
Vit-D3  for various periods of time, as determined by trypan blue staining. Error 
bars show ± 1 SD of the mean from three experiments.  
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2.5.2 Macrophage markers and morphology treatment 
The RNA extracted from the LPS transformed cells that was run on 
electrophoresis to verify the integrity of the RNA is shown in Figure 2.4.  (PMA 
and Vit-D3 transformed cells are not shown).  The bands are clearly visible in the 
gel indicating intact 18s and 28s.  To confirm that cDNA could be produced from 
the extracted RNA, the primer set for β-actin was used to amplify cDNA 
generating a 90bp amplicon.  Representative results are presented in Figure 2.5.  
The cDNA from LPS, PMA and Vit-D3 activated cells were amplified with primers 
for HCgp-39 and CPM, with β2M used as the housekeeping control.  Figures 2.6 
and 2.7 show the images of electrophoresis gels for PCR reactions for HCgp-39 
and CPM primer sets respectively. A strong band indicates successful 
amplification from cDNA.  These PCR results demonstrate that the macrophage 
marker HC-gp39 is expressed in THP-1 monocytes just as strongly as in 
transformed THP-1 cells.  There was no visible expression of CPM in THP-1 
monocytes and only a weak expression for Vit-D3 transformed THP-1 cells (24 h 
stimulation) represented by a weak band  (primer-dimer also visible in lane 6 of 
Figure 2.7).  The LPS and PMA transformed cells (24 h stimulation) produced a 
strong band for CPM indicating it is strongly expressed.  After 72 h all three 
treatments induce strong expression of the CPM gene.  After 7 days stimulation 
the expression of CPM was identical to the 72 hour expression rate for each 
treatment (results not shown).  This indicates that Vit-D3 treatment is slower to 
transform the monocytes than the other treatments.  These results combined 
suggest that CPM is a superior macrophage marker to HC-gp39 in THP-1 cells. 
At the time intervals indicated, the transformation from monocyte to 
macrophage was expected to have been completed as indicated by the 
morphology observations for each of the treatments. Representative images of 
the cells’ morphology before and after treatment are shown in Figures 2.8 – 2.11.  
To assess the morphological change in cell shape from the typical spherical 
monocyte phenotype to the amoeboid, adherent macrophage phenotype, cells 
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were microscopically examined daily until their shape was no longer considered 
spherical.  The cells shown in Figure 2.9 – 2.11 were at this stage. 
 
       
Figure 2.4.  THP-1 RNA electrophoresed on 2% gel showing the 28s and 18s 
bands.  A 1 kbp ladder is shown.  Lane 2 had a higher concentration of RNA 
loaded than lane 3. 
 
            
Figure 2.5.   A 2% agarose gel showing the PCR products (90 bp) amplified using 
the β-actin primer set. Lane 1, 100 bp ladder; Lane 2, negative control; Lane 3, 
monocyte cDNA; lanes 4-6, cells activated for 48 h with LPS, PMA, Vit-D3 
respectively.  The strong band indicates successful amplification of β-actin cDNA 
from both monocytes and macrophages.    
           1 kbp     Lane2    Lane 3 
28s band 
18s band 
 100 bp       2           3           4            5            6     
 
 
90 bp 
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Figure 2.6.   A 2% agarose gel showing the PCR products amplified using the β2M 
(295 bp) and HCgp-39 (236 bp primer sets. Lane 1, 100 bp ladder; Lane 2, 
negative (primer dimer band visible); Lanes 3-6, β2M from control Monocytes and  
LPS-, PMA-, Vit-D3- activated macrophages after 1, 3 or 7 days treatment 
respectively; lane 7, blank; Lanes 8-11, HCgp-39 from Monocytes and LPS-, PMA-, 
Vit-D3-activated macrophages respectively after 1, 3 or 7 days treatment 
respectively .   
 
 
 
Figure 2.7.   A 2% agarose gel showing the PCR products amplified using the β2M 
and CPM primer set. Lane 1: 100 bp ladder, lanes 2 and 3: β2M (295 bp) 
expression for monocyte and LPS-activated macrophage cells respectively.  Lane 
4: CPM (233 bp) expression for THP-1 monocytes.  Lanes 5-7: THP-1 CPM 
expression for PMA, Vit-D, LPS, 24 h treatment respectively Lanes 8-10: CPM 
expression for PMA, Vit-D3, LPS 72 h stimulated THP-1 cells respectively. 
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Figure 2.8.  THP-1 monocytes showing the non-activated 
phenotype (400 x magnification). 
 
 
Figure 2.9.   LPS-activated THP-1 cells after 24 hours 
activation with 100 ng/ml LPS.  A non-activated spherical 
THP-1 cell is visible in the centre (400 x magnification). 
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Figure 2.10.  PMA-activated THP-1 cells after 3 days 
activation with 10 nmol/l   PMA (400 x magnification). 
 
 
 
Figure 2.11.  Vit-D3-activated THP-1 cells after 7 days 
activation with 100 nmol/l Vit-D3 (400 x magnification). 
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The morphological changes between the cell activation treatments varied 
greatly.  The PMA treatment caused the cells to enlarge, become flat and 
amoeboid, with long pseudopodia extensions and become comparably slow 
moving. The PMA-treated cells seemed to increase 2–3 times in volume (visually 
assessed). They resembled dendritic cells in their appearance.  PMA-treated cells 
became the most adherent population, fixing to the cell culture flasks and 
becoming removable only by trypsin treatment.   
LPS-treated cells were moderately adherent, possibly due to the fact that they 
were very mobile and therefore not fixed to the culture flask like PMA-treated 
cells.  They could be removed from the flask with rigorous tapping, or direct 
pipetting of fluid on to the cells to dislodge them.  Pseudopodia were much 
shorter but more numerous than with PMA-activated cells, radiating from the 
cell in all directions.  LPS-treated cells had approximately twice the volume of 
untreated THP-1 cells (visual assessment).  
The Vit-D3-treated cells were less adherent than those from the other 
treatments, only needing a slight tap of the flask to dislodge them.  Their 
appearance remained generally spherical like the untreated THP-1 cell, but they 
developed a ruffled membrane.  This was possibly due to pseudopodia 
extensions but in a much reduced form compared with that of PMA- and LPS-
treated cells. 
2.5.3 Phagocytosis assay 
Figure 2.12 shows time-lapse photography of an LPS-activated macrophage 
phagocytising a fluorescent particle.  The FTIC-labelled latex particles were easily 
visualised within the cell.  The pseudopodia are clearly visible binding the particle 
and bringing it closer to be phagocytosed.  This is available to view as a movie on 
the DVD rom supplied in Appendix 1.  The results from the quantitative 
phagocytosis assay are displayed in Figure 2.13.   
Chapter 2                                    Characterising THP-1 
55 
 
It can be seen that all three treatments gave a significant increase in 
phagocytosis with the treatments giving significantly different degrees of 
activation of phagocytosis from each other.  The effect of PMA was 
approximately twice that of Vit-D3 and of LPS was a further three times greater. 
 
 
 
Figure 2.12. Time lapse photographs under a fluorescent microscope 
of an LPS-activated macrophage (100 ng/ml LPS for 1 day) 
phagocytising a FITC-labelled latex particle.  The whole event took 
approximately 25 seconds. As the cell moves, other particles already 
phagocytosed become visible (400 x magnification). 
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Figure 2.13.  Results from phagocytosis assays for the three THP-1 
activating treatments, 100 ng/ml LPS, 10 nmol/l PMA, 100 nmol/l Vit-D3 
after 1, 3 or 7 days activation respectively (these times optimal for each 
specific treatment as indicated in Section 2.5.1). The control received no 
activating treatment.  Error bars show ± 1 SD of the mean of five 
experiments.  *Results are significantly different (p<0.001) analysed by 
ANOVA and Tukey’s multiple pairwise comparisons compared with the 
non-activated control.  Results not showing the same letter are 
significantly different to each other. 
 
 
2.5.4  Proliferation 
Cell density was checked after 48 hours of treatment to indicate the extent of 
proliferation after exposure to the treatment.  Macrophages are not proliferative 
cells unlike the monocyte precursor.  A reduction in proliferation after receiving 
the activating treatment is an indicator for a change in phenotype as long as the 
viability remains greater than 95%. Cells that received treatment with the 
activating substance were compared with the non-treated control cells 
(monocytes).  Any treatment that affects cell proliferation will be noticeable 
after 48 hours due to the cell cycle of THP-1 being 26 hours.  Viability remained 
above 95% for the duration of the activation treatment determined by the 
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Trypan Blue assay (Section 2.4.2 results not shown).  The proliferation results are 
displayed in Figure 2.14.  PMA-activation generated a significantly less 
proliferative cell population than Vit-D3- and LPS-activated cells, though all three 
treatments reduced the proliferation rate significantly from that of the control 
monocyte population. 
 
 
 
Figure 2.14 Results from the proliferation assays for the three THP-1 activating 
treatments; 100 ng/ml LPS, 10-8 mol/l PMA, 10-7mol/l Vit-D3 after 48 hours 
activation compared with the final count of the control cells (un-activated 
monocytes which displayed a normal increase in cell numbers over the treatment 
time. Error bars show ± 1 SD of the mean of five experiments. *Results are 
significantly different (p<0.001) analysed by ANOVA and Tukey’s multiple 
pairwise comparisons compared with the non-activated control.  Results not 
showing the same letter are significantly different to each other. 
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2.6 Discussion 
A non-cytotoxic concentration of each activating treatment was determined.  At 
this level the cells maintained a high viability yet displayed characteristics which 
would indicate successful transformation to a macrophage phenotype.  The PMA 
and Vit-D3 concentrations were similar to those found in most of the literature.  
The optimum LPS concentration, however, was a lot lower than commonly 
reported (up to 1 µg/ml).  It is not known, however, if in the reported studies the 
viability of the cells was checked after the assay was completed.  In the present 
study at 6 hours post-treatment, all three treatments had an identical viability 
rate to that of the monocyte control.  However, this viability dropped off 
suddenly over the next 18 hours for high concentrations, indicating that the cell 
line was not surviving the treatment.  This would indicate that for the duration of 
the first 6 hours, cells may be starting to undergo necrosis.  Any results (for 
example cytokine expression profiles) obtained from an assay during this time 
may not accurately show the effect of prolonged treatments being assayed.  It 
was for this reason that the highest possible concentration of activating 
treatment that did not alter viability rate was chosen.  These concentrations 
were used for the remainder of the research in this chapter and following 
chapters unless otherwise stated.  Final concentrations were as follows: LPS, 100 
ng/ml; PMA, 10 nmol/l; Vit-D3, 100 nmol/l.  At these concentrations proliferation 
remained positive.  PMA-activated macrophages however had a significantly 
lower proliferation rate that LPS- and Vit-D3-activated macrophages (p>0.001).  
Recently it has been found that tissue macrophages undergo rapid in situ 
proliferation in order to increase population density (Jenkins, Ruckerl et al. 
2011). This inflammatory mechanism occurs during TH2-related pathologies 
(corresponding to M2 macrophages with wound healing or tissue-remodelling 
functions) under the control of the TH2 cytokine IL-4.  This is a fundamental 
component of TH2 inflammation because exogenous IL-4 causes accumulation of 
tissue macrophages through self-renewal (Jenkins, Ruckerl et al. 2011).  This 
information may indicate that the expansion of innate cells necessary for 
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pathogen control or wound repair can occur without recruitment of potentially 
tissue-destructive inflammatory cells.  It may be useful in future studies to 
determine if PMA-activated macrophages are producing higher amounts of 
chemokines for the purpose of cell recruitment than LPS- or Vit-D3-activated 
macrophages do, and whether honey may have an effect on this process. 
Macrophage marker gene expression was assayed using conventional RT-PCR to 
identify if the treatments initiated the change-over to a macrophage phenotype.  
CPM was found to be more definitive for this than HC-gp39 which gave a uniform 
expression between monocytes and macrophages.  This suggests that the THP-1 
cell line is already expressing HC-gp39 unlike fresh peripheral blood mononuclear 
cells as reported in the literature.  CPM expression was initiated after treatment 
with the activating agents, indicating that the cell was responding to the 
treatment by modifying its expression of this gene along with its morphology.  All 
three treatments were found to activate the THP-1 cell line to express the CPM 
macrophage marker with maximum expression achieved after 72 hours for all 
three treatments.  The LPS treatment and PMA treatment showed a greater 
increase in the first 24 hours of CPM gene expression compared with Vit-D3.  
However after 72 hours all three treatments gave the same expression.  As 
previously established, Vit-D3 treatment takes 7 days to achieve a macrophage 
phenotype, so CPM is useful in indicating the transformation is taking place 
before this time.  It may be speculated from these combined results that Vit-D3 
treatment transforms cells at a much slower rate than LPS and PMA. 
To assess which was the best activating treatment to provide a phagocytising 
cell, the three treatments were compared at these above-mentioned 
concentrations in a phagocytic assay which assayed the amount of FITC-labelled 
latex particles phagocytosed in a set amount of time (4 hours). 
In this time the LPS-activated THP-1 cells provided the cells with the most 
phagocytic potential, with rates reaching over 70% of the cells phagocytising at 
least three particles.  This was achieved after only 24 hours of treatment with 
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LPS.  At this time point PMA- and Vit-D3-treated cells had a very low 
phagocytosis rate yet all three treatments produced phagocytic cells that 
underwent significantly more phagocytosis events than the non-treated control 
monocytes.  This may indicate that the PMA and Vit-D3 treatments activate a 
macrophage for a purpose other than phagocytosis, as the macrophage marker 
genes were still expressed. When the PMA- and Vit-D3-activated cells were 
additionally assayed for phagocytosis after longer treatment times, the 
phagocytosis rates did not alter (results not shown).   
LPS was selected for ongoing research as it provided the most phagocytic cell 
with macrophage characteristics.  The shorter treatment time using LPS also 
provides a more practical time period for the experiment. 
Phagocytic activity, adherence, proliferation rate and mobility between the 
treatments were found to differ greatly, suggesting that not all of the three 
treatments produce similarly activated cells.  All three treatments produced cells 
with very different morphologies, proliferation rate, size and phagocytic ability.  
This research demonstrates how results can be misinterpreted in a study where 
gene expression is exclusively relied upon to indicate a successful transformation 
from monocyte to macrophage. 
It was observed that the three different treatments, all thought to activate the 
cell to the macrophage phenotype for phagocytosis assays, did not give uniform 
results.  Upon visualisation it was apparent the cells had different morphologies 
and functions.  Cells treated with LPS became highly phagocytic whereas those 
treated with Vit-D3 did not.  PMA activated cells to a very different phenotype 
and one could be forgiven for mistaking it for another cell entirely.  All cell 
treatments, however, produced a positive result in the RT-PCR for CPM, 
confirming that macrophage-specific genes were up-regulated by the treatment. 
Since this study was undertaken, other reports have been published supporting 
this hypothesis.  Mosser and Edwards (2008) suggest three basic macrophage 
populations, host defence, wound healing and immune regulation, which can be 
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assigned categories much like primary colours, which may “blend into various 
other 'shades' of activation” depending on their location, state of activation etc. 
This challenges the proposal of two activation states (M1, M2) discussed 
previously, yet possibly explains why three different cell-activating treatments 
resulted in three different morphologies in this research.  The term “alternatively 
activated” should perhaps apply to macrophages other than type one, of which 
there may be several types.  Mosser and Edwards (2008) suggest that 
macrophages populations that switch phenotypes may be responsible for many 
diseases such as atherosclerosis which is considered an inflammatory disease 
due to the high levels of pro-inflammatory cytokines released from macrophage 
plaques.  
It is recommended for future studies that macrophages from chronic wounds 
and acute wounds be compared by assaying for macrophage type markers.   A 
switch in macrophage phenotype may take place prior to the onset of 
complications in wound healing, causing the release of high amounts of 
inflammatory cytokines and ROS damaging surrounding tissue and preventing 
healing taking place.  It would be of interest to see if the anti-inflammatory effect 
of honey is targeting one phenotype of macrophage over other phenotypes. 
 
 
  
 
Chapter 3 
The effect of honey on cytokine expression in THP-1 cells 
 
 
 
3.1   Summary 
It was hypothesised that the induction of the expression of anti-inflammatory 
cytokines, or suppression of the expression of inflammatory cytokines, may be 
the mechanism(s) by which honey works in its anti-inflammatory activity. 
The messenger RNA expression of inflammatory and anti-inflammatory cytokines 
induced by honey was investigated. To test the modulatory effects of honey on 
gene expression, THP-1 cells were exposed to LPS (100 ng/ml), Manuka honey 
(0.25%) or LPS and Manuka honey simultaneously.  Artificial honey (0.25% 
osmotic control) or medium alone were used as controls. 
RNA was removed from cells using Trizol then cDNA was made from the cells’ 
mRNA.  Conventional reverse transcriptase-PCR was used to amplify cDNA using 
the primer set for the β-actin gene to quantify the cDNA.  Quantitative real-time 
RT-PCR was then used to quantify the abundance of cytokine mRNA transcripts 
expressed from human THP-1 cell lines  at a range of times (0, 6, 8 or 24 hours 
post-treatment). Seven genes were selected for the study; IL-1β, IL-6, IL-10, IL-
1ra, TGF-β, PDGF, and TNF-α.  β2M was used as the house-keeping gene for RT-
PCR. 
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The results showed that honey increased expression of TNF-α, IL-1β, IL-10, IL-1ra 
and TGF-β but reduced expression of PDGF in monocytes.  In conjunction with 
LPS, honey increased expression of all cytokines and growth factors assayed in 
THP-1 cells.  There were no conclusive results for IL-6.  These results indicate, 
that while gene expression for inflammatory cytokines is increased by honey, so 
is the gene expression for anti-inflammatory cytokines and growth factors, which 
may allow inflammation to proceed but at a controlled and modulated level. 
3.2  Introduction 
Cytokines are messengers of the immune system which help regulate an immune 
response.  They are soluble glycoproteins released by white blood cells and 
certain other cells of the host when an antigen is detected.  There are many 
types which affect different parts of the immune system.  Cytokines may 
stimulate or inactivate the immune system, recruit cells, or help end the immune 
response.   
Cytokines possess typical activities such as: 
1. They are released by certain cell types that react specifically with 
other cells, (target cell types) and regulate specific vital functions that 
are controlled by feedback mechanisms; 
2. They generally act at short range in a paracrine manner or autocrine 
manner.  Some can act in an endocrine manner depending on their 
ability to enter the circulation and their half-life; 
3. They interact with high-affinity cell surface receptors and through this 
regulate the transcription of a number of cellular genes which results 
in changes in cell behaviour. 
 
Chemokines are a class of cytokines that have chemo-attractant properties, 
inducing cells with the appropriate receptors to migrate towards the source of 
the cytokine.  Chemokines function mainly as chemo-attractants for leukocytes, 
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recruiting monocytes, neutrophils and other effector cells from the blood to sites 
of infection (Rottman 1999).   Because they were first identified in cytokine 
assays they were initially named as interleukins.   Since then members of the 
chemokine family are divided into four groups depending on the spacing of their 
first two cysteine residues; CC, CXC, C, CX3C. The current nomenclature for 
chemokines is, e.g.: CCL1 for the ligand 1 of the CC-family of chemokines, and 
CCR1 for its respective receptor (Fernandez and Lolis 2002). 
Because of the potent effects of cytokines their activities are tightly regulated, 
most notably at the levels of secretion and receptor expression.   Cytokines can 
be grouped into two categories, pro-inflammatory and anti-inflammatory.  Pro-
inflammatory cytokines are produced predominantly by activated macrophages 
and are involved in the up-regulation of inflammatory reactions.  Anti-
inflammatory cytokines are T-cell-derived cytokines and are involved in the 
down-regulation of inflammatory reactions.  The functional definition of an anti-
inflammatory cytokine is one which inhibits the function of pro-inflammatory 
cytokines (Opal, et al. 2006).  The influence of honey on the secretion of the pro-
inflammatory cytokines; IL-1β, IL-5, IL-12, IL-18, TNF-α and INF-γ has been 
previously studied by Dr. Nichola Harcourt at the University of Waikato.  
Harcourt reported that honey up-regulated the expression of TNF-α, IL-1β, and 
TGF-β in bovine blood cells. It has also been reported that honey at a 
concentration of 1% significantly increased the production of pro-inflammatory 
cytokines TNF-α, IL-1β and IL-6  in a human monocyte cell line MonoMac-6 
(MM6) (Tonks, Cooper et al. 2003), and that honey stimulated the production of 
TNF-α in un-activated monocytes but not if activated by LPS (Tonks, Cooper et al. 
2001).  To broaden the reported findings on the bioactivity of honey, this chapter 
focuses on the anti-inflammatory cytokines, growth factors and pro-
inflammatory cytokine, IL-6.   
To choose a set of cytokines for the present study, consideration was given to 
other studies on cytokine mRNA expression and factors that stimulate or 
suppress their release.  Several studies on the effects of anti-inflammatory 
Chapter 3                     Cytokine expression of THP-1 
65 
 
substances on cytokine expression have been undertaken.  The effects of 
Melaleuca alternifolia essential oil on human peripheral blood monocytes 
(PBMC) were studied and it was found that the essential oil reduced  pro-
inflammatory IL-2 secretion, and increased anti-inflammatory IL-4 and IL-10 
secretion, as determined by ELISA following incubation of PBMCs with essential 
oil for 24 hours (Caldefie-Chezet, Fusillier et al. 2006).  The essential oil also 
exerted an antioxidant effect by decreasing ROS production. It was concluded 
that essential oil may work as an anti-inflammatory mediator through its 
antioxidant activity, and may also efficiently protect the organism by reducing 
the proliferation of inflammatory cells, without affecting their capacity to secrete 
anti-inflammatory cytokines. 
The possible therapeutic effect of garlic as an anti-inflammatory agent was also 
investigated by looking at cytokine expression in the treatment of patients with 
irritable bowel disease, an inflammatory condition (Hodge, Hodge et al. 2002).   
Garlic (Allium sativum) has several compounds known to modulate leukocyte cell 
proliferation and cytokine production.  In vitro results showed that production of 
pro-inflammatory IL-12 by monocytes was inhibited significantly in the presence 
of low concentrations of garlic extract.  Production of anti-inflammatory IL-10 
significantly increased.  At slightly higher concentrations of garlic extract the 
production of pro-inflammatory TNF-α, IL-1β, IL-2, IL-6, IL-8 and IFN-γ decreased 
significantly.  Methylprednisolone is an anti-inflammatory glucocorticosteriod 
commonly used for irritable bowel disease. It was stated that the inhibitory 
activity of methylprednisolone combined with garlic extract on leukocyte 
cytokine production was additive. 
A separate study found that methylprednisolone may act to inhibit the release of 
pro-inflammatory cytokines IL-1α and β, IL-2, IFN-γ, and TNF-α and up-regulate 
the anti-inflammatory cytokine IL-10 (Hodge, Hodge et al. 1999).  IL-10 decreases 
pro-inflammatory cytokines in circulation so has an over-all anti-inflammatory 
effect (Opal and DePalo 2000). 
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Two recent studies used ELISA and RT-PCR to show a dose-dependent inhibition 
of TNF-α, IL-1 and IL-6 by the immunosuppressive drug dexamethasone.  
Production of cytokines IL-2, IL-4, IL-6, IL-10, INF-γ and TNF-α indicate that 
dexamethasone is a broad-range immunosuppressant at the level of both the 
secreted product and mRNA (Bruin, Hommes et al. 1995; Rowland, McHugh et al. 
1998). 
The functional definition of an anti-inflammatory cytokine is the ability of the 
cytokine to inhibit the synthesis of IL-1, tumour necrosis factor (TNF), and other 
major pro-inflammatory cytokines. The principal anti-inflammatory cytokines are 
IL-1ra (Interleukin-1 receptor antagonist), IL-4, IL-10, IL-11, IL-13 and TGF-β and 
in some cases TNF-α as mentioned previously.  Cytokines act in concert with 
specific cytokine inhibitors and soluble cytokine receptors to regulate the human 
immune response (Opal and DePalo 2000).  IL-1ra blocks the action of IL-1α and 
IL-1β functional ligands by competitive inhibition at the IL-1 receptor level.  The 
anti-inflammatory cytokines IL-4, IL-6, IL-10, and IL-13 inhibit the synthesis of IL-
1β, and stimulate the synthesis of IL-1ra (Dinarello 1997).   
3.2.1 Tumor necrosis factor-α 
TNF-α most commonly acts as an inflammatory cytokine that binds the TNF 
receptor (TNFR).  Contact with the ligand causes a conformational change to 
occur in the receptor, leading to the dissociation of the inhibitory protein SODD 
from the intracellular domain. This dissociation enables the adaptor protein 
TRADD to bind to the domain, serving as a platform for subsequent protein 
binding. Following TRADD binding, three pathways can be induced (Locksley 
2001).  Of key importance to inflammation is the NF-κB pathway.  To get 
activation of NF-κB, TRADD recruits TRAF2 and RIP.  TRAF2 in turn recruits the 
multi-component protein kinase IκB, enabling the serine-threonine kinase RIP to 
activate it.  An inhibitory protein, IκBα, that normally binds to NF-κB and inhibits 
its translocation, is phosphorylated by IκB and subsequently degraded, releasing 
NF-κB. NF-κB is a heterodimeric transcription factor that translocates to the 
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nucleus and mediates the transcription of proteins involved in cell survival and 
proliferation, inflammatory response, and anti-apoptotic factors (Stegmaier, 
Kirchhoff et al. 2008).  
When TNF-α acts as an anti-inflammatory cytokine it negatively regulates the IL-1 
system by inducing the release of IL-1 type II decoy receptor.  This results in an 
overall reduction of IL-1 stimulus to the cells resulting in an anti-inflammatory 
effect through a multifunctional aminopeptidase (Orlando, Matteucci et al. 
1997). 
3.2.2  Interleukin-1 
One of the earliest cytokines described, IL-1 was found to induce fever and 
control lymphocytes.  There are two forms of IL-1, IL-1α and IL-1β, which are 
both pro-inflammatory.   The IL-1 receptor antagonist (IL-1ra) is a molecule that 
competes with IL-1α and IL-1β for receptor binding to the IL-1 receptor (IL-1r), 
but does not induce any intracellular response, thus acting as an anti-
inflammatory agent (Gabay 1997).  IL-1α, IL-1β and IL-1ra are produced by both 
macrophages and monocytes during an inflammatory response (Dinarello 2000).  
IL-1ra is produced by monocytes and macrophages and is released into the 
systemic circulation in greater than 100-fold excess over either IL-1α or IL-1β 
after stimulation by LPS.  The synthesis of IL-1ra and IL-1β are differentially 
regulated at their own promoter sites. Although bacterial LPS stimulates the 
synthesis of both IL-1β and IL-1ra, other stimuli cause differential release of IL-
1ra and IL-1β, but these anti-inflammatory stimuli must be present in far greater 
concentrations than those of pro-inflammatory IL-1α and IL-1β cytokines to 
inhibit their actions (Gabay 1997; Arend, Malyak et al. 1998). This explains why 
acute inflammation can develop into chronic inflammation.  IL-1ra has been 
proposed to be expressed in the skin as a protective measure to ensure that the 
antagonist is immediately available to counteract the potent effects of IL-1 as a 
result of injuries. The expression of IL-1ra in the skin suggests that it also could 
serve to attenuate effects of IL-1 in damaged tissue (Arend, Malyak et al. 1998). 
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3.2.3  Interleukin-6 
In wound repair, expression of IL-1α, IL-1β, TNF-α and IL-6 was shown to be 
strongly up-regulated during the inflammatory phase of healing (Gallucci, 
Simeonova et al. 2000).  For this reason these cytokines are labelled pro-
inflammatory cytokines.  Wounds in IL-6 knock-out animals were found to take  
up to three times longer to heal than those inflicted in wild-type controls and 
their subsequent granulation tissue formation was impaired (Gallucci, Simeonova 
et al. 2000). These abnormalities were completely rescued by administration of 
recombinant murine IL-6 protein 1 hour before wounding. Researchers 
concluded that IL-6 is crucial for kick-starting the healing response, both via its 
mitogenic effects on wound edge keratinocytes and via its chemoattractive effect 
on neutrophils (Gallucci, Simeonova et al. 2000). 
3.2.4  Interleukin-10 
IL-10 is an anti-inflammatory cytokine thought to play a major role in the 
limitation and cessation of inflammatory responses. IL-10 decreases production 
of monocyte/macrophage-derived pro-inflammatory cytokines TNF-α, IL-1, IL-6, 
IL-8 and IL-12 (Opal and DePalo 2000).  Produced primarily from monocytes, it 
regulates growth and/or differentiation of various immune cells, as well as 
keratinocytes and endothelial cells during the process of wound healing 
(Gallucci, Simeonova et al. 2000).  Wounded IL-10 null mice were characterized 
by a significantly higher inflammatory cell infiltration and collagen deposition 
compared with control mice, showing that IL-10 inhibits the infiltration of 
neutrophils and macrophages toward the site of injury as well as inhibiting the 
expression of several chemokines and pro-inflammatory cytokines (Liechty, Kim 
et al. 1999). 
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3.2.5  Growth factors 
Also of interest to this research are growth factors.  A growth factor is a naturally 
occurring substance capable of stimulating cellular growth, proliferation and 
cellular differentiation. Growth factors are important for regulating a variety of 
cellular processes, including wound healing and inflammation.  Growth factors 
typically act as signalling molecules between cells, with actions mediated by 
specific receptors on the surface of their target cells (Pierce, Mustoe et al. 1991).  
They often promote cell differentiation and maturation, the extent of which 
varies between growth factors. For example, bone morphogenic proteins 
stimulate bone cell differentiation, inducing the formation of bone and cartilage 
(Vukicevic, Stavljenic et al. 1995), while fibroblast growth factors and vascular 
endothelial growth factors stimulate blood vessel differentiation (angiogenesis) 
(Risaua 1990).   
3.2.5.1  Platelet derived growth factor 
A key player in wound healing is platelet-derived growth factor (PDGF).  PDGF is 
one of the numerous growth factors, or proteins, that regulate cell growth and 
division. In particular, it plays a significant role in angiogenesis. Migration of 
human dermal fibroblasts is critical for skin wound healing.  The platelet-derived 
growth factor (PDGF) is the major pro-motility factor in human serum for 
fibroblast motility on type I collagen (Guan, Fan et al. 2009).  Fibroblasts play 
essential roles in cutaneous wound repair and remodelling. They proliferate to 
expand, migrate into the wound bed, synthesize new extra cellular matrix, and 
express thick actin bundles as myo-fibroblasts to bring about contraction of the 
wound (Singer 1999).  A number of growth factors/cytokines have been reported 
to affect, directly or indirectly, fibroblast motility. They include basic and acidic 
fibroblast growth factors, transforming growth factor-β1 and β2, vascular 
endothelial growth factor and PDGF (Singer 1999; Imanishi 2000).  
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PDGF-BB elicits its biological responses via binding to its specific cell surface 
receptors, PDGFR-α and PDGFR-β. These two receptor isoforms dimerise upon 
binding the PDGF dimer, leading to three possible receptor combinations, 
namely -αα, -ββ and -αβ.  PDGF binding activates the PDGFR protein tyrosine 
kinase within seconds, leading to auto-phosphorylation of the receptor creating 
binding sites for downstream signal transduction molecules, which in many cases 
also are substrates for the kinase.  Examples of the different signaling cascades 
induced by PDGFR tyrosine kinase receptors are the mitogen-activated protein 
kinase (MAPK) pathway, the phosphatidyl-inositol-3 kinase (PI3Κ) pathway and 
the phospholipase-γ (PLCγ) pathway (Heldin 1999).    
MAPK family members have been found to regulate various biological functions 
by phosphorylation of particular target molecules (such as transcription factors, 
other kinases etc.) located in cell membrane, the cytoplasm and the nucleus, and 
thus contribute to the regulation of different cellular processes such as cell 
proliferation, differentiation, apoptosis and immune responses.   
PI3Κ is activated by the majority of tyrosine kinase receptors. Similarly to other 
SH2 domain-containing proteins, PI3Κ forms a complex with PY sites on activated 
receptors. The main function of PI3K activation is the generation of PIP3, which 
functions as a second messenger to activate downstream tyrosine kinases Btk 
and Itk, and the Ser/Thr kinases PDK1 and Akt.  The major biological functions of 
Akt activation can be classified into three categories – cell survival, cell 
proliferation and cell growth (Schabbauer, Tencati et al. 2004), all of these being 
important in inflammation. 
In vivo, direct application of PDGF-BB to skin wounds induces increased 
formation of granulation tissue (Grotendorst 1985; Sprugel 1987) and increased 
wound breaking strength, thereby increasing the rate of healing (Pierce 1994).  
Honey has been shown to have almost identical actions on wounds to those of 
PDGF-BB (Subrahmanyam 1991; Subrahmanyam 1998; Misirlioglu, Eroglu et al. 
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2003) so it was of interest to include this growth factor in the cytokine analysis to 
determine if honey had an effect on the transcription of PDGF. 
3.2.5.2  Transforming growth factor-β 
Transforming growth factor beta (TGF-β) is a secreted protein that exists in three 
isoforms; TGF-β1, TGF-β2 and TGF-β3. TGF-β was the original name for TGF-β1 
which was the first factor described.   TGF-β1 is a multifunctional growth factor.  
It plays a pivotal role in wound healing and has been shown to accelerate 
impaired wound healing. However, high systemic levels of TGF-β1 have generally 
been associated with fibrotic disease processes such as myelofibrosis and 
pulmonary fibrosis (Hakvoort 2000).  It is always present in platelets, but it is also 
produced by several cell types present in wounds, including activated 
macrophages, granulocytes, fibroblasts and keratinocytes (Martin 1992).  TGF-β 
receptors are widely distributed and found on essentially all cell types (Slavin 
1996). Immediately after wounding, TGF-β1 is released in large amounts from 
platelets. This initial kick-start of active TGF-β1 from platelets serves as a chemo-
attractant for neutrophils, macrophages, and fibroblasts, and these cell types 
further enhance TGF-β1 levels. TGF-β is released as an inactive peptide, and 
requires activation either by proteolysis or as a result of the acidic environment 
within a wound (Werner and Grose 2003). 
 
3.2.6  Real-time PCR 
Real-time PCR is a rapid, highly sensitive and high-throughput molecular 
technique to quantify nucleic acids by amplifying particular regions of DNA 
between two predetermined positions termed the amplicon.  The procedure 
follows the general principle of polymerase chain reaction; its key feature is that 
the amplified DNA is detected as the reaction progresses in real time. This is a 
new approach compared with standard PCR, where the product of the reaction is 
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detected at the end of the reaction.  For mRNA-based PCR the RNA sample is first 
reverse transcribed to cDNA with reverse transcriptase, and the cDNA is 
amplified in order to robustly detect and quantify gene expression from small 
amounts of RNA.  
PCR has three phases, exponential phase, linear phase and plateau phase. The 
exponential phase is the earliest phase in the PCR, in which product increases 
exponentially since the reagents are not limited.  During the exponential phase 
the PCR product (cDNA) will ideally double during each cycle if efficiency is 
perfect, i.e. 100% (maximum efficiency is therefore calculated as 2) if the PCR 
conditions, primer characteristics, template purity, and amplicon lengths are 
optimal.  The linear phase is characterized by a linear increase in product as PCR 
reagents become limited. The PCR will eventually reach the plateau phase during 
later cycles, and the amount of product will not change, because some reagents 
become depleted. Real-time PCR exploits the fact that the quantity of PCR 
products in the exponential phase is in proportion to the quantity of initial 
template under ideal conditions.  This allows calculations to be made estimating 
the initial copy number of the expressed gene that was present, comparing this 
with the initial copy numbers of a reference gene and other sample genes 
quantified in the same run (Yuan, Reed et al. 2006).  A “house-keeping gene” 
(one expressed in constant amounts in cells) is used as the reference gene. 
Detection is fluorescence-dependent at the end of each PCR cycle.  A fluorescent 
marker is hybridised to the cDNA between two PCR primers for the gene of 
interest.  As the PCR proceeds, the 5’ nuclease activity of the Taq polymerase 
cleaves the probe, releasing the tag such that the fluorescence is proportional to 
the amount of cDNA present.  Several methods are available for analysis of 
results.  The method chosen for this study is fully described in Section 3.4.8. 
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3.3  Aims 
The aim of this study was to determine the effect of honey on the expression of 
cytokine genes in THP-1 cells. The growth factors PDGF and TGF-β and the 
following cytokines were selected for this study: IL-1ra, IL-1β, IL-6, IL-10 and TNF-
α.  Their expression was assayed using real time-PCR.  Specific incubation times 
were chosen according to current research on cytokine and growth factor 
expression in THP-1, to achieve maximal expression or change in expression of 
the individual gene.  Expression of TNF-α was assayed after 6 hours incubation, 
IL-1β and IL-6 after 24 hours (Segura 2001),  TGF-β and PDGF after 8 hours 
(Shiffman, Mikita et al. 2000) and  IL-10 after 6 hours (Lee 1996). 
 
3.4  Methods 
3.4.1  Reagents 
3.4.1.1  Honey solutions 
The required concentrations of Manuka honey and artificial honey were achieved 
by dilution of the honey with sterile RPMI 1640 complete medium. Manuka 
honey (M144) was obtained from the Honey Research Unit, University of 
Waikato, NZ and had a non-peroxide antibacterial activity equivalent to 12% w/v 
phenol (Allen, Molan et al. 1991).  Honey was diluted by weighing out 1.37 g (1 
ml) of honey and diluting this with 19 ml of sterile RPMI 1640 ( to achieve a V/V 
concentration of 5%) immediately prior to use and filtered (50 µm, 8 µm and 3 
µm, Minisart Sartorius filters, Millipore corporation) to remove pollen, bee 
tissues etc.  Undiluted honey was kept at 4°C in dark coloured containers to 
prevent enzyme denaturation and degradation.  Artificial honey was used to 
provide a control for the osmotic effect of the natural sugars found in honey.  
The composition of this simulated the sugar composition of honey, as published 
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(White 1975).  Throughout the thesis honey concentrations are shown as % V/V.  
Endotoxin-free flasks, disposable equipment and reagents were used throughout 
this research. 
3.4.1.2   LPS solutions 
A 1 mg/ml stock solution of LPS (E. coli serotype 0127:B8; Sigma-Aldrich UK; Cat. 
No.# L4516) was diluted to working concentrations of 100 µg/ml diluted with 
endotoxin-free RPMI 1640 medium. A final assay concentration of 100 ng/ml was 
achieved after adding to the cells according to viability testing in Section 2.3.3.   
3.4.1.3 THP-1 cell lines 
THP-1 cells were cultured in suspension and passaged as required to maintain 
densities between 5 x 105 and 1 x 10 6 cells/ml as described in Section 2.3.1.  Cells 
were grown in RPMI 1640 complete medium with 10% foetal calf serum, at 37°C 
(95% air, 5% CO2) as described in Section 2.3.2.   
3.4.2  Osmotic tolerance 
Preliminary work on osmotic tolerance ranges for THP-1 cell lines was 
undertaken and an acceptable honey concentration of 0.25% was chosen for the 
study.  This concentration was also used by Dr Nichola Harcourt as mentioned 
previously.  Briefly cells were exposed to varying concentrations of honey (0.05%, 
0.15%, 0.25%, 0.5%, 1%, 2%).  The mortality of the cells was assessed after 24 
hours and 48 hours using the MTT assay (Section 2.3.3.).  Viability remained over 
95% for concentrations of honey up to 1%, results not shown. 
3.4.3  Assay design 
THP-1 cells were incubated with Manuka honey and/or LPS to investigate the 
effect of honey on the expression of cytokine mRNA.  THP-1 cells with medium 
alone served as controls for constitutive cytokine expression.    
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Cells were cultured for 24 hours in endotoxin free tissue culture flasks (Nunc) 
with six treatments; (1) RPMI growth medium alone (negative control), (2) 
Manuka honey (to measure stimulatory effects), (3) artificial honey (osmotic 
control), (4) LPS (positive control), (5) Manuka honey and LPS and (6) artificial 
honey and LPS (to measure modulatory effects).  A 7 ml sample of freshly sub-
cultured cells was treated in each flask.  To achieve the final 0.25% concentration 
of honey, 50 µl of 5% diluted honey was added per ml of cells treated (350 µl per 
flask) or the equivalent in medium for the negative control.  To achieve a final 
concentration of 100 ng/ml LPS for cell treatment, 1 µl of 100 µg/ml working 
solution LPS was added per ml of cells (7 µl per flask).   
At specific time intervals (0, 6, 8 or 24 hours) flasks were inverted carefully to re-
suspend cells and 1 ml samples were removed and placed on ice.  The RNA was 
then removed.  In the case of adherent LPS-treated cells the flasks were tapped 
to loosen adhered cells prior to sample removal or attached cells were lysed in 
the flask with Trizol. 
3.4.4  Lysis of cells and RNA extraction 
The protocol from Section 2.4.3.1 was followed for RNA extraction and storage. 
3.4.5   First strand cDNA synthesis 
The procedure described in Section 2.4.3.2 was followed for synthesis of cDNA.   
3.4.6   Conventional RT-PCR 
3.4.6.1   Oligodeoxynucleotide primers 
All oligo-deoxynucleotide primers were purchased from Sigma-Aldrich.  Oligo-
deoxynucleotide primer pair sequences used in this Chapter are listed in Table 1 
of Appendix 2 and prepared according to the method described in Section 2.3.12. 
Working oligo-deoxynucleotide primer solutions were prepared for each 
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cytokine by adding 80 µl of TE buffer (described in Section 2.3.10.2.) to 10 µl 
each of forward and reverse primer stock, and stored at 4°C. 
3.4.6.2  Conventional RT-PCR analysis 
The procedure in Section 2.4.3.3 was followed for conventional RT-PCR analysis 
to confirm cDNA synthesis from RNA, using the primer set for the housekeeping 
gene β-actin.    
3.4.6.3  Electrophoresis of DNA 
A 2% gel was run to confirm that cDNA had been successfully amplified using the 
primer pairs for β-actin.  Samples (10 µl) were run along-side 10 µl of 100 bp DNA 
ladder (Invitrogen).  Gels were prepared and electrophoresed as described in 
Section 2.4.3.4.  DNA was illuminated using UV and photographed using the GEL-
DOC system (Bio-Rad).  Once the presence of β-actin was confirmed the samples 
were then used to further quantify the cytokine levels in quantitative real-time 
RT-PCR (qRT-PCR). 
 
3.4.7  Quantitative Real-Time PCR 
The method qRT-PCR was used to provide a quantitative measure of the 
transcription of mRNA of target genes for the proteins of interest.  SYBER Green®   
(Roche) was used as a fluorescent marker, allowing any double-stranded DNA 
generated during PCR to be selected.  Specificity of the PCR products was 
confirmed by dissociation curve analysis and electrophoresis on a 2% agarose 
gel. 
Purified RNA was prepared for qRT-PCR according to a published method 
(Konnai, Usui et al. 2003) adapted by Dr Ray Cursons (University of Waikato) as 
follows.   
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All steps were carried out in a dedicated PCR cabinet.  Quantitative RT-PCR was 
performed using a Rotor-Gene™ 6000 instrument (Corbett Research) to perform 
the PCR reaction, including fluorescent emission and detection of the signals.  
The qRT-PCR reactions were carried out in a total volume of 20 µl in 100 µl thin-
walled tubes (Corbett Research).   
3.4.7.1  qRT-PCR reaction master mix 
A reaction master mix was prepared consisting of: Master Mix (10x) 
Thermostart®  Reaction Buffer (AB Ltd), 1/20,000 dilution of SYBR® Green I dye 
(Invitrogen), 250 µmol/l deoxynucleotide triphosphates (Invitrogen), 5 mmol/l 
MgCl2 (pH 8.5) (Invitrogen), 0.5 U of ABGene Thermostart® DNA polymerase (AB 
Ltd), 5 pmol of specific primers, and 200 ng of cDNA (measured using a Nanodrop 
Spectrophotometer).     
A frequent cause of concern among investigators performing qRT-PCR is false 
positives caused by genomic DNA contamination from the sample itself or the 
environment it was prepared in.  For this reason a negative control was used to 
check there was no genomic DNA contamination of the reagents by substituting 
cDNA with sterile water for every reaction set. 
3.4.7.2  RT-PCR thermo-cycling program 
Touchdown thermo-cycling steps were as follows: 
1. Initial denaturation at 95°C for 10 minutes 
2. 94°C for 20 seconds 
3. Annealing temperature started at 70°C for 20 seconds and then 
decreased at 1°C/cycle for 20 seconds for the first 15 cycles 
4. Extension at 68°C for 40 seconds 
5. Fluorescence acquisition step at 80°C for 15 seconds (excitation at 
470 nm, detection at 510 nm) 
6. Steps 2-5 repeated 39 times 
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3.4.7.3  SYBR® Green I melting curve analysis 
A melting curve analysis followed touchdown thermo-cycling to ensure products 
were specifically amplified.  PCR products were heated from 75°C to 99°C in 
0.5°C increments every 5 seconds.  The denaturing conditions dissociated the 
double stranded DNA into single strands as the melting temperature (Tm) was 
reached for each specific PCR product.  As a consequence of denaturing, the 
SYBR® Green I dye is released and fluorescence intensity drops.  This indicates 
the correct Tm for the gene. 
Seven genes were selected for study and each sample was analysed for both the 
target gene and an endogenous control gene β2-microglobµlin (β2M), a 
housekeeping gene with expression that remains fairly consistent regardless of 
treatment (Ishii, Wallace et al. 2006).  The expression levels of the target genes 
were reported relative to the expression levels of β2M. 
Each primer pair has a specific product melting point above 80°C influenced by 
product length and GC%.  Examples are shown in Figures 3.1 and 3.2. 
 
 
Figure 3.1:  CYBR® Green I melting curves for β2M (85.6 °C) and IL-1β (88.9 °C).   
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Figure 3.2:  CYBR® Green I melting curves for IL-10 (85.6 °C) and TGF-β (88.9 °C). 
 
Products with melting points different from those expected were considered to 
be miss-primed or non-specific, and therefore the mRNA not present in large 
enough copy numbers to be detected.  A result of zero was given to these 
samples for the purposes of comparing amplification for gene of interest (GOI) to 
the housekeeping gene, β2M.  All primers were selected to span intron 
sequences so that genomic DNA amplification was not possible. 
End products for real-time PCR were further analysed by gel electrophoresis  
(Figure 3.3). This verifies the size of the amplified product by comparison with 
the standard ladder, and shows up contamination in the form of multiple bands.  
The agarose gel was prepared as described in Section 2.4.3.4 omitting the 
ethidium bromide because SYBER Green® dye was present.  Product bands were 
visualised using a GIBCO BRL ultra-violet trans-illuminator (Life Technologies) at 
312 nm, photographed using a COHU High Performance CCD camera and digitally 
stored.  All product band base-pair lengths were checked by comparison with a 
100 bp DNA ladder (Invitrogen) unless otherwise stated. 
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Figure 3.3:   Quantitative real-time RT-PCR products run on a 2% gel.  IL-1β      
(315 bp) and β2M (295 bp) are shown alongside a 100 bp ladder. 
 
 
3.4.8  Analysis of real-time quantitative RT-PCR results 
A linear regression program (LinReg) used exported fluorescence level data from 
each cycle during the real-time quantitative PCR runs. Regression lines for each 
sample were calculated to fit the log-linear phase of the data points.  A minimum 
of four data points were included in the data analysis for each sample, and the 
slope was chosen for each data set by taking in combination the slope closest to 
the maximum and the highest r2 value.   
Only samples with PCR efficiencies above 1.5 were selected.  The initial copy 
number (ICN - the starting concentration (No) of the cDNA template of each 
sample was calculated from the intercept extrapolated from the straight line that 
fitted best to include the data points which were expressed in terms of 
fluorescence intensity. 
All values were expressed as the expression relative to the control sample (time 
0) and corrected for β2M gene expression (endogenous control gene).  To 
normalise the level of fluorescence of each gene of interest the following 
equation was used: 
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Step 1 
Relative expression at time 0 =  
 
Step 2 
For each time point (x) the relative expression of the GOI was calculated by 
normalising the levels of fluorescence to that obtained for β2M at the same time 
point: 
 
Relative expression at time x =  
     
Step 3 
The relative expression of the GOI at time x was then normalised for the relative 
expression of the same gene at time 0, by dividing the value obtained from Step 
2 by the value obtained from Step 1. 
 
3.5  Results 
Results from RT-PCR are displayed graphically (Figures 3.4 – 3.9) by the 
calculated individual initial copy number (ICN) of the GOI cDNA templates, 
relative to the reference gene (housekeeping β2M).  This provides a normalised 
expression so that the results can be compared with each other directly.  Results 
were analysed by ANOVA and Tukey’s multiple pairwise comparisons compared 
Concentration No value for GOI a time 0 
    Concentration No for β2M at time 0 
Concentration No value for GOI at time x 
Concentration No value for β2M at time x 
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with the non-activated control (monocytes) and or the LPS-activated control 
(macrophages).  A confidence level of p<0.001 was selected for the analysis.   
Figure 3.4 shows LPS had a significant effect (p<0.001) of increasing the 
expression of IL-1β (from 0.009 to 0.7) compared with non-treated control 
monocytes, whereas honey does not.  The expression of IL-1β in LPS-activated 
macrophages was not significantly affected by the addition of honey.   
 
 
Figure 3.4.  The effect of honey (0.25%) and LPS (100 ng/ml), separately and in 
combination, on IL-1β gene expression after 24 h treatment. Results were calculated as 
individual initial copy number (ICN) of the GOI cDNA templates, relative to the reference 
gene (housekeeping β2M) from the same cell population. Error bars show ± 1 SD of the 
mean of five experiments.  *p<0.001 analysed by ANOVA and Tukey’s multiple pairwise 
comparisons compared with un-treated monocytes. 
 
Figure 3.5 shows that LPS and honey each significantly (p<0.001) increased the 
expression of the IL-1ra (from 0.6 to 1.5 and 1.1 respectively), from the 
expression in non-treated control monocytes.  The effect of honey on the 
expression of the IL-1ra in macrophages activated by LPS was to give a significant 
(p<0.001) further increase (about four times the increase that resulted from LPS 
alone, from 1.5 to 6). 
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Figure 3.5.  The effect of honey (0.25%) and LPS (100 ng/ml), separately and in 
combination, on IL-1ra gene expression after 24 h treatment. Results were calculated as 
individual initial copy number (ICN) of the GOI cDNA templates, relative to the reference 
gene (housekeeping β2M) from the same cell population. Error bars show ± 1 SD of the 
mean of five experiments.  *p<0.001 analysed by ANOVA and Tukey’s multiple pairwise 
comparisons compared with the un-activated monocytes.   #p<0.001 analysed by ANOVA 
compared with the LPS-activated control. 
 
Figure 3.6 shows that LPS and honey each significantly (p<0.001) increased the 
expression of TNF-α compared to non-treated control monocytes, but the 
increase with honey was less than that with LPS.  When honey was added to LPS-
activated macrophages this resulted in a significant (p<0.001) reduction of TNF-α 
expression (decreased from 6 to 1), yet the expression level was still higher than 
with honey alone (0.1). 
Figure 3.7 shows that LPS and honey each increased the expression of IL-10 
significantly (p<0.001) (0.065 and 0.05 respectively) compared with the 
expression of non-treated control monocytes (0.006).  In the LPS-activated 
macrophages honey had a significant (p<0.001) effect of increasing the 
expression of IL-10 beyond that caused by LPS (from 0.065 to 0.6). 
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Figure 3.6.  The effect honey (0.25%) and LPS (100 ng/ml), separately and in 
combination, on TNF-α gene expression after 6 h treatment. Results were calculated as 
individual initial copy number (ICN) of the GOI cDNA templates, relative to the reference 
gene (housekeeping β2M) from the same cell population. Error bars show ± 1 SD of the 
mean of five experiments.  *p<0.001 analysed by ANOVA and Tukey’s multiple pairwise 
comparisons compared with the un-activated monocytes.   #p<0.001 analysed by ANOVA 
compared with the LPS-activated control. 
 
 
Figure 3.7. The effect of honey (0.25%) and LPS (100 ng/ml), separately and in 
combination, on IL-10 gene expression after 6 h treatment.  Results were calculated as 
individual initial copy number (ICN) of the GOI cDNA templates, relative to the reference 
gene (housekeeping β2M) from the same cell population. Error bars show ± 1 SD of the 
mean of five experiments.  *p<0.001 analysed by ANOVA and Tukey’s multiple pairwise 
comparisons compared with the un-activated monocytes.   #p<0.001 analysed by ANOVA 
compared with the LPS-activated control. 
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Figure 3.8 shows that LPS and honey each significantly (p<0.001) increased the 
expression of TGF-β compared to the expression in non-treated control 
monocytes (from 0.5 to 1 and 7.5 respectively).  In LPS-activated macrophages 
honey significantly (p<0.001) reduced the expression of TGF-β compared with 
that caused by LPS (from 1 to 0.75) yet this expression level was still significantly 
(p<0.001) higher than in non-activated monocytes (0.5).  
 
 
Figure 3.8.  The effect of honey (0.25%) and LPS (100 ng/ml), separately and in 
combination, on TGF-β gene expression after 8 h treatment.  Results were calculated as 
individual initial copy number (ICN) of the GOI cDNA templates, relative to the reference 
gene (housekeeping β2M) from the same cell population. Error bars show ± 1 SD of the 
mean of five experiments.  *p<0.001 analysed by ANOVA and Tukey’s multiple pairwise 
comparisons compared with the un-treated monocytes.   #p<0.001 analysed by ANOVA 
compared with the LPS-activated control. 
 
Figure 3.9 shows that LPS and honey each significantly (p<0.001) reduced the 
expression of PDGF compared with the expression in non-treated control 
monocytes (from 1 to 0.001 and 0.085 respectively).  In LPS-activated 
macrophages honey significantly (p<0.001) increased the expression of PDGF 
compared with that caused by LPS (from 0.01 to 4). The expression level with 
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honey combined with LPS was significantly (p<0.001) higher (4) than in non-
activated monocytes (1). 
 
 
 
Figure 3.9.  The effect honey (0.25%) and LPS (100 ng/ml) on PDGF gene expression after 
8 h treatment.  Results were calculated as individual initial copy number (ICN) of the GOI 
cDNA templates, relative to the reference gene (housekeeping β2M) from the same cell 
population. Error bars show ± 1 SD of the mean of five experiments.  *p<0.001 analysed 
by ANOVA and Tukey’s multiple pairwise comparisons compared with the un-treated 
monocytes.  #p<0.001 analysed by ANOVA compared with the LPS-activated control. 
 
Table 3.1.  Summary of cytokine gene expression in response to honey (0.25%), in un-
activated THP-1 cells (monocytes) and LPS activated THP-1 cells (macrophages).  A 
significant increase or decrease in relative ICN gene expression is cited compared to the 
non-honey treated controls.  Data taken from Figures 3.4-3.9. 
Cytokine/growth 
factor 
Un-activated 
monocytes 
LPS activated 
macrophages 
IL1-β No change No change 
IL1ra Increase     0.3 - 1 Increase      1.5 - 6 
TNF-α Increase     0.04 - 0.1 Decrease    6 - 1 
IL-10 Increase     0.0065 - 0.05 Increase      0.065 - 0.6 
TGFβ Increase     0.5 - 7.5 Decrease    1 - 0.75 
PDGF Decrease   1 - 0.85 Increase     0.01 - 4 
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3.6   Discussion 
Artificial honey had no effect on cytokine expression in monocytes or LPS-
activated macrophages which is to be expected due to the low dilution rate of 
0.25% (results not shown).  This low concentration adds only a very small 
amount of extra sugars to what was already available to the cells in the medium.  
A similar finding has been reported by other researchers as well (Tonks, Cooper 
et al. 2003).   
Shown in Figures 3.4 – 3.9 are the effects of LPS, honey or a combination on the 
expression of cytokines in THP-1 cells.  Honey induced TNF-α expression 
significantly (p<0.001), but the increase was not to the magnitude expected in 
THP-1 cells compared with research reported elsewhere (Tonks, Cooper et al. 
2003).  This may be due to the different cell lines or honey varieties being used in 
the different studies.  It can be concluded that honey has a modulating effect, 
reducing the expression of TNF-α stimulated by adding LPS to the cells, and this 
is in line with published findings (Tonks, Cooper et al. 2003).   This may not be a 
direct effect of honey on TNF-α expression, but as a result of increasing one or 
more of the anti-inflammatory cytokines, which, in turn, cause a decrease in TNF-
α expression through various feedback loops etc.   
As mentioned previously, the significance of increasing the cytokine expression 
of TNF-α may lie in one of two possibilities (or both): 1) TNF-α can acts as an anti-
inflammatory cytokine by negatively regulating the IL-1 system by inducing the 
release of IL-1 type II decoy receptor, 2) TNF-α can act in a pro-inflammatory 
manner by initiating the NF-κB pathway important in the onset of inflammation.  
The research presented in this chapter potentially explains one of the 
mechanisms at least, for the therapeutic properties of honey of reducing 
inflammation.  A topical application of honey to an uninfected wound (ie: no 
bacterial LPS present) would be expected to initiate inflammation allowing 
healing to begin or allow inflammation to conclude in a controlled way by slightly 
increasing the expression of TNF-α and initiating the NF-κB pathway.  Whereas a 
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topical application of honey to an infected wound where LPS is present and 
therefore the tissue is inflamed, would reduce the expression of TNF-α 
preventing a chronic state of inflammation by allowing the inflammation to 
resolve. 
IL-1β gene expression was significantly (p<0.001) increased by LPS activation in 
monocytes.  Honey did not significantly affect the gene expression of IL-1β either 
with or without LPS treatment.  Interestingly, there was an increase in IL-1ra 
expression by honey.  Honey and LPS separately had a significant (p<0.001) effect 
by increasing the expression of IL-1ra from that in non-activated monocytes, and 
honey had a significant (p<0.001) additive effect by increasing the expression 
from that in LPS-activated macrophages (from 1.5 – 6).  So while the 
inflammatory IL-1β was not changed in response to honey as previously 
published, the anti-inflammatory competitor (for receptor sites) was increased.  
This may allow the monocytes/macrophages to recruit more immune cells to the 
affected site, yet dampen down the inflammatory response of these recruited 
cells so inflammation is not uncontrolled and thus healing can take place. 
The anti-inflammatory cytokine IL-10 was also significantly (p<0.001) increased in 
honey-treated THP-1 cells.  Honey had approximately the same effect on IL-10 
expression levels as LPS did on non-activated THP-1 cells, but when used in 
conjunction with LPS had a significant (p<0.001) additive effect (from 0.065 – 
0.6).    As mentioned previously, research has shown that increasing levels of IL-
10 inhibit macrophage differentiation from monocytes by 20%, resulting in an 
anti-inflammatory effect (Gredmark 2004).  IL-10 works as an anti-inflammatory 
cytokine to down-regulate the switch from monocyte to macrophage and is 
primarily produced by monocytes.  Increased levels of IL-10 at the wound site 
will reduce the number of macrophages being activated.  Fewer active 
macrophages at a wound site will mean fewer recruited inflammatory cells.  
While this percentage is not large it may be all that is required to switch the 
trend towards chronic inflammation back to controlled acute inflammation.  
Gredmark (2004) noticed that increased levels of IL-10 also resulted in 
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macrophages with a lower ability for attachment to a Transwell filter system 
designed for migration assays, resulting in a more monocyte phenotype.  
Monocytes are much more spherical and uniform in appearance and this was 
definitely observed in honey-treated cells.  While their activity increased from 
that of untreated monocytes, they were more spherical in phenotype than the 
LPS-activated THP-1 cells (see Appendix 1 for comparison of phenotype and 
activity between treatments).   
The expression of the growth factors, PDGF and TGF-β, was examined and 
conflicting results were produced.  In honey-treated cells PDGF expression was 
significantly decreased.  A reduction in PDGF will result in reduced cell migration 
to the site, which results in an anti-inflammatory effect (Guan, Fan et al. 2009).  
So in controlled inflammation, this would be of benefit to the tissue.  LPS-treated 
cells also had a significant (p<0.001) reduction in PDGF expression but to a 
greater extent.  When honey and LPS were used in conjunction, the expression of 
PDGF significantly increased to that above the normal control level.  Increased 
levels of PDGF induce increased formation of granulation tissue and increased 
wound-breaking strength, hastening the rate of healing as mentioned previously.  
This would be of great benefit to an inflamed wound, especially a chronic wound 
where healing is delayed.  Indeed, these therapeutic properties have already 
been identified in honey-treated wounds, as mentioned previously and this 
increase in PDGF may be responsible for these findings.  Perhaps the reason for 
reduced healing in chronic wounds is explained by the decrease in PDGF in LPS-
treated monocytes.  A badly infected wound that will not heal obviously benefits 
from honey application, and it may be due to the PDGF levels increasing from the 
reduced rate observed here. 
Expression of TGF-β was observed to significantly increase when either honey or 
LPS was present.  The honey-induced expression in the cells was significantly 
higher than that induced by LPS.  When honey was used in conjunction with LPS 
there was significantly less expression than with either alone but expression 
remained at a significantly higher level than in the untreated control suggesting 
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that honey partially abrogates the effect of LPS.  As mentioned previously, TGF-β 
has been shown to slow wound healing, yet excessive levels are associated with 
fibrotic disease (Hakvoort 2000; Zhou, Li et al. 2004).   
The ability of honey to increase the expression of TGF-β will be of great benefit 
to the wound as the healing rate will be increased.  In the absence of LPS, honey 
increased TGF- β  expression 15-fold, while in the presence of LPS only a partial 
(50%) reversal was seen.  To speculate, the reduced expression of TGF-β when 
LPS is present may prevent any fibrotic impairment.  Future work on the effect of 
honey on fibroblasts will be necessary to confirm this.  Based on these results it 
can be theorised that honey will reduce the time a wound takes to heal and 
prevent excessive scar tissue being formed.  These therapeutic properties have 
already been reported for honey (Al-Waili and Saloom 1999, Al-Waili, 2011) so 
these findings may provide the mechanism of action. 
When these results are considered together it seems highly likely that honey may 
be having an anti-inflammatory effect on monocytes, and that these effects 
could also be taking place in vivo on monocytes through its effects on expression 
of genes for cytokines, and potentially other immune cells such as neutrophils 
and fibroblasts.  It must be appreciated though, that the gene expression of a 
gene does not mirror the translation and production of the protein.  Certainly it 
has been shown that honey hastens wound healing, reduces redness and pain 
associated with inflammation and reduces scaring (Molan 1999).  Achieving a 
therapeutic balance between limiting inflammation and stimulating repair is 
important, and honey may be doing this by modulating expression of growth 
factors as well as cytokines.  Further work on protein translation for the 
cytokines gene expression mentioned here will be important. 
As honey increased and decreased the expression of different cytokines, it was of 
interest to see how the THP-1 cellular phenotype changed during these 
treatments.  The honey-treated monocytes were observed to have increased 
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pseudopodia activity and it was postulated that these cells would have an 
increased phagocytosis rate.  This became the focus of study for Chapter 4. 
Future studies should aim to investigate the effect of honey on neutrophil and 
monocyte attachment to endothelial cell monolayers.  Published work indicates 
that anti-inflammatory drugs decrease attachment (Diaz-Gonzalez, Gonzalez-
Alvaro et al. 1995).  While honey-treated cells seemed to clump, with increased 
attachment to each other, the increased IL-10 levels may result in less 
attachment to other cell types, thus reducing cell migration and damping down 
the inflammatory feedback loops.  Investigating the mechanism of the clumping 
observed in honey-treated cells should be undertaken.  This would be relevant to 
the current work on inflammation. 
These results confirmed previous findings that honey increases the expression of 
TNF-α (Tonks, Cooper et al. 2001; Tonks, Cooper et al. 2003), though their finding 
that is also increased the expression of IL-1β and IL-6 was not confirmed in the 
present study.  This was thought to be due to low expression of the IL-6 gene.  An 
ELISA assay may prove to be more sensitive.  
 
 
 
 
  
 
Chapter 4 
The effect of honey on the phagocytic activity in THP-1 
macrophages 
 
 
 
4.1  Summary 
In the work in Chapter 3 it was observed that treatment of monocytes with LPS 
and Manuka honey increased pseudopodia activity, resulting in clumping of cells 
and increased mobility. As mentioned earlier (Section 2.2) monocytes do not 
phagocytose yet can be transformed into phagocytic macrophages after 
exposure to activators such as LPS.  It was hypothesized that the honey 
treatment may be acting as an activator by causing differentiation of monocytes 
into macrophages, and therefore may be causing an increase in phagocytosis.  A 
phagocytosis assay was used to quantify the effect of Manuka honey on the 
phagocytosis of LPS-activated THP-1 macrophages and non-activated THP- 
monocytes.  Manuka honey had the unexpected effect of reducing the rate of 
phagocytosis in THP-1 cells.   
 
Manuka honey (up to 1%) prevented up to 80% of the phagocytosis of latex 
particles, E.coli and BCG, and zymosan particles. To characterize the component 
in Manuka honey contributing to the change in the phagocytosis rate, honey was 
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dialysed to separate the sugars from the honey and the dialysate and retentate 
were assayed in the phagocytosis assay with latex particles.  
It was established that the active component in Manuka honey was a high 
molecular weight compound, inhibiting phagocytosis.   
 
4.2 Introduction 
Phagocytosis is a specific form of endocytosis involving the actin-based vesicular 
internalization of solid particles, such as bacteria, a major mechanism used to 
remove pathogens and cell debris.   Phagocytosis is distinct from other forms of 
endocytosis such as pinocytosis which is the vesicular internalization of various 
liquids (Doherty and McMahon 2009). 
Phagocytosis can be viewed as either an opportunity or an obstacle for microbial 
organisms.   Some pathogens have evolved strategies to enter and survive within 
phagocytic cells and others have developed ways to prevent their phagocytosis 
as part of their pathogenic profile (Celli and Finlay 2002).  Of interest to this 
research are the receptors for phagocytosis.  To discriminate between pathogens 
and self, macrophages have evolved a number of phagocytic receptors, such as 
the mannose receptor, that recognize conserved motifs on pathogens. When a 
pathogen binds to a receptor the innate immune system is initiated, which, in 
turn, coordinates the adaptive response where the immune cells are primed to 
recognize non-self antigens and form an immunological memory. Pathogens and 
foreign objects are also phagocytosed by complement receptors after relatively 
nonspecific opsonization with complement, and by Fc receptors after specific 
opsonization with antibodies.  All these receptors induce rearrangements in the 
actin cytoskeleton leading to internalization of the particle and subsequent 
degradation (Allen and Aderem 1996; Aderem and Underhill 1999; Celli and 
Finlay 2002). 
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The best characterized phagocytic receptors on macrophages are the 
complement receptor 3 (CR3), Fc gamma receptor (FcγR), mannose receptor 
(MR) and scavenger receptor (SR).  The CR3 and FcγR are involved in the uptake 
of opsonized micro-organisms during infection. Opsonization involves the binding 
of an opsonin (antibody), to an receptor (antigen) on the pathogen's cell 
membrane. After opsonin binds to the membrane, phagocytes are attracted to 
the pathogen and phagocytose it.  CR3 binds C3bi on complement-opsonized 
targets, whereas FcγR bind to immunoglobulin G (IgG)-coated targets.  Mannose 
receptors and scavenger receptors are involved in phagocytosis of un-opsonised 
targets.  Phagocytosis by both types of receptors is driven by the reorganization 
of filamentous actin (f-actin), but to different extents and the mechanisms of 
uptake are different (Newman, Mikus et al. 1991; Allen and Aderem 1996).   
CR3- and FcR-mediated phagocytosis is a relatively passive process where 
complement-opsonized particles appear to sink into the cell with elaboration of 
small, if any, pseudopodia.  During FcR-mediated phagocytosis, the membrane 
rises above the cell surface and tightly surrounds the particle before drawing it 
into the body of the macrophage.  Unopsonised targets are bound by the MR and 
SR and are dependent on actin rearrangement in a similar manner to FcγR  
(Kaplan 1977; Castellano, Chavrier et al. 2001; May and Machesky 2001; Tricker 
and Cheng).  FcR, MR and SR actin rearrangement is accompanied by the 
activation of the respiratory burst (producing ROS) and by the production of 
arachidonic acid metabolites, a key inflammatory intermediate, and 
inflammatory cytokines, such as TNF-α (Celli and Finlay 2002).  CR3-dependent 
uptake can occur in the absence of any of these pro-inflammatory signals (Caron 
and Hall 1998). 
A substance or process which impedes or prevents the action of phagocytes is 
termed anti-phagocytic.  Cytochalasin B is a cell-permeable mycotoxin.  It 
shortens actin filaments by blocking monomer addition at the fast-growing end 
of polymers.  At high concentrations it inhibits motility, adhesion and 
macrophage fusion, but at lower concentrations F-actin-dependent phagocytosis 
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and macrophage fusion is inhibited (DeFife, Jenney et al. 1999).  It is therefore an 
anti-phagocytic agent and routinely used to identify which phagocytic receptors 
are being used in an assay for phagocytosis (DeFife, Jenney et al. 1999; May and 
Machesky 2001). 
Yeast mannans have been shown to inhibit binding and phagocytosis of zymosan 
(yeast cell wall particle) by macrophages (Sung, Nelson et al. 1983).  β-glucan 
also binds Dectin-1 preventing phagocytosis. (Brown, Taylor et al. 2002; Esteban, 
Rodriguez et al. 2004; Taylor, Brown et al. 2004).  
Phagocytosis can be enhanced by opsonisation agents.  Mannan-binding lectin 
(MBL) constitutes an important part of the human innate immune defence 
system. It has been shown to mediate the activation of complement upon 
binding to specific microbial carbohydrate motifs, to directly opsonise organisms, 
and to enhance the phagocytosis of targets (Arora, Munoz et al. 2001). 
During cell preparation for RT-PCR assays (Chapter 2) it was observed that after 
activation with LPS, THP-1 cells adhered to the flask.  Microscopy work showed 
that the cells were changing morphology and that different activation treatments 
(PMA, LPS, Vit-D3) gave different cell morphologies (Section 2.4).  Time-lapse 
photography of these cells showed that with activation the cells became 
adherent, motile and possessed pseudopodia.  Honey treatment in conjunction 
with LPS treatment caused the cells to clump and form large mobile 
aggregations.  It was assumed that honey was increasing their ability to adhere 
or perhaps increase their scavenging ability.  It was postulated that honey 
increased phagocytosis, based on these observations during time-lapse movies 
(presented in Appendix 1).   
The phagocytosis assay was modified to test the effect of the addition of honey 
on phagocytosis of fluorescent latex particles, two strains of bacteria, E. coli and 
BCG (Bacille Calmette Guerin), and zymosan.  Versions of E.coli and BCG 
expressing green fluorescent protein and FITC-labeled zymosan particles, were 
obtained so that the phagocytosis of the bacteria/particles could be viewed and 
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counted in the same way as the fluorescent latex particles.  The green 
fluorescent protein (GFP) is a 27 kDa protein originally isolated from the jellyfish 
Aequorea victoria/Aequorea aequorea/Aequorea forskalea that fluoresces green 
when exposed to blue light (Prendergast 1978).  GFP has many characteristics 
that make it useful for localization studies in bacteria, primarily its ability to 
fluoresce when fused to target polypeptides without the addition of exogenously 
added substrates (Tsien 1998).  
Latex particles, E. coli and zymosan are all commonly used in phagocytosis assays 
using THP-1 cells (Akiko, Ikuko et al. 2008).  Mycobacterium tuberculosis is a 
facultative intracellular pathogen, which can reside within the macrophages of 
the host. The major immune-pathology associated with tuberculosis results from 
interactions between the live tubercle bacillus and the host’s immune response. 
Mycobacteria have the ability to enter a number of different cell types, but the 
primary cell type that they are thought to replicate within during human disease 
is macrophages (El-Etr and Cirillo 2001). It gains entry to the host cell by taking 
advantage of the phagocytic cells’ ability to phagocytose as a result of binding 
the mannose receptor (Kang 1998; Astarie-Dequeker, N'Diaye et al. 1999; Diaz-
Silvestre, Espinosa-Cueto et al. 2005).  BCG is an attenuated vaccine strain, yet it 
retains its ability to survive within the macrophage (Monahan, Betts et al. 2001).   
4.2.1  Outline of experiments 
The phagocytosis assay utilizing fluorescent latex particles (Section 2.4.4) was 
modified to include the addition of honey (0.25% - 2%) to measure its effect on 
the phagocytosis rate of THP-1 macrophages (Section 4.3.1 and Section 4.3.2).  
Further assays used E.coli (Section 4.3.3), BCG (Section 4.3.4) and zymosan 
(Section 4.3.5) as the phagocytic particle.  To determine whether honey was 
directly affecting the cytokine expression a medium change was done prior to 
assay (Section 4.3.6).  Then honey was fractioned to characterize the component 
responsible for the inhibition of phagocytosis which honey was found to give.  
This included dialysis of honey which identified the high molecular weight 
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component being active (Section 4.3.7).  Cytochalasin B was used in a 
phagocytosis assay to identify whether f-actin rearrangement was taking place in 
latex particle phagocytosis (Section 4.3.8). 
4.3 Methods 
4.3.1 Phagocytosis assay with latex particles 
The phagocytosis assay procedure was as described in Section 2.4.4 with various 
final concentrations of honey (0.125% - 2%) added at various time points.  
Freshly sub-cultured cells (500 µl ~ 1 x 10 
6 cells) were transformed with LPS (100 
ng/ml) for 24 hours before treatment with honey in the assay wells.  A control 
was included which received only medium.  The method used to calculate the 
reduction of phagocytosis was as described in Section 2.4.4. 
4.3.1.1  Honey 
The honey solutions used are described in Chapter 3.4.1.1. Manuka (M144) and 
Pasture (P59), Kanuka (K17) and Clover (CLO42) and artificial honey were 
selected for individual assessment using this assay.  All other honeys referred to 
can be found in Appendix 3.  Honey was added to wells to achieve final 
concentrations ranging from 0.125% - 2% diluted in culture medium.  Control 
wells had only culture medium added.  To achieve the final 0.125% concentration 
of honey, 25 µl of 5% diluted honey was added per 500 µl of cells, 50 µl for 
0.25%, 100 µl for 0.5%, 200 µl for 1%, 400 µl for 2% respectively.  The medium 
was topped up to achieve a final assay volume of 1 ml per well.  The honey 
solution was added to the well after the extra medium. 
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4.3.2  Phagocytosis assay with GFP E.coli 
The phagocytosis assay described in Section 4.3.1 was carried out replacing the 
latex particles with GFP E.coli. 
4.3.2.1  Luria-Bertani medium 
A Luria-Bertani (LB) medium was made by dissolving 40 g LB powder (Invitrogen 
Cat. No.# 12795-0-84) in 1 l of deionized water. The pH of the solution was 
adjusted to 7.4 using sodium hydroxide. The solution was then autoclaved at 
121°C for 20 minutes to sterilize the medium. The mixture was allowed to cool 
down to about 50 to 60°C then the antibiotics (50 µg/ml ampicillin) were added.  
The medium was then stored at 4°C. 
4.3.2.2  Luria-Bertani plate 
Bacteriological agar (15 g) was added to the LB medium before autoclaving.  The 
solution was mixed and then autoclaved at 121°C for 20 minutes.  The solution 
was allowed to cool down to about 50 to 60°C then the antibiotics (50 µg/ml 
ampicillin) were added.   The solution was poured into petri dishes and kept at 
room temperature for the medium to solidify. The plates were stored at 4°C in 
plastic bags.  
4.3.2.3 GFP E.coli  pBAD24 
A GFP E. coli pBAD24 strain was purchased (Bio-Rad).  One loop scraping from an 
inoculated LB plate was re-suspended in LB medium and grown at 37°C overnight 
using sterile techniques.   
GFP E.coli were induced to fluoresce using the arabinose-inducible pBAD24 
vector, a plasmid vector containing the PBAD promoter of the araBAD 
(arabinose) operon.  In the presence of arabinose, low levels of the GFP protein 
rapidly saturate the cell and when observed under blue light glow green. 
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GFP E. coli pBAD24 were induced with arabinose (0.1% final concentration) 2 
hours before use.  Cells were grown for a further 2 to 3 h, harvested by 
centrifugation, and washed and re-suspended in LB medium. The fluorescent E. 
coli cells were counted prior to assay on a haemocytometer. 
4.3.2.4  Phagocytosis assay 
The assay with GFP E. coli was carried out the same way as for the latex particle 
assay (Section 4.3.1) with the following modifications: 
Cultures of THP-1 macrophages were inoculated with approximately 25 E.coli 
cells per THP-1 cell, with or without 0.5% honey present and left to incubate at 
37°C for 2 hours for phagocytosis to take place.    
Cells were checked for viability with trypan blue prior to counting to ensure cells 
had not been overwhelmed by the bacterial inoculation.  Pasteurisation of E.coli 
was trialled to prevent adverse effects on THP-1 cells but this weakened the GFP 
fluorescence, preventing distinguishable phagocytosis.  In the shortened two-
hour incubation time viability was found to be comparable to un-infected cell 
lines not exposed to the infection, so the effect of phagocytosed bacteria was 
not considered to be lethal. 
Cells were placed on a haemocytometer (20 µl of cell suspension) and THP-1 cells 
that phagocytosed bacteria counted the same as in the latex particle assay. 
4.3.3  Phagocytosis assay with GFP BCG 
The phagocytosis assay described in Section 4.3.1. was carried out replacing the 
latex particles with GFP BCG. 
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4.3.3.1  GFP BCG 
GFP BCG were gifted by Dr Ray Cursons, University of Waikato, grown in Sauton's 
medium (0.2 g KH2PO4, 0.2 g MgSO4, 1.6 g L-asparagine, 0.02 g FeNH4 citrate, 
0.96 g citric acid, 24 ml glycerol, made up to 400 ml with purified water. The pH 
was adjusted to pH 7.2.  The solution was microwaved for 2 minutes to dissolve 
the agar, then autoclaved).  Cultures were grown at 37°C. 
4.3.3.2  Phagocytosis assay 
The phagocytosis assay procedure was the same as the latex particle assay 
(Section 4.3.1.) but with honey added at a final concentration of 0.5%.  BCG  cells 
were counted on a haemocytometer and sub-cultured prior assay and used at a 
ratio of 25:1 (BCG:THP-1 cells). 
Cells were placed on a haemocytometer (20 µl of cell suspension) and THP-1 cells 
that phagocytosed bacteria counted in the same way as the latex particle assay. 
4.3.4  Phagocytosis assay with zymosan particles 
The phagocytosis assay described in Section 4.3.1. was carried out replacing the 
latex particles with FITC zymosan particles. 
4.3.4.1  Zymosan particles 
Fluorescent labelled (FITC) zymosan particles prepared from the cell wall of the 
yeast Saccharomyces cerevisiae were purchased from Sigma-Aldrich (Cat. No.# 
Z4250). 
4.3.4.2  Phagocytosis assay 
The phagocytosis assay procedure was the same as the latex particle assay 
(Section 4.3.1.) but with honey added at a final concentration of 0.5%.  Zymosan 
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particles were counted on a haemocytometer and diluted prior assay and used at 
a ratio of 25:1 (zymosan particles: THP-1 cells). 
Cells were placed on a haemocytometer (20 µl of cell suspension) and THP-1 cells 
that phagocytosed zymosan particles counted in the same way as the latex 
particle assay. 
4.3.5  Assay for the effect of cytokines on phagocytosis  
It was established in the previous Sections that honey prevents phagocytosis by 
macrophages.  It was hypothesized that the macrophages were responding to 
honey by releasing cytokines that somehow prevented other cells from 
undertaking phagocytosis by changing the function of the macrophage.  In 
Chapter 3 it was identified that there was a modification of cytokine expression 
in response to exposure of the cells to honey.  The cytokine expression profile of 
a monocyte or macrophage determines its function (Chapter 3).  Factors that 
increase or decrease the pro- and/or anti-inflammatory cytokine expression will 
ultimately decide the function of the transformed macrophage and therefore its 
phagocytic ability. 
To test this theory, activated THP-1 cells were treated with Manuka honey and 
/or LPS as described in Section 3.4.3.  These cells were washed to remove honey 
and LPS, and placed in fresh growth medium.  They were incubated for four 
hours to express cytokines. This conditioned medium (cell free but containing 
cytokines released from the THP-1 cells) was then removed and fresh THP-1 cells 
(not previously exposed to LPS or honey) were placed in the medium to respond 
to any cytokines released from the honey- or honey- and LPS-treated cells.  Latex 
particles were then added to the cells as described in Section 3.4.3 and the rate 
of phagocytosis was quantified and compared with control cells that had the 
same treatments but not exposed to honey.   
Artificial honey was used as a control for the sugar content of Manuka honey.  
The details of the procedure are given below in Section 4.3.5.1.  As it has been 
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previously established (Chapter 2) that un-activated THP-1 cells (no activating 
treatment) do not phagocytose it was deemed not necessary to include a 
monocyte control. 
4.3.5.1  Phagocytosis assay 
THP-1 cells (5 ml) were treated in growth medium with 100 ng/ml LPS and 0.5% 
honey (flask 1).  A control was repeated with artificial honey (flask 2).  The flasks 
were incubated for 24 hours 37°C, 5% CO2, and 95% relative humidity to allow 
activation. 
After the incubation time the spent medium was removed in the honey treated 
flask and the control flask.  The cells and flasks where washed 3 times in fresh 
growth medium.  After this, 3 ml fresh growth medium was added to the flasks.  
The flasks were re-incubated for a further 4 hours to allow cells to release 
cytokines. 
After the incubation the medium was removed from the honey treated flask (1) 
and the control flask (2).  This conditioned medium was added to fresh 
monocytes, to give final volume of 3 ml (the growth medium from the fresh 
monocytes was removed first). 
The flasks then had latex particles added (25 latex particles per cell) and the 
flasks incubated for 4 hours to allow phagocytosis.  The cells that phagocytosed 
latex particles were then counted on a haemocytometer. 
4.3.6  Phagocytosis assay with dialysed honey 
In an attempt to characterize the component of honey responsible for the 
inhibition of phagocytosis, honey was dialysed to a high and low molecular 
weight fraction.  These fractions were assayed for their effect on phagocytosis in 
the same manner as whole honey in Section 4.3.1. 
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4.3.6.1 Dialysis of honey 
Twenty-five grams (18.2 ml) of Manuka honey (M144,) and Pasture honey (PS9) 
were each suspended in 25 ml of purified water and dialyzed against 1 l of tap 
water for 48 h at 4°C with three changes of water during this time. Dialysis tubing 
with a molecular mass cut off of 3 500 Da (Cellu Sep T1, Membrane Filtration 
Products, Inc., Seguin, TX; EEUU) was used.  The dialysate and retentate was 
lyophilized and then reconstituted to 5 ml in purified water to concentrate the 
sample.  Both samples were kept at -20°C until required. 
4.3.6.2  Phagocytosis assay 
The phagocytosis assay procedure was the same as for the latex particle assay 
(Section 4.3.1.) but with the addition of a 1% final concentration of honey 
retentate or dialysate.   
4.3.7  The effect of Cytochalasin B on phagocytosis 
Cytochalasin B was used in a phagocytosis assay to identify whether f-actin 
rearrangement was taking place during the latex particle phagocytosis. 
4.3.7.1  Cytochalasin B 
Dihydro-Cytochalasin B was purchased from Sigma-Aldrich (Cat. No.# C6762-1 
mg) and dissolved in 1 ml dimethyl sulfoxide to create a stock solution.  
Cytochalasin B was then used at 12.5 µmol/l, 25 µmol/l and 50 µmol/l 
concentrations in RPMI 1640 medium. 
4.3.7.2  Phagocytosis assay 
The phagocytosis assay procedure was the same as for the latex particle assay 
(Section 4.3.1.) but Cytochalasin B added.   
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4.4  Results 
All phagocytosis assays were performed in triplicate (at least) using the same 
equipment throughout the research.  The latex particles were present for four 
hours unless otherwise stated.  Bacteria and zymosan were present for two 
hours.  After this time some bacteria/zymosan particles were digested and 
unable to be singularly identified in the macrophage, resulting in a glowing THP-1 
cell.  This may have resulted in a higher or lower result than for the latex 
particles. 
4.4.1 Phagocytosis assay with latex particles 
The results from main assay variations are presented here.  The effect of varying 
concentrations of one sample (M144) of Manuka honey on phagocytosis after 
four hours of incubation are shown in Figure 4.1, and for 0.5% of the same 
Manuka honey, Pasture and Artificial honey on phagocytosis over different time 
periods are shown in Figure 4.2.  Four hours after incubation with Manuka 
honey, all concentrations used (0.125% -2%) showed a significant (p<0.001) 
reduction in phagocytosis of latex particles compared with the phagocytosis of 
cells not treated with honey (Figure 4.1). A dose dependent response was 
observed, with higher concentrations of honey giving a higher inhibition of 
phagocytosis.  Manuka honey gave a significant inhibition of phagocytosis at all 
the time points, but the degree of inhibition steadily decrease over time.  Pasture 
honey gave a significant (p<0.001) reduction of phagocytosis at 2, 4 and 24 hours 
after latex bead addition but to a lesser extent than Manuka honey (14% 
reduction compared with 65% reduction for Manuka honey at 4 hours).  Artificial 
honey had the opposite effect to honey by significantly (p<0.001) increasing the 
phagocytosis of latex particle at all time-points though this promotion of 
phagocytosis gradually reduced (32% at 2 hours, to 3% promotion at 24 hours 
after latex particle addition).   
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These results show that honey has a bioactivity beyond that of the sugar content 
alone, and that the bioactivity of Manuka honey is better than that of Clover 
honey.  The bioactivity of both Manuka honey and Pasture honey could still be 
detected after 24 hours of treatment suggesting a lasting effect. 
 
 
 
Figure 4.1:  The effect of increasing concentrations of Manuka honey on 
phagocytosis of latex particles in LPS-activated THP-1 cells.  The assay was 
performed 4 h after latex particle addition.  Error bars show ± 1 SD of the mean of 
3 experiments.  * p<0.001 analysed by ANOVA and Tukey’s multiple pairwise 
comparisons compared with the control (not treated with honey).  
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Figure 4.2:   The effect Manuka honey, Pasture honey and artificial honey (all at a 
concentration of 0.5%) on phagocytosis of latex particles in LPS-activated THP-1 
cells at different time points after addition of latex particles compared to the 
control which received no honey treatment.  Error bars show ± 1 SD of the mean of 
3 experiments.  A negative value indicates a promotion of phagocytosis compared 
to the control. The phagocytosis inhibition results were analysed by ANOVA and 
Tukey’s multiple pairwise comparisons.  * p<0.001 compared with control (not 
treated with honey) at the same incubation time point.  # p<0.001 compared with 
artificial honey at the same incubation time points. Ж p<0.001 Manuka honey 
compared with Pasture honey at the same incubation time points.  Changes in 
inhibition of phagocytosis between incubation time points for each type of honey ( 
(a,b,c Manuka),(x,y,z Pasture),(1,2,3 artificial) p<0.001)). Values not showing the 
same letter are significant to each other.  
 
The effect of a small range of honey varieties on phagocytosis of latex particles is 
shown in Figure 4.3.  The sample of Manuka honey had a significantly (p<0.001) 
larger effect on the reduction of phagocytosis compared with the samples of 
other honey varieties.   
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Figure 4.3:   The effect of different types of honey (at a concentration of 0.5%) on 
phagocytosis of latex particles in LPS-activated THP-1 cells.  The assay was 
performed 4 h after latex particle addition. Error bars show ± 1 SD of the mean of 
3 experiments. * p<0.001 analysed by ANOVA and Tukey’s multiple pairwise 
comparisons compared with the non-Manuka samples.   
 
Figure 4.4 shows the results from comparing a larger number of samples of 
honey of different floral varieties excluding Manuka honey (compiled from 
honeys presented in Appendix 3).  Again there was a difference in phagocytosis 
inhibition between honey varieties.  Only Rewarewa and Kanuka honey had a 
phagocytosis inhibition of over 10% (a figure that Manuka honey with no 
detectable NPA scored higher than in Figure 4.5).    
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Figure 4.4:   The effect of different types of honey excluding Manuka at a 
concentration of 0.5%, multiple samples of some of the types of honey tested 
(The number of samples of each type of honey is shown in brackets) on 
phagocytosis of latex particles in LPS-activated THP-1 cells.  The assay was 
performed 4 h after latex particle addition. Error bars show ± 1 SD of the mean of 
3 experiments for individual samples of honey.  Compiled from honeys presented 
in Appendix 3.  
 
 
There was a large variability between different Manuka honey samples.  Figure 
4.5 shows the effect on the phagocytosis of latex particles of a 0.5% 
concentration of a small selection of Manuka honeys with various levels of NPA.  
There appeared to be no relationship between the degree of inhibition of 
phagocytosis and the level of NPA of the sample.  Manuka honey samples were 
examined individually in Chapter 8 to examine this variability.  In Appendix 3 the 
phagocytosis rate of THP-1 after exposure to all individual honey samples is 
presented.   
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Figure 4.5:   The effect of different types of Manuka honey (at a concentration of 
0.5%) of varying NPA on phagocytosis of latex particles in LPS-activated THP-1 
cells.  The assay was performed 4 h after latex particle addition.  Error bars show 
± 1 SD of the mean of 3 experiments.  
 
 
 4.4.2  Phagocytosis assay with GFP E.coli 
E.coli was used in place of latex particles in the phagocytosis assay to determine 
how extensive the effect of honey in inhibiting phagocytosis was with a biological 
particle in place of a synthetic material.  The results are shown in Figure 4.6.  
Manuka honey gave a significant (p<0.001) reduction of phagocytosis of E.coli, 
though this was less than the inhibition observed with latex particles. Pasture 
honey also reduced the phagocytosis of E.coli when compared to artificial honey 
but to a lesser degree.   
 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
<4      
M197 
7.5     
M38 
8.2     
M190 
8.3      
M22 
11.1  
CJA10 
25.3    
MO1 
28.8 
MBD28 
%
 r
e
d
u
ct
io
n
 o
f 
p
h
ag
o
cy
to
si
s 
NPA of honey 
Chapter 4                        Phagocytic activity of THP-1 
110 
 
 
 
 
Figure 4.6:  The effect of Manuka honey (at a conc. of 0.5%) on phagocytosis of E. 
coli in LPS-treated THP-1 cells.  The assay was performed 2 h after the addition of 
E. coli.  Error bars show ± 1 SD of the mean of 3 experiments.  * p<0.001 analysed 
by ANOVA compared with the non honey-treated control.   
 
 
4.4.3  Phagocytosis assay with GFP BCG 
BCG was used in place of latex particles in the phagocytosis assay to further 
determine how extensive the effect of honey was at inhibiting phagocytosis on 
different types of biological particles.  The results are shown in Figure 4.7.  
Manuka honey gave a significant (p<0.001) reduction of phagocytosis of BCG, 
though this was less than the inhibition observed with latex particles.  Pasture 
honey also reduced the phagocytosis of BCG when compared to artificial honey 
but to a lesser degree.   
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Figure 4.7:  The effect of Manuka honey (at a concentration of 0.5%) on the 
phagocytosis of BCG in LPS-activated THP-1 cells.  The assay was performed 2 h 
after the addition of BCG. Error bars are ± 1 SD of the mean of 3 experiments. * 
p<0.001 analysed by ANOVA compared with the non honey-treated control.   
 
 
4.4.4 Phagocytosis assay with zymosan 
Zymosan was used in place of latex particles in the phagocytosis assay to further 
determine how extensive honey was at inhibiting phagocytosis on different types 
of biological particles.  The results are shown in Figure 4.8.  All Manuka honey 
concentrations had a significant (p<0.001) reduction of phagocytosis of zymosan 
in a somewhat dose-dependent manner.  However this dose dependent 
inhibition is lost after the concentration of honey reached 0.5%, unlike the 
inhibition seen with latex particles (Figure 4.1).  This possibly indicates that 
zymosan is only bound by one receptor that honey blocks, whereas latex 
particles bind more than one. 
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Figure 4.8:  The effect of a range of concentrations of Manuka honey on 
phagocytosis of zymosan particles in LPS-activated THP-1 cells.  The assay was 
performed 4 h after zymosan addition.  Error bars show ± 1 SD of the mean of 3 
experiments.  *p<0.001 analysed by ANOVA compared with the non honey-treated 
control. (a,b,c)p<0.001 analysed by ANOVA and Tukey’s multiple pairwise 
comparisons compared to other honey concentrations.  Values not showing the 
same letter are significant to each other.  
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cells (Chapter 2).  To determine if the effect of honeys on reducing phagocytosis 
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suggesting that an influence on cytokine production is not playing a role in the 
phagocytosis-inhibiting effect of honey. 
 
 
 
Figure 4.9:  The effect on phagocytosis of THP-1 cells treated with the 
conditioned medium from cells pre-treated with LPS, Manuka honey or artificial 
honey or from control cells not treated with LPS.  The assay was counted at 2 
and 6 h after the addition of the latex particles.  Error bars show ± 1 SD of the 
mean of three measurements.  There was no significant difference between 
treatments analysed by ANOVA compared with the LPS-treated control.   
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reducing phagocytosis of latex particles compared with the low molecular weight 
components, acting in a dose-dependent manner.   
 
 
Figure 4.10: Effect of high and low molecular weight (MW) components of 
Manuka honey on phagocytosis of latex particles in LPS-activated THP-1 cells.   
The assay was performed 4 h after addition of the latex particles. Error bars 
show ± 1 SD of the mean of three measurements. * p<0.001 analysed by 
ANOVA comparing the high and low MW components for each honey 
concentration.  (a,b,c)p <0.001 analysed by ANOVA and Tukey’s multiple pairwise 
comparisons compared to other honey concentrations.  Values not showing the 
same letter are significant to each other. 
  
 
4.4.7  Phagocytosis assay of latex particles with Cytochalasin B 
Cytochalasin B (12.5 and 25 µmol/l) had a 100% inhibitory effect on the 
phagocytosis of latex particles (results not shown).  Cytochalasin B inhibits F-
actin-dependent phagocytosis. This indicates that for latex particle phagocytosis, 
f-actin rearrangement is occurring.   At 12.5 µmol/l and 25 µmol/l Cytochalasin B 
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viability dropped off slightly suggesting the cells could not tolerate a high level of 
blocking of f-actin polymerization. 
 
4.5 Discussion 
Certain samples of Manuka honey at low concentrations (0.5%) significantly 
(p<0.001) reduced phagocytosis of latex particles, E.coli, BCG and zymosan 
particles in the macrophage cell line THP-1.  A range of concentrations of these 
Manuka honeys showed that honey gave a dose-dependent effect.  Other 
honeys tested had a lower inhibitory effect than these Manuka honeys. Pasture 
honey and Kanuka honey at the same concentration had only 20% of the 
inhibitory effect of Manuka honey yet this was still a significant reduction.  There 
is a probability that there was Manuka nectar present in these samples which 
was responsible for the inhibition observed.   
The variability of the effect of Manuka honey with varying NPA was explored 
briefly and even a Manuka honey with no anti-bacterial activity (NPA 0) had a 
higher phagocytosis inhibiting action than all but two of the honey varieties 
assayed.  The two honey varieties that had higher activity were Kanuka (14 %) 
and Rewarewa (20 %).  As mentioned previously there is a probability that there 
was Manuka nectar present in these samples which was responsible for the 
inhibition observed.  This variability between all honey samples is explored in 
Chapter 8. 
The component responsible being in the high molecular weight fraction of honey 
suggested a protein or protein complex.  BCG (Kang 1998; Diaz-Silvestre, 
Espinosa-Cueto et al. 2005) and E.coli (Akiko, Ikuko et al. 2008) are known to be 
phagocytosed by interaction with the mannose receptor.  It was hypothesized 
that the high molecular weight component of Manuka honey exerted its effect 
on phagocytosis by interacting with the mannose receptor, possibly 
blocking/immobilizing receptors or preventing their recycling back to the 
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membrane (Stahl, Schlesinger et al. 1980).  Indeed there have been reports of 
proteins in honey that have high-mannose type carbohydrate glycoproteins 
(Kimura, Miyagi et al. 2000) that may able to bind the mannose receptor.  This 
hypothesis may be backed up by the observed prevention of phagocytosis of 
latex particles by addition of cytochalasin B which indicated that for phagocytosis 
of these the rearrangement of f-actin is essential, ruling out CR3 type 
phagocytosis.  This suggests that the mannose or scavenger receptors are 
responsible for latex particle phagocytosis.     
This finding is important regarding the inflammatory aspects of wound healing.  
Chronic wounds are overpopulated with active macrophages causing large 
amounts of pro-inflammatory cytokines and ROS to be released, aggravating the 
situation and creating feedback loops that worsen the condition.  By reducing the 
phagocytosis of active macrophages these cytokines and ROS would be reduced.   
It has been reported that Manuka honey reduces ROS production in 
macrophages (Tonks, Cooper et al. 2001) but it was not reported by what 
mechanism.  The possibility exists that the antioxidants in honey may have 
scavenged the ROS free radicals that Tonks et al. were measuring.   
It is important to be aware of the different states achievable by activated 
macrophages.  Currently there are two widely accepted activation states, type 1 
and type 2.  Type 1 is the classical inflammatory state where upon stimulation by 
LPS or similar factors, the cell releases pro-inflammatory cytokines such as TNF-α 
and IL1-β.  Type 2 is termed alternative activation where an anti-inflammatory 
cytokine profile is produced. Both states have membrane-bound mannose 
receptor though type 1 has less than type 2, which could mean type 2 
Macrophages are more able to respond to the active compound in honey.  
The THP-1 cell line used in this study could be activated by LPS, PMA or Vit-D3 to 
achieve a macrophage phenotype (Chapter 2).  With all of these it was confirmed 
that the monocytes had achieved a macrophage phenotype according to 
expression of macrophage-specific gene HCgp-39 detected by RT-PCR.  The LPS-
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stimulated cells were found to perform best in the phagocytosis assay (higher 
rates of phagocytosis in controls) suggesting different states of activation 
between the treatments (Chapter 2).  Manuka honey may have an effect on only 
one state ensuring adequate protection/clearance of foreign particles in the 
wound with the other macrophage state/s and immune cells.  This should be 
investigated in future work. 
The effect of honey on phagocytosis was lost gradually over time, with a 
reduction in the inhibition of approximately 50% after 24 hours of incubation 
with the latex particles.  At two hours after latex particle addition, Manuka honey 
had a 70% inhibitory effect on latex particle phagocytosis compared with 35% 
inhibitory effect after 24 hours.  This may indicate that the inhibitory component 
in honey is either being depleted or the cells are able to increase the number of 
receptors available for phagocytosis or manufacture a different receptor.  If the 
cell is making more of the receptor that binds the honey component then the 
rate of uptake of the active component will be faster, therefore depleting it.  If 
the cell is able to make a different type of receptor that does not bind the active 
component in honey then honey will have less effect on the cell.  Both these 
scenarios could explain why the inhibitory action of the honey component lost its 
effect over time.   
A further assay was carried out to test whether the observed phagocytosis 
reduction is caused by a compound in honey (e.g. a protein found in honey), or a 
cell response to honey (e.g. a cytokine released that stimulates other cells).  The 
assay took active macrophages and placed them in fresh medium with no 
treatment.  After a period of time where the cells could theoretically release 
agents, these cells were removed and resting monocytes were added.  These 
cells were left to be activated by the medium containing the conditioned 
medium.  Latex particles were added to these cells and phagocytosis was 
measured, (Figure 4.9).  The activation of the cells (ability to phagocytose) was 
significantly (p<0.001) reduced to 12% and 15% at the two hour and six hour 
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time points respectively, compared with the usual direct stimulation with LPS 
giving activation rates up to 70-90% (Chapter 2).   
These results suggest that LPS needs to stay in contact with the cells for 
activation to proceed.  The activation rate was low, and a slightly lower amount 
of phagocytosis was observed in the honey-treated cells, but this result was not 
significant.  This indicates that the factor(s) in the medium produced as a result 
of stimulation of the monocytes by LPS gave a low level of activation of fresh 
monocytes, but that the factor(s) was not as potent as direct LPS exposure. The 
agent(s) responsible for the activation in the absence of LPS may be cytokine(s), 
the mRNA for which have been observed to change after treatment with honey 
or LPS, as demonstrated by RT-PCR analysis (Chapter 3).   
Treatment with Manuka honey (but not artificial honey) gave a slightly lower 
activation indicating a slight suppressive effect on production of the factor(s) 
after removal of the Manuka honey but this result was not significant.  The 
overall conclusion is that honey is not acting via an effect on cytokine production 
(or other factors) when it suppresses phagocytosis. 
These findings have numerous possible implications involving the mannose 
receptor or other phagocytic receptors with regards to honeys’ anti-
inflammatory effects.  One important consideration is that myeloperoxidase 
released by neutrophils during immune activity is bound through the mannose 
receptor on macrophages (Shepherd and Hoidal 1990).  Myeloperoxidase is a 
strong signalling factor for macrophages to initiate and amplify inflammation 
(Rodrigues, Rodriguez et al. 2002).  If honey does block the mannose receptor 
then this signal would be downgraded, preventing an over-production of 
inflammatory cytokines at the site. 
Another consideration is the possible effect on tissue-type plasminogen activator 
(t-PA), a serine protease that activates fibrinolysis by converting plasminogen 
into plasmin, which cleaves fibrin into soluble degradation products.  Recent 
research has shown that fibrin plays a key role in the inflammatory response and 
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is also involved in forming scar tissue (Bouma and Mosnier 2006).  Thus t-PA is 
beneficial to healing wounds.  It has been shown that t-PA is cleared from plasma 
through the mannose receptor probably through its high mannose-type 
oligosaccharide (Biessen, van Teijlingen et al. 1997; Noorman, Barrett-Bergshoeff 
et al. 1997).   
Because of its rapid clearance in humans, t-PA is often administered in large 
doses to achieve efficient thrombolysis.  Mannosides can inhibit t-PA binding to 
the mannose receptor by immobilizing the receptor, effectively inhibiting t-PA 
clearance.  The active component in Manuka honey may also inhibit t-PA 
clearance by blocking the mannose receptor.  One of the benefits of using 
Manuka honey in wounds is the reduction of scarring (Topham 2002).  This 
action of honey may be through allowing t-PA to stay in circulation for longer.  
Future research should be directed to exploring this possibility. 
The suppression of phagocytosis in macrophages by honey on the face of it 
seems non-beneficial as this would delay pathogen clearance.  But when 
consideration is given to the nature of phagocytosis, an anti-inflammatory 
benefit can be clearly seen.   
Phagocytosis produces large amounts of inflammatory ROS, arachidonic acid 
metabolites and inflammatory cytokines.  As it is excessive inflammation that 
prevents wound healing, reducing phagocytosis may reduce the amount of these 
pro-inflammatory mediators allowing chronic wounds to heal, and acute wounds 
to heal with-out entering a chronic state.   
This action may also protect the organism by reducing the proliferation of 
inflammatory cells without affecting their capacity to secrete anti-inflammatory 
cytokines.  Phagocytosis of pathogens and other debris can then be carried out at 
a controlled level and by the other phagocytic cells already present in the tissue.   
This theory agrees with recent research (Harcourt 2005) which found that honey 
increases the rate of phagocytosis in neutrophils.  Future research should look at 
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the effects of honey on other immune cells that phagocytose such as dendritic 
cells and mast cells. 
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Chapter 5 
The effect of honey on the release of reactive oxygen species 
in THP-1 macrophages 
 
 
 
5.1   Summary 
This chapter expands on work completed in Chapter 4 where it was found that 
Manuka honey reduced phagocytosis in activated THP-1 macrophages.  It was 
necessary to see if this reduction in phagocytosis also resulted in a reduction of 
the level of reactive oxygen species (ROS), a by-product of phagocytising cells 
that when accumulated in high amounts can cause tissue damage and 
inflammation. 
A dichlorofluorescein (DCFH) assay was used to quantitate ROS release by 
actively phagocytising THP-1 cells in the presence of 0.5% honey. 
Manuka honey was found to decrease ROS release from macrophages but not 
monocytes.  Artificial honey increased the release of ROS and Rewarewa honey 
had no effect on ROS release.                                                                                                          
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5.2   Introduction 
ROS, also known as reactive oxygen intermediates (ROI), are ions or very small 
molecules that include oxygen and hydroxyl free radicals and peroxides, both 
inorganic and organic. ROS are highly reactive due to the presence of unpaired 
valence shell electrons able to participate in bonding of other atoms.  Peroxides 
are termed ROS because from such species ROS form as a natural by-product of 
their normal reactions, or directly from their metabolism for destruction of 
phagocytosed microbes and cell debris.  Microbial phagocytosis triggers 
production of pro-inflammatory cytokines, and generation of ROS. ROS function 
in antigen processing and presentation, as well as suppression of genes encoding 
molecules involved with bacterial recognition and internalization (Reth 2002).  
Hydrogen peroxide (H2O2) and superoxide (O2
•–
, which forms hydrogen peroxide) 
can cause or contribute to various kinds of oxidative stress and they can react 
directly with tissue components themselves. However since these molecules are 
comparatively non-toxic, cells have well-known means of dealing with them, and 
they are even used in cellular signalling under normal conditions.  O2
•–
 is a 
relatively un-reactive intermediate on its own.  In living tissue O2
•– can be 
converted into H2O2 enzymatically by superoxide dismutase (SOD) isoforms, or 
non-enzymatically.  H2O2 is a major ROS contributor to oxidative stress which is 
formed from the superoxide that leaks from the mitochondria.  Catalase 
minimises the damaging effects of hydrogen peroxide by converting it to oxygen 
and water but this conversion is not 100% efficient as residual peroxides remain.  
Normal cellular functioning produces minimal amounts which can be tolerated, 
yet excessive amounts can cause deleterious effects (Horton 2003). 
ROS levels may increase during certain conditions, stressing the surrounding cells 
and causing significant damage called oxidative stress to cell structures.   
Oxidative stress leads to considerable DNA damage (Evans 2004) and to the 
polymerisation and denaturation of proteins (Davies 2005). The most common 
damaging species, the hydroxyl radical, is created by the reaction of peroxide 
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and superoxide with un-liganded or incompletely liganded iron ions.  The 
hydroxyl radical is exceptionally damaging, and a major cause of chronic 
inflammation (Kell 2009). The hydroxyl radical ( •OH) has a very short half-life  
(10-9 s) and high reactivity. In biological systems it does not diffuse from the site 
of generation and can rapidly damage any surrounding carbohydrates and 
macromolecules, including proteins, potentially leading to their 
inactivation/denaturation (Novo and Parola 2008).   
Phagocytic cells such as neutrophils, macrophages and eosinophils generate ROS 
via NADPH oxidase upon activation, due to the increased energy requirements 
for membrane reorganization required for actin polymerisation during 
phagocytosis (Castellano, Chavrier et al. 2001; Novo and Parola 2008) and 
produce it for directly killing pathogens.  This may cause an increased localised 
ROS load which, under normal conditions, can be successfully controlled by 
cellular control feedback loops via cell signalling pathways, which, in turn, 
activate various effector functions that make up the initial immune response 
(Gwinn 2006). 
Inducible nitric oxide synthase (iNOS), which was first identified in macrophages 
and then in other cells, including hepatocytes, is known to be up-regulated by 
pro-inflammatory cytokines and/or bacterial lipopolysaccharide, and is able to 
generate low levels of nitric oxide.  Nitric oxide exerts physiological effects by 
controlling vascular tone, cell adhesion, vascular permeability and platelet 
adhesion.  It also exerts several potentially toxic effects. Nitric oxide is not 
particularly toxic in vivo because of efficient systems able to minimize its 
accumulation.  Nitric oxide is removed as a consequence of its rapid diffusion 
through tissues. Under pro-inflammatory conditions, simultaneous production of 
O2
•– and nitric oxide can be strongly activated and significant amounts of 
peroxynitrite (ONOO
–
) are generated, which may cause significant injury to 
different cellular structures (Pacher, Beckman et al. 2006). 
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ROS causing oxidative stress can activate transcription factors, most importantly    
nuclear factor κB (NF-κB).  NF-κB is a protein complex that acts as a transcription 
factor involved in cellular responses shown to respond to stimuli such as stress, 
cytokines (such as IL-1 and TNF-α), inflammation, control of cell growth and the 
balance between ultimate cell survival and apoptosis (Chapter 3.2.1).  NF-κB 
plays a key role in regulating the immune response to infection by initiating 
transcription of a range of inflammatory cytokines (Baldwin 1996). It is activated 
by H2O2 produced by the respiratory burst, and controls the inducible expression 
of genes whose products are part of the inflammatory response.  In this way, 
H2O2 increases the inflammatory response.  This is a critical link between the 
respiratory burst and other inflammatory responses (Iles and Forman 2002).  
Incorrect regulation of NF-κB has been linked to cancer, inflammatory and auto-
immune diseases, septic shock, viral infection, and improper immune 
development (Perkins 2007).  NF-κB recognises DNA sequences called κB sites 
and is involved in maintaining mitochondrial integrity and in regulating 
antioxidant activity.   
In resting cells, the NF-κB dimers are sequestered in the cytoplasm by a family of 
inhibitors, called IκBs (Inhibitor of κB).   Activation of NF-κB is initiated by the 
signal-induced degradation of IκB proteins.  This occurs primarily via activation of 
a kinase called the IκB kinase (IκK). With the degradation of the IκB inhibitor, the 
NF-κB complex is then freed to enter the nucleus where it can 'turn on' the 
expression of specific genes that have NF-κB binding sites within promoter 
regions. Many of these NF-κB response genes are pro-inflammatory or immune 
related.  NF-κB turns on expression of its own repressor, IκBα. The newly 
synthesized IκBα then re-inhibits NF-κB and, thus, forms an auto feedback loop, 
which results in oscillating levels of NF-κB activity. ROS, produced intra-cellularly 
as a part of the response induced by inflammatory cytokines, contribute to 
reinforce the signal to activate NF-κB by oxidising and activating IκK causing IκBα 
degradation (Nelson, Ihekwaba et al. 2004). 
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Many signalling pathways that have a ROS signal component can be overloaded 
with excess ROS.  ROS can bypass the initial ligand binding step, entering the 
pathway midway creating a false positive activation, upsetting balance and the 
controlling of feedback loops. 
Agents that control ROS levels or inhibit ROS production can therefore have 
therapeutic properties in certain diseases.  Antioxidants are commonly used to 
control excess ROS in tissue.  Antioxidative agents include small-molecule ROS 
scavengers, inhibitors of ROS-generating enzymes, and antioxidative enzymes 
(Fang, Seki et al. 2009).  Antioxidants are very successful in assisting wound 
healing such as burns (Horton 2003).  Antioxidants prevent the oxidation of other 
molecules by removing ROS, thus inhibiting oxidation reactions by being oxidized 
themselves.  In wounds where chronic inflammation is present or likely to occur, 
controlling excessive ROS will be beneficial.  This may be achieved by either 
preventing/decreasing the release of ROS, or removing excess ROS by way of 
antioxidants.  Honey has been shown to quench free radicals in a cell-free system 
(Gheldof, Wang et al. 2002; Henriques, Jackson et al. 2006; van den Berg, van 
den Worm et al. 2008), but it is not known if honey can reduce the production of 
ROS in cells actually phagocytising pathogens or particles.   
ROS scavengers have been shown to inhibit production of IL-8 in LPS-stimulated 
whole blood, thus reducing inflammation, while addition of hydrogen peroxide 
caused a dose-dependent stimulation of IL-8 production, thus increasing 
inflammation (DeForge, Fantone et al. 1992; Stegmaier, Kirchhoff et al. 2008).  IL-
8 is a cytokine produced by monocytes, endothelial cells and fibroblasts in 
response to inflammatory stimuli such as LPS and pro-inflammatory cytokines 
such as TNF-α and IL-1β.  IL-8 transcription can be activated by NF-κB when the 
nuclear factor binds the gene after translocation into the nucleus (Baldwin 1996; 
Stegmaier, Kirchhoff et al. 2008).  IL-8 activates neutrophils causing their 
migration and accumulation at the site of its release and causing consequent 
inflammation due to active phagocytosis releasing bioactive lipids, enzymes and 
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excessive ROS, mediating extensive tissue damage (Baggiolini, Walz et al. 1989).  
This provides evidence that excessive levels of ROS play an important role in 
cytokine expression, resulting in increased inflammation. 
Macrophage activation has been found to generate high levels of 
myeloperoxidase (MyPo) (Rodrigues, Rodriguez et al. 2002). The increase in 
MyPo content is accompanied by an increased capability of macrophages to 
generate hypochlorous acid and increased peroxidase activity.  Lowering the 
amount of MyPo generated and received by macrophages could greatly reduce 
inflammation.  In an experimental model of inflammatory bowel disease, intra-
rectal honey administration was as effective as prednisolone treatment, a steroid 
drug commonly used to treat the condition.  Its activity was attributed to the 
reduction of MyPo levels (Bilsel, Bugra et al. 2002). 
It was found in the present study (Chapter 4) that Manuka honey decreased 
phagocytosis.  One possible explanation for this is that honey reduces the 
activation rate of macrophages, thus reducing the release of MyPo.  Therefore it 
was hypothesised that this resulted in less actin polymerisation in the cells for 
cytoplasmic movement of phagosome.  As actin polymerisation produces large 
amount of ROS, it was also hypothesised that less actin polymerisation would 
result in less ROS production for microbial killing. This would reduce ROS levels, 
consequently reducing cellular damage and feedback loops, exerting an anti-
inflammatory effect in wounds. To test this hypothesis a commonly used assay 
for measuring cell-generated ROS was used. 
Cell-generated ROS levels can be measured using the Dichlorofluorescein (DCFH) 
assay. When applied to intact cells, 2′,7′-dichlorofluorescin diacetate (DCFH-DA) 
crosses cell membranes and is hydrolyzed enzymatically by intracellular 
esterases to non-fluorescent DCFH.   In the presence of ROS, DCFH is oxidized to 
highly fluorescent dichlorofluorescein (DCF). Therefore, the intracellular DCF 
fluorescence can be used as an index to quantify the overall ROS released from 
phagocytising cells (LeBel, Ischiropoulos et al. 1992).  
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This chapter investigates ROS formation in actively phagocytising THP-1 cells and 
its decrease due to honey.  To find out if the honey was actually preventing ROS 
release, or simply working as an anti-oxidant mopping up ROS as it was formed 
by the cell, a honey with high antioxidant properties was used.  Rewarewa honey 
has been shown to have high anti-oxidant activity (personal communication with 
Professor Peter Molan), so was compared with Manuka honey.  Latex beads 
were used to induce phagocytosis 
LPS-activated cells were previously identified as producing the most actively 
phagocytosis cells (Chapter 2) so LPS was initially used for the DCFH assay.  PMA 
was used as an alternative cell treatment to activate monocytes.  PMA was found 
in earlier research to activate monocytes to macrophages but these cells showed 
less phagocytic activity.  It was expected that PMA-activated cells would have 
less ROS release corresponding with the lower level of phagocytosis observed.   
A control replicated the experiment using resting monocytes.  Monocytes have 
little or no phagocytic activity and so would not produce the same levels of ROS 
as active macrophages.  Any fluorescence developed from ROS reactions with 
DCFH would be generated by normal cell ROS levels and not by ROS produced 
when there is actin polymerisation or microbial killing.  It was hypothesised that 
honey would have no effect on release of ROS by monocytes. 
 
5.3  Methods 
5.3.1  Reagents 
5.3.1.1  THP-1 Cells 
THP-1 cells were maintained at 37°C, 5% CO2, and 95% relative humidity in 
growth medium (as described in Section 2.3.2).  Cells were split with fresh 
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growth medium prior to the assay and assessed for viability (as described in 
Sections 2.3.1 and 2.3.4).  The cells were activated with LPS or PMA as described 
in Section 2.4.1.  Phagocytosis of latex beads was carried out as described in 
Section 2.4.4. 
5.3.1.2   Dichlorofluorescin 
6-Carboxy-2′,7′-dichlorofluorescin diacetate (DCFH-DA) was purchased from 
Sigma-Aldrich (Cat. No.# 35845-1 G) and dissolved in DMSO to create a 0.5 
mg/ml stock solution.  DCFH-DA was mixed with growth medium to a final 
concentration of 100 μmol/l when added to the cells. 
5.3.1.3  Honey 
Stock solutions of Manuka honey (M144) and Rewarewa honey (Re37-807) were 
as described in Section 3.4.1.1.  Honey solutions (0.5% final concentrations) were 
added to wells diluted in growth culture medium.  Control wells had only the 
medium added.  Artificial honey (as described in Section 3.4.1.1) was used to 
provide a control for the osmotic effect of the natural sugars found in honey.  
5.3.2  DCFH assay procedure 
THP-1 cells were split in fresh growth medium, counted, and checked for viability 
by trypan blue exclusion (as described in Chapter 2.3.4).  Viable cells were 
treated with 100 ng/ml LPS or 10 nmol/l PMA or left untreated to have resting 
monocytes for comparison with the macrophages.  Then 200 µl cell suspensions 
(106 cells/well) were plated into 96-well sterile black plates for fluorescence 
detection (Nunc) and incubated (5% CO2/95% air at 37°C) for 24 hours prior to 
experiments to allow differentiation to the macrophage phenotype.   Two hours 
prior to adding DCFH-DA, Manuka honey, Rewarewa or artificial honey was 
added to each well to give a final concentration of 0.5%.  Control wells had 
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equivalent amounts of RPMI medium added. Latex beads (25/cell) were added to 
the wells to initiate phagocytosis, and plates were further incubated.   
After 2 hours incubation, DCFH-DA in 50 µl assay medium was added to each 
well to give a final concentration of 100 μmol/l DCFH-DA.  The assay was 
performed at 4 C to slow the reaction down, which allows for higher accuracy of 
readings across the plate.   Fluorescence was measured on a LAS -1000 imaging 
system (Fuji Film life Sciences) using the fluorescence setting (λex 473 nm/λem 
520 nm) and analyzed using the provided software.  Preliminary experiments 
indicated that a 30 minutes incubation time gave the highest fluorescence 
readings before dropping which indicates the end of the reaction.  Figure 5.1 
shows an example of the intensity of the fluorescence of the LPS-activated THP-1 
cells after a 30 minute DCFH assay.   
 
 
               
Figure 5.1.  LPS activated THP-1 cells after 30 minutes incubation with DCFH-DA.  
Cells are adherent to culture plate.  Pictures taken on an Axostar plus Zeiss 
fluorescent microscope, phase II, 40x lens with a canon digital camera, λex 470 
nm, λem 505 nm. 
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5.3.3  Fluorescence readings and calculation 
An initial fluorescence reading was taken immediately after adding DCFH-DA and 
a subsequent reading 30 minutes later.  Fluorescence measurements are shown 
in arbitrary units (AU) to illustrate the differences between maximal fluorescence 
generation using LPS-, PMA- or un-activated THP-1 cells.  To compare honey 
types the percentage increase in fluorescence per well was calculated by the 
formula;   [(Ft30 − Ft0)/Ft0* 100], were Ft30 = fluorescence at time 30 minutes and 
Ft0 = fluorescence at time 0 minutes. This method of analysis has advantages 
over analyzing just the net change in fluorescence in that not only did the 
calculated data directly reflect the percentage changes of fluorescence over time 
from the cells in the same well, they also effectively control for any variability 
among wells (Wang and Joseph 1999) and variability in latex bead fluorescence.   
Background fluorescence was monitored using a control with cells and latex 
beads only, as the latex beads had their own fluorescence. The fluorescence 
generated from the latex beads was minimal (~ 500 AU) compared to the 
fluorescence due to oxidation of DCFH in control cells (~ 13 000 AU). These 
measurements remained unchanged for the duration of the assay.  Three 
replicates were used.   
 
5.4  Results 
Manuka honey had a significant (p<0.005) effect by decreasing ROS release in 
phagocytosing macrophages activated with LPS (Figure 5.2) or PMA (Figure 5.3) 
whereas artificial honey did not.  This shows that the decrease in production of 
ROS was not due to an osmotic effect of the sugar content.   Figure 5.4 shows the 
effect of honey on ROS release in resting monocytes which shows that resting 
monocytes produce less than half the ROS than actively phagocytosing activated 
macrophages do, and this was not affected by honey.  Neither Manuka honey 
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nor artificial honey had a significant effect on the release of ROS (p=0.527 and 
p=0.722 respectively).  Figure 5.5 shows a comparison of the effect of Manuka 
honey, Rewarewa honey and artificial honey on the release of ROS from LPS-
activated macrophages with the measurements reported in % increase in 
fluorescence.  Only Manuka honey gave a significant decrease in ROS release 
(p=0.003 for Manuka honey, p=0.655 for Rewarewa honey and  p=0.824 for 
artificial honey). 
 
 
 
Figure 5.2:  The effect of honey on release of ROS in phagocytosing LPS-activated 
THP-1 cells.  a Fluorescence measurements are in arbitrary units (AU) and show 
the increase in fluorescence after 30 minutes exposure to DCFH-DA, compared 
with the fluorescence measured at the start of the experiment (Ft0).  Error bars 
show the mean ± 1 SD of three experiments.  * p<0.001 analysed by ANOVA 
comparing honey treated cells with control cells not treated with honey.   
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Figure 5.3:  The effect of honey on release of ROS in phagocytosing PMA-activated 
THP-1 cells.  a Fluorescence measurements are in arbitrary units (AU) and show the 
increase in fluorescence after 30 minutes exposure to DCFH-DA, compared with the 
fluorescence measured at the start of the experiment (Ft0).  Error bars show the 
mean ± 1 SD of three experiments.  * p<0.001 analysed by ANOVA comparing honey 
treated cells with control cells not treated with honey.   
 
 
Figure 5.4:  The effect of honey on release of ROS in resting THP-1 cells (monocytes).  
a Fluorescence measurements are in arbitrary units (AU) and show the increase in 
fluorescence after 30 minutes exposure to DCFH-DA, compared with the fluorescence 
measured at the start of the experiment (Ft0).  Error bars show the mean ± 1 SD of 
three experiments.  Latex particles were used as the phagocytic stimulus. 
0 
2000 
4000 
6000 
8000 
10000 
12000 
14000 
16000 
no honey Manuka honey artificial honey 
In
cr
ea
se
 in
 f
lu
o
re
sc
e
n
ce
 a
   
Treatment 
0 
2000 
4000 
6000 
8000 
10000 
12000 
14000 
16000 
no honey Manuka honey artificial honey 
 In
cr
ea
se
 in
 f
lu
o
re
sc
e
n
ce
 a
  
Treatment 
* 
Chapter 5                                    ROS release in THP-1 
133 
 
  
Figure 5.5:  Comparison of the effect of Manuka honey, Rewarewa honey and 
artificial honey on the release of ROS in LPS-activated THP-1 cells compared with 
control cells which received no honey treatment.  Fluorescence measurements 
are in arbitrary units and show the increase in fluorescence after 30 minutes 
exposure to DCFH-DA compared to the fluorescence at the start of the 
experiment (Ft0).  Error bars show the mean ± 1 SD of three experiments.  * 
p<0.005 analysed by ANOVA comparing honey treated cells with control cells not 
treated with honey. 
 
5.5 Discussion 
The monocyte control provides an indication of how much ROS is produced by 
resting monocytes during normal cell replication and maintenance.  After 
providing latex particles to stimulate phagocytosis, the fluorescence did not 
increase beyond 6 000 AU (compared to the fluorescence measured at the start 
of the assay Ft0= ~ 500 AU) for each honey treatment after the assay time of 30 
minutes. When this assay was repeated using monocytes activated with LPS or 
PMA (to form macrophages), this fluorescence increased to 13 000 AU and 12 
000 AU respectively. 
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In LPS-activated phagocytosing cells Manuka honey had a large, significant 
(p<0.001) effect in decreasing ROS production, preventing fluorescence from 
increasing much beyond the baseline achieved by the monocyte control.  This 
effect was not seen with Rewarewa honey which is known for its high 
antioxidant levels.  This suggests that Rewarewa honey does not scavenge ROS 
from actively phagocytising macrophages, and perhaps the antioxidant 
properties are limited to scavenging ROS free in solution.  Manuka honey may be 
preventing the formation of ROS, not neutralising already released ROS.  
However it may be that the antioxidants in Rewarewa honey do not cross all 
membranes and those in Manuka honey do. 
The results were similar in PMA-activated THP-1 cells.  Unexpectedly the ROS 
production was similar in LPS- and PMA-activated cells.  As mentioned 
previously, activation with PMA produced a much less mobile cell and it was 
expected that the ROS production would also be less.  Manuka honey still had an 
inhibitory effect on ROS production in these macrophages. 
Interestingly, artificial honey slightly increased the ROS release in macrophages, 
though this increase was not significant.  It was noted in Chapter 4 that artificial 
honey also increased the phagocytosis of latex beads.  This may be due to the 
increased energy supplement that sugars provide.  None the less it can be said 
that increasing the rate of phagocytosis also increased the ROS release from 
macrophages.  The sugars in the artificial honey are also present in Manuka 
honey and if taken into account would give the inhibitory factor in Manuka 
honey a greater inhibition of ROS release.  The results from these assays show 
that the osmotic effects of the sugars in honey cannot be simply inhibiting cell 
activity/vitality with regards to the phagocytosis rate.   
Research has been published on the effect of honey on ROS release, which is in 
agreement with these results. It was reported that ROS production was 
significantly (p<0.001) decreased by Pasture honey and Manuka honey (Tonks, 
Cooper et al. 2001) and more recently that honey appears to modify the 
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oxidative burst process by inhibiting phagocytic MyPo activity causing an 
inhibition of ROS production including H2O2, •OH and hypochlorous acid (Mesaik, 
Azim et al. 2008).  This is because MyPo produces hypochlorous acid and •OH 
from H2O2 during the respiratory burst (Rodrigues, Rodriguez et al. 2002). 
Future work should attempt to identify the actual mode of action honey has on 
reducing ROS.  Currently it would seem that honey may be working to decrease 
MyPo activity which will ultimately reduce the production of ROS (Mesaik, Azim 
et al. 2008) and research should look in this direction.    Evidence also suggests 
that MyPo released from macrophages is involved in, and is possibly responsible 
for, atherosclerosis (Gelderman 1998).  
Research also indicated that MyPo derived from neutrophils is cleared by the 
macrophage mannose receptor (Shepherd and Hoidal 1990) suggesting the 
macrophage mannose receptor plays a potentially physiological role in regulating 
extracellular MyPo levels. The receptor-mediated uptake may either support the 
macrophage to contribute to oxidant-mediated tissue damage or may function to 
clear extracellular MyPo during the resolution phase of the inflammatory 
process.   
Future work should focus on the role of the mannose receptor, MyPo and honey.  
A wide range of honeys should also be tested using the DCFH assay. 
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Chapter 6  
Identifying the anti-inflammatory agent in honey 
 
 
 
 
6.1  Summary 
This Chapter covers the work done to isolate and identify the component of 
honey that in previous Chapters that was found to have anti-inflammatory 
properties by way of inhibiting phagocytosis and ROS release.  Fractions of 
Manuka honey were subjected to a series of different treatments to determine 
the likely properties of the phagocytosis-inhibiting component of Manuka honey.  
Trypsin treatment and heat treatment resulted in a loss of the inhibitory activity 
in a phagocytosis assay, indicating that the active component was a protein. 
The active protein fraction in Manuka honey was identified by separating the 
proteins out, using gel permeation chromatography on a Sephadex column and 
subsequently assaying these fractions in the phagocytosis assay.  The active 
fraction was isolated as an early peak on the elution trace, suggesting a larger 
protein or protein complex.  It was determined that the high molecular weight 
protein fraction was active in the phagocytosis assay.  This fraction was further 
separated into two peaks by FPLC (fast protein liquid chromatography) on a 
Superose 12 FPLC gel permeation column and one of these peaks was identified 
as having the inhibitory activity.  This fraction was then run on a reverse phase 
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FPLC column to further separate out the proteins in the fraction but the products 
were not able to be identified by MALDI mass spectrometry due to low 
concentrations.  Instead the whole fraction was subjected to analysis by MALDI 
mass spectrometry. 
This fraction was identified as having the protein Apalbumin-1 (MRJP-1) by 
matrix-assisted laser desorption/ionization (MALDI) mass spectrometry, it being 
found to have a molecular weight of 48.8 kDa.  Apalbumins are proteins secreted 
by the bee into the gathered nectar during honey maturation.  Apalbumin-1 is 
the most abundant protein in honey, and known to be a glycoprotein. The 
protein bound to a ConA lectin column and showed loss of activity after 
mannosidase treatment, indicating mannose modifications on the protein 
conferred at least some of the activity.  A second protein in the fraction was 
identified by MALDI mass spectrometry as being Apalbumin-3 (MRJP-3).  
Apalbumin-3 is a slightly larger 61.6 kDa glycoprotein.   
 
6.2  Introduction 
In Chapter 4 it was found that honey reduced the phagocytosis of latex particles 
and a range of other biological materials.  This was hypothesised to have an anti-
inflammatory effect by reducing the amount of ROS produced which is a pro-
inflammatory agent. This hypothesis was backed up by the observations made in 
Chapter 5 which showed that honey did reduce the release of ROS which results 
in an anti-inflammatory effect.  Further to that it was found that honey changed 
the expression of cytokines to have a net anti-inflammatory effect on THP-1 cells.  
It was for these reasons that an attempt was made to isolate and identify the 
active component in honey.  In Chapter 4 the high molecular weight component 
of honey was found to contain the active component of honey.  This Chapter 
focuses on further isolating this component and identifying it. 
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6.2.1  Royal jelly proteins 
The honey bee (Apis mellifera) caste determination occurs when young worker 
bees in the hive (nurse bees) produce, secrete, and feed a substance called royal 
Jelly to developing larvae.  Royal jelly is a natural source of essential amino acids, 
lipids, vitamins, acetylcholine, and other nutrients (Schmitzová, Klaudiny et al. 
1998; Lerrer, Zinger-Yosovich et al. 2007).  In the initial 3 days of development, 
all larvae are fed royal jelly, but thereafter only larvae designated by workers to 
become queens receive royal jelly. In its place, a mixture of honey, pollen, and 
water is fed to larvae selected to become workers.   
Royal jelly proteins make up 50% (dry mass) of royal jelly (Schönleben, Sickmann 
et al. 2007). Of these proteins more than 80% are from the major royal jelly 
protein family (MRJP) also called the yellow protein family.  Multiple yellow-like 
proteins have been found in all insect genomes including that of the honeybee. 
MRJPs are restricted to honeybees. Nine MRJP proteins, termed MRJP I-9, have 
been characterized so far (Albert and Klaudiny 2004) with MRJP 1-5 being the 
most prominent.  These are named apalbumins.  They range in size from 49 kDa 
– 87 kDa.  Size polymorphisms exist, with MRJP-3 having at least five different 
isoforms (Albert, Klaudiny et al. 1999).   MRJP-1 is reported to constitute 48% of 
the royal jelly proteins (Scarselli, Donadio et al. 2005).  The genes of these 
proteins have been identified and the proteins are suggested to be 
multifunctional, performing diverse nutritional, physiological and developmental 
roles affecting various tissues (Schmitzová, Klaudiny et al. 1998).  
Royal jelly products have been used for various therapeutic purposes including 
cholesterol-lowering (Guo, Saiga et al. 2007), anti-inflammatory (Kohno, 
Okamoto et al. 2004), antioxidant, anti-tumour (Viuda-Martos, Ruiz-Navajas et 
al. 2008), or wound-healing (Calli, Tugyan et al. 2008), and for their anti-bacterial 
effects (Fujiwara, Imai et al. 1990).  MRJPs have also been identified as having 
immuno-stimulatory properties (Simuth, Bilikova et al. 2004).  MRJP-1 is 
described as the major honey protein.  It is a glycoprotein with various biological 
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properties, and is able to stimulate macrophages to release TNF-α (Majtan, 
Kovacova et al. 2006).  Honey contains around 1% protein (Lerrer, Zinger-
Yosovich et al. 2007) with MRJP-1 being the major honey protein. 
6.2.2  Importance of structural integrity of proteins 
Many proteins play important roles in cell signalling, often due to their specific 
folding properties, allowing them to correctly fit into receptor sites of 
membranes, initiating signalling cascades.  For many proteins the correct three-
dimensional structure is essential to function (Anfinsen 1972).  Failure to fold 
into the intended shape usually produces inactive proteins with different 
properties, unable to bind receptors as their interactive sites are lost.   
Denaturation of proteins involves the disruption and possible destruction of both 
the secondary and tertiary structures. Since denaturation reactions are not 
strong enough to break the peptide bonds, the primary structure (sequence of 
amino acids) remains the same after a denaturation process. Denaturation 
disrupts the normal alpha helix and beta sheets in a protein and uncoils it into a 
random shape. 
In tertiary structure there are four types of bonding interactions between "side 
chains" including: hydrogen bonding, salt bridges, disulfide bonds, and non-polar 
hydrophobic interactions which may be disrupted. Therefore, a variety of 
reagents and conditions can cause denaturation. The most common observation 
in the denaturation process is the precipitation or coagulation of the protein.  
High temperatures disrupt hydrogen bonds and non-polar hydrophobic 
interactions (Shortle 1996).  This occurs because heat increases the kinetic 
energy and causes the molecules to vibrate so rapidly and violently that the 
bonds are disrupted, causing loss of ordered folding and thus loss of activity. 
Protease treatment also causes a loss of activity by cleaving the peptide chain.  
Trypsin is a serine protease found in the digestive system of many vertebrates, 
where it breaks down proteins (Walsh, Gertrude et al. 1970).  Trypsin 
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predominantly cleaves peptide chains at the carboxyl side of the amino acids 
lysine and arginine.  The conventional source for trypsin is porcine or bovine 
pancreas.  It is commonly used in proteomics for protein digestion prior to mass 
spectrometry and other protein assay work. 
The previous work in Chapter 4 showed that the phagocytosis-inhibiting activity 
in Manuka honey was of high molecular weight and therefore possibly a protein, 
so it was important to see if the activity could be lost by denaturing or digesting 
the proteins, while keeping all the honey components in solution, to find out if 
the phagocytosis-inhibiting component is a protein.   Then, is it modified in any 
way with sugars.   
6.2.3  Glycoproteins 
Proteins with sugar modifications (glycoproteins) often have additional 
properties.  Glycoproteins play an important role in many biological processes 
including immune regulation, inflammation, cell-to-cell adhesion and contact 
inhibition, cell signalling, protection against proteolytic degradation, and several 
other biological processes.  Several papers have reported that proteins in honey 
have a high glycosylation with mannose (Schmitzová, Klaudiny et al. 1998; 
Simuth, Bilikova et al. 2004).   
One method for identifying the types of modifications is by using a lectin 
isolation column.  Lectins are proteins that have a selective affinity for 
carbohydrate moieties. The Concanavalin A (ConA) lectin preferentially 
recognizes α-linked mannose. These carbohydrates are attached to proteins 
through asparagine residues (Cummings 1997).  Mannosidase can be used to 
cleave off mannose-linked sugars from proteins, this reducing the effect of the 
proteins if the sugar additions are responsible for binding the recognition sites. 
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6.2.4  Characterising and identifying proteins 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is a 
technique used to separate proteins according to their molecular size.  The 
electrophoretic mobility of a protein without SDS added is a function of length of 
polypeptide chain or molecular weight as well as higher order protein folding, 
post-translational modifications and other factors.  The addition of SDS causes 
the protein molecules to unfold, and this massive negative charge (from the SDS 
molecules which attach to the protein molecules) swamp any effects on 
modifying from the protein molecules’ own charges, thus the protein molecules 
migrate according to their size.  The gel after running SDS-PAGE is stained to 
visualise the protein bands and these bands are cut from the gel.  This technique 
will be used to isolate active protein(s) from honey in an attempt to identify 
them from that molecular weight. 
Identification of the proteins from honey will be attempted using MALDI mass 
spectrometry after removing the stained bands from the gel piece.  In order to 
have molecules small enough to be mobilised the protein is digested with trypsin 
to form peptides.   
MALDI is a soft ionization technique used in mass spectrometry, allowing the 
analysis of biomolecules (biopolymers such as proteins, peptides and sugars) and 
large organic molecules which tend to be fragile and fragment when ionized by 
more conventional ionization methods. The ionization is triggered by a laser 
beam (normally a nitrogen laser). A matrix holding the protein is used to protect 
it from being destroyed by the direct laser beam and to facilitate vaporization 
and ionization. 
The laser is fired at the crystals in the MALDI spot. The matrix absorbs the laser 
energy and it is thought that primarily the matrix is ionized by this event. The 
matrix then transfers part of its charge to the analyte molecules (e.g. protein), 
ionizing them while still protecting them from the disruptive energy of the laser.  
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The type of mass spectrometer most widely used with MALDI is the TOF (time-of-
flight mass spectrometer), mainly due to its large mass range. The TOF 
measurement procedure is also ideally suited to the MALDI ionization process 
since the pulsed laser takes individual 'shots' rather than working in continuous 
operation. MALDI-TOF instruments are typically equipped with an "ion mirror", 
deflecting ions with an electric field, thereby doubling the ion flight path and 
increasing the resolution 
These results are matched with a library of a published protein sequence 
database of fragments of proteins previously studied by MALDI-TOF mass 
spectrometry.   Preferred libraries are Swiss-Prot and NCBInr. 
6.2.5  Aims and experimental approach 
The aim for this Chapter was to isolate the active component of honey and 
identify it.  Honey was treated in various ways and assayed for its phagocytosis 
inhibiting activity to determine if the activity was lost.  Diluted honey was treated 
with heat and trypsin to see if the phagocytosis-inhibiting effect was lost with 
protein denaturation or enzyme digestion (Sections 6.3.3 and 6.3.4).  The results 
suggested protein was indeed a large part, at least, of honey’s phagocytosis-
inhibiting activity.  The honey proteins were fractioned using gel permeation 
chromatography, and the individual fractions tested to isolate the activity 
(Section 6.3.5). These fractions were run on SDS-PAGE and the bands containing 
the proteins thought to have the activity were then identified by MALDI-TOF 
mass spectrometry (Section 6.3.7).  A ConA glycoprotein affinity column was 
used to find if the active proteins bound to ConA, which would indicate that the 
active proteins had terminal modifications with mannose (Section 6.3.8). A 
mannosidase treatment of whole fractions was used to determine if these sugar 
modifications of the protein were important in the inhibition of phagocytosis 
(Section 6.3.9) and these proteins were separated on SDS mini-gels to examine 
the molecular weight of the proteins before and after mannosidase treatment. 
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6.3  Methods  
6.3.1  Honey dilutions 
Manuka honey (M144) was used for assays in this Chapter and the method of 
dilution is as described in Chapter 3.   
6.3.2  THP-1 cell culturing 
THP-1 cells for the phagocytic assay were maintained at 37°C, 5% CO2, and 95% 
relative humidity in growth medium (as described in Section 2.3.2).  Cells were 
split with fresh growth medium prior to the assay and assessed for viability as 
described in Sections 2.3.1 and 2.3.4. 
6.3.3  Heat treatment of honey 
Diluted honey solutions (10% in water) and undiluted honey samples were 
incubated at different temperatures to denature the proteins present: 65°C for 2 
hours and 99°C for 10 minutes.  Additional incubations were at 4°C and 37°C, 
each for 24 hours to test the stability of the proteins.  All honey incubations were 
assayed in the phagocytosis assay as described in Section 4.3.1 but with a 0.5% 
final concentration of honey (V/V). 
6.3.4  Trypsin treatment of honey 
Manuka honey proteins were treated with high grade trypsin to see if the 
phagocytosis-inhibiting activity would be lost with degradation of the protein.   
Trypsin was purchased from Sigma-Aldrich (Cat. No#T8128 Porcine pancreas) and 
dissolved in RPMI 1640 medium (with no FCS) to get a 5% solution.  Trypsin was 
used at a final concentration of 2.5%. 
Chapter 6              Identifying the active component 
144 
 
A 5% Manuka honey solution (M144) was treated with a 5% trypsin solution (500 
µl of each) at 37°C for 2 hours.  A control honey solution was incubated at 37°C 
for the same amount of time with RPMI 1640 medium added instead of enzyme 
solution.  An additional control included trypsin-treated honey incubated at 4°C. 
A trypsin inhibitor (Sigma-Aldrich Cat. No#T6522-25 MG) was used to end the 
reaction.  Trypsin inhibitor was used at a final concentration of 2 mg/ml (40 µl of 
a 50 mg/ml solution).  After the trypsin inhibitor was added to the honey/trypsin 
solution, the solution was incubated at 65°C for 10 minutes. 
The phagocytosis assay with latex particles was carried out as described in 
Section 4.3.1 but using a 0.5% final equivalent concentration of 0.5% trypsin 
treated honey or control.   
6.3.5 Fractioning honey 
The fractionation of honey was carried out by Stacey Meyer from the Honey 
Research Unit, University of Waikato.  Honey was initially dialysed to remove the 
sugars and low molecular weight compounds (Section 6.3.5.1) Then 
chromatography on Sephadex G-50 (Section 6.3.5.2) and Superose 12 FPLC 
(Section 6.3.5.3) chromatography columns was carried out.  A reverse phase 
column was used to further separate out the proteins to determine if the 
fraction was made up of more than one protein (Section 6.3.5.4). 
6.3.5.1  Elimination of the low molecular weight components of honey 
Twenty-five grams of honey (M141) were suspended in 25 ml of distilled water 
and dialyzed (Cellu Sep T1 tubing, Membrane Filtration Products, Inc., Seguin, TX; 
EEUU, molecular mass cut off 3 500 Da) against 1 litre of purified water for 48 h 
at 4°C with four changes of the 1 litre of water during this time. The dialysis 
retentate was lyophilized and then stored at −20 °C until used. The lyophilized 
samples were reconstituted to 2 ml with 0.3 mol/l ammonium acetate solution.  
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6.3.5.2 Chromatographic separation on Sephadex G-50 
The reconstituted retentate from dialysis (2 ml) was then loaded onto a 
Sephadex G-50 column (180 ml) and the material was eluted in 1 ml fractions 
(flow rate 0.5 ml/minute monitored at 280 nm).  The fractions obtained from the 
2 peaks were lyophilized and reconstituted to 100 µl with purified water for 
preliminary assessment in a SDS gel and tested in the phagocytosis assay.  This 
assay indicated that the inhibitory activity was in the peak that was eluted first, 
but an assortment of protein sizes were present (37 kD – 250 kD) indicating the 
possibility of flow-though proteins.  Further chromatographic separation was 
undertaken to generate a larger amount of protein.  The chromatography on the 
Sephadex G-50 column was repeated three times and the fractions in the first 
peak on the elution trace from each run were pooled all together, rotary 
evaporated to 200 µl and then this pooled fraction further separated on a 
Superose 12 column (Section 6.3.5.3). 
6.3.5.3  FPLC separation of protein on Superose 12  
To further fractionate the first peak on the Sephadex G-50 elution trace, a 100 μl 
amount of the reconstituted sample was injected on a Superose 12 FPLC column 
(25 ml) and eluted as 1 ml fractions with phosphate-buffered saline (pH 7.11), 
flow rate 0.5 ml/minute, 0.5 cm/ml, monitored at 280 nm.  These fractions were 
frozen at -20°C until further use.  Two clearly separated major peaks (Fractions 8 
and 14 as shown in Figure 6.6) were obtained and assayed for inhibitory activity 
in the phagocytosis assay (Section 6.3.5.6).  These fractions were run on a 10% 
SDS-PAGE gel and processed for MALDI-TOF mass spectrometry identification 
(Section 6.3.7). 
6.3.5.4  Reverse phase of active fractions 
The fraction from chromatography on Superose 12 found to have phagocytosis-
inhibiting activity (Fraction 8) was chromatographed on a reverse phase column 
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to further purify proteins for MALDI mass spectrometry identification.  
Chromatography was performed using a a FPLC system (Pharmacia-LKB, Uppsala, 
Sweden).  A 500 μl amount of the Fraction 8 sample was injected on the column 
and eluted with a mobile phase in a gradient from 100% water to 100% of 
acetonitrile at a flow rate of 1 ml/minute monitored at 260 nm.  The fractions 
comprising the two major peaks obtained (Fractions 23 and 26) were rotary 
evaporated to 50 μl.  The 5 μl of the fractions were loaded onto 10% SDS mini 
gels to visualise and processed for MALDI-TOF mass spectrometry (see Section 
6.3.6 and 6.3.7).  The resulting proteins for each fraction obtained returned no 
results in the phagocytosis assay indicating the concentrations were too low. 
6.3.5.5  Estimating protein concentration of fractions 
Fractions from the Superose 12 FPLC chromatography column where assessed 
using a Nanodrop-1000 spectrophotometer to estimate protein concentration 
(results not shown).  The fractions were rotary evaporated to achieve the 
approximate protein concentrations there would have been in un-fractionated 
honey. 
6.3.5.6  Phagocytosis assay  
The phagocytosis assay with latex particles was carried out as described in 
Section 4.3.1 but in place of honey, the protein fractions obtained from column 
chromatography (Superose 12, Section 6.3.5.3) were used.  Fractions were used 
at approximately 1% of the concentration they would have been in honey.  A 200 
µl assay sample size was used due to the smaller amounts of protein available 
from the fractioning of honey.   
6.3.6  Electrophoresis on SDS mini gels 
Proteins obtained by fractionation of honey were run on SDS-PAGE gels to give 
an estimate of their molecular weight.  Resolving gels with 10% and 12% 
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acrylamide were used for separating a different range of proteins.  The 10% gel is 
best for separating 14-205 kDa proteins and 12% gel for 14-66 kDa proteins.  The 
gels were made in an OWL Separation System gel caster (BioLab Scientific LTD) 
using assembled clean glass plates.  The resolution gel was poured first, using a 
syringe, and left to set covered with a layer of butanol to ensure an even gel 
surface.  When the gel was set the butanol was removed and the stacking gel 
was poured and a gel comb inserted to make wells for sample loading.  The 
composition of the gels was: 
10% resolution gel 
6.8 ml 37% Acrylamide 
2 ml 1 mol/l Tris pH 9.0 
5.9 ml water 
150 µl 10% Sodium Dodecyl Sulfate (SDS)  
15 µl N,N,N',N'tetramethylenediamine (TEMED) 
150 µl 10% ammonium persulfate (APS)  
12% resolution gel 
8.2 ml 37% Acrylamide 
2 ml 1 mol/l Tris pH 9.0 
4.5 ml water 
150 µl 10% SDS  
15 µl TEMED 
150 µl 10% APS  
5% stacking gel 
0.66 ml 37% Acrylamide 
1.25 ml 0.5 mol/l Tris pH 6.8 
3.0 ml water 
50 µl 10% SDS  
5 µl TEMED 
50 µl 10% APS 
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When the stacking gel was set, the gel was inserted into the electrophoresis 
chamber and running buffer (3.0 g Tris, 14.4 g Glycine, 1 g SDS, in 1 l MilliQ 
water) added in the top and bottom chamber.  The comb was removed and the 
sample wells washed with electrophoresis buffer.  The gel was then run for 10 
minutes at 10 mA to remove any un-polymerised acrylamide.  
Samples to be loaded on the gel were mixed 1:1 with 2X Tricine Sample Buffer 
(0.1 mol/l Tris pH 6.8, 24% (w/v) glycerol, 8% (w/v) SDS, 0.2 mol/l dithiothreitol, 
0.02% (w/v) Coomassie Blue G-250) and heated at 99°C for 5 minutes, then left 
to cool.  Samples were centrifuged (2 000 x g for 20 seconds) to pellet any 
sediment and 10 µl of sample loaded per lane.  A BIORAD Precision Plus Dual 
Colour protein standard ladder (Cat. No.#161-0374) was run alongside the 
samples to provide an estimated protein size for the samples.  The standard 
contained proteins sized 10-250 kDa: 6 µl was loaded at each end of the gel.   
The gel was run at 10 mA until samples had migrated through the stacking gel 
into the resolution gel. The current was then increased to 20 mA. When the dye 
in the sample had run off the edge of the gel, the current was switched off and 
the gel removed and stained. 
Two methods were used to visualize bands.  Silver staining was used to identify 
fainter bands as it is more sensitive.  A Fast Blue method was used prior to 
MALDI-TOF mass spectrometry work as the stain is more readily removed than 
silver.  Fast blue is modified Coomassie Brilliant Blue which binds with less 
affinity to glycoproteins making it ideal for honey which has a large proportion of 
glycoproteins.  This allows for better stain removal prior to protein MALDI mass 
spectrometry work as remaining stains can interfere with quantification 
(Deutscher 1990). 
All reagents were made fresh 5 minutes before staining took place and kept at 
4°C until required.  The gel was first fixed for 30 minutes in 50% ethanol/12% 
acetic acid, then soaked in 30% ethanol for 15 minutes. Then 100 ml of 0.02% 
sodium thiosulfate was added and left for 1-2 minutes. The gel was soaked in 
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100 ml 0.1% silver nitrate + 100 µl formaldehyde for 10 minutes. It was then 
washed in water for 10 seconds and 100 ml developer (3 g sodium carbonate, 
100 µl formaldehyde, 40 µl 1% sodium thiosulfate in 100 ml MilliQ water) added. 
Development was stopped with 10% acetic acid after the bands became visible. 
Developed gels were stored in MilliQ water until required.  
Fast Blue was obtained from Fisher Biotec (Cat. No.#FS-100).  Fast Blue was 
diluted (8 ml of Fast Stain concentrate, 32 ml MilliQ water, 10 ml 45% methanol 
with 10% acetic acid) before use. Gels were first washed in 40% methanol with 
10% acetic acid for 10-20 minutes followed by a rinse in MilliQ water.  Then 100 
ml of diluted Fast Blue was added and the gel was gently swirled in the solution 
for 20 minutes.  Gels were de-stained with 10% acetic acid for 10 minutes, then 
stored in MilliQ water until required. 
6.3.7  MALDI-TOF mass spectrometry identification of active honey proteins 
The MALDI-TOF work was completed in collaboration with Jonathan Puddick, 
from the Waikato Mass Spectrometry Facility, University of Waikato. 
The single protein bands were cut from the 10% SDS mini-gels after 
electrophoresis of both the Superose 12 Fraction 8 and Fraction 14 (both were 
50-65 kDa molecular weight) and prepared for MALDI-TOF identification.  The 
reverse phase fractions were not concentrated enough to visualize a distinct 
band on the gel, so a band was cut at the expected location of the target protein 
according to the molecular weight ladder.  Unfortunately no results could be 
obtained from these gel pieces 
6.3.7.1  Preparation of proteins 
A clean scalpel was used to excise the bands which were then de-stained with 
30% ethanol to remove the Fast Blue dye by incubating at 60°C for 15 minutes or 
until the gel pieces appeared colourless.  The bands were washed twice in 30% 
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ethanol and then shrunk with 100% acetonitrile for 10 minutes.  Acetonitrile was 
removed by aspiration and the gel piece was dried by vacuum in a Speed Vac to 
remove residual moisture for 30 minutes. 
The protein in the gel pieces was cleaved into peptides for analysis by MALDI-
TOF mass spectrometry by digesting the protein in the gel piece with trypsin.  
The method used was adapted from details given by Dr. Jo McKenzie, University 
of Waikato.  To each gel piece 10 µl of 25 mmol/l ammonium bicarbonate was 
added, followed by 10 µl of sequencing grade trypsin solution (49 µl 25 mmol/l 
ammonium bicarbonate in 10% acetonitrile, 1 µl sequencing trypsin (1 mg/ml 
Promega Cat. No.#V5111).  Tubes were then left overnight at 37°C.   To each 
tube 14 µl 50 % acetonitrile with 0.3% trifluoroacetic acid was added and the 
tubes vortexed and sonicated for 10 minutes.  The gel piece was discarded and 
the solutions were refrigerated until use. 
6.3.7.2  Preparation of matrix  
The method used was obtained from Jonathan Puddick, Waikato Mass 
Spectrometry Facility, University of Waikato. 
Five mg α-Cyano-4-hydroxycinnamic acid (CHCA) was added to 500 µl 65% 
acetonitrile with 1% trifluoroacetic. The solution was vortexed for 2 minutes, 
sonicated for 10 minutes, vortexed again for 2 minutes then centrifuged at        
12 000 x g for 5 minutes. The prepared protein digest solutions and matrix were 
combined (2:1) and 1 µl was spotted onto the MALDI Anchor chip target plate. 
The spots were allowed to air dry and then washed by pipetting 5 µl of 1% 
trifluoroacetic onto and off the dried matrix spot and allowed to dry. 
6.3.7.3  Autoflex operating procedure  
The external calibration was conducted with the Bruker Daltonics Peptide 
standard 206 195 prior to analysis.  A monoisotopic peptide calibration was used 
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with a zooming of ± 0.1%. Once a good, clean spectrum had been collected the 
mass spectrometer automatically recalibrated. The fit result was accepted if the 
error was no more than ± 10 ppm. 
Internal calibration can be conducted if products resulting from the autolysis of 
the trypsin are present. These products yield peaks at 842 and 2 211 Da. The 
peaks are assigned as internal calibrants in the flex analysis program.  
A Bruker Autoflex II TOF/TOF mass spectrometer was used to analyze peptide 
digests. An average of 30 shots per sample was taken to build the peptide mass 
fingerprint spectrum. The mass range selector was set at low range and the 
detector gain voltage offset was set at 1 400 v. The detection settings were set in 
the range of 480 – 3 540 Da. The instrument was manually operated using flex 
control software. Suitable spectra were saved and exported into flex analysis.   
6.3.7.4  Analysing MALDI spectra 
Using the Biotools software the spectrum collected can be searched against a 
variety of protein databases.  The databases of preferred use are Swiss-Prot and 
NCBInr. The parameters for the searching of Eukaryota proteins in Swiss-Prot are 
a peptide tolerance of ± 200 ppm and 1 missed cleavage.  A protein score greater 
than 64 is significant for Swiss-Prot.  The parameters for searching of Eukaryota 
proteins in NCBInr are 1 missed cleavage and a peptide tolerance of ± 200 ppm.  
The protein score required for a significant hit in NCBInr is 78.  These parameters 
were correct, at least, up until May 2009.  Molecular masses can be measured to 
within an accuracy of 0.01% of the total molecular mass of the molecule/peptide.  
This is sufficient to allow minor mass changes to be detected, e.g. the 
substitution of one amino acid for another or a post-translational modification. 
The main function of the mass analyser is to separate, or resolve, the ions 
formed in the ionisation source of the mass spectrometer according to their 
mass-to-charge ratios. The peptides produced by the tryptic digest are separated 
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by ionisation due to their mass and this mass can be calculated.   The detector 
monitors the ion current, amplifies it and the signal is then transmitted to the 
data system where it is recorded in the form of a mass spectrum. The mass to 
charge values of the ions are plotted against their intensities to show the number 
of components in the sample, the molecular mass of each component, and the 
relative abundance of the various components in the sample. When using 
MALDI-TOF to identify a protein, the ions generated must form a clear mass 
spectrum with intense peaks, indicating that only one protein (in large quantities 
at least) is present in the band cut from the SDS electrophoresis gel.  When more 
than one protein is present in the sample there are typically no clear peaks 
correlating to large amounts of the same peptide.    
6.3.8  Isolating glycoproteins from the protein fraction 
A 1% solution of diluted Manuka honey (in purified water) and the fractions 
containing the phagocytosis-inhibiting activity (Fraction 8) was assayed using a 
glycoprotein isolation kit utilising a Concanavalin A (ConA)-Sepharose column to 
identify any glycosylation with mannose the proteins may have.  The honey and 
Fraction 8 were separated on a ConA column and both the flow-through proteins 
and the retained proteins were used in the latex particle phagocytosis assay.    
6.3.8.1 Procedure for glycoprotein isolation using ConA 
A glycoprotein isolation kit was purchased from Thermo Scientific (Cat. No.# 
89804 ConA) and for preparation of the sample the manufacturer’s directions 
were followed.  Briefly, binding/wash and elution buffers were brought to room 
temperature and then the samples diluted with 5X binding/wash buffer stock 
solution (1 to 1.5 mg of total protein/ml  mixed 4:1 with 5X Buffer, not exceeding 
800 μl total final volume). 
The isolation of glycoproteins was as follows; 1X Binding/Wash Buffer was 
prepared by diluting 460 μl 5X Binding/Wash Buffer with 1 740 μl of ultrapure 
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water per sample.  A fresh column was prepared by adding 200 μl ConA lectin 
gel, centrifuging for 1 minute at 1 000 × g and discarding the storage buffer.  The 
column was placed in a collection tube and 200 μl 1X Binding/Wash Buffer was 
added to the gel. The top cap was closed and the column centrifuged for 1 
minute at 1 000 × g and the rinse was discarded. This was repeated twice.  The 
protein sample was added and the column incubated for 10 minutes at room 
temperature with end-over-end mixing using a rotator.  The column was then 
centrifuged for 1 minute at 1 000 × g and the flow-through liquid collected. This 
step was repeated once more.  The column was then rinsed with 400 μl 1X 
Binding/Wash Buffer and incubated for 5 minutes at room temperature with 
end-over-end mixing using a rotator.  The column was then centrifuged for 1 
minute at 1 000 × g and the rinse discarded.  This step was repeated once more.  
Then 200 μl of Elution Buffer was added to the column and which was then 
incubated for 5 minutes at room temperature with end-over-end mixing.  The 
column was then centrifuged for 1 minute at 1 000 × g and the eluate was 
collected.  This step was repeated once more.  The non-retained and the eluted 
retained fractions were stored on ice for immediate use or frozen for later 
analysis. 
6.3.8.2  SDS electrophoresis of glycoproteins 
The wash-through and the eluted bound proteins from the ConA column from 
whole honey (1% dilution) and Fraction 8 were subjected to electrophoresis on a 
12% SDS gel as described in Section 6.3.6.  The ConA binding proteins and the 
flow through non-binding proteins from Fraction 8 were concentrated by using a 
Vivaspin column 5 kDa molecular weight cut-off (Viva Science, 1 200 x g for 30 
minutes at 10°C to 50 µl) and then a Nanodrop-1000 spectrophotometer was 
used to estimate protein concentration compared with the 1% solution of diluted 
honey 
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6.3.8.3  Phagocytosis assay with glycoproteins 
Phagocytosis assay conditions were as described in Chapter 4. ConA binding 
glycoproteins and the flow through (non-ConA binding proteins) were used in the 
phagocytosis assay.  As a control, a sample of Fraction 8 prior to ConA isolation 
was used.  Fractions were used at concentrations that would equal that of 1% 
diluted Manuka honey.  This was achieved by using a Vivaspin column 5 kDa 
molecular weight cut-off (Viva Science, 1 200 x g for 30 minutes at 10°C) to 
concentrate and a Nanodrop-1000 spectrophotometer was used to estimate 
protein concentration compared with a 1% solution of diluted honey.  
6.3.9  Mannosidase treatment 
To determine the importance of the mannose terminal modifications, dialysed 
honey (1%) and the glycoprotein that bound the ConA column (Section 6.3.8) 
from Fraction 8 (Section 6.3.8.1) were subjected to mannosidase treatment.  A 
sample of Fraction 8 prior to ConA separation was also subjected to mannosidase 
treatment for use in the phagocytosis assay.  The resulting fractions were 
subjected to electrophoresis on a 12% SDS gel. 
6.3.9.1  Mannosidase 
α-Mannosidase from Canavalia ensiformis (Jack bean) was purchased from 
Sigma-Aldrich (Cat. No.#M7257) and used at 1 mg/ml in 1% diluted Manuka 
honey, ConA fractions (Section 6.3.8) and Fraction 8  (Section 6.3.5.3) and 
incubated at 37° for 4 hours.  As a control, equal amounts of enzyme were added 
to a 1% dilution of Manuka honey and the solution incubated at 4°C for 4 hours.  
Proteins separated on ConA (Section 6.3.8) and Fraction 8 (Section 6.3.5.3) after 
treatment with mannosidase were subjected to electrophoresis on a 12% SDS gel 
as described in Section 6.3.6. 
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6.3.9.2  Phagocytosis assay modification 
The phagocytosis assay with latex particles was the same as for Chapter 4 using a 
an equivalent concentration as in 0.5%  honey of the mannosidase-treated honey 
fractions of both ConA separated protein from Fraction 8, and a 1% dilution of 
Manuka honey separated on a ConA column.  The honey equivalent 
concentration of 0.5% was achieved by using a Vivaspin column 5 kDa molecular 
weight cut-off (Viva Science, 1 200 x g for 30 minutes (approximate) at 10°C) to 
concentrate.   A Nanodrop-1000 spectrophotometer was used to estimate the 
protein concentration by comparing the protein to the protein content of a 0.5% 
solution of diluted honey.   
6.4  Results 
6.4.1  Heat treatment of honey 
Manuka honey proteins were subjected to heat treatment (37°C, 65°C and 99°C) 
with two non-heat treated honey dilutions being freshly diluted honey or diluted 
honey stored at 4°C for 24 hours prior. All honey dilution treatments were 
compared with a non honey-treated control. Whole honey incubated at 99°C was 
unable to be diluted successfully due to caramelisation so was not assayed. The 
results are shown in Figure 6.1.   
All treatments assayed of diluted and whole honey (excluding whole honey 
incubated at 99°C) had a significant (p<0.001) effect by reducing the 
phagocytosis-inhibiting effect of honey compared to the control with no honey 
added.  Heat treatments of 65°C and 99°C of diluted honey, and 65°C of whole 
honey, had a significantly reduced effect on the inhibition of phagocytosis 
compared to freshly-diluted non-heat-treated honey.  This indicated that 
denaturation had taken place. Whole honey retained all of its activity at 37°C and 
4°C, possibly due to protection by the sugar in undiluted honey.  Diluted honey 
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incubated at 37°C for 24 hours had a significantly reduced effect on the inhibition 
of phagocytosis compared to freshly-diluted non-heat-treated honey. 
 
  
Figure 6.1. The effect of heat on the phagocytosis-inhibiting activity of Manuka 
honey in LPS-stimulated THP-1 cells. Manuka honey was exposed to various 
temperatures for various times prior to an assay for phagocytosis.  Results show 
% reduction of phagocytosis by honey compared with the control with no honey 
added. The assays were done with a 5% concentration of honey.  Whole honey at 
99°C was not assayed.  Error bars show ±1 SD of the mean from at least three 
experiments.  * p<0.001 analysed by ANOVA compared with the non honey-
treated control.  # p<0.001 analysed by ANOVA compared with the freshly diluted 
honey control. 
 
6.4.2 Trypsin treatment of honey 
Manuka honey proteins were subjected to trypsin treatment at 37°C for two 
hours with a control treatment at 4°C, to see if an intact protein is important in 
the phagocytosis-inhibiting activity of Manuka honey.  The results from the assay 
of phagocytosis-inhibiting activity after this treatment are shown in Figure 6.2.  
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Trypsin treatment of honey at 37°C gave a significant (p<0.001) reduction in the 
phagocytosis-inhibiting effect of honey whereas there was little difference in the 
honey treated with trypsin at 4°C, indicating that the effect was due to the 
enzyme activity of trypsin. 
 
 
 
Figure 6.2.  The effect of trypsin on the phagocytosis-inhibiting activity of Manuka 
honey in LPS-stimulated THP-1 cells.  Manuka honey was treated with trypsin (4°C 
or 37°C) prior to assay for phagocytosis.  A 0.5% honey solution was assayed.  
Results show % reduction of phagocytosis.  Error bars show ±1 SD of the mean 
from three assays.  * p<0.001 analysed by ANOVA compared with the untreated 
control.   
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6.4.3 Honey fractions obtained by chromatography 
Honey was dialysed (Section 6.3.5.1) and the retentate proteins fractionated on 
a Sephadex G-50 chromatography column (Section 6.3.5.2).  Figure 6.3 shows the 
elution trace from the Sephadex G-50 chromatography column and Figure 6.4 
shows the silver-stained SDS electrophoresis gel image of the fractions obtained 
from the G-50 chromatography.   
The first peak eluted from the column was seen to contain several proteins, with 
molecular weights up to >200 kDa.  The major ones had molecular weights of 
approximately 37 kDa, 55 kDa and 65 kDa.  The second peak eluted from the 
column was seen to contain little protein, with just a trace of the one with a 
molecular weight of 65 kDa. 
 
 
Figure 6.3.  Elution trace from chromatography of the dialysis retentate of 
Manuka honey on a 180 ml G-50 Sephadex column.  The fraction size was 1 ml. 
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Ladder        5         7        14        16        20        22        24       26 
 
 
 
Figure 6.4.  Image of a silver-stained SDS electrophoresis gel run with fractions 
shown in Figure 6.3 from the G-50 chromatography on Sephadex G-50 
numbered as in Figure 6.3. 
 
Preliminary phagocytosis assays suggested the bulk of the inhibitory activity was 
in the first peak (Fractions 4-10) from the chromatography.  Figure 6.5 shows the 
results of the phagocytosis assay.   The inhibitory activity was only in the early 
fractions (Fractions 4-16), with Fraction 6 and 8 having the most.  The SDS gel 
(Figure 6.4) showed no obvious protein in the Fractions 14 and 16 yet these 
fractions had some inhibitory activity.  It is assumed that the protein 
concentration was too low to be detected by staining in the SDS gel.   
Fractions 4-10 from the chromatography on Sephadex G-50 shown in Figure 6.3 
were pooled from three repeated runs. The pooled fractions were 
chromatographed on a Superose 12 FPLC column to further separate the 
different molecular weights of the proteins, as the SDS gel (Figure 6.4) showed a 
range of high molecular weight proteins present in the fraction.  The results are 
shown in Figure 6.6.  
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Figure 6.5.  Phagocytosis-inhibiting activity of Fractions 4-26 (even numbers only 
tested) obtained from G-50 Sephadex chromatography shown in Figure 6.3.  
Results show % reduction of phagocytosis compared with that by the non-treated 
control in LPS-stimulated THP-1 cells. Error bars show ±1 SD of the mean from 
three assays. 
 
    
Figure 6.6. Elution profile from chromatography on a 25 ml Superose 12 FPLC column 
of Fractions 4-10 from chromatography on Sephadex G-50 shown in Figure 6.3.  The 
fraction size was 1 ml. 
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Ladder                8     10    12     14    16  
The two major peaks (Fractions 8 and 14) were run on an SDS PAGE minigel.  The 
results from this are shown in Figure 6.7.  Fraction 8 was seen to contain a major 
band of molecular weight 65 kDa with a trace of protein spread around 200 kDa.  
Fraction 14 was seen to contain a major band of molecular weight 55 kDa.  These 
fractions were also tested in the phagocytosis assay (Figure 6.8).  Fraction 8 was 
seen to contain the phagocytosis-inhibiting activity whereas Fraction 14 
contained no more inhibitory activity than Fraction 23 which was included as a 
control because it contained little or no protein.  The main bands seen in the 
SDS-PAGE of Fractions 8 and 14 were excised from the gel for analysis by MALDI-
TOF as indicated by the arrows in Figure 6.7. 
 
 
 
          
 
Figure 6.7. Image of a silver-stained SDS electrophoresis gel run with fractions 
shown in Figure 6.6 from the Superose 12 chromatography column. Arrows 
indicate bands excised for MALDI-TOF analysis. 
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Figure 6.8.  Phagocytosis-inhibiting activity of Fractions 8, 14 and 23 obtained 
from Superose 12 chromatography in Figure 6.6.  Results show % reduction of 
phagocytosis compared with that by the non-treated control in LPS-stimulated 
THP-1 cells. Error bars show ±1 SD of the mean from three assays.  Fraction 23 
was included as a control as it contained little/no protein.  * p<0.001 analysed by 
ANOVA compared with Fractions 14 and 23.   
 
6.4.4  Reverse phase chromatography of active fraction 
The active fraction from the chromatography on Superose 12 (Fraction 8 in 
Figure 6.6) was chromatographed on a reverse phase column to determine if 
more than one protein was present in this fraction.  Figure 6.9 shows the elution 
profile for the reverse phase chromatography.   
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Figure 6.9.  Elution profile from chromatography on a reverse phase column of 
Fraction 8 from chromatography on Superose 12 shown in Figure 6.6.  The 
fraction size was 0.5  ml.    
 
The proteins in Fraction 8 separated by reverse phase were run on a 12% SDS 
electrophoresis gel but this failed to show any bands possibly, due to low 
concentrations.  Phagocytosis assays on its fractions from the reverse phase 
chromatography also failed to get a result possibly due to the low protein 
concentrations. 
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6.4.5  MALDI-TOF mass spectrometry identification of active proteins 
The proteins recovered from the excised bands in the gels from SDS 
electrophoresis, Fractions 8 and 14  from the Superose 12 chromatographic 
separation, were subjected to a tryptic digest for MALDI-TOF  mass spectrometry 
analysis for identification (bands excised indicated by arrows in Figure 6.7).  
The Autoflex operating procedure described in Section 6.3.7.3 was used to 
obtain a peptide mass fingerprint spectrum of Fraction 14 isolated from the 
Superose 12 chromatography column.  The mass spectrum generated by MALDI-
TOF mass spectrometry is presented in Figure 6.10 a. The molecular weight of 
each peptide was entered into the Swiss-Prot library and searched for matches.  
Two hits/matches of the molecular weight of the tryptic peptides to the Swiss-
Prot library were obtained.  The peptide matches are displayed under the 
sequence for the most significant matching protein in Figures 6.10 b and 6.10 c.  
The most significant hit/match was for the protein Apalbumin 3 (MRJP-3).  The 
second hit Apalbumin 1 (MRJP-1), is not a significant match in itself, but because 
the mass spectrum peaks which correspond to this match are different from the 
ones which contribute to the match for MRJP-3, it is very likely to be present in 
the sample. 
This was also done for Fraction 8 isolated from the Superose 12 chromatography 
column.  The MALDI mass spectrum of the peptides from Fraction 8 is displayed 
in Figure 6.11 a. One significant hit was obtained for the mass spectrum, MRJP-1.  
The sequence coverage for the peptides and the protein match MRJP-1 are 
displayed in Figure 6.11 b.  
The two major peaks (Fractions 23 and 26) from the run of Fraction 8 on reverse 
phase chromatography (Figure 6.9) were digested for MALDI-TOF mass 
spectrometry analysis straight from the chromatography but no significant hits 
were obtained, probably due to due to a low concentration of protein.  Attempts 
were made to concentrate the proteins but still no suitable peptide mass 
spectrum or significant hits were obtained. 
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Figure 6.10 a.  Mass spectrum of peptides obtained by tryptic digest of Fraction 
14 isolated with a Superose 12 chromatography column (Figure 6.6).  The single 
protein band seen on SDS electrophoresis of this fraction (Figure 6.7) was cut 
from gel and digested with trypsin prior to MALDI-TOF mass spectrometry. 
 
 
Figure 6.10 b. Sequence coverage of the mass spectrum  displayed  in  Figure  
6.10 a.  The peptides have a molecular weight that matches that of the peptides 
generated from tryptic digest of the protein MRJP-3 precursor – Apis mellifera 
(Honeybee)  MRJP3_APIME generating a  significant hit  (Score of 66).  The bars 
indicate peptides that were observed in the MALDI-TOF data. 
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Figure 6.10 c.  Sequence coverage of  the  mass  spectrum displayed in Figure 6.10 
a.  The peptides have a molecular weight that matches that of the peptides 
generated from tryptic digest of the protein MRJP-1 precursor – Apis mellifera 
(Honeybee)  MRJP1_APIME did not generate a  significant hit  (Score of 59).  The 
bars indicate peptides that were observed in the MALDI-TOF data. 
 
 
Figure 6.11 a.  Mass spectrum of peptides obtained by tryptic digest of Fraction 8 
isolated with a Superose 12 chromatography column (Figure 6.6).  The single 
protein band seen on SDS electrophoresis of this fraction (Figure 6.7) was cut 
from gel and digested with trypsin prior to MALDI-TOF mass spectrometry. 
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Figure 6.11 b. Sequence coverage of the mass spectrum displayed in Figure 6.11 
a.  The peptides have a molecular weight that matches that of the peptides 
generated from tryptic digest of the protein MRJP-1 precursor – Apis mellifera 
(Honeybee)  MRJP1_APIME gi|58585098  generating a  significant hit  (Score of 
117).  The bars indicate peptides that were observed in the MALDI-TOF data 
 
6.4.6  ConA glycoprotein isolation column 
A ConA column was used to separate mannose-containing glycoproteins from 
other proteins in fractions identified as having phagocytosis-inhibiting activity 
(Fractions 4 -10 obtained from Sephadex G-50 chromatography column, Figure 
6.3).  The separated proteins were subjected to SDS electrophoresis on a 12% gel 
and an assay of phagocytosis-inhibiting activity.  The results of the SDS 
electrophoresis are shown in Figure 6.12.  The results show that the mannose-
binding lectin bound proteins of molecular weight of 35 kDa, 50 kDa and 65 kDa. 
Results using the glycoproteins isolated on ConA were inconclusive for the 
phagocytosis assay, possibly due to the high manipulation and low 
concentrations of protein after glycoprotein isolation.  It was necessary to 
remove the buffer from the glycoproteins as it proved to be toxic to the THP-1 
cells in the phagocytosis assay, and this removal resulted in a loss of protein. 
Protein (brown in colour) was observed to be stuck on the filter membrane after 
washing steps and could not be fully removed. 
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6.4.7  Mannosidase treatment 
Eluted glycoprotein that was retained and the flow-though from running dialysed 
honey through a ConA column were treated with mannosidase. The results from 
the SDS electrophoresis of these treated fractions are displayed in Figure 6.13.   
 
Compared with the bands visible without the mannosidase treatment 
(approximately 37 kDa, 55 kDa, 65 kDa and 150 kDa), the enzyme-treated protein 
had two major additional bands.  These bands generated from the mannosidase 
treatment appeared at approximately 43 kDa and 46 kDa and were from the 
protein that bound to the ConA column.  This indicates that these bands must 
represent the mannose-containing glycoproteins, confirming that the ConA 
column bound such proteins. 
 
The results from the phagocytosis assay using mannosidase-treated fractions 
obtained from chromatographic separation or ConA column separations were 
inconclusive, possibly due to over-manipulation of the protein, or low 
concentrations, so instead mannosidase-treated 1% dialysed honey was used in 
the phagocytosis assay.  The results are shown in Figure 6.14. 
 
Mannosidase treatment of dialysed honey caused a 21 % reduction of 
phagocytosis inhibiting activity (from 52 % to 41 %) compared with control 
dialysed honey that was incubated at 37 °C without the enzyme showing that the 
presence of the mannose units on the glycoprotein was important for the 
phagocytosis-inhibiting activity.  This was a significant reduction (p<0.001). 
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Figure 6.12.  SDS electrophoresis gel of active honey protein fraction from Sephadex 
G50 separated with a ConA column.  Lane 2 was the protein that bound the ConA 
column.  Lane three was the protein that did not bind the ConA column. 
 
 
 
 
Figure 6.13. SDS electrophoresis gel of honey proteins before and after mannosidase 
treatment. The proteins had been fractionated with a ConA column, into ‘bound’ 
(mannose-containing glycoprotein) and the ‘flow-through’ protein which did not 
bind.   FT= Flow though, Man= mannosidase treated. Arrows indicate bands 
generated by mannosidase treatment. 
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Figure 6.14.  The effect of Mannosidase treatment (4 hr incubation at 37°C or 
4°C) of 1% dialysed honey on LPS-stimulated THP-1 cells in the phagocytosis 
assay.  Results show % reduction of phagocytosis compared with that by the 
control not treated with honey. Error bars show ±1 SD of the mean from at least 
three assays.  * p<0.001 analysed by ANOVA compared with the non enzyme-
treated control.   
 
6.5  Discussion 
Heat treatment of Manuka honey showed there was a significant (p<0.001) loss 
of phagocytosis-inhibiting activity, indicating that most of the activity of honey is 
due to a native protein.  Three heat treatments were assayed with diluted honey 
(10%): 37°C, 65°C and 99°C and a control treatment at 4°C. Whole honey was 
also incubated at these temperatures.  At 99°C whole honey appeared to 
caramelise/burn and could not be used in the phagocytosis assay due to the 
difficulties in diluting and filtering the honey.   At 4°C both whole honey and 
diluted honey had the same effect, indicating that activity is not lost by being in a 
diluted form for 24 hours at this temperature.   
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At 37°C for 24 hours, whole/undiluted honey had the same activity after heating 
as non heat-treated honey did, indicating that proteins in whole honey are stable 
at this temperature in a non-diluted form.  The diluted honey, however, lost a 
significantly (p<0.001) large proportion of its activity (~ 60%) after 24 hours of 
incubation at 37°C compared with fresh/non heat-treated honey, possibly 
because of enzyme activity increased resulting from the increased water activity, 
or the possibility that there may be hydrolysis of the inhibitory glycoproteins in 
honey.  Although honey contains 17% water, this is bound to the sugars in honey 
so the water activity is very low due to little free water. The free water is what is 
measured as the water activity (aw).  Mean aw values for honey have been 
reported from 0.562 to 0.62 (Molan 1992 a).  With such low aw values in honey, 
the glycoproteins may be protected from hydrolysis due to reduced enzyme 
activity (Molan 1992 a).  This finding is important to consider because it indicates 
that the active proteins are not stable in lower sugar concentrations at 37°C, 
which would be a consideration in the situation of wound dressings where the 
honey is diluted by wound exudate and incubated at body temperature.   This 
would imply that fresh honey needs to be applied regularly.  It is recommended 
for future research that this incubation (37°C for 24 hours) be repeated using 
higher concentrations of honey to find at what concentration these proteins are 
stable for longer, or rather at what concentrations the enzymes, or hydrolysis, in 
honey become activated.  From the point of wound dressings, honey is applied at 
a concentration of 100% and then becomes diluted slowly by wound exudate, 
which may cause it to lose its effectiveness.  There needs to be further 
investigation of the speed of loss of activity with various degrees of dilution. 
At 65°C for 2 hours and 99°C for 10 minutes, diluted honey lost a significant 
(p<0.001) amount of activity (approximately 60%).  At 99°C proteins lose their 
secondary, tertiary and quaternary structure but at lower temperatures some 
proteins can refold.  Of interest is the fact that with heat treatments of 37°C, 
65°C and 99°C approximately 40% of the phagocytosis-inhibiting activity was 
retained.  This remaining activity is higher than the activity found in other honey 
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types not treated with heat suggesting that either denatured proteins in Manuka 
honey have superior phagocytosis-inhibitory activity to correctly folded proteins 
in other honey, or that the denatured proteins (at 65°C and 99°C) are able to 
refold at the assay temperature of 37°C and that their tertiary structure is 
sufficient to bind the receptors.  The activity of refolded or denatured proteins 
may be due to partial binding of mannose receptors by oligosaccharides released 
by enzymic or non-enzymic hydrolysis.  Another possibility is that the interaction 
of oligosaccharides still on the protein may still bind with the receptor, but not so 
well due to altered folding of the protein.   Noorman, et al. (1997) found that 
cluster mannoside ligands with longer chains of mannose residues had more 
affinity for the mannose receptor (Noorman, Barrett-Bergshoeff et al. 1997) 
indicating that the whole protein may not be required to successfully ligate a 
receptor. 
It was important to incubate at 37°C for 24 hours as this is the temperature at 
which the cells are incubated in the phagocytosis assay, and it is also the body 
temperature in patients receiving honey treatment.  The loss of activity over 
time in the phagocytosis assay (Chapter 4) may be due to the temperature and 
dilution causing direct decrease in activity of the honey proteins, rather than 
receptors on the macrophage cell being renewed or recycled as hypothesised.  It 
may be that the proteins are not being depleted, but, rather are becoming 
ineffective due to the incubation affecting their structure.  Either scenario still 
requires that honey be applied regularly to a wound to continue effective 
treatment. 
At 99°C the sugars in the diluted and whole honey appeared to caramelise.  
Whole incubated honey (99°C) was not used in the assay due to dilution/ filtering 
complications.  Diluted honey incubated at 99°C was used in the phagocytosis 
assay and approximately 60% of the activity was lost due to the heat treatment.  
While the activity was lost in the diluted honey, other factors may come into play 
when there is a chemical change occurring in the honey, such as caramelisation. 
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For future work it is suggested that other heat treatments of temperatures up to 
65°C for varying time periods be tested for loss of phagocytosis-inhibiting 
activity.  This would define prime storage conditions in light of the new discovery 
of methylglyoxal (MGO) which forms in honey at higher rates during storage at 
higher temperatures (personal communication with Professor Peter Molan).  
Beekeepers may be encouraged by higher prices to store their honey at higher 
temperatures, to increase the MGO content in shorter amounts of time.  
Unfortunately, this may destroy any anti-inflammatory activity.   MRJP 1-3 in 
royal jelly are sensitive to heat when stored for long periods (Li, Feng et al. 2008).  
It is not known, however, if the proteins in honey are affected in the same way.  
Honey has evolved to be a storable food for bees when nectar is in low demand 
during winter, or in rainy periods when collection of nectar is not possible 
whereas royal jelly is a product used freshly made.  The proteins may be 
preserved by the high sugar content or other components in honey. 
Trypsin treatment of diluted honey confirmed that denaturing proteins in honey 
reduced the phagocytosis-inhibiting effect.  However, no residual effect was 
found, unlike heat treatment which left approximately 40% inhibitory activity.  
This suggests that the heat-denatured honey proteins were better able to bind 
receptors than trypsinised protein.  This may be due to the remaining size of the 
ligand: as mentioned earlier, larger ligands usually bind the receptor with greater 
avidity. This also rules out hydrolysis, if there is complete hydrolysis, as an 
explanation of loss of activity in incubated diluted honey. 
The phagocytosis-inhibiting activity was isolated to the protein that eluted first 
from the chromatography column.  Manuka honey was separated by 
chromatography on Sephadex G-50 and these fractions assayed in the 
phagocytosis assay to determine where the most of the phagocytosis-inhibiting 
activity was.  This indicated that the activity was due to a large molecule.  This 
area of the elution profile was pooled and re-run on a second chromatography 
column (Superose 12).  Four separate peaks were obtained and the major of the 
Chapter 6              Identifying the active component 
174 
 
two (the fractions with the highest protein concentrations), Fraction 8 and 14, 
were assayed for phagocytosis-inhibitory activity.  Fraction 8 had strong 
phagocytosis inhibiting activity and Fraction 14 had very little activity.  Both 
fractions were identified with significant hits by MALDI-TOF mass spectrometry.  
The fraction with the majority of the anti-inflammatory activity (Fraction 8) was 
Apalbumin 1 (MRJP-1).  Fraction 14 returned two hits, one being significant 
which was Apalbumin 3 (MRJP-3).  The non-significant hit was Apalbumin 1 
(MRJP-1). Apalbumin 1, may have been present also, just at lower 
concentrations, too low to give a phagocytosis-inhibitory action or definite 
identification from its peptides. 
The degree of confidence for the identification of the active proteins being 
correct is convincingly high due to the scores being above the accepted margin of 
error.  As mentioned previously, when more than one protein is present in the 
sample there are typically no clear peaks correlating to large amounts of the 
same peptide.   The mass spectra obtained for this research returned clear peaks 
which were appropriate for use in the Swiss-Prot database.  The two identified 
proteins belonged to the Apis mellifera genome.  These proteins have been 
reported to be in honey (Scarselli, Donadio et al. 2005; Schönleben, Sickmann et 
al. 2007).   No other significant hits for protein were returned in either fraction 
indicating that the sample was composed predominantly of the identified 
proteins.  Three peptides returned identical molecular weights between the two 
different proteins (peaks at 1 144, 1 397 and 1 614 Da on the Mass Spectra in 
Figure 6.10 and 6.13) indicating that these peptides are homologous to both 
proteins (or from yet another protein).  This may also explain why an insignificant 
match for Fraction 14 returned MRJP-1. Indeed the MRJPs are reported to be 
highly homologous (Schönleben, Sickmann et al. 2007). The molecular weight 
returned from the Swiss-Prot database for MRJP-1 and MRJP-3 was 48.9 kDa and 
61.6 kDa respectively.  These are calculated from the known sequence and will 
not include glycosylation, which will increase the molecular weight slightly.  This 
is very similar to reported molecular weights in other research, Scarselli and 
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Donadio et al. reported molecular weights for MRJP-1 and MRJP-3 as being 49.3 
kDa 61.9 kDa respectively, determined by mass spectrometry.  MRJP-3 exists in 
five isoforms: it was not determined in this study which isoforms was identified.  
This should be done in future research.  The two identified proteins combined 
may contribute to the majority of the phagocytosis-inhibitory activity.  As MRJP-1 
is present in much larger amounts it may be responsible for most of the 
phagocytosis-inhibitory activity. 
The most active fraction from chromatography on Superose 12 (Fraction 8) was 
further assessed using a column specific bearing the lectin ConA, a mannose-
specific ligand.  While this was unsuccessful, using the whole active fraction 
(obtained by Sephadex G-50) showed that MRJP-1 was a target for ConA but 
MRJP-3 was not.  This was determined by identifying the proteins by their 
molecular weight in the SDS electrophoresis gel.  MRJP-3 was made up of both 
ligands and non-ligands.  This can be determined by comparing the molecular 
weight of the bands of the two ConA-separated fractions correlating to the 
expected position for MRJP-3 on the SDS electrophoresis gel.  The protein that 
bound to the lectin column is the same molecular weight as the protein that did 
not bind the column.  These two bands would appear at the same position on a 
gel and give a denser band if they had not been separated.  This may be due to 
there being two similar but different sized proteins in the band, one a mannose-
terminated glycoprotein and the other not, or one protein may have different 
degrees of glycosylation.  Attempts to identify these two bands by MALDI-TOF 
mass spectrometry were unsuccessful due to the concentration being too low.   
The molecular weight for Fraction 8 (MRJP-1) estimated from the SDS gels is 60 
kDa which is 10 kDa larger than would be expected as the Swiss-Prot returned a 
protein size of only 48.9 kDa.  The size disparity could be explained by 
glycosylation.  Three predicted N-linked glycosylation sites have been reported 
on MRJP-1 (Srisuparbh, Klinbunga et al. 2003). Glycosylation of these sites would 
increase the molecular weight.  When the mannosidase treated protein was run 
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on a SDS electrophoresis gel, extra bands were visualised on the gel, indicating 
that these proteins were running at a similar band position as a larger protein.  
As Fraction 8 was in the void volume, (meaning macromolecules that are 
sufficiently large to be excluded from the column beads elute first from the 
column (the void volume of the Superose 12 column is 11 ml), this may indicate 
that MRJP-1 is highly glycosylated and/or cross-linked, as at 48.9 kDa (the 
molecular weight of MRJP-1 returned by Swiss-Prot) the monomer protein 
should easily enter the column (Size exclusion limit for Superose 12 is 2 000 kDa).   
As the protein is boiled in SDS to disrupt protein complexes, the actual size of the 
protein complex was not established.  Oligomers of MRJP-1 have been reported 
with a molecular weight of 290 kDa, identified using native-PAGE (Tamura, 
Amano et al. 2009).  The MRJP-1 oligomer was separated into 55 kDa and 5 kDa 
spots on 2-D blue native/SDS-PAGE.  The 55 kDa protein was identified as MRJP-1 
monomer by proteome analysis, whereas the 5 kDa protein was identified as 
Apisimin by N-terminal amino acid sequencing, and this protein may function as 
a subunit-joining protein within MRJP-1 oligomers.  Another study separated 
royal jelly of A. mellifera by ultracentrifugation and reported the existence of 
different forms of MRJP-1. These included a monomer (55 kDa) and an oligomer 
(approximately 420 kDa) (Simuth 2001).  It is not known if an oligomer of MRJP-1 
exists in honey. 
With the current knowledge of the presence of MGO in honey, glycation of 
MRJPs is to be expected and may give a plausible explanation for the different 
ConA binding states.  MGO is involved in the formation of advanced glycation 
endproducts (AGEs).  In this process, MGO reacts with free amino groups of 
lysine and arginine and with thiol groups of cysteine forming AGEs.  It is an 
irreversible process and alters the molecular weight of the resulting protein. The 
modification of proteins by MGO has been reported to be a potent signal for the 
degradation of proteins by monocytic cells (including THP-1) in which the 
arginine derivative is the receptor recognition factor (Westwood, Argirov et al. 
1997).  It therefore seems highly likely that MGO modifies MRJP in honey 
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creating a ligand for THP-1 cells which were the cell type used in the current 
research. 
Mannosidase was used on whole honey and active honey fractions.  The gel 
image of mannosidase-treated honey shows that extra bands were formed on 
the gel after treatment (at approximately 35 kDa, 43 kDa and 46 kDa) which 
shows their size was reduced by the treatment.  This protein may have been 
present in the SDS electrophoresis gel as a protein or protein-complex with a 
higher molecular weight.  A possibility is that these were present at 55 -60 kDa as 
this is the only band that has decreased in proportion to the other bands, if the 
protein had not been treated with the enzyme.  However these extra bands have 
a molecular weight too low to be MRJP’s.  The MRJP family have been reported 
to have molecular weights ranging from 49 kDa - 87 kDa (Schmitzová, Klaudiny et 
al. 1998).  If the extra bands came from a larger protein complex that sits higher 
in the SDS electrophoresis gel, the mannosidase treatment could have disrupted 
the large protein complex into monomers. As there was a small amount of 
activity lost it could be assumed that the protein from the extra bands would 
have run at around 60 kDa, the molecular weight of the MRJP-3 that bound the 
ConA column and may be responsible in conjunction with MRJP-1 for the 
phagocytosis-inhibiting activity.  If this is the case, the change in size indicates 
that sugars have been cleaved off a monomerric protein as no low molecular 
weight protein bands were visualised on the gel that would make up the size 
difference for a protein complex.   
Another possibility for the reduced phagocytosis-inhibitory activity is that 
Mannosidase-treated whole honey had little hydrolysis.  Future research should 
aim to develop this assay so that more hydrolysis can be realised if this is the 
case.  A suitable control would need to be included to gauge the level of 
hydrolysis after mannosidase treatment. Secondly, the proteins could be 
separated by size and then treated with mannosidase.  This was attempted in the 
current research but the concentrations were not high enough to get good 
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results.  Higher concentrations would need to be achieved.  The reduced 
phagocytosis-inhibitory activity suggests that these sugars are important, 
perhaps by enabling protein complexes to form or by additional properties 
gained by becoming a glycoprotein.  Future work should look at identifying the 
extent of glycosylation on these proteins and whether an oligomer of MRJP-1 
exists in honey. 
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Chapter 7 
Identifying the phagocytic receptor blocked by Manuka 
honey 
 
 
 
7.1  Summary 
In the work described in Chapter 6 it was found that the phagocytosis-inhibiting 
fractions obtained by FPLC column chromatography bound a ConA glycoprotein 
isolation column.  It was thus concluded that the proteins with mannose 
terminated glycoconjugates were important in the anti-inflammatory action of 
Manuka honey.  To determine if these proteins were acting on the macrophage 
mannose receptor, which triggers phagocytosis, mannan and β-glucan were used 
in place of honey in the phagocytosis assay.  Results showed that mannan but 
not β-glucan reduced phagocytosis in the assay, indicating that Manuka honey 
was likely to be acting on the mannose receptors of macrophages, reducing the 
phagocytosis capabilities of the cells resulting in an anti-inflammatory action.   
 
7.2  Introduction 
It has been determined in work described in previous chapters that Manuka 
honey in low concentrations decreases phagocytosis of latex particles, E. coli, 
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zymosan and mycobacteria by activated macrophages in a dose-dependent 
manner by up to 80% which would be expected to give an anti-inflammatory 
effect.   
7.2.1  C-type letins 
Several mechanisms are available to the macrophage for engulfment of particles, 
this Chapter focuses on phagocytosis. Phagocytosis is a complex process that is 
instrumental in the control of extracellular pathogens mediated by several 
pattern recognition receptors, including a number of C-type lectins. The C-type 
lectin family is a large group of proteins that are characterised by the presence of 
one or more C-type lectin-like domains (CTLDs) (Kerrigan and Brown 2009).  
The C-type lectins are divided into 17 groups based on their phylogeny and 
domain organisation (Drickamer and Fadden 2002).  C-type lectins are 
functionally diverse and have been implicated in various processes including cell 
adhesion, tissue integration and remodelling, platelet activation, complement 
activation, pathogen recognition, endocytosis, and phagocytosis.  The mannose 
receptor (MR) and  β-glucan receptor, called Dectin-1, are C-type lectin receptors 
that recognize glycoproteins terminated in D-mannose, L-fucose or N-acetyl 
glucosamine (MR),  (Esteban, Rodriguez et al. 2004) or β-1,3 and or β-1,6 glucans 
(Dectin 1) (Brown and Gordon 2001; Taylor, Gordon et al. 2005b; Rothfuchs, 
Bafica et al. 2007). These glycoproteins are found in abundance on the cell 
surface of bacteria and other lower organisms.   
Both receptors are expressed in macrophages and a range of other phagocytic 
cells.  Bound β-glucan or mannan ligands activate macrophages, stimulating their 
phagocytic activity and the production of ROS, inflammatory mediators and 
cytokines (Janusz, Austen et al. 1986; Stahl and Ezekowitz 1998).  The precursor 
monocyte does not express the MR but does express the glucan receptor 
(Esteban, Rodriguez et al. 2004).   
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The MR is not the only receptor with specificity for mannose.  Other receptors 
sharing similar pattern of ligand binding include SIGNR1 (mouse)/DC-SIGN 
(human) and Endo-180 (Taylor, Martinez-Pomares et al. 2005a), though the 
mannose receptor is the most studied. 
7.2.2  Mannose receptor 
The MR is a type-I membrane protein with a single trans-membrane domain and 
a cytoplasmic domain that mediates receptor internalisation and receptor 
recycling. It contains three types of domains at its extracellular region, an N-
terminal cysteine-rich domain capable of Ca2+-independent binding to sulphated 
sugars terminated in SO4-3-Gal or SO4-3/4-GalNAc (Taylor, Gordon et al. 2005b), 
a fibronectin type II domain involved in collagen binding especially collagen types 
I, II, III, and IV (Martinez-Pomares, Wienke et al. 2006) and eight tandemly 
arranged C-type lectin-like domains responsible for Ca2+-dependent binding 
(Taylor, Gordon et al. 2005b). 
The cysteine-rich domain recognises glycoprotein hormones.  The C-type lectin-
like domain region binds myeloperoxidase (MyPo) and lysosomal hydrolases. The 
interaction of MR with lysosomal hydrolases and MyPo suggests a crucial role for 
the MR during the resolution of inflammation, as both initiate the activation of 
macrophages (Taylor, Gordon et al. 2005b).  The C-type lectin-like domain region 
can also bind to ligands of microbial origin, as mannose is frequently found on 
the surface of many micro-organisms. In this way the MR is considered a pattern 
recognition receptor. 
Studies have shown that MyPo, which is released from neutrophils, is involved in 
cell killing and induces macrophages to secrete interleukin-1, interferon and 
tumor necrosis factor.  In the neutrophil phagosome, MyPo converts H2O2 and 
chloride into hypochlorous acid, a strong oxidant that acts as a bactericidal agent 
in phagocytes. MyPo also binds to the MR in macrophages and this interaction 
between neutrophils and macrophages induces a state of chronic inflammation 
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(Lefkowitz, Mills et al. 1995).  Recently D-fructose from honey has been found to 
have a role in suppressing MyPo-catalyzed ROS production from neutrophils, 
thus reducing inflammation (Mesaik, Azim et al. 2008). 
 
Patterns produced by pathogens and recognised by the MR include those of 
Mycobacterium tuberculosis (Fraser, Koziel et al. 1998; Astarie-Dequeker, 
N'Diaye et al. 1999) Candida albicans (Marodi, Korchak et al. 1991) and 
Streptococcus pneumonia (Zamze, Martinez-Pomares et al. 2002) and the 
common baker’s yeast Saccharomyces cerevisiae (Fraser, Koziel et al. 1998).  Due 
to its pattern regognition feature, the MR has been reported to mediate the 
uptake of pathogenic and non-pathogenic mycobacteria and bypasses 
bactericidal responses in macrophages via a 19-kDa antigen (Diaz-Silvestre, 
Espinosa-Cueto et al. 2005).  This antigen has been shown to bind the MR in THP-
1 cells promoting its phagocytosis (Astarie-Dequeker, N'Diaye et al. 1999).  
When a mannose-terminated glycoconjugate binds the MR, the cell membrane 
forms a vesicle enclosing the bound receptor and travels though the cell to fuse 
with a lysosome were degradation of the foreign particle will occur.  An 
appropriate immune response follows. The receptor is recycled, returning to the 
cell membrane within 15 minutes. The MR recycles between the plasma 
membrane and the early endosomal compartment, even in the absence of any 
ligand.  At a steady state 10–30% of the receptor is found at the cell surface and 
the remaining 70% is localised intracellularly (Gazi and Martinez-Pomares 2009). 
Mannan (a yeast cell wall component with high mannose content) inhibits 
phagocytosis by binding the MR and preventing recycling of the receptor to the 
membrane (Sung, Nelson et al. 1983). 
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7.2.3  Dectin 1  the β-glucan receptor 
Beta-glucans  extracted from the common baker’s yeast Saccharomyces cervisiae 
are composed of chains of 20-30 glucose units.  β-glucan will not bind the MR so 
can be used as a control in a phagocytosis assay investigating the MR.  β-glucan is 
a chain of sugars, as is mannan, with a similar affinity for its receptor, Dectin-1.  
Mycobaterium turberculosis has also been demonstrated to bind Dectin-1 
(Rothfuchs, Bafica et al. 2007).   β-glucan reduces phagocytosis of Mycobaterium 
turberculosis by macrophages, as does mannan.  If β-glucan reduces 
phagocytosis of latex particles in the previously used assay then it is possible that 
honey too binds the β-glucan receptor.  Thus it was decided to use β-glucan and 
mannan to determine which receptors may be involved in the phagocytosis of 
carboxylated-latex particles by THP-1, thus indicating were honey may be 
working. 
7.2.4  Manuka honey 
In the work described in Chapter 6 the active proteins in Manuka honey were 
found to bind to ConA lectin, a lectin specific for mannose-terminated 
glycoconjugates, indicating the honey proteins contain terminal mannose units.  
As mannose is the primary lectin for the mannose receptor it was postulated that 
the active Manuka honey proteins are binding to this receptor to exert their anti-
inflammatory effect. 
Work done by Noorman et al. (1997) showed that longer mannose-containing 
oligosaccharides inhibited antigen uptake better that shorter oligosaccharides.  
The MR contains eight carbohydrate recognition domains (CRD) and has a high 
affinity for mannan.  When truncated receptor forms were expressed, it was 
concluded that CRD 4, 5 and 7 are essential for the high-affinity binding of 
mannan, as mannan had a much lower affinity for the mutant receptors.  Shorter 
mannosides have fewer CRDs to bind to and therefore have a lower affinity 
(Noorman, Barrett-Bergshoeff et al. 1997).  In Chapter 6 MRJP-1 and MRJP-3 
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where identified as being present in the fraction of honey having phagocytosis-
inhibiting activity.  These proteins are glycosylated with mannose units (Li, Feng 
et al. 2008).  ConA interactions with MRJPs  have been  characterized and the 
typical high-mannose-type structure (Man9-4 GlcNAc2) accounts for about 72% of 
them, followed by a biantennary structure (GlcNAc2 Man3 GlcNAc2) (about 8%), 
and a hybrid-type structure (GlcNAc1Man4GlcNAc2) (about 3%), all of them 
reacting with ConA (Kimura, Miyagi et al. 2000; Kimura, Hama et al. 2002). 
It was postulated that the MRJPs in Manuka honey, due to their high mannose 
glycosylation, bind the MR, preventing phagocytosis by blocking the receptor as 
an antagonist, or like mannan, binds and prevents receptor recycling. 
 
7.2.5  Involvement of methylglyoxal 
All honey contains bee proteins with MRJP-1 the major one (Schmitzová, 
Klaudiny et al. 1998), yet Manuka honey has superior phagocytosis-inhibiting 
activity due to these proteins.  The content of bee proteins would be expected to 
be similar in all honeys, which raises the question why would the activity in 
Manuka honey be higher of that in other honeys?  A unique feature of Manuka 
honey is the recently discovered content of very high levels of methylglyoxal 
(MGO).  MGO is responsible for the majority of the non-peroxide antibacterial 
activity (NPA) (Adams, Boult et al. 2008; Mavric, Wittmann et al. 2008).  MGO is a 
highly reactive 1,2-dicarbonyl compound formed in foods and beverages 
susceptible to degradation due to processing, cooking and prolonged storage.  To 
date, no honey other than Manuka honey has been found to contain high levels 
of MGO, which have been up to 828 mg/kg (Adams, Boult et al. 2008; Mavric, 
Wittmann et al. 2008).   
MGO irreversibly reacts with proteins by modifying the arginine and lysine 
residues to form advanced glycation end-products (AGEs), which can cause cross-
linking of protein molecules (Yim, Yim et al. 2001).  MGO-modified arginine 
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residues on human serum albumin have been shown to bind endocytic cell 
surface receptors and undergo internalisation and degradation in THP-1 cells 
(Westwood, McLellan et al. 1994).  Highly modified glucose-derived human 
serum albumin AGEs were also found to bind specifically to macrophage 
receptors in this manner, suggesting the irreversible modifications by MGO on 
albumin are a potent signal for degradation (Westwood, Argirov et al. 1997).  
Westwood et al. (1997) did not identify any receptors in their study but it was 
suggested that scavenger-like receptors may be involved which are highly similar 
to the MR.   
Another receptor important to the present study is the receptor for advanced 
glycation end-products (RAGE) which reportedly triggers cellular responses 
implicated in the pathogenesis of diabetes (Yan, Ramasamy et al. 2009).  When 
AGEs bind and activate RAGE, vascular cell adhesion molecule-1 (VCAM-1) 
expression is increased from vascular endothelial cells and TNF-α secretion by 
mononuclear cells in induced. However, AGE modification and high RAGE binding 
affinity are not sufficient to generate pro-inflammatory signalling molecules 
(Valencia, Mone et al. 2004).   
It is likely the MGO present in Manuka honey is actively modifying the proteins, 
forming novel ligands for the receptors responsible for phagocytosis which then 
act in a decoy manner or prevent receptor recycling.  Another possibility is that 
binding of receptors to cross-linked mannose glycoproteins effectively cross-links 
the receptors preventing them from being internalised by phagocytosis and thus 
preventing their recycling. 
Extensive work has been carried out on MGO-modified human serum albumin 
and bovine serum albumin.  Research shows MGO-modified proteins, such as 
human serum albumin, are of clinical significance due to their involvement in the 
development of retinopathy, neuropathy or nephropathy in diabetes mellitus 
(McLellan, Thornalley et al. 1994).  
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Clearly human cells are able to recognise these modifications if they are involved 
in disease.  It is highly likely that the MGO in Manuka honey is able to modify 
albumins in honey, as it does with other albumins such as human serum albumin 
and bovine serum albumin.  Possibly Apalbumin-1 (MRJP-1) is modified in this 
way.  Apalbumin-1 was identified as being the protein in Manuka honey with 
anti-inflammatory activity in Chapter 6.  This could explain why Manuka honey 
has greater effect than other honeys.  Other honeys may have less glycation of 
proteins caused by little or no MGO present.   As these MGO-modified proteins 
have been determined to bind the macrophage receptors, proteins from other 
honey varieties then, would not bind to the receptors with the same affinity, or 
even at all. 
 
7.2.6  Aims and experimental approach 
To check the hypotheses mentioned above, mannan, and β-glucan as a control, 
were used with and in place of honey in the latex bead phagocytosis assay to 
determine if the mannose receptor was likely to be involved in the effect of 
Manuka honey in inhibiting phagocytosis.  
 
7.3   Methods 
7.3.1 Phagocytosis assay with latex particles 
The phagocytosis assay using latex particles, was the same as described in 
Section 4.3.1, but with various concentrations of mannan and β-glucan added.  
The concentrations of both mannan and β-glucan selected were taken from  
publications (Esteban, Rodriguez et al. 2004; Kang and Schlesinger 1998).  
Preliminary assays found the concentrations appropriate, but a range of 
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concentrations was used to determine if inhibition was dose-related as it is with 
Manuka honey.  Mannan was used at concentrations of 1.25 mg/ml – 5 mg/ml.  
β-glucan was used at concentrations of 50 µg/ml – 200 µg/ml.  Manuka honey 
was used at concentrations ranging from 0.125% - 1%.  One objective was to see 
if either mannan or β-glucan had an additive effect when assayed in conjunction 
with Manuka honey.  To do this 0.125% Manuka honey was used in the 
phagocytosis assay in conjunction with 1.25 mg/ml mannan or 50 µg/ml β-
glucan.  Also, in case the cell would use either the MR or Dectin-1 receptor to 
phagocytose latex particles, mannan and β-glucan were assayed together. 
7.3.1.1   Reagents 
A solution of Manuka honey (M144) honey was prepared as described in Chapter 
3.  THP-1 cells for the phagocytic assay were maintained at 37°C, 5% CO2, and 
95% relative humidity in growth medium as described in Section 2.3.1.  Cells 
were split with fresh growth medium prior to the assay and assessed for viability 
as described in Section 3.2.  All conditions of the phagocytosis assay were the 
same as described in Section 4.3.1 but with mannan or β-glucan either replacing 
or additional to honey. 
 7.3.1.2  Mannan 
Mannan from baker’s yeast Saccharomyces cerevisiae was purchased from 
Sigma-Aldrich (Cat. No.# M7504) and dissolved in MilliQ water to give a stock 
solution of 100 mg/ml.  The stock solution was stored at -20° until required.   
Mannan stock solution was added at a rate of 15 µl – 50 µl stock solution per ml 
of cell suspension, to give final concentrations of 1.25 mg/ml – 5 mg/ml.  
Mannan at a concentration of 4 mg/ml has been reported in the literature to 
inhibit phagocytosis in macrophages (Kang and Schlesinger 1998). 
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7.2.1.3   β-glucan 
β-glucan from barley was purchased from Sigma-Aldrich (Cat. No.# G6513) and 
dissolved in MilliQ water to give a stock concentration of 100 mg/ml.  A working 
solution of β-glucan (10 mg/ml)   was made by diluting the stock solution 1/10 in 
RPMI-1640 medium.  Both the stock solution and working solution was stored at 
-20° until required.  β-glucan was used at a rate of 5 µl – 20 µl of working 
solution, to give a final concentration of  50 µg/ml – 200 µg/ml.  β-glucan at a 
concentration of 125 µg/ml has been reported in the literature to inhibit 
phagocytosis in macrophages (Esteban, Rodriguez et al. 2004).  
 
7.4   Results 
Results comparing the effect of mannan and β-glucan with that of Manuka honey 
in the phagocytosis assay are displayed in Figures 7.1-7.3.  Results show the 
percent inhibition of phagocytosis caused by the inhibitor (mannan, β-glucan or 
Manuka honey) compared with the control with no inhibitor.  Mannan was seen 
to have dose-dependent activity like Manuka honey did.  When used in 
combination with Mannan, Manuka honey significantly (p<0.001) increased this 
phagocytosis inhibiting activity (Figure 7.1).   The activity of the combination was 
close to the sum of the activity of each alone.  β-glucan at 50 µg/ml and 100 
µg/ml had no significant effect on reducing phagocytosis.  At 200 µg/ml there 
was a slight reduction of phagocytosis.    β-glucan in combination with Manuka 
honey, (Figure 7.2) or mannan, (Figure 7.3) gave no additional inhibition to 
either, demonstrating that the mannose receptor is most likely involved as 
opposed to Dectin-1 in the inhibition of phagocytosis of latex particles in THP-1 
cells.  
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Figure 7.1.  The inhibitory effect of a range of concentrations of mannan, Manuka 
honey or a combination of these on the phagocytosis of latex particles by LPS-
activated THP-1 cells.  Error bars show ± 1 SD of the mean from three experiments. 
*p<0.001 analysed by ANOVA compared with the control not treated with honey or 
mannan.  #p<0.001 analysed by ANOVA compared with 0.125% Manuka honey 
alone.   
 
Figure 7.2.  The inhibitory effect of increasing concentrations of β-glucan, Manuka 
honey or a combination of these on the phagocytosis of latex particles by THP-1 cells.  
Error bars show ± 1 SD of the mean from three experiments. *p<0.001 analysed by 
ANOVA compared with the control not treated with honey or β-glucan.  No 
significance was found with 50 µg/ml β-glucan/0.125% Manuka honey and 0.125% 
Manuka honey alone, analysed by ANOVA. 
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Figure 7.3.  The inhibitory effect of β-glucan and mannan, and a combination of 
these on the phagocytosis of latex particles by THP-1 cells.  Error bars show ± 1 
SD of the mean from three experiments. 200 µg/ml β-glucan had no significant 
effect on the inhibition by mannan analysed by ANOVA. 
 
7.5  Discussion 
An antigen of Mycobacterium tuberculosis has been identified that binds the 
mannose receptor of THP-1 cells, promoting the phagocytosis of the bacteria 
(Diaz-Silvestre, Espinosa-Cueto et al. 2005).  As it was found in the present study 
that Manuka honey reduces the phagocytosis of Mycobacteria in THP-1 cells, it 
seems plausible that the active compound of the honey is preventing 
phagocytosis by blocking the MR.  Similar hypotheses can be advanced for 
zymosan and E. coli, both of which have been reported to bind the MR in THP-1 
cells (Akiko, Ikuko et al. 2008) and were found in the present study to have 
phagocytosis of them inhibited by Manuka honey. 
β-glucan was used as a control for mannan.  As mentioned previously, β-glucan 
will not bind the MR but will bind phagocytic receptors such as Dectin-1.  As it 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
mannan 2.5 mg/ml β-glucan 200 µg/ml β-glucan 200 µg/ml & 
mannan 2.5 mg/ml 
%
R
e
d
u
ct
io
n
 o
f 
p
h
ag
o
cy
to
si
s 
Concentration of inhibitor 
Chapter 7                              Identifying the receptor 
191 
 
was hypothesised that a component of Manuka honey was binding the MR, it 
was useful to include β-glucan in the phagocytosis assay.  If phagocytosis of the 
latex particles was being triggered by their being bound by the Dectin-1 receptor 
then β-glucan may have an inhibitory effect on phagocytosis.  Even at the highest 
dose (200 µg/ml) β-glucan gave very little inhibition of the phagocytosis of latex 
particles and even then was only 1/10 of that of mannan.   This concentration is 
almost double the reported effective concentration, where up to 50% inhibition 
of phagocytosis is reported (Esteban, Rodriguez et al. 2004).  It is likely that a 
higher concentration may provide more inhibition. This is recommended for 
future work.  To check if it was the case that the cell can use either the MR or 
Dectin-1 receptor to phagocytose latex particles, β-glucan and mannan were 
assayed together, thus blocking both receptors.  This did not result in additional 
inhibition to that with mannan alone (p<0.294) In the case of using Manuka 
honey together with mannan or β-glucan, only mannan caused a significant 
(p<0.001) additional increase in the inhibition of phagocytosis using published 
concentrations.   It is possible that a higher concentration of β-glucan would 
increase the inhibition by Manuka honey, though it was noted that the highest 
concentration used in this study (200 µg/ml) did not increase the inhibition of 
phagocytosis of latex particles by mannan, suggesting they work on different 
receptors. 
Zymosan is a yeast-derived particle composed primarily of polysaccharides 
namely mannan and β-glucan that reportedly binds the MR or the Dectin-1 (β-
glucan) receptor.  Unopsonized zymosan phagocytosis can be inhibited by 
laminarin, a β-glucan commonly found in brown algae (Brown, Taylor et al. 2002) 
and mannan (Sung, Nelson et al. 1983).  As Manuka honey stops phagocytosis of 
zymosan it is likely to be blocking one of these receptors.   In the work described 
in Chapter 4, Manuka honey at a concentration of 0.5% was found to give 
approximately 50% inhibition of phagocytosis of zymosan.   
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In this Chapter, mannan was used in place of Manuka honey in the latex particle 
phagocytosis assay and the effect was like that of Manuka honey.  The inhibitory 
effect of Mannan was also dose-dependent like that of Manuka honey.  When 
used in conjunction with Manuka honey, mannan increased the inhibition of 
phagocytosis, yet β-glucan did not. Other studies (Sung, Nelson et al. 1983; 
Speert and Silverstein 1985; Brown, Taylor et al. 2002) have found up to 50% 
reduction of phagocytosis of unopsonized zymosan by either β-glucan or 
mannan, suggesting that each receptor binds zymosan in roughly equal 
proportions.  This suggests that mannan and Manuka honey work on the same 
receptors, namely the MR, and indicates that the apalbumin glycosylation with 
mannose terminal sugars is important as it may bind the MR and possibly other 
receptors that bind this moiety.   
It is still possible that a receptor other than the MR is involved.  Conclusive 
evidence of the involvement of the MR is important for future work.  Possible 
experiments may include transfection studies with MR or MR knockdown.  If the 
MR is involved it may be that free mannan has a higher affinity for the MR than 
latex beads. 
Mannan-binding lectin, a serum protein, has been shown to mediate the 
activation of complement upon binding to specific microbial carbohydrate 
motifs, to directly opsonize organisms, and to enhance phagocytosis, enhancing 
FcR-mediated phagocytosis by both monocytes and macrophages in vitro (Arora, 
Munoz et al. 2001; Wallis, Lynch et al. 2005).  The serum mannose-binding 
protein and the macrophage MR are both pattern recognition molecules that 
recognise mannose-terminated glycoproteins.  When they bind a mannose ligand 
they initiate an immune response (Fraser, Koziel et al. 1998).  The active protein 
in Manuka honey may bind the MR, but somehow prevent phagocytosis or an 
immune response.  This may be due to the cross-linking of mannose 
glycoproteins blocking the receptors as mentioned previously, or a in a decoy 
fashion where the large amounts of ligands that honey presents, simply floods 
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the receptors so that pathogens, or in this case latex particles, are not able to be 
phagocytosed as freely or as quickly. 
Future work should look at testing whether honey, by blocking MR sites on 
macrophages, prevents the communication of neutrophils and macrophages via 
released MyPo. This would give a great reduction in chronic inflammation as 
mentioned earlier.  
Another area which should be investigated is the effect Manuka honey may have 
on the MR binding of tissue-type Plasminogen Activator (t-PA).  This activator is a 
serine protease that activates fibrinolysis by converting plasminogen into 
plasmin, which cleaves fibrin into soluble degradation products.  Recent research 
has shown that fibrin plays a key role in the inflammatory response and is also 
involved in forming scar tissue (Bouma and Mosnier 2006).  Thus t-PA is 
beneficial in wound healing.  It has been shown that t-PA is cleared from plasma 
through the MR (Biessen, van Teijlingen et al. 1997; Noorman, Barrett-
Bergshoeff et al. 1997).  Mannosides work by immobilizing the receptor, 
effectively inhibiting t-PA clearance.  Manuka honey may exert its anti-
inflammatory effects in this manner. 
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Chapter 8 
The effect of methylglyoxal on proteins in Manuka honey 
 
 
 
  
8.1   Summary 
Manuka honey has been shown to have high levels of methylglyoxal (MGO) 
(Adams, Boult et al. 2008; Mavric, Wittmann et al. 2008).  As MGO is a highly 
reactive compound that is capable of modifying proteins to produce fluorescent 
derivatives, a wide range of Manuka and non-Manuka honey was screened for 
fluorescence to see if this reaction occurs in Manuka honey. 
 
Fluorescence was detected using a fluorescence imaging system and determined 
to be due to modification of proteins in honey by MGO.  It was found that the 
active fractions obtained from chromatography of Manuka honey in Chapter 6 
were fluorescent whereas other fractions were not.  It was hypothesised that 
incubating honey would increase the fluorescence and also increase the anti-
inflammatory activity determined by the phagocytosis assay.  Honey with high 
MGO but low fluorescence was incubated for three months and monitored 
throughout this period for an increase in fluorescence and anti-inflammatory 
activity.  Honey with no natural MGO was incubated with high levels of added 
MGO and monitored in the same way.  As a control BSA was also incubated with 
MGO and monitored for a gain of fluorescence. 
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A method using thin layer chromatography plates (TLC) and filter paper was 
developed to visualise the fluorescent protein of Manuka honey, MGO-treated 
Clover honey and MGO-treated BSA.  It was found that by incubating honey or 
BSA with MGO at 37°C, fluorescence increased.  After incubation at 37°C for 
three months Manuka honey with high MGO levels became more anti-
inflammatory, determined by the phagocytosis assay. 
8.2   Introduction 
8.2.1  Methylglyoxal 
During the early part of this research project two independent groups of 
researchers published the finding stated that the major anti-bacterial component 
of Manuka honey was MGO (Adams, Boult et al. 2008; Mavric, Wittmann et al. 
2008).  They demonstrated that the bioactivity of MGO, at the levels at which it 
is present in the honey, is equivalent to the NPA (Adams, Boult et al. 2008; Atrott 
and Henle 2009).  The levels of MGO and other 1,2-dicarbonyls have been 
determined in a range of foodstuffs and beverages but this was the first time it 
had been identified in honey at such high levels.  Manuka honey had very high 
amounts of MGO, ranging from 38 to 828 mg/kg, which is up to 100-fold higher 
compared with non-Manuka honeys (Mavric, Wittmann et al. 2008).   
 
MGO is a highly reactive compound that irreversibly modifies proteins.  Until the 
discovery of there being high levels of MGO present it was unclear why Manuka 
honey had a high level of anti-inflammatory activity due to bee proteins yet 
other honeys which had the same amount of protein did not.  It was 
hypothesised in Chapter 6 that at these levels the MGO in Manuka honey could 
modify the protein in honey over time, either in the hive or during storage by the 
apiarist, which conferred anti-inflammatory properties to the honey.   
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One of the most obvious signs of modification of proteins by MGO is the 
resulting fluorophore, a component of a molecule which causes the molecule to 
be fluorescent.  Proteins highly modified by MGO fluoresce (Westwood, 
McLellan et al. 1994).   The high levels of MGO in Manuka honey may modify the 
proteins resulting in fluorophores, yet to date no other research has investigated 
this.   
 
It is widely published that carbohydrates in foods and beverages are susceptible 
to degradation by processing, cooking and prolonged storage, forming reactive 
1,2-dicarbonyl compounds, including MGO, glyoxal and 3-deoxyglucosone). The 
non-enzymatic reactions involving the formation of these compounds are 
collectively referred to as either caramelisation or, if amino-containing 
compounds are present, non-enzymatic glycation called Maillard reactions.  
Often these processes are considered to be desirable as they confer much of the 
taste and colour upon cooked foods.   
 
8.2.2  Colour of honey and the Maillard reaction 
The colour of table honey is one of the factors that determine its price, with the 
lighter honeys having a more mild and popular taste than dark-coloured honeys. 
Manuka honey is traditionally a darker honey, with the best NPA Manuka honeys 
having a typically darker colour.  The rate of darkening of honey has been related 
to the ratio of glucose to fructose, nitrogen content, free amino acids and 
moisture, alongside temperature, indicating the Maillard reaction is responsible 
(Gonzales, Burin et al. 1999).  Dark honeys traditionally have a higher nitrogen 
content than paler honeys, with a range of 0.04% to 0.1% (White and Landis 
1980).  MGO is formed endogenously in numerous enzymatic and nonenzymatic 
reactions (Nemet, Varga-Defterdarovi et al. 2006).  It is formed by the 
spontaneous degradation of triosephosphates, oxidative metabolism of ketone 
bodies and catabolism of threonine (Thornalley 1993).  MGO reacts rapidly with 
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the side chains of arginine, lysine and cysteine residues in proteins to form 
advanced glycation end products (AGEs) (Thornalley 1993).  It is generally 
believed that the reaction of MGO with proteins produces adverse products, in 
terms of protein structure and function. However, a few studies have shown 
beneficial effects, particularly on the chaperone function of human α-crystallin in 
the eye lens where chemical modification of α-crystallin by MGO enhances its 
chaperone function which helps in maintaining the transparency of the lens, and 
by protecting the lens proteins from various stress conditions (Nagaraj, Oya-Ito 
et al. 2003; Kumar, Reddy et al. 2004). 
8.2.3  MGO-formed fluorophores and AGE formation 
The fluorescence of honey has been investigated and found to be a method of 
successfully determining levels of adulteration with sugar cane syrup or corn 
syrup to bulk honey, using the natural fluorescence of antioxidant components 
(Ghosh, Verma et al. 2005).  However these studies have not tested Manuka 
honey nor looked for the MGO-formed fluorophores which have a different 
wavelength with higher intensity.  Along with brown colour, fluorescence is one 
of the qualitative properties used to estimate AGE formation (Ulrich and Cerami 
2001), with many of the AGEs detected and isolated based on their fluorescent 
properties. 
Human serum albumin (HSA) and bovine serum albumin (BSA) have been 
modified with MGO (MG-BSA, MG-HSA) to give fluorescent derivatives, 
characterised by the arginine-derived fluorphore (Westwood and Thornalley 
1995).  Further it was shown that MGO binds and irreversibly modifies BSA, 
producing a protein that binds endocytic receptors initiating uptake of the 
protein.  MGO-modified arginine residues have been identified as the signal for 
receptor-mediated endocytosis and degradation of proteins by THP-1 cells, 
indicating there are receptors recognising this modification. These modified 
proteins are a potent signal for their degradation by monocytic cells, cellular 
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activation or stimulation (Westwood, Argirov et al. 1997).  This implies that the 
immune system is readily capable of detecting and responding to AGEs.  AGE-
modified proteins have also been implicated in the impairment of the respiratory 
burst of macrophages in diabetic patients (Ramírez, Bedoya et al. 1997) and are 
thought to be linked to the development of diabetic complications as MGO and 
AGE levels are higher in diabetic patients.  AGEs have also been proposed to play 
a crucial role in the development of atherosclerosis due to plaques forming of 
macrophages expressing the receptor for AGE (RAGE) in excessive quantities 
(Uchida, Khor et al. 1997).  When there is binding of AGEs to RAGE it initiates 
inflammatory responses (Beckman, Creager et al. 2002; Tekabe, Li et al. 2008).  
The formation of AGEs increases ROS in the tissue, resulting in lipid peroxiation 
products implicated in Parkinson’s disease (Yoritaka, Hattori et al. 1996), 
Alzheimer disease (Mark, Lovell et al. 1997) and cancer (Okamoto, Toyokuni et 
al., 1994).  This leads to the assumption that MGO represents one of the primary 
sources of oxidative damage to proteins in complex biological matrices. 
 
AGE-modified proteins bind to several cellular receptors such as RAGE (Yan, 
Ramasamy et al. 2009), AGE-R1, AGE-R2, AGE-R3 (Thornalley 1998), macrophage 
scavenger receptor (SR-A and CD36) (Takata, Horiuchi et al. 1988; Miyazak, 
Nakayama et al. 2002), and the macrophage receptor (Vlassara, Brownlee et al. 
1985).  AGE-RAGE interaction is thought to activate nuclear factor-κB (NF-κB) 
which plays a key role in regulating the immune response to infection (Yan, 
Ramasamy et al. 2009).   A membrane-associated macrophage receptor has been 
identified that specifically recognised proteins to which AGEs are bound.  This 
macrophage receptor binds AGEs and induces the synthesis of cytokines such as 
TNF-α, IL-1β and growth factors PDGF and IGF-1, suggesting that the AGE 
receptor system plays an important role in normal tissue remodelling (Kirstein, 
Brett et al. 1990; Kirstein, Aston et al. 1992).  Glycation of arginine residues by 
MGO is expected to have significant impact on the functional activity of proteins, 
due to a loss of positive charge and consequent protein miss-folding (Ahmed, 
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Dobler et al. 2005 ).  This may target modified proteins for ligation to receptors 
on immuno-competent cells otherwise not encountered.   
 
AGE formation in vivo is a major source of ROS that leads to oxidative damage, 
and AGE accumulation in tissues is one of the main causes of diabetic vascular 
damage (Brownlee 1995).  When AGEs bind RAGE receptors in THP-1 cells, a 
chronic inflammatory cascade is initiated with the release of pro-inflammatory 
cytokines accelerating damage to the surrounding tissue (Shang-Ming Huang 
2006). 
8.2.4  AGE inhibitors 
Binding of these receptors does not necessarily cause an increase in 
inflammation (Valencia, Mone et al. 2004).  AGE inhibitors have been identified 
that bind the same receptors yet have an anti-inflammatory response on 
monocytes and macrophages, conferring beneficial effects for the treatment of 
inflammation.  These inhibitors may act as decoys, simply preventing the AGE 
from binding receptors.  The drug LR-90 has been identified as belonging to a 
new class of AGE inhibitors that inhibits inflammatory responses in THP-1 cells in 
a dose-dependent fashion (Figarola, Shanmugam et al. 2007).  Treatment with 
LR-90 results in reduced expression of RAGE and other pro-inflammatory genes 
and NF-κB promoter transcriptional activity.  LR-90 also prevented oxidative 
stress in macrophages by reducing intra-cellular superoxide production, 
preventing other ligands from binding RAGE and inducing ROS formation.  It also 
blocks monocyte adhesion to endothelial cells (Figarola, Scott et al. 2003; 
Figarola, Shanmugam et al. 2007).  It has been proposed that targeting RAGE 
may lead to treatments of inflammatory disorders, as ligation to RAGE by AGE in 
THP-1 monocytes leads to increased expression of inflammatory cytokine 
expression, growth factors and adhesion molecules as well as initiating 
chemotaxis (Yan, Ramasamy et al. 2009). 
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8.2.5  Aims and experimental approach 
It is hypothesised that the protein in honey may be modified by MGO, resulting 
in a novel ligand for macrophage receptors that initiates an immune response 
down-regulating the inflammatory pathways.  This may also result in a 
fluorescent protein product easily identifiable for the screening of anti-
inflammatory potency of Manuka honey.  The aim of the research in this chapter 
was to determine if in fact there was MGO-formed fluorphores in honey.  
Therefore a variety of Manuka and non-Manuka honeys was screened for 
fluorescence and this was related back to the NPA, MGO content and 
phagocytosis-inhibiting activity.  A range of honeys was selected for assaying 
fluorescence.  Also the colour of honey was rated on a scale of 1-12.  A colour 
scale was developed for use in this study and further detailed in Appendix 4.  The 
brown colour constitutes one of the qualitative properties of AGEs (Ulrich and 
Cerami 2001). 
8.3   Methods  
A range of Manuka honeys were obtained from the collection in the Honey 
Research Unit, University of Waikato, NZ. The fluorescence and phagocytosis-
inhibiting activity was measured for each of these honeys.  Measurement of the 
NPA of the honeys had been carried out by Kerry Allen in the Honey Research 
Unit.  MGO levels were determined by Dr. Chris Adams from the Chemistry 
Department, University of Waikato, which involved treating the honey sample 
with o-phenylenediamine, to react with 1,2-dicarbonyl compounds forming the 
corresponding quinoxaline derivatives.  These derivatives were analysed by HPLC 
using UV detection (Adams, Boult et al. 2008).  All the honeys used in this 
Chapter are outlined in Table 8.1.  The fluorescence and colour for all the honeys 
used for the whole research project are outlined in Appendix 3.  Preparation and 
filtration of solutions of honey prior to assay was as described in Chapter 2.  
Honeys were assayed at the concentrations mentioned for the procedures 
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described below.  BSA and a honey with naturally low fluorescence were 
incubated with MGO to determine if fluorophores could be developed. 
8.3.1   Measuring fluorescence 
The fluorescence of whole honey and honey fractions isolated by 
chromatography in Chapter 6 was measured. 
8.3.1.1  Whole honey 
Honey was brought to room temperature and diluted to 10% V/V in purified 
water.  Dilute honey (5 ml) was then filtered through a 0.2 µm Minisart sterile 
single use syringe filter (Sartoris) to remove pollen and impurities.  It was then 
pipetted (100 µl) into 5 wells of a 96 well black plate (Nunc Cat. No.# 137101).  
The fluorescent intensity of the honey was measured on a fluorescence imaging 
system, a Fujifilm LAS-1000 instrument equipped with an intelligent darkbox II 
(Alphatech).  The plate was placed inside the darkbox (level 4) and focused using 
the Image reader LAS-1000 Plus programme.  The blue light fluorescence setting 
was used with the standard wavelength filters provided used to detect emission 
at 470 nm.  Data was analysed using the provided software, Image Reader LAS-
1000 Plus Lite version 1.5 and Image Gauge 4.0. The fluorescence was measured 
across the well in arbitrary units (AU) and the background intensity subtracted to 
give a reading.   In each plate there was a standard honey with previously 
measured fluorescence along with water blanks and empty wells for background 
readings. Measurements from the 5 wells for each sample were averaged to 
obtain a final reading.  So that the honeys could be compared between plates 
readings were adjusted relative to the standard honey. In some cases the 
fluorescence intensity was too high for individual honeys and exposure time was 
reduced to avoid over-exposure.  The measurement from the standard honey 
was used to derive the correct measurement for the honeys in these plates.  
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Results ranged from 3 000 AU to 260 000 AU, with typical standard deviation of 
+/- 1 500 AU.   
8.3.1.2  Honey fractions 
Fractions obtained from Sepharose 12 FPLC chromatography columns (1 ml 
fractions) in Chapter 6 (Section 6.3.5.3) were screened for fluorescence 
according to the protocol as described in Section 8.3.1.1.   
8.3.2  Phagocytosis assay  
The latex bead phagocytosis assay using incubated honey proceeded the same as 
previously (Section 4.3.1).   THP-1 cells and LPS activation were unchanged.   
8.3.3  Colour grading 
A colour scale was developed by sorting honey into the closest possible match, 
which resulted in a scale from one to twelve, with one being the palest honey to 
twelve being the darkest honey.  The scale can be found in Appendix 4.  The 
colour of honey was graded by filling a standard size (1.5 cm diameter x 5 cm 
long) small plastic vial with honey and finding the closest match on the colour 
scale developed.   
8.3.4  Honey incubation 
Both Manuka and non-Manuka honeys were incubated.  Manuka honey was 
selected for incubation based on its initial high MGO levels and low fluorescence.  
Non-Manuka honey was selected based on its low fluorescence and lack of MGO.  
Honey was incubated for three months, during which time fluorescence readings 
were tracked.  Each honey incubated also had a sample stored at -20° to 
maintain the original qualities.  The incubated honey and the frozen honey were 
assayed for inhibition of phagocytosis and were subjected to SDS electrophoresis 
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on a mini-gel to determine any protein size modifications due to the incubation. 
A Manuka honey with high fluorescence and Manuka honey with low 
fluorescence was also subjected to SDS electrophoresis for comparison to the 
incubated and non-incubated honey. 
Whole Clover honey and Pasture honey were incubated with MGO or without 
MGO for three months at 37°C to determine if the presence of MGO would 
generate fluorescence over time in the non-fluorescent honey and increase the 
phagocytosis-inhibiting activity.  The honey had been assayed previously for 
phagocytosis-inhibiting activity and had low activity.  The honey was 
electrophoresed on a SDS mini-gel to determine any protein size modifications 
due to the incubation.  The MGO treated honey was assayed in the phagocytosis 
assay to determine what effect the incubation had on the phagocytosis-inhibiting 
activity. 
8.3.4.1  Methylglyoxal 
Methylglyoxal (40%) was purchased from Sigma-Aldrich (Cat. No.#M0252) and 
used at final concentrations correlating to a NPA activity of 15 (approximately 
400 mg/kg honey or 1 ml of 40% MGO per kg honey). 
8.3.4.2  Honey incubation 
Whole Manuka honey (20 g of MSB20, NPA 20+), Pasture honey (20 g of P59) and 
Clover honey (20 g of CLO1) were incubated for three months at 37°C.    Clover 
honey, (20 g of CLO1) treated with 400 mg/kg MGO mixed into it, was also 
incubated for three months at 37°C.  Control samples of all the honeys (20 g) 
were frozen for the duration.  The fluorescence of honey immediately after 
adding the MGO was measured, and at the concentrations added to honey, the 
fluorescence was found to not increase due to the added MGO.  After six weeks 
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and three months incubation of the honey, the fluorescence was measured as 
described in Section 8.3.1.1. 
8.3.4.3  SDS polyacrylamide gel electrophoresis of incubated honey 
Honey (described in Section 8.3.6.1) was run on a 12% SDS mini-gel (prepared 
and run as described in Section 6.3.6).  Also included for comparison was 
Manuka honey with high fluorescence (M149) and Manuka honey with low 
fluorescence (M26). Honey was diluted to 10%.  Samples to be loaded on the gel 
were mixed 1:1 with 2X Tricine Sample Buffer and heated at 99°C for 5 minutes, 
then left to cool prior to loading.  Prior to staining, gels were imaged on a UV gel 
illuminator to observe the fluorescence of the protein band (this fluorescence 
was not visible after staining).  SDS minigels were silver-stained as described in 
Section 6.3.6. 
8.3.5  Bovine serum albumin incubation with methyglyoxal 
Bovine serum albumin (BSA) was purchased from Sigma-Aldrich (Cat. No.# 
85040c fraction 5) and dissolved in sterile phosphate buffered solution to 
achieve a concentration of 10 mg/ml.  It was incubated with or without 400 
mg/kg MGO (1 µl 40% MGO /g BSA for two days at 37°C.  Preliminary results 
indicated that only short incubation was required to develop fluorescence, 
accordingly BSA was incubated for two days.  Absorbance of the protein was 
measured at 280 nm before and after modification by MGO was carried out.  
Unmodified BSA has a molecular weight of 66 kDa.  The MGO-modified BSA 
(from incubation for two days) was electrophoresed on a SDS mini-gel to 
determine any protein size modifications due to incubation with MGO.  Prior to 
staining, gels were imaged on a Fujifilm imaging system LAS-1000, to observe the 
fluorescence of the protein band.  The SDS mini-gels were then silver stained 
following the protocol in Chapter 6.3.6.   
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8.3.6   Visualisation of colour and fluorescent protein on TLC plates 
A novel method of visualising the fluorescent protein in solution was developed 
using aluminium-backed TLC plates.  Approximately 50 µl of 10% honey, BSA or 
MGO-modified BSA was spotted onto a TLC plate (Merck Aluminium sheets, silica 
gel 60, without fluorescent indicator, Art. 5553) and left to spread by capillary 
action.  This resulted in a ring of protein which did not spread much from the 
point of application, surrounded by a larger ring where the sugars and other 
smaller molecules spread further than the protein.  The TLC plate was then 
visualised in the LAS-1000 instrument for comparison of fluorescence intensity 
before and after incubation, or for comparisons between honey samples.    The 
solutions applied to the plate were: 1 mg/ml BSA with and without 400 µg/g 
MGO as described in Section 8.3.7,  Manuka honey with low fluorescence (M32, 
M128 and MSB20), and Manuka honey with high fluorescence (MO5, MB102 and 
M141) and, Clover honey (CLO1 non-incubated, incubated and MGO-treated and 
incubated as described in Section 8.3.5.2).  The TLC plates were also observed 
before fluorescent imaging for their colour. 
In a variation of this experiment Whatman filter paper discs (no. 4) were used, on 
which the honey sample left a brown ring after the sample had spread by 
capillary action.  This showed the variation in colour between honey samples and 
gave a greater fluorescence than the TLC plates.  The filter paper was then 
imaged on the LAS-1000 for fluorescence to locate the fluorescent component.   
8.3.7   Obtaining a fluorescence emission spectrum for Manuka honey 
A 10% Manuka honey solution (M141) was compared with MGO-modified BSA 
for fluorescence emission wavelengths.  An emission spectrum plot was obtained 
from each using a Confocal microscope imaging system to detect the 
fluorphore/s present.  This work was completed in conjunction with Dr Barry 
O’Brien from The University of Waikato’s Confocal Microscopy Imaging Facility. 
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8.4  Results 
The honeys assayed during this research are listed in Appendix 3.  In this Section 
a range is given of the measurements obtained for each assay.  Table 8.1 shows 
the data for honeys that had the MGO and NPA values tested. 
Table 8.1.  Results from measurements of various parameters for a range of 
honeys of different varieties of floral source.  Colour was graded on a scale of 1 
(lightest colour) to 12 (darkest colour).  Fluorescence (Fluor) of the honeys is 
shown in Arbitrary Units x 103.  Anti-inflammatory activity (AI) is shown as the 
mean inhibition (%) of phagocytosis of latex beads.  Non-peroxide activity (NPA) 
is shown as % phenol with equivalent activity.  Content of MGO and is shown as 
µg/kg honey.  Data are sorted by AI in ascending order.  
Code Variety Colour Fluor  AI NPA MGO 
M128 Manuka 4 20 4 11.8 192 
M158 Manuka 4 30 5 13.3 330 
M160 Manuka 4 21 5.1 8.3 170 
M161 Manuka 4 23 5.6 9.4 223 
M165 Manuka 4 28 7 11.8 280 
M159 Manuka 4 29 7.2 11.8 280 
M197 Manuka 4 20 9 ND 115 
M162 Manuka 4 26 9 8.7 360 
M181 Manuka 4 72 10 ND 130 
M163 Manuka 4 34 10 14 352.8 
M24 Manuka 3 10 11 7.9 96.6 
M206 Manuka 4 51 12 ND 110 
M196 Manuka 4 21 13 ND 130 
M28 Manuka 4 19 14 8.6 112 
M34 Manuka 7 33 15 4.5 58.6 
M173 Manuka 4 50 15 ND 150 
P59 Pasture 3 35 15 0 10 
M38 Manuka 4 29 16 7.5 89.9 
M22 Manuka 3 34 16 8.3 106 
M23 Manuka 3 26 16 9.3 141 
M13 Manuka 5 25 16 11 167 
M188 Manuka 4 66 17 8.7  130 
M168 Manuka 4 60 18 ND 140 
M169 Manuka 4 68 18 ND 150 
M31 Manuka 7 39 20 7.5 107 
M209 Manuka 5 81 20 ND 140 
M176 Manuka 4 46 20 ND 145 
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Code Variety Colour AU AI NPA MGO 
M170 Manuka 4 45 20 ND 160 
M26 Manuka 6 47 21 7.3 67 
M30 Manuka 4 30 21 10 103 
M21 Manuka 3 35 21 9.2 121 
M177 Manuka 4 65 21 ND 150 
M32 Manuka 6 40 23 5.9 71 
M164 Manuka 4 80 23 ND 118 
M198 Manuka 4 77 24 ND 80 
M185 Manuka 4 57 24 ND 110 
M12 Manuka 5 52 24 14.9 272 
M184 Manuka 4 58 25 ND 110 
M171 Manuka 4 74 25 ND 150 
M167 Manuka 4 61 25 ND 151.2 
M207 Manuka 5 80 28 ND 120 
M178 Manuka 4 68 28 ND 150 
M27 Manuka 6 65 29 7.3 107 
M07 Manuka 8 58 29 13.9 205 
M201 Manuka 4 73 29 12.4 280 
M174 Manuka 4 90 30 ND 85 
M175 Manuka 4 102 30 ND 85 
M172 Manuka 4 89 30 ND 160 
M205 Manuka 5 96 30 8.9  170 
M10 Manuka 6 54 30 13.9 219 
M36 Manuka 3 53 31 5.4 25.4 
M179 Manuka 4 89 31 ND 120 
M166 Manuka 4 92 31 ND 145.9 
M15 Manuka 7 63 31 15.3 267 
M182 Manuka 4 116 32 ND 110 
M202 Manuka 4 96 32 ND 150 
M16 Manuka 7 68 32 14.4 272 
M187 Manuka 4 94 33 8.1  110 
M183 Manuka 4 107 34 ND 115 
M200 Manuka 4 85 34 ND 140 
M11 Manuka 6 74 34 14.8 249 
M09 Manuka 8 62 34 17.7 329 
M204 Manuka 5 120 35 ND 160 
M186 Manuka 4 87 35 ND 95 
102 Manuka 9 153 35 0 100 
M29 Manuka 5 73 35 8 114 
M03 Manuka 7 75 37 23.6 599 
M180 Manuka 4 97 38 ND 150 
M199 Manuka 4 93 38 ND 160 
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Code Variety Colour AU AI NPA MGO 
CJA10+ Manuka 5 92 38 11.1 189 
M17 Manuka 4 97 39 14.2 243 
M01 Manuka 8 95 40 25.3 650 
M203 Manuka 5 156 41 ND 150 
CJA30+ Manuka 7 147 41 27 679 
M05 Manuka 9 162 43 17.5 312 
M192 Manuka 5 175 44 8.1  130 
M193 Manuka 5 214 49 ND 100 
M190 Manuka 5 195 49 8.2 105 
MBD28.8 Manuka 9 167 49 27.3 708 
M191 Manuka 5 216 51 ND 110 
M189 Manuka 5 204 55 ND 85 
P59 Pasture 3 35 10 0 10 
VB6468 Vipers Bugloss 1 3 0 0 0 
NPA values ND=non-detectable in the standard assay which has a minimum 
level for measurements of 8.2.  For NPA values listed lower than 8.2, these were 
measurements made with honey solutions double the usual concentration and 
corrected by dividing the NPA by 2. 
 
 
8.4.1  Fluorescence of honey 
The range in fluorescence measurements was 3 000 AU – 227 000 AU (± 1 500 
AU), with the lowest reading recorded for Vipers Bugloss honey (VB6468) and 
the highest for an aged Manuka honey (MB102).  The lowest fluorescence 
recorded for a Manuka honey was 10 000 AU (M24).  Fluorescence 
measurements for all samples tested are listed in Appendix 3.   
A highly fluorescent aged Manuka honey (MB102) was electrophoresed on an 
SDS gel and its fluorescence visualised using the LAS-1000 instrument.  Figure 8.1 
shows the position of the fluorescent protein after electrophoresis (but before 
staining) and the same gel lane after silver staining. 
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Figure 8.1.  SDS electrophoresis gel (12%) with whole Manuka honey 
run on it.  The image to the left shows the visible fluorescent band of 
Manuka honey protein taken before silver-staining. The image to the 
right shows the same lane after silver staining. 
 
8.4.2  Colour of honey 
The colour grading of each honey in the range of samples studied is shown in 
Table 8.1.  The range was 1-12, with the lowest grade recorded for Vipers 
Bugloss honey (VB6468) and the highest for an aged Manuka honey (MB102).  
The lowest grade recorded for a Manuka honey was 3 (M24).  The colour scale 
used is in Appendix 4.  The colour score for all the honeys tested is shown in 
Appendix 3. 
8.4.3  Fluorescence of fractionated honey 
The fluorescence measurements for the fractions obtained from column 
chromatography on Sephadex G-50 (described in Chapter 6) are shown in Table 
8.2 alongside their phagocytosis-inhibiting activity (data are taken from Section 
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6.4.3).  The fractions with the highest fluorescence were also the fractions that 
had the most anti-inflammatory activity. 
 
Table 8.2.  Fluorescence of fractions isolated from G-50 Sephadex 
chromatography compared with their phagocytosis-inhibiting activity (data from 
Chapter 6).   
Fraction 
 no. 
Fluorescence 
(AU x 103) 
Phagocytosis-inhibiting 
activity (% inhibition) 
4 22 42 
6 26 53 
8 26 55 
10 22 39 
12 24 43 
14 20 20 
16 22 30 
18 6 0 
20 0 0 
22 0 0 
24 0 0 
26 0 0 
 
8.4.4  Finding  correlation in assay results 
Correlation between parameters in the data presented in Table 8.1 was sought in 
the graphs shown in Figures 8.2 – 8.9.  Only honeys with a full data set have been 
included.  For the comparison it was assumed that there was a linear relationship 
between the parameters, and the correlation coefficient is given as R2. Only anti-
inflammatory activity plotted against fluorescence (Figure 8.5) returned a 
significant result for the regression (p<0.0001).  The lack of correlation between 
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the other variables suggests that a complex reaction is occurring.  One possibly 
very relevant variable that is missing is the age of the honey, as the age of the 
honey samples taken from storage is unknown.  The age was known for some 
fresh honeys from the new season (Codes M159-M209) and some old honeys 
which were known to be over 10 years old (Codes MB101-MB102 and Spbay old).    
 
 
Figure 8.2.  Colour plotted against MGO content for the range of Manuka honeys 
studied. Colour was graded on a scale of 1 (lightest) to 12 (darkest). 
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Figure 8.3.  Fluorescence plotted against Colour for the range of Manuka honeys 
studied. Colour was graded on a scale of 1 (lightest) to 12 (darkest).  Fluorescence 
is shown in Arbitrary Units x 10 3. 
 
 
Figure 8.4.  Fluorescence plotted against MGO content for the range of Manuka 
honeys studied.  Fluorescence of the honeys is shown in Arbitrary Units x 10 3. 
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Figure 8.5.  Anti-inflammatory activity plotted against fluorescence for the range 
of Manuka honeys studied.  Fluorescence of the honeys is shown in Arbitrary 
Units (AU) x 103.  Anti-inflammatory activity is shown as the mean inhibition (%) 
of phagocytosis of latex particles (data are sourced from Chapter 6).  The 
regression is highly significant (p=0.000 analysed by ANOVA) anti-inflammatory 
activity = 9.184 + 0.2236 fluorescence (AU). 
 
    
Figure 8.6.  Hydroxymethylfurfuraldhyde (HMF) plotted against fluorescence for 
the range of Manuka honeys studied. Content of HMF is shown as mg/kg.  
Fluorescence of the honeys is shown in Arbitrary Units x 10 3. 
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Figure 8.7.  Hydroxymethylfurfuraldhyde (HMF) content plotted against anti-
inflammatory activity for the range of Manuka honeys studied.  Content of HMF 
is shown as mg/kg. Anti-inflammatory activity is shown as the mean inhibition 
(%) of phagocytosis of latex particles (data are sourced from Chapter 6). 
 
    
Figure 8.8.  MGO content plotted against anti-inflammatory activity for the range 
of Manuka honeys studied. Anti-inflammatory activity is shown as the mean 
inhibition (%) of phagocytosis of latex beads, (data are sourced from Chapter 6). 
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Figure 8.9.  Colour plotted against anti-inflammatory activity for the range of 
Manuka honeys studied. Anti-inflammatory activity is shown as the mean 
inhibition (%) of phagocytosis of latex beads, (data are sourced from Chapter 6).  
Colour was graded on a scale of 1 (lightest) to 12 (darkest).   
 
8.4.5  Incubating honey 
Table 8.3 and 8.4 shows the fluorescence and colour measurements for selected 
honeys before, during and after incubation for three months at 37°C with natural 
MGO levels (Manuka) or 400 mg/kg MGO added (Pasture and Clover).  In the 
controls which were Manuka honey  (with a high natural MGO content) kept for 
three months at 4°C, and Pasture and Clover honey with 400 mg/kg MGO or no 
added MGO kept for three months at 4°C, there was no increase in fluorescence 
(results not shown).  Table 8.3 and 8.4 also shows the results from BSA also being 
incubated with or without MGO.  After incubation with MGO, BSA turned a pale 
yellow colour, whereas incubated BSA with no added MGO remained colourless.  
A further control found that MGO in water at the quantities used had no 
fluorescence (results not shown). 
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Table 8.3.  Fluorescence measurements (in Arbitrary Units x 103) before incubation, 
after 6 weeks incubation, and after 3 months incubation at 37°C, with the level of 
natural or added MGO shown for honey and BSA.  Manuka honey had natural MGO 
levels whereas Pasture and Clover had MGO added. 
Honey 
code 
MGO 
mg/kg 
Fluorescence 
before 
incubation 
Fluorescence 
after 6 weeks 
incubation 
Fluorescence 
after 3 months 
incubation 
Manuka 
MSB20 
576 88 149 170 
Pasture 
P59 
10 35 47 57 
Pasture 
P59 
410 35 64 89 
Clover 
CL01 
0 41 52 60 
Clover 
CL01 
400 41 66 82 
BSA 0 2 2 2 
BSA 400 2 245 250 
 
Table 8.4.  Colour score before incubation, after 6 weeks incubation, and after 3 
months incubation at 37°C, with the level of natural or added MGO shown for honey 
and BSA.  Manuka honey had natural MGO levels whereas Pasture and Clover had 
MGO added. 
Honey 
code 
MGO 
mg/kg 
Colour score 
before 
incubation 
Colour score 
after 6 weeks 
incubation 
Colour score 
after 3 months 
incubation 
Manuka 
MSB20 
576 8 9 9.5 
Pasture 
P59 
10 3 5 5 
Pasture 
P59 
410 3 6 6 
Clover 
CL01 
0 2 4 4 
Clover 
CL01 
400 2 4 5 
BSA 0 colourless colourless colourless 
BSA 400 colourless yellow yellow 
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The resulting effects on phagocytosis-inhibiting activity of incubating Manuka 
honey with natural MGO and Clover honey with MGO added (400 mg/kg) are 
shown in Figure 8.10.  Also assayed for phagocytosis-inhibiting activity was BSA 
before and after modification by incubating with 400 mg/kg MGO.  Neither of 
these gave any inhibitory activity (results not shown).  Activity significantly 
increased by incubation with added/natural MGO in both Clover honey and 
Manuka honey.  The controls showed no significant effect of incubating Clover 
honey (with no added MGO) or of the presence of MGO (Clover honey with MGO 
not incubated). 
 
 
 
Figure 8.10. Inhibition of phagocytosis with Manuka honey (MSB20) and Clover 
honey (CL01), untreated and incubated for 3 months at 37°C.  The Clover honey 
was incubated with and without 400 mg/kg MGO added.  As a control, non-
incubated Clover honey had 400 mg/kg MGO added immediately before the 
phagocytosis assay. *p<0.001 analysed by ANOVA compared to the non-
incubated Manuka honey control.  #p<0.001 analysed by ANOVA compared to 
the non-incubated Clover honey (with MGO added) control. 
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8.4.6  SDS electrophoresis gel images of incubated honeys  
The results of electrophoresis of honeys before and after incubation with MGO 
are shown in Figures 8.11 and 8.12.  In Figure 8.11 it can be clearly seen that 
there was a difference in molecular weight of the major protein  between Clover 
honey (58 kDa) and Manuka honey (63 kDa).  Figure 8.12 shows that incubating 
honey with MGO increased the molecular weight of the major protein (by about 
5 kDa) in both honey types.  Manuka honey had proportionally more of the 
higher molecular weight spread (110 kDa and above) than Clover honey.  This 
indicates cross-linking.   
Figure 8.13 compares the molecular weight of the major protein band for a range 
of honeys.  It can be clearly seen that Manuka honeys (M149, M26, MSB20) have 
a larger molecular weight (~ 63 kDa) than Pasture honey (P59) and Clover honey 
(~58 kDa).  Incubated MSB20 had a slightly larger again molecular weight (~65 
kDa) of the major honey protein compared with the non-incubated MSB20. 
 
 
Figure 8.11.  Silver-stained gel from SDS electrophoresis of untreated Manuka 
honey and Clover honey before incubation (each in duplicate). 
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Figure 8.12.  Silver-stained gel from SDS electrophoresis of Pasture honey after 3 
months incubation (Lane 1) and before incubation (Lane 2) and Manuka honey 
after 3 months incubation (Lane 3) and before incubation (Lane 4). 
 
 
 
Figure 8.13.  Silver-stained gel from SDS electrophoresis of incubated and non-
incubated Manuka honey (MSB20), compared with Manuka honey with high 
fluorescence (M149) and Manuka honey with low fluorescence (M26) and Clover 
and Pasture honey.  
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8.4.7  SDS electrophoresis of MGO-modified BSA 
The results from electrophoresis of BSA and MGO-modified BSA are shown in 
Figure 8.14 photographed before staining, using UV illumination to highlight the 
fluorescence generated by modifying BSA with MGO, and a different gel in Figure 
8.15 after staining.  A large proportion of MGO-modified BSA only just entered 
the gel due to the increased protein size or cross-linking of the protein (visible on 
the gel at approximately 300 kDa).  MGO-modified BSA that migrated in the gel 
formed two major bands (~ 270 kDa and 66 kDa).  The untreated BSA was not as 
visible in the gel, but a slight shadow is visible at 66 kDa. 
 
 
 
Figure 8.14.  Gel from  electrophoresis of BSA and MGO-modified BSA, prior to 
silver-staining.   Gel imaged on a LAS-1000 instrument.  The fluorescence of the 
MGO-modified BSA shows in the image of the gel as a dark colour. The 
molecular weight shown was estimated from the molecular weight ladder run 
on the gel. 
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Figure 8.15.  Silver-stained gel from SDS electrophoresis of MGO-modified BSA 
(incubated with 400 µg/kg MGO) (Lanes 2-4) and untreated BSA (Lane 5)  
8.4.8  Spot chromatography 
8.4.8.1  Fluorescence of spots of MGO-modified BSA and untreated BSA 
MGO-modified BSA and untreated BSA were aliquoted on to filter paper and 
chromatography TLC plates and left to spread by capillary action.  The papers 
were then imaged on the LAS-1000 instrument to highlight the development of 
fluorphores after incubation with MGO.  The results are shown in Figure 8.16 and 
8.18.  It was concluded that the protein was left at the meniscus of the initial 
aliquot.  On the filter paper the MGO-modified protein was very fluorescent 
(Figure 8.16).  A pale yellow inner ring was visible to the naked eye on the TLC 
plates.  Upon illumination from the LAS-1000, a clear fluorescent ring in the 
MGO-modified BSA but not the untreated BSA was present (Figure 8.18).  The 
outermost ring of the sample is fluorescent but not a property of the sample.  
This was concluded by running a water blank (Figure 8.17).  This was true for 
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both the filter paper and the TLC plates.  There is a surfactant that enables the 
samples to run evenly. This runs at the front of the liquid moving out from the 
point of application of the sample and it may be this surfactant ring that is 
fluorescing.   
The TLC plate allowed for better separation of the fluorescent component but 
the filter paper showed the greatest overall fluorescence. 
 
 
 
 
Figure 8.16. Image from the LAS-1000 instrument of untreated BSA (left) and 
MGO-modified BSA (right) on chromatography paper.  The dark colour shows 
fluorescence.  The outer ring of fluorescence may be the surfactant that runs at 
the front of the liquid moving out from the point of application. 
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Figure 8.17.  Image from the LAS-1000 instrument of water on chromatography 
paper.  The outer ring of fluorescence (shown as a dark colour) may be the 
surfactant that runs at the front of the liquid moving out from the point of 
application. 
 
 
 
 
Figure 8.18.  Image from the LAS-1000 instrument of MGO-modified BSA (left) 
and untreated BSA (right) on TLC plates.  The dark colour shows fluorescence.  
The outer ring of fluorescence may be the surfactant that runs at the front of the 
liquid moving out from the point of application. 
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8.4.8.2  Fluorescence and colour of spots of honey 
Manuka honey (10%) was separated out on filter paper resulting in a brown 
circle which may be MGO-modified protein adsorbed to the paper as the liquid 
phase was drawn away from the protein due to capillary action.  This enabled the 
comparison of the brown colour of the protein between honeys. The brown 
colour variation of the honeys is shown in Figure 8.19. Note, there is only one 
ring and its colour and thickness is dependent on the colour of the sample of 
honey, as mentioned previously.  Honey with high fluorescence typically had a 
darker colour.  Honeys with high fluorescence (top) and low fluorescence 
(bottom) are pictured. 
 
       
    MB102                               M141 
       
   M128                                  MSB20 
Figure 8.19. The colour of rings of honey protein on filter paper.  Manuka honey 
with high fluorescence (top) and low fluorescence (bottom) spotted on filter 
paper to show the coloured protein ring.  Honey with high fluorescence has 
darker coloured protein, as shown by the darker ring. 
 
2.5 cm 2.5 cm 
2.5 cm 2.5 cm 
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Images from the LAS-1000 instrument were then taken to show the variation in 
the fluorescence of the rings of the honey spots on TLC plates.  The TLC plates 
enabled better separation of the honey and consequently the liquid moved past 
the ring of adsorbed protein, leaving a centre ring of brown colour.  Two honey 
samples with different levels of fluorescence are shown in Figure 8.20.  There 
appeared to be two types of fluorescence.  The centre ring from honey with high 
fluorescence had a much more intense fluorescence than the ring from the 
honey with low fluorescence.  Surrounding the fluorescent ring was a halo-like 
fluorescence that was not present in honey with low fluorescence.  This halo-like 
fluorescence can be seen in Figure 8.20 as grey shading either side of the inner 
ring.  The fluorescence of Clover honey incubated with or without MGO is shown 
in Figure 8.21.  Incubation of Clover honey with MGO gave rise to increased 
fluorescence in the centre ring.  The background fluorescence was present but 
not as much as in Manuka honey with high fluorescence.  Incubation of Clover 
honey without MGO gave a small increase in the fluorescence of the centre ring 
but not to the same intensity as when incubated with MGO.  The centre rings in 
Clover honey are in the same position as the fluorescent rings in the Manuka 
honey. 
 
 
Figure 8.20.  Image from the LAS-1000 instrument of two Manuka honeys with 
high fluorescence (M05 left) and low fluorescence (M32 right) on TLC plates.  The 
outer ring of fluorescence may be the surfactant that runs at the front of the 
liquid moving out from the point of application. 
2.5 cm 
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Figure 8.21.  Image from the LAS-1000 instrument of incubated Clover honey with 
400 mg/kg MGO (left), without MGO (center), or non-incubated clover honey 
(right) on TLC plates.  The outer ring of fluorescence may be the surfactant that 
runs at the front of the liquid moving out from the point of application. 
 
8.4.9  Fluorescence emission spectrum of BSA and Manuka honey. 
Figure 8.22 and 8.23 show the emission spectrum obtained for Manuka honey 
(10%) and MGO-modified BSA, respectively, using a confocal microscope system 
to measure the fluorescence wavelength of the fluorphores present in the 
samples.  The analysis was three or four times illustrated by the multiple lines on 
the emission spectrum.  Both 10% Manuka honey and MGO-modified BSA had a 
maximum emission wavelength of 480-500 nm, and both had emission ≥ half-
maximal over the range 445-555 nm. 
 
 
2.5 cm 
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Figure 8.22.  Fluorescence emission spectrum of 10% Manuka honey (M144) with 
naturally high fluorescence.  The  multiple lines are from three repeats. 
   
 
 
 
Figure 8.23.  Fluorescence emission spectrum of BSA modified by incubating it at 
10 mg/ml with MGO 400 mg/kg MGO for two days.  The multiple lines are from 
four repeats. 
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8.5   Discussion 
It was found that Manuka honey is strongly fluorescent whereas non-Manuka 
honey had little fluorescence.  While this fluorescence is not significantly 
dependent on MGO levels, honeys with no MGO had low fluorescence indicating 
that the MGO may be responsible for the fluorescence of honey. The 
fluorescence of honey and the anti-inflammatory activity of honey, however, was 
highly significant (p<0.0001).  The majority of the fluorescence is produced from 
the protein in honey.  This is concluded from observation of honey fractions of 
high molecular weight having fluorescence, seen both in the fractions 
themselves after chromatography and from electrophoresis gels where the 
fractionated honey had a fluorescence that could be visualised in the non-
stained gel.   It was also established (Chapter 6) that it was the protein in honey 
that had the anti-inflammatory activity.  Correlation between MGO content and 
fluorescence was weak, but there was very little fluorescence in non-Manuka 
honeys which had no MGO in them.  An alternative explanation could be that 
there is a fluorescent phytochemical specifically from Manuka nectar not present 
in other types of honey.  It has been reported that there are fluorescent 
phytochemicals in honey (Ghosh, Verma et al. 2005) but these are not 
comparable in fluorescence intensity.   
A possible explanation for the intense fluorescence of Manuka honey is the 
formation of pentosidine.  Pentosidine is a fluorescent crosslink with visible wave 
length fluorescence, making it easy to detect.  This is one of the end-stage 
products of the Maillard reaction known as AGEs (Fagugli, Vanholder et al. 2001).  
Pentosidine levels can be determined by measuring the total fluorescence at a 
wavelength characteristic for these substances: Excitation 335 nm/Emission 385 
nm. The fluorescence emission spectrum of Manuka honey had a peak emission 
of 480 nm - 500 nm.  The fluorescence of Manuka honey must be due primarily 
to something other than pentosidine-crosslinks in the proteins as this emission 
range is too high.  The intensity of Manuka honey’s fluorescence ranged, in this 
study, up to 227 000 AU, whereas other floral types ranged up to 89 000 AU It is 
Chapter 8                              Measuring fluorescence 
229 
 
not known, however, if these other floral varieties had honey with Manuka 
nectar in them, which is very likely.  However, the fluorescence emission 
wavelength of Manuka honey was the same as MGO-modified BSA.  Upon 
incubation with MGO, BSA became highly fluorescent in as little as one day.  This 
reaction may be taking place in Manuka honey with naturally high levels of MGO.    
It has been reported that the fluorescence attributed to MGO-incubated amino 
acids, has a maximum emission at 520–530 nm and this emission was only 
present for MGO incubated with arginine and not with lysine (Schmitt et al. 
2005). Adams et al. (2009) found that adding arginine but not lysine to honey 
reduced the MGO content suggesting that MGO was modifying only the arginine.  
Therefore the fluorescence observed in Manuka honey is most likely derived 
from arginine modifications.   
As mentioned previously, one of the properties of proteins that have been 
modified by MGO is browning.  The colour of honey varied greatly in the sample 
used in this study.  This colour variation could be seen by separating diluted 
honey on filter paper.  The mobile phase tended to be yellow in colour, leaving a 
ring of colour which absorbed to the paper at the point of application of the 
sample.  It was concluded that this colour was due to the protein in honey, or at 
least modified protein, which varied depending on the honey type.  Earlier work 
in Chapter 6 attempted to remove low molecular weight components from 
fractionated honey using a spin column.  This was not successful as the protein in 
the sample stuck to the ultra filter membrane and was difficult to remove.  This 
protein was dark brown in colour as were the fractions that corresponded with 
the large peaks on the chromatography trace, indicating there was the most 
protein in those fractions.  By assessing the colour of protein using the TLC plates 
and filter paper, it was concluded that the majority of brown colour in Manuka 
honey comes from the protein component.  When assessed for fluorescence, 
these rings on the TLC plates had high fluorescence in Manuka honey but very 
little or none in other floral varieties of honey.  When MGO-modified BSA was 
visualised on filter paper, it left a yellow accumulation of what could only be 
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protein (as there was only protein in the sample) after the mobile phase moved 
out past the point of application.  This yellow accumulation was highly 
fluorescent.  It is not known if the non-modified protein adsorbed at this point 
also as it was not visible. 
No strong correlation could be found with the colour of honey and the MGO 
content or fluorescence, however.  The lack of correlation between colour and 
fluorescence could be because colour could develop from other Maillard 
reactions which don’t give the fluorescent structure.  It is postulated that as the 
MGO modifies the protein in honey over time, the MGO content is therefore 
reduced.  Thus, old, dark Manuka honeys would have a high fluorescence and a 
low MGO content.  Indeed this was true for the older honeys, one in particular 
(MB102) which had the highest fluorescence found but had no measurable non-
peroxide anti-bacterial activity (and therefore no MGO).  This honey was almost 
black and had the darkest colour score of 12.  This honey also had the highest 
anti-inflammatory activity measured by the phagocytosis assay.   
The fraction with the most anti-inflammatory activity obtained when Manuka 
honey was fractioned by FPLC (Chapter 6) was determined to have fluorescence.  
This fraction contained the MRJP-1 and MRJP-3 (determined in Chapter 6).  
These proteins show that the anti-inflammatory activity of Manuka honey in the 
phagocytosis assay was due to fluorescent MRJP.  The fluorescent form of these 
proteins were not found in other honey types in such high quantities, and the 
quantity of the fluorescent protein varied according to MGO content, storage 
conditions and possibly age.   The age was not known for most of the honey 
samples taken from storage, but it was observed that the oldest honeys (over 10 
years old) were much darker (colour score of 10-12) than honey that came in 
from the current season which received a colour score of 4.  Protein 
concentration is fairly uniform across all honey varieties though darker honeys 
have slightly more (White and Landis 1980; Azeredo, Azeredo et al. 2003) and so 
protein concentration alone could not account for the variation in fluorescence 
or colour due to the protein.  
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Not all Manuka honey with high MGO levels had high anti-inflammatory activity.  
The ones with low activity were young honeys which may develop anti-
inflammatory activity over time, during which the MGO modification process 
may occur.  Antioxidant content may come into play here also.  Honey with high 
antioxidant levels may retard the MGO modification process preventing or 
reducing fluorescence development.  The antioxidants act as AGE inhibitors, 
presumably through metal-ion chelation and sequestration of free-radical 
species (Prakash Reddy and Beyaz, 2006).  As MGO modification of proteins is 
inhibited by antioxidants it is hypothesised that Manuka honeys with high 
antioxidant levels and MGO levels will develop low fluorescence and therefore 
low anti-inflammatory activity, which explains some variation in the results for 
Manuka honey with high MGO levels.  The variation in antioxidant levels in 
Manuka honey may account for why some develop high anti-inflammatory 
activity and others do not. Time limits prevented measurement of the anti-
oxidant in honey but this work should be done in the future.   
Clover honey with very low fluorescence could be made to develop fluorescence 
by incubating with MGO at levels similar to those found naturally in a Manuka 
honey with a NPA rating of 15. The anti-inflammatory activity, determined by the 
assay of inhibition of phagocytosis, could also be made to increase upon 
incubation of Clover honey with added MGO and Manuka honey containing 
natural MGO, the fluorescence and molecular weight of the protein also 
increasing (5 kDa) as a result of this incubation.  The difference in size between 
the major protein (approximately 58 kDa and 63 kDa respectively) of both Clover 
and Manuka honey (Figure 8.11) is possibly due to the increased glycation of the 
Manuka honey proteins as the size difference is not high enough to be cross-
linking.  However, there is proportionately more diffuse protein >110 kDa in 
Manuka honey that could be due to cross-linking.  This was especially noticeable 
in the honeys incubated with MGO (Figure 8.12) were there is almost no trace of 
protein >75 kDa in Clover honey and a large amount of diffuse protein in the 
Manuka sample.  Also of interest is the lack of protein with low molecular weight 
Chapter 8                              Measuring fluorescence 
232 
 
(<37 kDa) in the Manuka honey sample, though there are clear bands in the 
Pasture honey sample at 15 kDa and 25 kDa.  These proteins may be cross-linked 
or highly glycosylated and found in the >100 kDa molecular weight range for the 
Manuka honey sample. 
Colour varied widely between honey varieties but more interestingly between 
Manuka honeys.  A selection of Manuka honeys from around New Zealand was 
obtained from the same harvest season (Codes M159-M209).  All of these 
samples had a similar colour but ranged in the fluorescence reading from low to 
high.  Fluorescence may start to develop in the hive which is kept at a fairly 
constant temperature of about 35°C.  Older honeys showed great colour 
variation.  Three honeys were obtained that were at least 10 years old and had 
not been refrigerated.  These honeys had the darkest colour grade and also the 
brightest fluorescence.  The causes of darkening in honey have been attributed 
to Maillard reaction, fructose caramelization and oxidation reactions of 
polyphenols (Gonzales, Burin et al. 1999), with the majority of these reactions 
occurring at relatively high ambient temperatures (37°C).   
An assay is available to measure the extent of heating that honey has undergone. 
HMF (Hydroxy-methyl furfuraldehyde), formed in honey by the action of acidity 
on fructose, increases with heating and is used as an indicator for storage 
conditions.   This assay provides useful information as high temperatures during 
storage can degrade proteins, most importantly to this study, MRJPs (Kamakura, 
Fukuda et al. 2001).  Kamakura et al. found that in royal jelly, the MRJPs 
degraded at room temperature over the period of one month as a result of 
acceleration of the Maillard reaction.  It is likely that the same degradation of 
MRJPs occurs in honey which is stored at room temperature or above but more 
slowly.  Fresh natural honey can have varying levels of HMF.  Normally this is 
below 1 mg/kg but levels soon start to rise with ambient temperatures above 
20°C (Castro-Vazquez, Daaz-Maroto et al. 2008; LeBlanc, Eggleston et al. 2009).  
As mentioned previously, as storage temperature increases, honey darkens 
because of the Maillard reaction and MGO levels increase.  HMF levels were 
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known for some of the honey samples in the current research and these can be 
found in Appendix 3.  Generally, the honeys assayed during this research had 
very low levels suggesting very little exposure to heat has occurred. 
One of the most obvious factors that may explain the lack of correlation of anti-
inflammatory activity or fluorescence with MGO, is the fact that all honey can 
contain nectar from a variety of floral sources.  Bees tend to take the most 
productive option for them when collecting nectar and cannot be easily directed 
to a particular source.  Apiarists may label their honey for what they believe is its 
floral source.  Manuka honey is of high value because of its health benefits so it is 
likely that much of the honey labelled Manuka actually contains very little 
Manuka nectar.  One of the major issues with Manuka honey is the similarity it 
has with Kanuka.  Both grow in the same location and often flower at the same 
time.  Kanuka does not contain dihydroxyacetone so MGO does not form in 
Kanuka honey (Adams, Manley-Harris et al. 2009).   
To date, there is no definitive way to distinguish the two varieties of honey.  
Most honey varieties can be identified by the morphologies of the pollen they 
contain, but Manuka and Kanuka have pollen identical in appearance.  The 
Kanuka honey in this study as well as the Rewarewa had more fluorescence and 
anti-inflammatory activity than the other floral types of honey (excluding 
Manuka).  As mentioned previously these honeys may contain higher amounts of 
Manuka nectar than the other floral types due to them often being in close 
proximity to Manuka shrub and flowering at the same time.  Until a reliable test 
is available, much of the industry can opt to avoid accurate labelling.  It is 
suggested that future research is directed to developing a test to distinguish 
Manuka and Kanuka honey.  The research presented here, strongly suggests that 
a fluorescence based assay may accurately predict honeys with high anti-
inflammatory activity, and therefore most likely to be Manuka honey. 
Further research is needed to determine if MGO formation takes time and 
whether or not the MGO-modification of proteins depends mainly on time or on 
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other factors as well.  This may explain the variation in fluorescence for the 
honeys.  It is also likely that as protein modification takes place the pool of MGO 
is reduced as it is an irreversible reaction and the rate of formation of MGO 
decreases with time (Adams et al. 2009).  Possibly old honeys with high 
fluorescence will have low MGO, whereas the level of MGO may have been 
higher previously. 
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Chapter 9 
Anti-inflammatory effect of honey in the hen’s egg 
chorioallantoic membrane test 
 
 
 
 9.1  Summary 
The anti-inflammatory action of Manuka honey seen in the phagocytosis assay 
was compared with that seen in a commonly used in vivo assay of anti-
inflammatory activity.    Previous work identified that Manuka honey with high 
fluorescence had the most inhibitory phagocytosis activity resulting in an anti-
inflammatory action by reducing inflammatory cytokine expression and ROS 
production in monocytes and macrophages.  Also it was found that Manuka 
honey had higher activity than other honeys in these assays.   It was therefore of 
interest to compare the effects of Manuka honey with high and low 
fluorescence, and a Pasture honey, in an assay that shows anti-inflammatory 
activity in vivo.  In the present chapter, the anti-inflammatory properties of 
Manuka honey were assessed against two irritants that cause inflammation, 
sodium dodecyl sulphate (SDS) and LPS, in a commonly used in vivo assay of anti-
inflammatory activity, the hen’s egg chorioallantoic membrane test (HET-CAM).   
 
In the SDS assays, it was concluded that highly fluorescent Manuka honey at a 
concentration of 5% had an anti-inflammatory effect equivalent to that of 5 
mg/ml hydrocortisone, observed by a complete lack of the typical inflammatory 
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response such as granulomas and a star-like pattern of vasculation observed with 
SDS alone. Manuka honey with low fluorescence had much less of an inhibitory 
effect.  Artificial honey and Pasture honey had little or no anti-inflammatory 
action.  Use of LPS to cause inflammation in this assay has not been documented 
in the literature but was used in place of SDS for further assays as LPS was used 
as the irritant in previous cell work where Manuka honey had an anti-
inflammatory effect.  Resulting inflammation from LPS stimulation was swelling 
of the tissue accompanied by redness, due to influx of blood to the tissue.  
Manuka honey and hydrocortisone both decreased these signs of inflammation, 
with highly fluorescent Manuka honey having a greater effect than Manuka 
honey with low fluorescence, and Pasture and artificial honey showed little or no 
anti-inflammatory effect. The inflammatory response to the two irritants was 
different suggesting that Manuka honey may have two modes of action in its 
anti-inflammatory effect. 
 
9.2  Introduction 
The HET-CAM assay uses the chorioallantoic membrane, which is a vascular 
foetal membrane, composed of the fused chorion and allantois surrounding a 
developing chick embryo.  It is a complete tissue lacking sensory innervations 
that responds to injury with classical inflammatory reactions without the sense 
of pain (Leighton, Nassauer et al. 1985).  The HET-CAM assay was chosen as it is a 
commonly used method for testing substances for anti-inflammatory activity in 
vivo and it is readily accessible for experimentation.  The chorioallantoic 
membrane has been proposed as a model for a living membrane with good 
correlation between results obtained by the HET-CAM test and those of other 
widely accepted irritant/inflammatory models such as the Draize rabbit eye test 
and croton oil ear test which use adult animals (D'Arcy and Howard 1967; 
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Leighton, Nassauer et al. 1985; Brantner, Quehenberger et al. 2002; Tavaszi and 
Budai 2007).   
Topical application of various substances onto the chorioallantoic membrane 
results in local injury and reactions that differ in severity from one substance to 
another.  For any single substance, tested as a sequence of dilutions on a series 
of membranes, the chorioallantoic membrane responds with decreasing intensity 
that parallels the decreasing dosage (Leighton, Nassauer et al. 1985). It is 
assumed that acute effects induced by a test substance on the small blood 
vessels and proteins of the membrane are similar to effects induced by the same 
test substance on the eye of a treated rabbit (Leighton, Nassauer et al. 1985) or 
the ear of a mouse (Brantner, Quehenberger et al. 2002).  These methods are 
commonly used to assay anti-inflammatory agents but are not ideal as they use 
live adult animals, increasing costs and requiring ethics approval.  Research on 
chorioallantoic membranes has concluded that HET-CAM is acceptable as the 
results are comparable with studies using adult animals, and as the assay uses an 
embryo at less than half of its gestation meaning ethics approval is not required. 
 Inflammation and angiogenesis are co-dependent, with many of the 
mechanisms involved in inflammation also involved with angiogenesis (Ribatti, 
Vacca et al. 1996; Jackson, Seed et al. 1997).  The chorioallantoic membrane may 
be evaluated for the development of irritant or inflammatory end points such as 
hyperaemia, hemorrhage, formation of granulomas and coagulation and 
angiogenesis.  Relevant to the research presented in this thesis, is the finding 
that pro-inflammatory macrophages participate in the formation of granulomas, 
which reflects chronic inflammation (Levine, Smith et al. 2005).  In Chapter 4 it 
was found that honey had an inhibitory effect on phagocytosis in THP-1 
macrophages, resulting in an anti-inflammatory effect in vitro. Therefore it is 
relevant to assay honey for its anti-inflammatory effect in vivo, focusing on the 
formation of granulomas. 
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The HET-CAM assay depends on the experimental production of inflammation on 
the chorioallantoic membrane and the reduction of this inflammation with an 
anti-inflammatory substance.  If an irritant is applied in conjunction with an anti-
inflammatory substance, complete normalisation of the membrane irritation is 
observed (Bürgermeister, Paper et al. 2002).  SDS is commonly used as the 
irritant in the HET-CAM assay (Marchesan, Paper et al. 1998; Bürgermeister, 
Paper et al. 2002; Dietrich, Karall et al. 2005).  SDS is an anionic surfactant that 
causes disruption of cell membranes, which causes an inflammatory effect.  Test 
substances can be applied in a diluted liquid form directly to the chorioallantoic 
membrane or dissolved on a filter disc and placed on the chorioallantoic 
membrane (Leighton, Nassauer et al. 1985; Marchesan, Paper et al. 1998; 
Chakraborty and Brantner 2001).  The assay was modified by Dietrich et al. 
(2005) to measure the anti-inflammatory properties of test substances dissolved 
in agarose pellets.  Hydrocortisone, a commonly prescribed anti-inflammatory 
drug used for the treatment of allergic rashes and other inflammatory skin 
conditions, is commonly used as an anti-inflammatory control compound in the 
HET-CAM assay (Marchesan, Paper et al. 1998; Bürgermeister, Paper et al. 2002; 
Dietrich, Karall et al. 2005).  The egg is then incubated for 24 hours to allow the 
inflammation to develop and the chorioallantoic membrane is then harvested 
from the egg and observed under magnification for the appearance of 
membrane irritation, typically in the form of a granuloma and a star-like blood 
vessel pattern surrounding the granuloma.  
Ethics approval was not required for this experiment as the embryo used is at 
less than half its gestation period (The Animal Welfare Act 1999, Section 6, 2.1).   
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9.3  Materials and Methods 
9.3.1   Materials 
9.3.1.1  Agarose bead 
A 2.5% solution of agarose (Ultra Pure™ Agarose, Invitrogen) was made in PBS 
and sterilized by boiling for 5 minutes.  When cooled, but still above its setting 
temperature, test substances were added and pellets formed by placing 10 µl 
amounts on parafilm to gel.  The pellets were 3 – 4 mm in diameter.  They were 
made freshly before each placement on a chorioallantoic membrane. 
9.3.1.2  Sodium dodecyl sulphate (SDS) concentrations 
The SDS concentration used was taken from current literature (Marchesan, 
Paper et al. 1998; Dietrich, Karall et al. 2005).  SDS was purchased from Roche 
and diluted in purified water to a working stock concentration of 0.1 g/ml.  A 
final concentration of 5 mg/ml (50 µg/agarose pellet) was achieved by diluting 
the stock SDS solution with agarose.  Results from preliminary assays at this 
concentration concurred with the published results. 
9.3.1.3  Lipopolysaccharide 
LPS from E.coli (E. coli serotype 0127:B8; Cat No.# L4516-1 mg) was purchased 
from Sigma-Aldrich, UK.  The LPS was dissolved in sterilised purified water to a 
working concentration of 1 mg/ml and used at a final concentration in agarose of 
50 µg/ml (500 ng per agarose pellet), based on preliminary testing on 
chorioallantoic membranes.  At this concentration a noticeable irritation 
occurred yet the embryo remained viable. 
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9.3.1.4  Hydrocortisone 
The hydrocortisone concentration used was taken from current literature 
(Marchesan, Paper et al. 1998; Dietrich, Karall et al. 2005). Hydrocortisone was 
purchased from Sigma-Aldrich (Cat No.# HO888-1 G) and diluted to 500 mg/ml in 
ethanol for a stock solution.  The stock solution was diluted to a final 
concentration of 5 mg/ml in agarose (50 µg per agarose pellet).  Results from 
preliminary assays at this concentration concurred with the published results.  
9.3.1.5.  Honey concentrations 
Honey was obtained from the Honey Research Unit, University of Waikato, NZ, 
and was tested for its non-peroxide antibacterial activity (NPA) (Allen, Molan et 
al. 1991).  Two Manuka honeys were selected based on their fluorescence, 
phagocytosis-inhibiting activity and their NPA.  Two Manuka honeys with similar 
high NPA ratings were chosen for the study, one with high fluorescence and the 
other with low fluorescence (as determined in Chapter 8).  Selecting honeys with 
similar high NPA ensures that each honey was a mono-floral Manuka honey, not 
a blend with other floral types.  These were selected from the honey survey 
presented in Appendix 3, and detailed in Table 9.1. 
The required concentrations of Manuka and artificial honey were achieved by 
dilution of the honey with sterile purified water as described in Section 3.4.1.1.   
Artificial honey was used to provide a control for the osmotic effect of the 
natural sugars found in honey.  It was prepared using a published recipe (White 
1975).  Preliminary assays with diluted honey indicated that a 5% concentration 
of Manuka honey would be sufficient in neutralising the effect of SDS on a 
chorioallantoic membrane.  Consequently concentrations of 2% and 5% honey 
were used for all the honeys tested. 
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9.3.2     HET-CAM Methods 
9.3.2.1  Egg preparation for HET-CAM 
Fresh fertilised eggs were collected on the day of laying from a poultry farm 
(Alstra Poultry Lodge, Ngaruawahia).  Preferred eggs were white, 55 g and 
unsoiled.  Prior to incubation eggs were candled to check for cracks or fractures 
in the shell, and any damaged eggs were discarded.  One day old eggs were 
preferred for the assay.  Eggs not used on the day of collecting were stored at 
18°C for no more than two days.  Eggs were incubated in a horizontal position for 
72 hours at 37°C and 80% relative humidity.  The eggs were rotated in an 
automated incubator several times a day to stop the developing membrane from 
attaching to the shell. 
After 72 hours of incubation the eggs were candled to observe embryo 
development.  Eggs that had no embryo were discarded.  Eggs were then 
swabbed with 70% ethanol at both ends. A small patch (5 mm) of shell was 
ground away using a rotary tool (a cordless Dremal hobby tool was used) with a 
sterile cutting/grinding disk, on the pointed end of the egg leaving the outer 
membrane intact.  The egg was then held pointed side down.  A hypodermic 
syringe with a 19 gauge needle was inserted through the hole ground in the 
shell, piercing the outer membrane and 10 ml of albumin was aspirated out 
slowly, ensuring the yolk was not disturbed.  The egg was then inverted and the 
hole was sealed with molten candle wax.  The egg was then placed pointed end 
down in an egg tray.  A 3 cm diameter circle was then ground into the egg shell 
using the Dremal hobby tool from the top of the egg leaving the outer 
membrane untouched.  The outer shell membrane was then cut using a sterile 
scalpel blade, removing the shell and attached shell membrane with tweezers, 
exposing the chorioallantoic membrane on the yolk.  The prior removal of the 
albumin causes the chorioallantoic membrane to sit low in the egg leaving 
approximately a 4 cm diameter chorioallantoic membrane to do testing on.  The 
yolk floats in the albumin, orientating the embryo and chorioallantoic membrane 
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to the top of the egg enabling good viewing.  The embryo was checked for 
viability by noting the presence of a beating heart, and for haemorrhaging, which 
would indicate imminent death.  The egg was covered with parafilm and set back 
in the incubator for a further 72 hours.  The eggs were left stationary during this 
period.  Figures 9.1 to 9.5 show the process of preparing the egg for the HET-
CAM work. 
 
 
Figure 9.1.  Removing a small patch of shell using a 
rotary hobby tool.  The outer membrane still intact. 
 
Figure 9.2.  Aspirating 10 ml albumin through the 
exposed outer shell membrane. 
Chapter 9                                              HET-CAM assay 
243 
 
 
Figure 9.3.  Sealing the egg using molten candle wax 
after aspirating albumin. 
 
 
 
Figure 9.4.  Preparing the egg for removal of the shell 
to expose the chorioallantoic membrane.  The shell is 
cut through without cutting the outer shell 
membrane. 
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Figure 9.5.  The exposed chorioallantoic membrane 
covered with parafilm. 
 
9.3.2.2  HET-CAM assay using SDS as an irritant 
SDS in an agarose pellet was used to cause inflammation on chorioallantoic 
membranes.    As a positive control for detecting anti-inflammatory activity, the 
SDS was combined with hydrocortisone. The negative controls included agarose-
only pellets, hydrocortisone-only, and honey-only pellets at the same 
concentrations used in the assay. 
9.3.2.3  Modified HET-CAM assay using LPS as an irritant. 
In the experiments in previous Chapters, LPS was used to cause an inflammatory 
response in THP-1 cells in cell culture.  It was therefore of interest to use a 
similarly induced inflammatory response with the HET-CAM assay.  LPS use in 
this assay has not been documented in the literature.  A range of concentrations 
of LPS was used in control chorioallantoic membranes to find a suitable 
concentration to create inflammation.  A final concentration of 50 µg/ml in the 
agarose pellet was selected for further assays.  Conditions of the HET-CAM assay 
remained the same as those for the SDS treatments.   
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The chorioallantoic membranes responded differently to the LPS compared with 
when SDS was used.  No granuloma was identified in any of the chorioallantoic 
membranes, and the capillary net remained virtually unchanged.  The most 
obvious reaction to LPS was an intense redness due to the influx of blood in to 
the tissue surrounding the agarose pellet.  Honeys were used at the same 
concentrations as previously mentioned. 
 
9.3.3  Agarose pellet compound combinations 
Agarose pellets used in the HET-CAM assays contained the following 
combinations;   
Test:   Honey and SDS, honey and LPS 
Positive controls: SDS only, SDS and hydrocortisone, LPS only, LPS and 
hydrocortisone. 
Negative controls:  Hydrocortisone only, honey only and nothing added to the 
agarose. 
The details of the honey used in the section are given in Table 9.1. 
 
 
 
 
 
 
 
Chapter 9                                              HET-CAM assay 
246 
 
Table 9.1:  Details of the honeys used in the HET-CAM assays. 
Code Type NPA 
Fluorescence. 
(AU) 
Anti-inflam. 
property 
M144 Manuka 12 184 High 
M128 Manuka 11.8 20 Low 
PS9 Pasture 0 35 Low 
Artificial Artificial 0 0 Low 
Abbreviations: NPA = non-peroxide antibacterial activity; AU = Arbitrary units;  
Inflam = inflammation. 
 
9.3.4  Agarose pellet placement 
Pellets were placed on each membrane in duplicate (two per egg) away from any 
major blood vessels and 1 cm from the shell.  This allowed the pellet to be found 
easily and prevented the pellet from being dislodged by the active embryo.  The 
test substances were each placed on at least four eggs, thus giving a total of 
eight tests for each of the honey concentrations. At least three eggs were used 
for each control, each having the control in duplicate.  In some experiments, the 
embryo died during the incubation and these eggs were not included in the final 
count but the death was noted.   Death of the embryo was not specific to any 
one treatment and was minimal over the entire test period.  The length of the 
assay was 7 days from start of incubation to harvesting of the chorioallantoic 
membrane.   
9.3.5  Harvesting the chorioallantoic membrane 
After 24 hours of incubation with the test pellet, the chorioallantoic membrane 
was harvested from the egg with sterile scissors and tweezers.  The agarose 
pellet was removed from the membrane with tweezers.  The membrane was 
then placed in chilled phosphate-buffered saline and viewed under a stereo 
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microscope.  After observations, a digital picture was taken and the membrane 
was placed into 100% ethanol to preserve. 
9.3.6  Evaluation of results obtained 
The degree of irritation of the membrane was observed and graded using a scale 
of 0 – 2 with increments of 0.5 for SDS and a scale of 0 – 3 with increments of 1 
for the LPS assays.  These scores were then used to calculate a proportional 
inhibition of inflammation.  Table 9.2 and 9.3 details the score systems used for 
SDS and LPS respectively.  A positive effect, corresponding to anti-inflammatory 
activity, exists if the irritation of the membrane by SDS or LPS is reduced or 
appears normal and the blood-vessel net appears normal.   
 
 
Table 9.2:  Score used for the evaluation of the anti-inflammatory effect of test 
substances in SDS-irritated chorioallantoic membranes. 
      Score Effects Observed 
0 
no effect/strongly 
irritated 
Large granuloma, strongly vascularised, 
large capillary net surrounding granuloma. 
0.5 
weak effect/weakly 
irritated 
Large granuloma, reduced capillary net 
surrounding granuloma. 
1.0 
weak-medium 
effect/weakly normalised 
Granuloma smaller than score 0 or 0.5, 
significantly reduced capillary net. 
1.5 
medium-strong 
effect/almost normalised 
No granuloma, slight increase in capillary 
growth at site of agarose bead. 
2.0 
strong effect/completely 
normalised 
No granuloma or obvious increase in 
capillary growth at site of agarose bead. 
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Table 9.3:   Score values for the evaluation of the anti-inflammatory effect of test 
substances in LPS-irritated chorioallantoic membranes in the HET-CAM assay. 
        Score Effects observed 
0 no effect Membrane extremely red surrounding area of pellet 
1 weak effect Membrane  red surrounding pellet but less than in score 0 
2 
medium 
effect 
Membrane has slight redness visible but less than in score 
0 & 1 
3 Strong effect Membrane normalised, no redness 
 
 
All results are expressed as mean values ± 1 SD.  Corresponding anti-
inflammatory effects were based on the degree of inhibition as in the publication 
of Bürgermeister, et al. 2002: 
 
Inhibition Effect 
  <40%: 
40-55%: 
55-70%: 
70-85%: 
  >85%: 
no anti-inflammatory effect 
uncertain anti-inflammatory effect 
weak anti-inflammatory effect 
good anti-inflammatory effect 
strong anti-inflammatory effect 
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9.4   Results 
Membranes from the HET-CAM assay where observed under a stereo 
microscope and scored.  Not all membranes were successfully photographed due 
to breakage however, all viable membranes were scored.  The images of some 
membranes are presented in Section 9.4.1 and the resulting scores are 
presented in Section 9.4.2. 
9.4.1 Observations of inflammation 
Figure 9.6 shows a normal membrane (control) after agarose bead placement 
with no LPS, SDS, hydrocortisone or honey.  The perimeter of the pellet is 
obvious as it leaves a slight indentation in the membrane were it was placed 
(Score 2).   
 
 
Figure 9.6:  Agarose control pellet.  No SDS, 
LPS, hydrocortisone or honey added. The 
perimeter of the pellet is obvious as it 
leaves a slight indentation in the 
membrane were it was placed.  Score 2.   
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Figure 9.7 shows the typical membrane irritation/inflammation by 50 µg SDS 
(Score 0).  In this inflammatory state there is an obvious formation of a 
granuloma and the number of blood vessels directed to and from the granuloma 
is high resulting in a star-like formation around the granuloma due to increased 
angiogenesis (Marchesan, Paper et al. 1998).   
 
   
Figure 9.7:  Irritation of the membrane 
caused by SDS (50 µg/pellet).  Note 
capillary growth is directed to and from the 
granuloma in centre.  Score 0. 
 
 
Figure 9.8 shows the typical membrane irritation/inflammation by 500 ng/pellet 
of LPS (Score 0).  The capillary net growth remains normal and no granuloma is 
formed, however, capillaries appear dilated.   
Figure 9.9 shows the reduction of irritation/inflammation by SDS resulting from 
the anti-inflammatory effect of 50 µg hydrocortisone.  This was a complete 
reduction of inflammation (Score 2).  The perimeter of the pellet is obvious as it 
leaves a slight indentation in the membrane were it was placed.   
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Figure 9.8:  The redness/inflammation 
resulted from 500 ng/pellet LPS agarose 
pellet (arrows mark the redness).  Score 0.   
 
 
 
Figure 9.9:  Inhibition by hydrocortisone (50 
µg/pellet) of membrane irritation by SDS. 
Score 2. 
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Figure 9.10 shows the reduction of irritation/inflammation by LPS resulting from 
the anti-inflammatory effect of 50 µg hydrocortisone.  This was a complete 
reduction of inflammation (Score 3).  The perimeter of the pellet is obvious as it 
leaves a slight indentation in the membrane were it was placed.   
 
 
 
Figure 9.10:  Inhibition by 50 µg/pellet 
hydrocortisone irritation of the membrane 
by LPS. Score 3. 
 
 
Figure 9.11 shows the reduction of irritation/inflammation by SDS resulting from 
the anti-inflammatory effect of 5% highly fluorescent Manuka honey.  This also 
was a complete reduction of inflammation (Score 2).   
Figure 9.12 shows the reduction of irritation/inflammation by LPS resulting from 
the anti-inflammatory effect of 5% highly fluorescent Manuka honey.  This also 
was a complete reduction of inflammation (Score 3).   
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Figure 9.11: Inhibition by 5% highly 
fluorescent Manuka honey of irritation of 
the membrane by SDS.  Score 2. 
 
 
Figure 9.12:  Inhibition by 5% highly 
fluorescent Manuka honey of irritation of 
the membrane by LPS. Score 3. 
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Figure 9.13 shows the reduction of irritation/inflammation by SDS resulting from 
the anti-inflammatory effect of 2% highly fluorescent Manuka honey. The 
granuloma size and number of blood vessels are reduced, but not completely 
(Score 1).   
  
Figure 9.13:  Some inhibition by 2% highly 
fluorescent Manuka honey of irritation of 
the membrane by SDS.  A small granuloma 
is present (marked with an arrow), and 
there is no obvious capillary net.  Score 1.   
 
Figure 9.14 shows the reduction of irritation/inflammation by LPS resulting from 
the anti-inflammatory effect of 2% highly fluorescent Manuka honey. The 
granuloma size and number of blood vessels are reduced, but not completely 
(Score 1.5).   
Figure 9.15 shows no reduction of irritation/inflammation by LPS resulting from 
the application of 5% Pasture honey (Score 0). 
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Figure 9.14:  Some inhibition by 2% highly 
fluorescent Manuka honey of irritation of 
the membrane by LPS.  A small granuloma 
is present (marked with an arrow), and 
there is no obvious capillary net.  Score 1.5.   
 
 
 
Figure 9.15: No inhibition by 5% Pasture of 
irritation of the membrane by LPS. Score 0.  
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9.4.2     Results of  HET-CAM assay 
The resulting scores assigned to each test membrane after harvesting from the 
egg are presented here.  Section 9.4.2.1 has the results from SDS irritated 
membranes and Section 9.4.2.1 has the results from the PLS irritated 
membranes. 
9.4.2.1  HET-CAM assay with SDS 
Each membrane was assessed and given a score out of 2 (0 = no anti-
inflammatory effect, membrane strongly irritated; 2 = strong anti-inflammatory 
effect/completely normalised membrane).  From these scores a percentage 
reduction in inflammation could be calculated for each substance for all the 
membranes assayed. This percentage is a measure of the anti-inflammatory 
activity of the substance tested.  Table 9.4 summarises the results of the SDS 
HET-CAM experiments and Figure 9.16 shows the reduction of inflammation, the 
score for anti-inflammatory activity being shown as a percentage of the 
maximum score of 2 which is assigned when a membrane has a completely 
normal appearance.  All Manuka honey treatments significantly (p<0.001) 
reduced the inflammation caused by SDS with the formation of a granuloma 
being absent and the capillary net appearing normal.   Manuka honey with high 
fluorescence had the greatest anti-inflammatory effect.  The 5% Manuka honey 
with low fluorescence was comparable in effect with the 2% concentration of 
Manuka honey with high fluorescence.  Artificial honey had no anti-inflammatory 
effect and Pasture honey had a slight effect but this was not significant 
compared with the artificial honey control. 
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Table 9.4: Results from HET-CAM assay.  The mean anti-inflammatory activity 
score is shown for various substances in comparison on SDS-irritated membranes. 
A score of 2 indicates a normal membrane was observed at the end of the assay.  
A score of 0 indicates inflammation was present in the form of a granuloma and 
increased capillary growth. 
Treatment 
per pellet 
No. 
of eggs 
No. of dead 
embryos 
No. of CAMs 
harvested 
Average score 
(out of 2) 
SDS 50 µg alone 4 1 6 0 
Hydrocortisone  
50 µg no SDS 
(control) 
3 0 6 2 
Manuka honey 
high AU 5% no 
SDS (control) 
3 0 6 2 
Hydrocortisone  
50 µg + SDS 50 µg 
4 0 8 1.88 
Manuka honey 
high AU 2% 
+ SDS 50 µg 
4 1 6 0.92 
Manuka honey 
high AU 5% 
+ SDS 50 µg 
4 0 8 1.81 
Manuka honey 
low AU 5% 
+ SDS 50 µg 
3 1 6 0.92 
Pasture honey 5% 
+ SDS 50 µg 
3 0 6 0.16 
Artificial honey 5% 
+ SDS 50 µg 
3 0 6 0 
Agarose only  
(control) 
4 0 8 2 
Abbreviations; SDS=Sodium dodecyl sulphate; AU=Arbitrary units measuring fluorescence; 
CAM=chorioallantoic membrane. 
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Figure 9.16:  Data from Table 9.4 for the mean anti-inflammatory activity score 
for SDS irritated chorioallantoic membranes, shown as a percentage of the 
maximum score of 2 which is assigned to a membrane showing no signs of 
inflammation.  Error bars show ± 1 SD of the mean from at least three 
experiments. * p<0.001 analysed by ANOVA compared with the control 
membrane treated with artificial honey.   
 
 
9.4.2.2  HET-CAM assay with LPS 
Each membrane was assessed and given a score out of 3 (0 = no anti-
inflammatory effect, membrane strongly irritated;  3 = strong anti-inflammatory 
effect/completely normalised membrane).  From these scores a percentage 
could be calculated for each substance for all the membranes assayed. This 
percentage is a measure of the anti-inflammatory activity of the substance 
tested.  Table 9.5 summarises the results of the LPS HET-CAM experiments and 
Figure 9.17 shows the reduction of inflammation, the score for anti-inflammatory 
activity being shown as a percentage of the maximum score of 3 which is 
assigned when a membrane has a completely normal appearance. 
0% 
94% 
46% 
91% 
46% 
8% 
0% 
sds 50 µg 
Hydrocortisone 50 µg + SDS 50 µg 
Manuka honey high Au 2%+ SDS 50 µg 
Manuka honey high Au 5%+ SDS 50 µg 
Manuka honey low Au 5%+ SDS 50 µg 
Pasture honey 5%+ SDS 50 µg 
Artifical honey 5%+ SDS 50 µg 
* 
* 
* 
* 
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Table 9.5: Results from HET-CAM assay.  The mean anti-inflammatory activity 
score is shown for various substances in comparison on LPS-irritated membranes. 
A score of 3 indicates a normal membrane was observed at the end of the assay.  
A score of 0 indicates inflammation was present in the in the form of redness. 
Treatment 
Per pellet 
No. 
of eggs 
No. of dead 
embryos 
No. of CAMs 
harvested 
Average 
score 
(out of 3) 
LPS 500 ng alone 3 0 6 0 
Hydrocortisone 50 
µg no LPS (control) 
3 0 6 2.88 
Manuka honey high 
AU 5% no LPS 
(control) 
3 1 6 2.83 
Hydrocortisone 50 
µg + LPS 500 ng 
4 0 8 2.63 
Manuka honey high 
AU 2%+ LPS 500 ng 
4 1 6 1.50 
Manuka honey high 
AU 5%+ LPS 500 ng 
4 0 8 2.50 
Manuka honey low 
AU 5%+ LPS 500 ng 
4 0 8 1.38 
Pasture honey 5%+ 
LPS 500 ng 
3 0 6 0.25 
Artificial honey 5%+ 
LPS 500 ng 
3 1 4 0.25 
Agarose only 
(control) 
4 1 6 3 
Abbreviations; LPS, lipopolysaccharide; AU, Arbitrary units measuring fluorescence. 
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Figure 9.17:  Data from Table 9.5 for the mean anti-inflammatory activity score 
for LPS irritated chorioallantoic membranes, shown as a percentage of the 
maximum score of 3 which is assigned to a membrane showing no signs of 
inflammation.  Error bars show ± 1 SD of the mean from at least three 
experiments. * p<0.001 analysed by ANOVA compared with the control 
membrane treated with artificial honey.  
 
All Manuka honey treatments significantly (p<0.001) reduced inflammation of 
the chorioallantoic membrane irritated by LPS.  The 5% concentration of highly 
fluorescent Manuka honey showed the greatest inhibition of chorioallantoic 
membrane irritation with all the membranes tested.  This was apparent by the 
reduction/lack of redness associated with LPS irritation.  At 5% the highly 
fluorescent Manuka honey was comparable in effect to hydrocortisone at a 
concentration of 5 mg/ml for LPS irritated chorioallantoic membranes.  At 2% 
Manuka honey that was highly fluorescent was comparable with 5% Manuka 
honey with low fluorescence. Artificial honey had no effect on inflammation.  
Pasture honey had a slight effect in reducing inflammation but this was not 
significant compared with the artificial honey control.  
8% 
88% 
50% 
83% 
46% 
8% 
0% 
LPS 500ng 
Hydrocortisone 50µg + LPS 500ng 
Manuka honey high Au 2%+ LPS 500ng 
Manuka honey high Au 5% + LPS 500ng 
Manuka honey low Au 5%+ LPS 500ng 
Pature honey 5%+ LPS 500ng 
Artifical honey 5%+ LPS 500ng 
* 
* 
* 
* 
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9.5  Discussion 
The typical chorioallantoic membrane inflammation due to SDS has been 
comprehensively examined by researchers and the characteristic scarring, 
granulomas and capillary nets are easily identifiable (Marchesan, Paper et al. 
1998; Bürgermeister, Paper et al. 2002).  By combining anti-inflammatory agents 
with the irritant a reduction of inflammation can be measured.  This assay is 
commonly used to test the anti-inflammatory properties of new compounds so it 
was employed for the testing of the anti-inflammatory effect of Manuka honey.  
SDS was seen to stimulate typical membrane irritation.  In this inflammatory 
state the number of blood vessels is high and there is formation of a large 
granuloma.  In all cases the blood vessels have a star form around the granuloma 
and the granuloma is raised above the capillary net.    
LPS was also used to irritate the membrane as this had been used in previous 
work to activate macrophages for phagocytosis assay.  Preliminary work 
ascertained a concentration of LPS that did not kill the embryo but still had a 
visible inflammatory effect.  Redness and swelling were the visible symptoms of 
the resulting inflammation observed from LPS application.  This inflammation 
was able to be prevented by the addition of hydrocortisone proving its anti-
inflammatory action against LPS irritation.   
Previous work identified that the Manuka honey with high fluorescence had 
more inhibitory activity on phagocytosis than Manuka honey with low 
fluorescence did.  This activity was presumed to result in an anti-inflammatory 
action as in conjunction with reduced phagocytosis, inflammatory cytokine 
expression and ROS production in monocytes and macrophages was reduced.   
Manuka honeys with high and low fluorescence, were tested at a 5% 
concentration. Manuka honey with high fluorescence was also tested at 2% after 
preliminary work identified the lowest limit of activity and the maximum amount 
of honey required to neutralise the effects of SDS at commonly used 
concentrations of SDS.  Pasture honey and artificial honey were tested at the 
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highest concentration of 5%.  The same honey concentrations were used in the 
LPS-irritated chorioallantoic membranes as the SDS-irritated chorioallantoic 
membranes.   
The 5% concentration of highly fluorescent Manuka honey showed the greatest 
inhibition of chorioallantoic membrane irritation with both SDS- and LPS-irritated 
membranes.  At 5% the highly fluorescent Manuka honey was comparable in 
effect to hydrocortisone at a concentration of 5 mg/ml for both the SDS and LPS 
irritated chorioallantoic membranes.  At a concentration of 2% Manuka honey 
that was highly fluorescent had the same effect as 5% Manuka honey with low 
fluorescence confirming the greater anti-inflammatory properties of Manuka 
honey with high fluorescence.  The results from these initial HET-CAM assays 
suggest that the anti-inflammatory activity of honey may be attributed to the 
fluorescent component.  Further assays need to be completed with a wider 
range of honey samples, both Manuka and non-Manuka, with varying 
fluorescence, to show statistically that there is a correlation between high 
fluorescence and anti-inflammatory activity. 
These results agree with those found in vitro with the phagocytosis assay, 
indicating that the phagocytosis assay gives a reliable indication of anti-
inflammatory activity in vivo.  Artificial honey had no effect in reducing the 
inflammation caused by LPS or SDS irritation and while Pasture honey had a 
slight affect this was not significant.  As mentioned in earlier Chapters, it is highly 
likely that some Manuka nectar was present in the Pasture honey giving this 
activity.   
It was not proven that the granuloma formed in response to SDS irritation was 
predominately consisting of macrophages as most granulomas are deemed to 
be.  Future work may look at determining this to show that the active 
component in honey is working on macrophages in vivo as it was determined to 
in vitro by the phagocytosis assay.   
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Future work using the HET-CAM assay should include comparison of the anti-
inflammatory activity of Manuka honey with that of other commonly used anti-
inflammatory agents such as phenylbutazone and sodium diclofenac.  More 
honeys should be tested in the HET-CAM such as RewaRewa and Kanuka which 
have similar properties to Manuka honey yet lack the fluorescence and content 
of MGO.  Further work should use the HET-CAM assay to test more Manuka 
honeys with a range of phagocytosis-inhibiting activity to determine the 
correlation coefficient.  HET-CAM assays should also be completed using 
fractionated Manuka honey as was done in Chapter 6 when isolating the active 
protein using the phagocytosis assay.  This would confirm that it is the 
phagocytosis-inhibiting glycated MRJP-1 that is responsible for the anti-
inflammatory affect seen in vivo, and not some other component in honey acting 
through a different mechanism. 
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Chapter 10  
Summary and discussion of thesis 
 
 
 
10.1  Summary  
To summarise, it was found during this research that honey reduced 
phagocytosis in activated THP-1 cells and that certain Manuka honeys had a 
superior ability to other types of honey to do this.   MRJP-1, the major protein in 
honey, and MRJP-3 was identified as being present in the fraction having this 
activity in Manuka honey.   This finding is important to the anti-inflammatory 
aspects of wound healing due to the large amounts of ROS released from 
phagocytising macrophages.  Chronic wounds are overpopulated with active 
macrophages and the high levels of ROS released, creates feedback loops that 
worsen the situation.   
An in vitro assay for inflammation utilizing the chorioallantoic membrane of a 
fertilized hen’s egg, (HET-CAM) showed that the phagocytosis-inhibiting activity 
seen in the phagocytosis assay was a reliable indicator for measuring anti-
inflammatory activity of honey in vivo, though it was not proven that the honey 
was working via the same means.   
The protein in the active fraction was found to bind a ConA lectin 
chromatography column indicating it had mannose-terminating glycosylation.  
The phagocytosis inhibiting activity could be significantly reduced by treating 
Chapter 10                                                    Discussion 
265 
 
honey with mannosidase suggesting these mannose components are important 
in the protein’s phagocytosis-inhibiting activity.   
Attempts to identify the receptor narrowed it down to a mannose-binding 
receptor by using mannan and β-glucan as inhibitors of phagocytosis in the 
phagocytosis assay.  It was hypothesised that the receptor was the mannose 
receptor.   
MRJP-1, as is most likely to occur with all proteins in honey, was found to be 
modified by the MGO present in Manuka honey.  It appears that this 
modification occurs gradually over time upon storage of the honey.  This 
modification resulted in Manuka honey developing fluorescence at a wavelength 
characteristic of that of AGEs formed by reaction of MGO with arginine residues, 
and this fluorescence can be used to identify which honeys have a high level of 
anti-inflammatory activity as determined by the phagocytosis assay and the HET-
CAM assay.   
 
10.2   Discussion 
There may be several anti-inflammatory agents in honey, one of them at least 
was identified in this research as MRJP-1.  It is likely that this protein has several 
modes of action, as discussed in Chapter 9.  The LPS- and SDS-irritated 
membranes each had a different inflammatory reaction to the treatment, yet 
Manuka honey normalised both types of inflammation of the membranes.  It was 
not proven that the anti-inflammatory activity seen in the HET-CAM assay was 
due to MRJP-1, though it was present in the fraction of honey that had this 
activity.  However, it was noted that honey with high anti-inflammatory activity 
in the phagocytosis assay also had had a high score in the HET-CAM assay 
(indicating high anti-inflammatory activity also).  These honeys had a high 
fluorescence, which was shown to be due to MGO modifying the protein in 
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honey.  This indicated that MGO-modified MRJP-1 was present.   To a lesser 
extent MRJP-3 may have some anti-inflammatory activity also as it was present 
in the active fraction.  Manuka honey with low fluorescence had a low level of 
anti-inflammatory activity in both assays.  MGO presence alone was not able to 
inhibit phagocytosis, so the correlation for MGO and fluorescence was low.  
However, only honey that had MGO developed fluorescence.  There is most 
likely another variable influencing the development of the fluorescence, such as 
antioxidants retarding the modification of the protein, age of the honey or 
temperature the honey was stored at.  This will need to be investigated further. 
THP-1 cells activated by three different agents, LPS, PMA and Vit-D3, all 
generated macrophages (Chapter 3) which responded to Manuka honey by 
having reduced phagocytosis ability (Chapter 4).  This indicates that the 
macrophage activation state is diverse as discussed in Chapter 4 which is to be 
expected due to the different mechanisms of activation.  It may mean that in the 
HET-CAM assay different states of activation of macrophages may occur.  The 
HET-CAM assay could be tested with PMA and other irritants to determine 
further modes of anti-inflammatory action for Manuka honey.  As mentioned 
previously in Chapter 9, it will be of great importance to confirm which cells are 
being targeted in the HET-CAM assay.  While macrophages are considered to be 
the main cellular component in granulomas, it needs to be confirmed in this 
instance before assumptions can be made about the anti-inflammatory 
component of honey.  The activity may be active via the same mechanisms in the 
phagocytosis assay and the HET-CAM assay yet this remains to be proven. 
The anti-inflammatory effect could have been due to the stabilization of cytokine 
expression, anti-oxidants preventing ROS formation activating further 
inflammation, MGO-modified MRJP-1 blocking mannose receptors, reduction of 
ROS production or a combination of these.  As mentioned previously, adding 
arginine but not lysine to honey reduced the MGO content of honey, suggesting 
that MGO was modifying only the arginine on the proteins in honey (Adams, et 
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al. 2009).  In addition to that it has been reported that MGO-modified arginine 
residues are a signal for receptor mediated endocytosis by THP-1 cells 
(Westwood, et al. 1997).  Thus it is highly likely that the natural MGO content of 
Manuka honey is modifying the arginine of the protein in honey, the majority of 
being MRJP-1, which then become ligands for THP-1 macrophage receptors.  In 
light of the current research, this is most likely the mechanism that honey works 
in its anti-inflammatory activity. 
Anti-inflammatory activity had a highly significant correlation with the 
fluorescence of honey.  Honey with high fluorescence had high anti-
inflammatory activity.  This finding proves fluorescence is a good indicator for 
the anti-inflammatory effect of honey.  The assay for fluorescence is a much 
more economical assay than the one for phagocytosis or the HET-CAM assay, 
both in terms of actual cost and time.  It may be possible that future screening of 
honey for its anti-inflammatory activity be done using only the fluorescence of 
honey.   
Attempts to find correlation between anti-inflammatory activity and other 
factors such as MGO content, or NPA were unsuccessful, suggesting a complex 
process is occurring.  The mode of action for modulating the cytokine expression 
was not determined for Manuka honey, but it is likely that it is due to another 
component entirely.  It was shown that decreasing phagocytosis decreased ROS 
release in vitro but it was only hypothesised that this would contribute to the 
reduction of inflammation in vivo.   
Research should be directed towards discovering the bioavailability of glycated 
MRJP-1.  Does the MRJP-1 cross membranes? Can it be absorbed from the gut 
and work systemically?  Can it diffuse through intact skin, or does it work only on 
exposed phagocytes where the mannose receptor is present to bind it? If honey 
cannot do this, then this would indicate that honey may be restricted to treating 
inflamed wounds with exposed phagocytes such as skin trauma wounds, 
stomach ulcers, mouth ulcers, and gingivitis.   Investigations into the ability of 
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the active component of honey to survive the highly acidic condition of the 
stomach and dilution through the intestines will be important in learning if 
honey can treat inflammation caused by stomach ulcers, irritable bowel 
syndrome or Crohn’s disease.  The HET-CAM work showed that the active 
component in honey can cross membranes as the chorioallantoic membrane was 
intact for this assay.  But as mentioned previously it is only hypothesised that the 
anti-inflammatory activity seen in the HET-CAM assay is due to the MGO-
modified MRJP-1 and not another component in honey with high fluorescence.  
It is important to know the bio-availability of the active component in honey, as 
other areas that might benefit from anti-inflammatory action of honey do not 
have exposed phagocytes, for example, sunburn and arthritis.     Research would 
also benefit by assaying a wider range of honeys in the HET-CAM. 
Obtaining high concentrations of MRJP-1 was a limiting factor for this research.  
Recombinant MRJP-1 has been prepared by heterologous expression in E. coli, 
retaining the immuno-stimulatory effect of native MRJP-1, by increasing TNF-α 
expression (Majtan, Kovacova et al. 2006). It is highly recommended that in the 
future MRJP-1 be manufactured by genetic engineering of insects to create 
larger quantities of pure glycosylated MRJP-1, and this protein be modified with 
MGO after isolation.  An insect cell line would give the correct terminal mannose 
residues needed to act on the mannose receptor of macrophages. This protein 
could then be used in the HET-CAM assay and the phagocytosis assay, 
eliminating the question of whether anti-oxidants or other components have the 
anti-inflammatory activity.  
The presence of cross-links in the active protein needs to be investigated as SDS 
gel electrophoresis of MGO-modified protein in honey and bovine serum 
albumin indicated MGO-modified protein became larger, possibly by forming 
cross-links.  The main Manuka honey protein estimated to be around 63 kDa on 
the SDS electrophoresis gel), was 5 kDa larger than the same protein band in 
Clover honey (estimated to be 58 kDa).  The reported molecular weight of MRJP-
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1 in honey is 55 kDa (Tamura, Kono et al. 2009).  The size differences are 
expected to be due to differences in glycosylation between the samples of 
honey.  Manuka honey and incubated Manuka honey with naturally high MGO 
content, both had a diffuse protein band in the higher molecular weight range 
(150 - 250 kDa) that was not visible in the Clover honey.  This is possibly due to 
glycation and/or cross-linking.  The bovine serum albumin had protein that 
increased in weight to around 240 - 280 kDa from 66 kDa after incubation with 
MGO.  Such a large increase in weight suggests cross-linking.  As mentioned in 
Chapter 5, cross-linked protein binds receptors with more affinity, which could 
partially explain the anti-inflammatory effect of Manuka honey if it is working on 
receptors as hypothesised.  
One aspect not investigated during this research was the cell-to-cell 
communication that occurs in inflammatory cascades and feedback loops.  It 
would be of great importance to investigate whether the anti-inflammatory 
activity of honey affects cell-to cell communication, for example; by way of MyPo 
as discussed earlier. Though the MyPo pathway is only one method of cell-to-cell 
communication, it is possible that this pathway is targeted by the active 
component of honey.  Macrophage activation has been found to generate high 
levels of MyPo and the increase in MyPo content is accompanied by an increased 
production of inflammatory mediators which recruit further inflammatory cells, 
both macrophages and other phagocytes, and MyPo derived from neutrophils is 
cleared by the mannose receptor of macrophages. 
Future work should investigate the contribution that anti-oxidants in the honey 
may make to the anti-inflammatory effect.  As mentioned earlier, antioxidants 
retard the reaction that produces MGO-modified protein.  This needs to be 
investigated in Manuka honey where the natural anti-oxidant content may be 
influencing the development of anti-inflammatory activity.  The antioxidant 
content may explain why there was a lack of correlation with MGO content and 
anti-inflammatory activity of honey.  With this knowledge it will be possible for 
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apiarists to select blends of honey so that honey can have an optimal anti-
inflammatory activity.  Having a method for quantifying the amount of anti-
inflammatory activity in individual honey will assist in the marketing of Manuka 
honey as an anti-inflammatory agent.  Depending on the circumstances a honey 
could be selected for greatest anti-bacterial or anti-inflammatory effect to speed 
up the wound healing process as not all wounds are infected or inflamed. 
It may be that antioxidants are anti-inflammatory but are superfluous if 
production of ROS is inhibited by the protein.  Decreasing ROS release from 
macrophages hypothetically will suppress inflammation by preventing the 
ongoing feedback loops in the inflammatory cascade generated by phagocytosis.  
Inflammatory pathways such as the NF-κB pathway, (NF-κB being a major 
transcription factor that regulates genes responsible for both the innate and 
adaptive immune response), won’t be activated, and cytokine expression may be 
diverted to anti-inflammatory production.   
These findings have obvious implications for honey and its use as a wound 
dressing with respect to its anti-inflammatory properties.  It would be beneficial 
for future work to re-run the HET-CAM assays with just the protein from Manuka 
honey, to see how the results compare with the whole honey.  Further to this, a 
wider range of honey, both Manuka and other floral varieties should be assayed 
to determine if any other honey types have this bioactivity. 
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Appendix 1 – DVD 
 
The DVD can be found attached to the inside cover of this thesis at the back.  The 
DVD can be played on a standard DVD player, or computer with DVD drive.  The 
following is a description of the files on the disc.   
 
Time-lapse movie of untreated-monocyte THP-1 cells, 1 frame every 20 seconds. 
Time-lapse movie of honey treated THP-1 cells, 1 frame every 20 seconds, 0.25% 
Manuka honey. 
Time-lapse movie of LPS-treated (100 ng/ml) THP-1 cells, 1 frame every 15 
seconds. 
Time-lapse movie of honey- and LPS-treated (100 ng/ml) THP-1 cells, 1 frame 
every 20 seconds, 0.25% Manuka honey. 
Time-lapse movie of LPS-treated (100 ng/ml) THP-1 cells 1 frame every second. 
Movie made of THP-1 cells for the Queenstown molecular biology conference. 
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Appendix 2 – Primer sequences 
 
Gene 
Primer sequence 
(forward and reverse, 5’–3’) 
 
length 
(bp) 
Product 
length 
(bp) 
Accn. 
no. 
Reference 
Melt 
temp 
IL-1β 
F-TACGAATCTCCGACCACCA 
R-GGGACAGGATATGGAGCAAC 
19 
20 
315 M15330  87 
IL-6 
F-CTGAGGGCTCTTCGGCAAA 
R-CTTTCCAAGAAATGATCTGGC 
19 
21 
192 M18403  84.7 
IL-10 
F-GCTGTTTTCCCTGACCTCC 
R-CATCTCCTGGGTTCAAGCA 
19 
19 
400 M57627  89 
IL-12 
F-CACCAAGCAAAGAGGGAGAG 
R-TTTTGCCTGTGTCTCGTCTG 
20 
20 
186 M65290  89.5 
TGFβ 
F-CAGCAACAATTCCTGGCGATA 
R-AAGGCGAAAGCCCTCAATTT 
21 
20 
155 X02812  89.5 
PDGF 
F-CCGTAGGGAGTGAGGATTCT 
R-GCTGCTTTAGGTGGGTTTTA 
21 
20 
487 U41745 
(Utsugi et 
al., 2002) 
87 
IL-1ra 
F-GGCCTCCGCAGTCACCTAATCACTCT 
R-TACTACTCGTCCTCCTGGAAGTAGAA 
26 
26 
500 M55646 
(Gabay, 
1997) 
91 
HCgp-
39 
F-TCAAGAACAGGAACCCCAAC 
R-AAATTCGGCCTTCATTTCCT 
20 
20 
236 Y08374   
CPM 
F-GAAAGCAGCAGTCAGGCAC 
R-CCTCTGCCTTCTGGGTTCA 
19 
19 
233 
AF36846
3 
(Rehli et al. 
1995) 
88.3 
β2M 
F-ATGTCTCGCTCCGTGGCCTTA 
R-ATCTTGGGCTGTGACAAAGTC 
21 
21 
295 
AB02128
8 
 86 
β-actin 
F-GGATGCAGAAGGAGATCACTG 
R-CGATCCACACGGAGTACTTG 
21 
20 
90 
NM_001
101 
 N/A 
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Appendix 3 – Sample data 
Code No. Description  NPA MGO Colour Fluor AI HMF 
bu496 Buttercup     10 51 5   
bu796 Buttercup 
  
10 66 1 
 clo42 Clover     2 21 2   
f1 Fennel mata 
  
8 31 5 
 hd1 Honey Dew     8 40 10   
k17 Kanuka 
  
5 59 13 
 k24 Kanuka     9 89 19   
k27 Kanuka 
  
8 64 10 
 k29 Kanuka     6 56 15   
ko1 Kanuka  
  
8 77 15 
 La6 Lavender      2 6 0   
CJA10+ Manuka 11.1 189 5 92 38 6.47 
CJA30+ Manuka 27 679 7 147 41 12.85 
M01 Manuka 25.3 650 8 95 40 3.13 
M03 Manuka 23.6 599 7 75 37 4.38 
M05 Manuka 17.5 312 9 162 43 5.10 
M07 Manuka 13.9 205 8 58 29 2.25 
M08 Manuka 14.7 219 7 50 25 2.31 
M09 Manuka 17.7 329 8 62 34 4.57 
M10 Manuka 13.9 219 6 54 30 3.07 
M11 Manuka 14.8 249 6 74 34 2.33 
M118 Manuka 
   
65 19 
 M119 Manuka       120 38   
M12 Manuka 14.9 272 5 52 24 1.58 
M120 Manuka 19.3   8 74 21   
M122 Manuka 
  
4 50 14 
 M124 Manuka 18   8 143 41   
M125 Manuka 16 
 
10 120 
  M126 Manuka     6 94 15   
M127 Manuka 19 
 
8 141 
  M128 Manuka 11.8 192 4 20 4   
M129 Manuka 14 
 
9 29 13 
 M13 Manuka 11 167 5 25 16 0.91 
M130 Manuka 15 
 
5 93 35 
 M140 Manuka 22   10 106 35   
M142 Manuka 25+ 
 
9 155 44 
 M144 Manuka 12+   10 184 51   
M145 Manuka 10+ 
 
6 112 41 
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Code No. Description  NPA MGO Colour Fluor AI HMF 
M146 Manuka 20+   8 88 30   
M149 Manuka 5+ 
 
7 205 52 
 M15 Manuka 15.3 267 7 63 31 3.86 
M150 Manuka 
  
3 61 10 
 M151 Manuka ND   2 16 4 0.30 
M152 Manuka 6.9 
  
15 5 
 M158 Manuka 13.3 330 4 30 5 5.00 
M159 Manuka 11.8 280 4 29 7.2 1.50 
M16 Manuka 14.4 272 7 68 32 3.80 
M160 Manuka 8.3 170 4 21 5.1 1.10 
M161 Manuka 9.4 223 4 23 5.6 0.70 
M162 Manuka 8.7 360 4 26 9 1.00 
M163 Manuka 14 352.8 4 34 10 1.10 
M164 Manuka ND 118 4 80 23 0.20 
M165 Manuka 11.8 280 4 28 7 1.20 
M166 Manuka ND 145.9 4 92 31 0.40 
M167 Manuka ND 151.2 4 61 25 0.50 
M168 Manuka ND 140 4 60 18 0.80 
M169 Manuka ND 150 4 68 18 0.30 
M17 Manuka 14.2 243 4 97 39 1.06 
M170 Manuka 1/4 PI 160 4 45 20 0.50 
M171 Manuka ND 150 4 74 25 0.90 
M172 Manuka ND 160 4 89 30 0.70 
M173 Manuka 1/4 PI 150 4 50 15 0.60 
M174 Manuka ND 85 4 90 30 0.20 
M175 Manuka ND 85 4 102 30 0.10 
M176 Manuka ND 145 4 46 20 0.50 
M177 Manuka ND 150 4 65 21 0.50 
M178 Manuka ND 150 4 68 28 0.90 
M179 Manuka ND 120 4 89 31 0.30 
M18 Manuka 14.2 257 4     0.82 
M180 Manuka ND 150 4 97 38 0.60 
M181 Manuka 1/4 PI 130 4 72 10 0.70 
M182 Manuka ND 110 4 116 32 0.40 
M183 Manuka ND 115 4 107 34 0.30 
M184 Manuka ND 110 4 58 25 0.80 
M185 Manuka ND 110 4 57 24 0.50 
M186 Manuka ND 95 4 87 35 0.20 
M187 Manuka 8.1 PI 3/4 110 4 94 33 0.40 
M188 Manuka 8.7 1/4 PI 130 4 66 17 0.40 
M189 Manuka ND 85 5 204 55 0.50 
M19 Manuka 11.9 186 
   
0.84 
M190 Manuka 8.2 PI 2/4 105 5 195 49 0.70 
M191 Manuka ND 110 5 216 51 0.40 
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Code No. Description  NPA MGO Colour Fluor AI HMF 
M192 Manuka 8.1 PI 1/4 130 5 175 44 0.80 
M193 Manuka ND 100 5 214 49 
 M196 Manuka ND 130 4 21 13 0.80 
M197 Manuka ND 115 4 20 9 0.70 
M198 Manuka ND 80 4 77 24 1.10 
M199 Manuka PI 2/4 160 4 93 38 0.90 
M20 Manuka   139 7 82 39 0.79 
M200 Manuka PI 1/4 140 4 85 34 
 M201 Manuka 12.4 280 4 73 29 1.80 
M202 Manuka ND 150 4 96 32 0.90 
M203 Manuka ND 150 5 156 41 0.90 
M204 Manuka ND 160 5 120 35 0.70 
M205 Manuka 8.9 PI 3/4 170 5 96 30 1.10 
M206 Manuka ND 110 4 51 12 0.50 
M207 Manuka ND 120 5 80 28 0.50 
M209 Manuka ND 140 5 81 20 1.30 
M21 Manuka 9.2 121 3 35 21 0.76 
M217 Manuka 
 
550+ 
 
149 35 
 M22 Manuka 8.3 106 3 34 16 0.66 
M23 Manuka 9.3 141 3 26 16 0.47 
M24 Manuka 7.9 96.6 3 10 11 0.50 
M26 Manuka 7.3 67 6 47 21 1.29 
M27 Manuka 7.3 107 6 65 29 0.61 
M28 Manuka 8.6 112 4 19 14 1.33 
M29 Manuka 8 114 5 73 35 0.82 
M30 Manuka 10 103 4 30 21 0.93 
M31 Manuka 7.5 107 7 39 20 1.55 
M32 Manuka 5.9 71 6 40 23 2.31 
M34 Manuka 4.5 58.6 7 33 15 2.99 
M36 Manuka 5.4 25.4 3 53 31 0.35 
M38 Manuka 7.5 89.9 4 29 16 1.04 
m999 Manuka 
  
4 32 10 
 MB02 Manuka 16.8   10 159 40   
MBD28.8 Manuka 27.3 708 9 167 49 17.98 
Mt1 Manuka     10 53 10   
Mt2 Manuka 
  
5 65 0 
 mwh Manuka     6 106 20   
sp bay 1 Manuka  20+ 
 
4 72 25 
 
MB101 
Manuka > 10 
yr old 15.3   10 141 41   
MB102 Manuka > 10 yr old 0 
 
12 227 55 
Spbay old 
Manuka > 10yr 
old   10 206     
 Mt3 Manuka comb 
  
10 114 25 
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Code No. Description  NPA MGO Colour Fluor AI HMF 
mb1 Mellow bush     7 89 10   
mk1 Mingimingi/Kowhai 
 
3 21 0 
 N13 Nodding Thistle   2 5 0   
N14 Nodding Thistle 
 
5 11 0 
 p132 Pasture     5 24 5   
P141 Pasture 
  
4 20 10 
 P59 Pasture 0 10 3 35 15   
bw50 Penny Royal 
  
7 14 0 
 bw49 Penny Royal      7 44 0   
PO10 Pohutakawa 
  
5 13 0 
 PO9 Pohutakawa     2 5 0   
r138 Rewarewa 
  
7 33 20 
 r139 Rewarewa     4 34 20   
r140 Rewarewa 
  
5 34 20 
 T18 Thyme     8 20 0   
Mf1 Urban floral 
  
5 20 0 
 VB4 Vipers Bugloss     3 5 0   
VB6468 Vipers Bugloss 0 0 1 3 0 20.00 
 
NB:  Missing data in spreadsheet indicates test was not completed.                                 
Abbreviations; NPA=non-peroxide antibacterial activity, MGO=methylglyoxal, 
Fluo.=fluorescence , AI.=Anti-inflammatory level, HMF=HydroxyMethylFurfuraldehyde. 
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Appendix 4 - Colour scale 
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Appendix 5  
Assesment of LPS as an irritant for the HET-CAM 
assay. 
 
Preliminary assays were conducted for the HET-CAM assay using varing 
concentrations of LPS to find a suitable concentration that would not kill the 
embryo but provide an observable inflammation as a direct result of the LPS 
application to the membrane.  Two embryos were assayed using the same 
protocol as listed in Chapter 9, Section 9.3.2.1 and 9.3.2.3.  A 50 µg/ml 
concentration of LPS was selected for further assays. 
 
Concentration 
of LPS 
Embryos 
alive 
(OUT OF 2) 
Granuloma 
present 
Cappilary 
net normal 
Redness 
observed 
5 µg/ml 2 NO YES NO 
50 µg/ml 2 NO YES YES 
200 µg/ml 1 NO hemorrhage YES 
500 µg/ml 0 NO N/A N/A 
 
  
 
 
